"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03286335","Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy",,"Recruiting","No Results Available","Brain Tumor","Radiation: Proton Radiation","Duration of Local Control|Quality of Life Assessment EORTC-QLQ-C30|Quality of Life Assessment EORTC-QLQ-BN20|Quality of Life Assessment HADS|Vision Loss|Ototoxicity|Neuroendocrine dysfunction|Neurocognitive effects|Alopecia|CD4 count","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-250","August 31, 2018","September 30, 2020","September 30, 2024","September 18, 2017","null","June 14, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03286335"
2,"NCT02740933","Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors",,"Not yet recruiting","No Results Available","Brain Tumor","Drug: Demeclocycline","Detectable fluorescence in brain tumors by confocal microscopy after oral dosing of demeclocycline (Y/N).|Sensitivity And Specificity Of Demeclocycline-Enhanced Multimodal Confocal Microscopy of Excised Glioma Specimens","Massachusetts General Hospital","All","21 Years and older   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15-280","April 2016","January 2019","January 2021","April 15, 2016","null","April 15, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02740933"
3,"NCT03328858","Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor",,"Recruiting","No Results Available","Brain Tumors","Other: Ketogenic Diet","Overall Response Rate|Quality of Life Measures|Ketosis Levels|Blood Glucose Levels|Correlation of ketosis levels and ketogenic diet","Nicklaus Children's Hospital f/k/a Miami Children's Hospital","All","12 Months to 35 Years   (Child, Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MCH05817","November 1, 2017","November 30, 2022","November 30, 2023","November 1, 2017","null","March 2, 2018","Nicklaus Children's Hospital, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT03328858"
4,"NCT02367469","Tryptophan Metabolism in Human Brain Tumors",,"Recruiting","No Results Available","Brain Tumors","","In newly diagnosed tumors|In previously treated tumors|Tryptophan metabolism","Wayne State University|National Cancer Institute (NCI)","All","13 Years and older   (Child, Adult, Older Adult)","","105","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NCI Tryptophan|CA123451","February 2014","January 2019","December 2019","February 20, 2015","null","December 5, 2017","Wayne State University, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02367469"
5,"NCT02956291","Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors",,"Recruiting","No Results Available","Brain Tumor","Device: Magnetic Resonance Fingerprinting","T1 relaxometry value of Region of Interest (ROI) in MRF scan for each tumor type|T2 relaxometry value of Region of Interest (ROI) in MRF scan for each tumor type|Number of patients whose clinical diagnosis and quantitative imaging diagnosis match|In treated tumors, difference in T1 relaxation times between baseline and 6 months post surgery|In treated tumors, difference in T2 relaxation times between baseline and 6 months post surgery|In treated tumors, difference in T1 and T2 relaxation times between recurrent tumor and radiation necrosis","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CASE8316","February 15, 2017","June 2018","July 2019","November 7, 2016","null","October 26, 2017","University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02956291"
6,"NCT02824731","Comparison of Proton and Photon Radiotherapy of Brain Tumors (ProtoChoice-Hirn)",,"Recruiting","No Results Available","Brain Tumors","Radiation: Radiation with protons|Radiation: Radiation with photons","late toxicity as cumulative measure|Local tumour control|Overall survival|acute toxicity","Technische Universität Dresden|German Cancer Research Center|National Center for Radiation Research in Oncology Dresden/Heidelberg","All","18 Years and older   (Adult, Older Adult)","Not Applicable","346","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STR - ProtoChoice-Hirn - 2015","July 2016","July 2025","July 2026","July 7, 2016","null","September 14, 2017","University Hospital Carl Gustav Carus, Department of Radiotherapy and Radiation Oncology, Dresden, Germany","","https://ClinicalTrials.gov/show/NCT02824731"
7,"NCT02947373","Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors",,"Recruiting","No Results Available","Pediatric Brain Tumors","Drug: Hyperpolarized Pyruvate","Number of Participants With Adverse Events as Assessed by CTCAE v4.0. Analyses will be performed for all patients having received at least one dose of study drug.|Secondary analyses will include assessment of imaging quality, which will be descriptive in nature.","University of California, San Francisco","All","3 Years to 18 Years   (Child, Adult)","Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PNOC 011|16088","January 25, 2017","December 15, 2018","February 2019","October 27, 2016","null","June 28, 2018","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02947373"
8,"NCT02428972","Assessment of Cognitive Functions and Quality of Life in Patients Undergoing Surgery for Supratentorial Brain Tumor",,"Not yet recruiting","No Results Available","Brain Tumor","Drug: Propofol|Drug: Sevoflurane","Cognitive functions|Adverse events","All India Institute of Medical Sciences, New Delhi","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","IEC/NP-55/06.02.2015","August 2017","July 2018","July 2018","April 29, 2015","null","January 24, 2017","","","https://ClinicalTrials.gov/show/NCT02428972"
9,"NCT02914067","Cognitive Biomarkers in Pediatric Brain Tumor Patients",,"Recruiting","No Results Available","Childhood Brain Tumor","Other: Neurocognitive testing|Device: rsfcMRI","Identify reliable peri-diagnostic estimators of cognition as measured by neurocognitive testing|Identify reliable peri-diagnostic estimators of cognition as measured by advanced resting-state functional connectivity MRI (rsfcMRI) data|Predictors of cognitive recovery in children as determined by multiplexed analyses of a combination of potential biomarkers across multiple modalities (rsfcMRI, structural MRI, NIH Toolbox, patient demographics, treatment information)|Identify reliable peri-diagnostic estimators of brain function as measured by neurocognitive testing|Identify reliable peri-diagnostic estimators of brain function as measured by advanced resting-state functional connectivity MRI (rsfcMRI) data","Washington University School of Medicine","All","4 Years to 18 Years   (Child, Adult)","Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","201609023","October 26, 2016","November 30, 2019","January 30, 2022","September 26, 2016","null","March 7, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02914067"
10,"NCT02191488","ALA-induced PpIX Fluorescence During Brain Tumor Resection",,"Recruiting","No Results Available","Brain Tumors","Drug: 5-aminolevulinic acid","Comparison of intraoperative measurements of PpIX concentration to coregistered histopathology","David W. Roberts|National Institute of Neurological Disorders and Stroke (NINDS)|Dartmouth-Hitchcock Medical Center","All","21 Years and older   (Adult, Older Adult)","Phase 1","540","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DMS 13066|R01NS052274-01A2","July 2014","July 2019","July 2020","July 16, 2014","null","March 15, 2018","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT02191488"
11,"NCT02754544","Using Electrocorticogram (ECoG) in Predicting Eloquent Cortex and Post-Op Functional Outcomes in Patients With Brain Tumors",,"Recruiting","No Results Available","Brain Tumor","Procedure: Electrocorticography (ECoG) with PMT Grids|Procedure: Electrocorticography (ECoG) with CorTec Grids|Procedure: Digital Glove Procedure|Procedure: Neurological Exam|Procedure: Electrocorticography (ECoG) with Ad-Tech Grids|Procedure: Direct Electrical Stimulation Mapping|Procedure: Grip Sensor Procedure","Comparison of the Electrocorticogram (ECoG) Data to Standard Mapping During Brain Surgery Using PMT High-Resolution Grids, CorTec High Density Grids or Ad-Tech Grids","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2015-0775|NCI-2016-00794","July 2016","July 2019","July 2019","April 28, 2016","null","January 5, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02754544"
12,"NCT03394716","Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain Tumors",,"Recruiting","No Results Available","Brain Tumor","Radiation: Radiotherapy","MRI parameters in the target volume|anatomical variations in position, shape and size in the target volume|the correlation between MRI parameters to the treatment outcome|the correlation between anatomical variations and the treatment outcome","The Netherlands Cancer Institute","All","18 Years and older   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","N17MRB","January 12, 2018","January 1, 2021","January 1, 2021","January 9, 2018","null","March 14, 2018","Antoni van Leeuwenhoek, Amsterdam, Noord-Holland, Netherlands","","https://ClinicalTrials.gov/show/NCT03394716"
13,"NCT03276676","[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors",,"Recruiting","No Results Available","Brain Tumor","Drug: Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine","Increased Overall Survival|Association between overall survival and quantitative markers|Association between progression free survival and quantitative markers|Ability of [18F]FLT and/or [18F]Fluciclovine alone or together to predict true progression from pseudoprogression|More predictive of overall survival than an MRI|More predictive of time to progression than an MRI","University of Utah|Blue Earth Diagnostics","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HCI104704","March 6, 2018","November 2022","November 2022","September 8, 2017","null","May 23, 2018","Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03276676"
14,"NCT03220646","The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.",,"Recruiting","No Results Available","Brain Tumor","Drug: abemaciclib","radiographic response rate|progression free survival (PFS)","Memorial Sloan Kettering Cancer Center|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","78","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-261","July 13, 2017","July 2020","July 2020","July 18, 2017","null","February 27, 2018","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03220646"
15,"NCT03090386","Evaluation of Cognitive-Communication Deficits Following Treatment of Primary Brain Tumor Patients",,"Recruiting","No Results Available","Brain Tumor","Other: Cognitive Surveys","Cognitive Communication Survey|Cognitive-linguistic Standardized Testing|Follow-up Survey","Mayo Clinic","All","18 Years to 89 Years   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","16-005834","February 25, 2017","February 2019","August 2019","March 24, 2017","null","February 8, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03090386"
16,"NCT02530749","Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients",,"Recruiting","No Results Available","Brain Tumors","","Number of patients with a Complication risk|Length of stay based on a Hopkins Frailty Score (HFS).|Number of patients Discharge to a skilled or assisted-living facility","University of Colorado, Denver","All","18 Years and older   (Adult, Older Adult)","","600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-0579","April 2014","June 2018","December 2018","August 21, 2015","null","July 28, 2017","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT02530749"
17,"NCT03451123","FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors",,"Recruiting","No Results Available","Pediatric Brain Tumors","Drug: FET PET/MRI","Percentage of patients whose surgical plan change with FET-PET/MRI compared to MRI alone.|Percentage of patients who have residual tumor after surgery detected with FET-PET/MRI","University of Alabama at Birmingham","All","6 Years to 18 Years   (Child, Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R17-077","April 23, 2018","February 2021","February 2021","March 1, 2018","null","May 15, 2018","UAB Advanced Imaging Facility, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03451123"
18,"NCT02129712","Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors","CRPBT","Recruiting","No Results Available","Brain Tumor","Behavioral: Cognitive training","NIH Toolbox-Cognition Battery","Vanderbilt University|National Cancer Institute (NCI)","All","7 Years to 16 Years   (Child)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","121214|1R21CA175840-01","February 1, 2014","December 31, 2017","December 31, 2017","May 2, 2014","null","April 12, 2017","Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02129712"
19,"NCT01535430","Assessment of Eloquent Function in Brain Tumor Patients",,"Recruiting","No Results Available","Primary Brain Tumor|Metastatic Brain Tumor","","Eloquent function","University of Nebraska","All","19 Years and older   (Adult, Older Adult)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","671-11-FB","January 2012","June 2019","June 2020","February 17, 2012","null","September 18, 2017","University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT01535430"
20,"NCT00811148","Florida Center for Brain Tumor Research","FCBTR","Recruiting","No Results Available","Brain Tumors","Procedure: Tissue Bank","Collect and maintain clinical data and tumor tissue removed during brain surgeries.","University of Florida","All","Child, Adult, Older Adult","","4000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FCBTR","March 2006","December 2020","December 2020","December 18, 2008","null","July 6, 2018","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT00811148"
21,"NCT00147056","MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors",,"Recruiting","No Results Available","Brain Tumor","Device: ExAblate transcranial system","Number of subjects with Serious and Non-Serious Adverse Events after MRI Guided Focused ultrasound treatment for brain tumors","InSightec","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BT002","August 2012","December 2018","December 2018","September 7, 2005","null","March 29, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States|Swedish Medical Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00147056"
22,"NCT02905110","Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors",,"Recruiting","No Results Available","Brain Tumor Recurrent","Drug: Methotrexate|Drug: Etoposide|Procedure: Ommaya Reservoir","Number of patients with grade 3 through grade 5 new neurological adverse events that are related to study drug, graded according to NCI CTCAE Version 4.0","The University of Texas Health Science Center, Houston","All","1 Year to 21 Years   (Child, Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-16-0639","October 2016","November 2020","November 2020","September 19, 2016","null","August 22, 2017","UTHealth & Children's Memorial Hermann Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02905110"
23,"NCT03068832","Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors",,"Not yet recruiting","No Results Available","Pediatric Brain Tumor","Biological: Personalized peptide vaccine|Drug: Poly ICLC|Procedure: Peripheral blood draw","Safety and tolerability of adjuvant personalized neoantigen peptide vaccine administration with poly-ICLC as measured by grade 3 and 4 adverse events|Feasibility of adjuvant personalized neoantigen peptide vaccine administration with poly-ICLC as measured by the number of participants who have a neoantigen specific long peptide vaccine identified and generated|Characterize tumor-infiltrating lymphocytes (TIL)|Frequency of expressed neoantigens using patient-specific HLA class I prediction algorithms","Washington University School of Medicine","All","up to 21 Years   (Child, Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-x032","December 31, 2018","June 30, 2020","May 31, 2023","March 3, 2017","null","June 21, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03068832"
24,"NCT01682746","Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors",,"Recruiting","No Results Available","Brain Tumor, Recurrent","Drug: Photofrin (porfimer sodium) & photodynamic therapy.","Maximum tolerable dose (MTD) of Photofrin® in pediatric subjects|Brain tumor response","Harry T Whelan, MD|Pinnacle Biologics Inc.|Medical College of Wisconsin","All","6 Months to 18 Years   (Child, Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","163588-1","March 2013","April 2019","April 2024","September 11, 2012","null","February 20, 2018","Children's Hospital of Wisconsin, Wauwatosa, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01682746"
25,"NCT03531307","Lactate Levels Correlates With Ki-67 in Brain Tumor Surgery",,"Recruiting","No Results Available","Brain Tumor|Anesthesia","Other: Data correlation","Evaluate the correlation between Lactate levels and Ki-67 Index","Ricard Valero|Fundacion Clinic per a la Recerca Biomédica","All","Child, Adult, Older Adult","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","Lac001Ki67","May 30, 2018","July 30, 2018","August 30, 2018","May 21, 2018","null","June 7, 2018","Anesthesia department, Hospital Clínic de Barcelona, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT03531307"
26,"NCT02150564","3D Ultra Sound for Resection of Brain Tumors","Sono RCT","Recruiting","No Results Available","Patients With Resectable Brain Tumors","Device: Sonowand|Procedure: Navigation","Percentage of patients where Gross total resection (GTR) achieved|Accuracy of US","Tata Memorial Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TMC-ACTREC 101","March 2014","January 2017","March 2017","May 30, 2014","null","October 21, 2016","Advanced Centre for Treatment Research and Education in Cancer, Mumbai, Maharashtra, India","","https://ClinicalTrials.gov/show/NCT02150564"
27,"NCT02458339","Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors",,"Recruiting","No Results Available","Brain Tumor, Recurrent|Malignant Neoplasm of Fourth Ventricle of Brain","Procedure: Ommaya Reservoir|Drug: Methotrexate","Maximum Tolerated Dose (MTD) of the direct administration of methotrexate into the fourth ventricle of the brain as determined by NCI's CTCAE","The University of Texas Health Science Center, Houston","All","1 Year to 21 Years   (Child, Adult)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-15-0035","December 2018","June 2019","June 2019","June 1, 2015","null","June 21, 2018","UTHealth & Children's Memorial Hermann Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02458339"
28,"NCT02691923","Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker",,"Recruiting","No Results Available","Brain Cancer","Drug: Fluorescein|Drug: Fluorescein + ALA","Fluorescein performance as an intraoperative biomarker for tumor tissue will be reported.|Fluorescein performance as visualized and measured with an intraoperative probe will be reported|Fluorescein versus fluorescein + ALA performance will be reported in patients in patients with 2 different types of tumors","David W. Roberts|National Institute of Neurological Disorders and Stroke (NINDS)|Carl Zeiss Meditec, Inc.|Dartmouth-Hitchcock Medical Center","All","21 Years and older   (Adult, Older Adult)","Phase 2","30","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","D12090|R01NS052274-01A2","March 2016","June 2018","December 2018","February 25, 2016","null","March 15, 2018","Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT02691923"
29,"NCT02307604","SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access","SPECTAbrain","Recruiting","No Results Available","Brain Neoplasms","Genetic: Tumour markers testing","Number of patients with brain malignancy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Older Adult)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EORTC-1313","May 2016","January 2019","January 2019","December 4, 2014","null","August 8, 2017","CHRU de Lille, Lille, France|Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere, Paris, France","","https://ClinicalTrials.gov/show/NCT02307604"
30,"NCT03033706","Intraoperative Goal Directed Fluid Management in Supratentorial Brain Tumor Craniotomy",,"Recruiting","No Results Available","Brain Tumor|Craniotomy","Procedure: Pulse pressure variation guided fluid therapy|Procedure: Traditional fluid therapy|Procedure: Brain tumor excision","Evaluation of brain relaxation|volume of intraoperative fluid requirements|Urine output|heart rate|number of episodes of hypotension|arterial blood gases|serum lactate|Hemoglobin concentration|prothrombin concentration","Cairo University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MD-4-2016","March 25, 2017","October 1, 2017","December 1, 2017","January 27, 2017","null","April 21, 2017","Cairo University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03033706"
31,"NCT02698254","Pilot Trial of Dose-Volume Constraints for Reirradiation of Recurrent Brain Tumors",,"Recruiting","No Results Available","Brain Cancer","Radiation: Re-Irradiation Therapy (RRT) to Brain|Behavioral: Questionnaires","Highest Grade of Central Nervous System (CNS) Necrosis","M.D. Anderson Cancer Center","All","Child, Adult, Older Adult","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0586|NCI-2016-00536","July 20, 2016","July 2020","July 2020","March 3, 2016","null","May 7, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02698254"
32,"NCT03216148","18F-FET PET in Childhood Brain Tumours",,"Recruiting","No Results Available","Brain Neoplasm","Diagnostic Test: FET-PET","Differentiating biologically active Tumor tissue from therapy related changes by using MRI (Magnetic Resonance Imaging) and FET PET|Sensitivity of FET-PET when differentiating biologically active Tumor tissue from therapy-related changes by using MRI (Magnetic Resonance Imaging) and FET PET|Assessment of the predictive value of FET-PET when differentiating biologically active Tumor tissue from therapy-related changes by using MRI (Magnetic Resonance Imaging) and FET PET|Assessment of Tumor grading by FET-PET when differentiating biologically active Tumor tissue from therapy-related changes by using MRI (Magnetic Resonance Imaging) and FET PET|Safety data on FET-PET in children with brain tumors","Charite University, Berlin, Germany","All","1 Year to 17 Years   (Child)","Phase 2","160","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FET PET 2010|2008-005786-60","July 2015","July 2018","July 2019","July 13, 2017","null","July 21, 2017","Klinikum Augsburg, Onkologie, Augsburg, Germany|Charité Universitätsmedizin Berlin, CVK, Onkologie, Berlin, Germany|Evangelisches Krankenhaus Bielefeld gGmbH, Onkologie, Bielefeld, Germany|Universitätsklinikum Bonn, Onkologie, Bonn, Germany|Klinikum Bremen-Mitte gGmbH, Onkologie, Bremen, Germany|Universitätsklinikum Düsseldorf, Onkologie, Düsseldorf, Germany|Universitätsklinikum Essen, Onkologie, Essen, Germany|Klinik für Nuklearmedizin, Freiburg, Germany|Klinik für Pädiatrische Hämatologie und Onkologie, Freiburg, Germany|Zentrum für Kinder- und Jugendmedizin, Angelika-Lautenschläger-Klinik, Onkologie, Heidelberg, Germany|Institut für Neurowissenschaften und Medizin, Physik der medizinischen Bildgebung, Forschungszentrum Jülich, Nuklearmedizin, Jülich, Germany|Uniklinik Köln, Pädiatrische Onkologie, Köln, Germany|Kliniken der Stadt Köln gGmbH, Köln, Germany|Universitätsklinikum Mainz, Onkologie, Mainz, Germany|Kinderklinik München Schwabing, Onkologie, München, Germany|Nuklearmedizinische Klinik und Poliklinik, München, Germany|Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie, Münster, Germany|Klinik für Nuklearmedizin, Münster, Germany|Klinikum Stuttgart - Olgahospital, Onkologie, Stuttgart, Germany|Klinikum Stuttgart, Nuklearmedizin, Stuttgart, Germany|Universitätsklinikum Tübingen, Onkologie, Tübingen, Germany|Universitäts-Kinderklinik Würzburg, Würzburg, Germany","","https://ClinicalTrials.gov/show/NCT03216148"
33,"NCT03465618","A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors",,"Recruiting","No Results Available","Brain Cancer","Drug: 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging|Other: Blood and Urine samples","distribution within these high-grade gliomas","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","17-599","March 7, 2018","March 2020","March 2020","March 14, 2018","null","May 23, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03465618"
34,"NCT00813566","Multi-Tracer PET Assessment of Primary Brain Tumors",,"Recruiting","No Results Available","Brain Tumors|Cancer","Radiation: Multi-tracer PET exams of 18F-FDG, 18F-FLT, 11C-ACE, and 15O-H2O","Rapid, single-scan multi-tracer PET imaging can recover PET imaging biomarker information of each tracer that are not significantly different from those obtained from conventional, single-tracer scans of each tracer.|Multi-tracer PET biomarkers, obtained in conjunction, are better able to predict tumor aggressiveness than individual-tracer biomarkers or conventional radiographic imaging.|Multi-tracer PET biomarkers, obtained in conjunction, are better able to detect functional changes in tumor state that occur in response to therapy than individual-tracer biomarkers or conventional radiographic imaging.|Characterization of multiple aspects of tumor function (glucose metabolism, proliferation, membrane growth, and perfusion) provides new insight into tumor status that can guide selection of the most appropriate therapy.","University of Utah","All","18 Years and older   (Adult, Older Adult)","","20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HCI31335","December 2008","July 2018","July 2018","December 23, 2008","null","January 4, 2018","Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00813566"
35,"NCT03373487","Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery",,"Recruiting","No Results Available","Brain Tumor, Primary|Cognitive Impairment","Behavioral: The cognitive rehabilitation program ReMind","Change in objective cognitive functioning|Change in working memory|Change in word fluency|Change in subjective cognitive functioning|Change in symptoms of fatigue|Change in symptoms of anxiety|Change in symptoms of depression|Change in subjective executive functioning|Change in professional functioning (1)|Change in professional functioning (2)|Change in (social) participation","Elisabeth-TweeSteden Ziekenhuis|University of Tilburg|ZonMw: The Netherlands Organisation for Health Research and Development|Erasmus Medical Center|Medical Center Haaglanden","All","18 Years and older   (Adult, Older Adult)","Not Applicable","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","842003009","July 1, 2015","June 30, 2019","June 30, 2019","December 14, 2017","null","February 13, 2018","Erasmus Medical Center, Rotterdam, Netherlands|Medical Center Haaglanden, The Hague, Netherlands|Elisabeth-TweeSteden Hospital, Tilburg, Netherlands","","https://ClinicalTrials.gov/show/NCT03373487"
36,"NCT03234309","Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors",,"Recruiting","No Results Available","Childhood Brain Neoplasm","Drug: Ferumoxytol|Procedure: Magnetic Resonance Imaging","Cerebral blood volume in small (< 1cm) enhancing lesions|Confidence in identifying the lesion corresponding areas on cerebral blood volume maps|Delineation of tumor from larger blood vessels|Overlay accuracy with 3-dimensional anatomical T1w post contrast scans|Ferumoxytol enhancement|Histology and genetic markers|Progression free survival|Relative cerebral blood volume value|Survival|Treatment response","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","5 Years to 18 Years   (Child, Adult)","Phase 2","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STUDY00016165|NCI-2017-00713|P30CA069533","October 20, 2017","April 14, 2021","April 14, 2022","July 31, 2017","null","November 6, 2017","OHSU Knight Cancer Institute, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03234309"
37,"NCT03248544","Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Brain Tumor Surgery",,"Recruiting","No Results Available","Brain Neoplasms","Drug: vitamin D|Other: control","Vitamin D level|Peri-operative Complications|Post-operative Complications|Duration of stay in ICU|Duration of stay in hospital|1-month mortality|6-month mortality","Shahid Beheshti University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1396-607","July 6, 2017","June 30, 2018","June 30, 2018","August 14, 2017","null","April 18, 2018","Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of|Shohada Tajrish Hospital, Tehran, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT03248544"
38,"NCT03361033","Components of Social Functioning in Survivors of Pediatric Brain Tumors",,"Recruiting","No Results Available","Brain Tumor, Pediatric|Medulloblastoma, Pediatric","","Significant predictors of social-cognitive and neurocognitive abilities on social functioning","St. Jude Children's Research Hospital|American Cancer Society, Inc.","All","8 Years to 12 Years   (Child)","","68","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SOCFUN","January 30, 2018","February 2021","February 2021","December 4, 2017","null","February 1, 2018","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03361033"
39,"NCT03179449","In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI",,"Recruiting","No Results Available","Childhood Brain Neoplasm","Diagnostic Test: Diagnostic (ferumoxytol-enhanced MRI)|Procedure: Surgery|Drug: Ferumoxytol|Other: Tissue Analysis","Iron concentration measurements|Macrophages on histopathology","Michael Iv|National Cancer Institute (NCI)|Stanford University","All","2 Years and older   (Child, Adult, Older Adult)","Early Phase 1","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PEDSBRNCNS0008|NCI-2017-00959|P30CA124435|IRB-39245","July 1, 2017","July 1, 2019","July 1, 2019","June 7, 2017","null","July 18, 2017","Stanford University, School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03179449"
40,"NCT03323450","Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory",,"Recruiting","No Results Available","Glioma|Brain Tumor, Primary","Behavioral: CogMed®","Treatment enrollment rates|Attrition rates|Change in scores on Behavior Rating Inventory of Executive Function-Adult (BRIEF-A) over time|Change in scores on Conners' Continuous Performance Test - Third Edition (CPT-3) over time|Change in scores on Delis-Kaplan Executive Function System (D-KEFS) over time|Change in scores on Repeatable Battery for the Assessment of Neuropsychological Status (RBANS-Update A, B, C, or D) over time|Scores on Test of Premorbid Functioning (TOPF) at baseline|Change in scores on Trial Making Test (TMT) over time|Change in scores on Wechsler Memory Scale - Fourth Edition (WMS-IV) over time|Change in scores on Beck Anxiety Inventory (BAI) over time|Change in scores on Beck Depression Inventory-II (BDI-II) over time","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MCC-17-13581","October 20, 2017","November 1, 2018","November 1, 2018","October 27, 2017","null","October 27, 2017","Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03323450"
41,"NCT03330197","A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG",,"Recruiting","No Results Available","Pediatric Brain Tumor|Diffuse Intrinsic Pontine Glioma","Biological: Ad-RTS-hIL-12|Drug: oral veledimex","The safety and tolerability of intratumoral Ad-RTS-hIL-12 and veledimex as measured by dose limiting toxicities and compliance.|To measure the veledimex in blood and brain tumor by using the LC-MS method|Evaluate preliminary efficacy of Ad-RTS-hIL-12 and veledimex by assessing survival and tumor response rates|Measure immune response of Ad-RTS-hIL-12 and veledimex by a quantitative multiplex immunoassay for determination of IL-12 and IFNg levels|Subjects with Ad-RTS-hIL-12 and veledimex related adverse events will be assessed for safety by CTCAE v4.0","Ziopharm","All","up to 21 Years   (Child, Adult)","Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATI001-103","September 26, 2017","March 2021","March 2021","November 6, 2017","null","June 26, 2018","University of California San Francisco, Benioff Children's Hospital, San Francisco, California, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Dana- Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03330197"
42,"NCT01534104","MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning",,"Recruiting","No Results Available","Brain Cancer","Procedure: preoperative fMRI. DTI and DSI with tractography","standard vs. probabilistic tractography|the utility of diffusion spectrum imaging (DSI)|feasibility of updated fMRI sequences","Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","185","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","12-008","February 2012","February 2019","February 2019","February 16, 2012","null","March 5, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01534104"
43,"NCT02537106","A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation",,"Recruiting","No Results Available","Brain Tumors","Procedure: 1.5% NaCl|Procedure: 3% NaCl","Changes in brain microcirculation|Changes in natremia|Changes in osmolarity|Concentration of natrium in cerebrospinal fluid","University Hospital Hradec Kralove","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201508-S23P","September 2015","December 2018","December 2018","September 1, 2015","null","October 27, 2017","University Hospital Hradec Kralove, Hradec Kralove, Czechia","","https://ClinicalTrials.gov/show/NCT02537106"
44,"NCT03208387","Understanding the Late Effects of Surviving a Pediatric Brain Tumor",,"Recruiting","No Results Available","Brain Tumor|Pediatric Brain Tumor|Pediatric Cancer","Diagnostic Test: Diffusion tensor imaging (DTI)|Diagnostic Test: Resting state functional connectivity MRI (rs-fcMRI)|Behavioral: Wechsler Intelligence Scale for Children - 5th edition (WISC-V)|Behavioral: California Verbal Learning Test (CVLT-C)|Behavioral: Beery Test of Visual Motor Integration 6th edition|Behavioral: Grooved Pegboard|Behavioral: PedsQL Multidimensional Fatigue Scale|Diagnostic Test: MRI","Feasibilty which is the number of eligible survivors consented per month","Memorial Sloan Kettering Cancer Center","All","6 Years to 16 Years   (Child)","","48","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","17-338","June 28, 2017","June 2019","June 2019","July 5, 2017","null","February 15, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03208387"
45,"NCT01538264","Blood Flow MRI for Monitoring Brain Tumors","Glioma","Recruiting","No Results Available","Brain Tumors","","","Beth Israel Deaconess Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","","125","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2006P000116|R01CA115745-05","June 2006","June 2019","December 2019","February 24, 2012","null","March 21, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01538264"
46,"NCT02153957","Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors",,"Recruiting","No Results Available","Brain Tumor","Behavioral: Physical Activity","Efficacy|Examine test scores pre- to post- intervention|Compare cognitive test scores between groups|Effects of lab treadmill on cognitive functioning|Effects of 12wk PA on circulating growth factors|Effects of 12wk PA on fatigue and QOL|Effects of 12wk PA on cognitive functions|Examine circulating growth factors with PA levels &amp; fitness|Feasibility","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","8 Years to 18 Years   (Child, Adult)","Phase 2","156","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","140116|14-C-0116","May 31, 2014","December 31, 2018","April 1, 2019","June 3, 2014","null","June 27, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02153957"
47,"NCT03067467","Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)","HPCIM","Not yet recruiting","No Results Available","Brain Tumor Adult","Drug: Hyperpolarized 13C-Pyruvate|Drug: Gadolinium","13C-pyruvate Metabolic Product Ratio","University of Texas Southwestern Medical Center","All","18 Years to 60 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STU 012017-070","May 1, 2018","December 31, 2020","December 31, 2020","March 1, 2017","null","April 13, 2018","","","https://ClinicalTrials.gov/show/NCT03067467"
48,"NCT01503086","Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy",,"Recruiting","No Results Available","Brain Neoplasm|Recurrent Brain Neoplasm","Procedure: Cognitive Assessment|Other: Computer-Assisted Cognitive Training|Procedure: Psychosocial Assessment and Care|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Intervention compliance defined as at least 80% of sessions completed (i.e., completing at least 20 sessions within 9 weeks of starting training)|Parent-rated executive function and working memory (WM) using the Metacognition subscales from the Behavior Rating Inventory of Executive Function (BRIEF)|Executive function using the Groton Maze Learning task of the CogState battery|WM by the one-back task from CogState and Digit Span from Wechsler Intelligence Scales|Verbal and visual memory using Dot Location from Children?s Memory Scale Spatial Span from Wechsler Scale|Technical feasibility based on the item responses to the 13-item Feasibility Interview|Adherence|Satisfaction and ease of use","Children's Oncology Group|National Cancer Institute (NCI)","All","6 Years to 16 Years   (Child)","Not Applicable","71","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","ACCL10P1|NCI-2012-00112|CDR0000721387|COG-ACCL10P1|U10CA095861|UG1CA189955","November 18, 2013","March 30, 2027","null","January 2, 2012","null","June 8, 2018","Children's National Medical Center, Washington, District of Columbia, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01503086"
49,"NCT01246869","Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water",,"Recruiting","No Results Available","Brain Cancer","","Determination of multi-tracer update times as related to overall survival and time to progression","University of Utah","All","18 Years and older   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","HCI44704","August 2011","February 2020","February 2020","November 23, 2010","null","September 27, 2017","Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01246869"
50,"NCT02343991","Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound",,"Recruiting","No Results Available","Brain Tumor","Device: Transcranial ExABlate","Number of Device and Procedure related adverse events|Severity of Device and Procedure related adverse events","InSightec","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BBB001|215600","October 2014","December 2018","December 2018","January 22, 2015","null","March 27, 2018","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02343991"
51,"NCT00067821","Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor Activity",,"Recruiting","No Results Available","Brain Tumors","","Comparison|Evaluate change","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 21 Years   (Child, Adult)","","150","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","030278|03-C-0278","August 27, 2003","null","null","August 28, 2003","null","June 13, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00067821"
52,"NCT03399864","Effectiveness of Musical Training in Hong Kong Chinese Childhood Brain Tumor Survivors",,"Recruiting","No Results Available","Brain Neoplasms|Child","Behavioral: musical training|Other: usual care","Change in depressive symptoms from baseline at 12-month follow-up between intervention and control group.|Depressive symptoms at baseline between intervention and control group|Change in depressive symptoms from baseline at 6-month follow-up between intervention and control group|Level of self-esteem at baseline between intervention and control group|Change in level of self-esteem from baseline at 6-month between intervention and control group|Change in level of self-esteem from baseline at 12-month between intervention and control group|Quality of life at baseline between intervention and control group|Change in Quality of life at 6-month follow-up between intervention and control group|Change in Quality of life at 12-month follow-up between intervention and control group","The University of Hong Kong","All","7 Years to 16 Years   (Child)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","UW16-023_2","February 20, 2017","August 31, 2018","August 31, 2018","January 16, 2018","null","February 7, 2018","The University of Hong Kong, Hong Kong, China","","https://ClinicalTrials.gov/show/NCT03399864"
53,"NCT03181581","Improving Ultrasound Images in Brain Tumour Surgery With the Use of an Acoustic Coupling Fluid Mimicking Brain Tissue.",,"Recruiting","No Results Available","Brain Neoplasms|Glioma","Biological: acoustic coupling fluid|Biological: Ringer's acetate","difference in serious adverse event rates (test minus control)|image artefacts|depiction of outline of the anatomy surrounding the resection cavity|image signal-to-noise ratio","St. Olavs Hospital|Norwegian National Advisory Unit for Ultrasound and Image-guided Therapy|SINTEF Health Research","All","18 Years and older   (Adult, Older Adult)","Phase 2","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic","ACF-02|2016-003025-42","March 1, 2017","December 31, 2018","December 31, 2018","June 9, 2017","null","June 12, 2018","Department of Neurosurgery, St Olavs Hospital, Trondheim, Norway","","https://ClinicalTrials.gov/show/NCT03181581"
54,"NCT02754908","Effectiveness of Musical Training in Children Surviving Brain Tumours",,"Recruiting","No Results Available","Brain Neoplasms|Child","Behavioral: musical training|Behavioral: tutoring classes","Change in neurocognitive function from baseline at 12 month follow-up between intervention and control group|neurocognitive function at baseline between intervention and control group|self-esteem at baseline between intervention and control group|Change in self-esteem from baseline at 6 month follow-up between intervention and control group|Change in self-esteem from baseline at 12 month follow-up between intervention and control group|quality of life at baseline between intervention and control group|Change in quality of life from baseline at 6 month follow-up between intervention and control group|Change in quality of life from baseline at 12 month follow-up between intervention and control group","The University of Hong Kong","All","7 Years to 19 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","UW16-023","January 2016","December 2017","December 2017","April 28, 2016","null","May 5, 2017","The University of Hong Kong, Hong Kong SAR, China","","https://ClinicalTrials.gov/show/NCT02754908"
55,"NCT02792608","Mindfulness-Based Therapy for Brain Tumour Survivors",,"Recruiting","No Results Available","Brain Tumour|Depressive Symptoms|Survivors","Behavioral: Mindfulness-based Therapy","Change from Baseline Depressive Symptoms at 5 Weeks|Change from Baseline Quality of Life at 5 Weeks|Change from Baseline Perceived Stress at 5 Weeks|Change from Baseline Mental Wellbeing at 5 Weeks","Sunnybrook Health Sciences Centre|Brain Tumour Foundation of Canada","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","169-2015","August 2016","November 2018","December 2019","June 7, 2016","null","June 5, 2018","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02792608"
56,"NCT03403361","Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Patient Outcomes for Locally Advanced Lung and Brain Tumor Patients Treated With Proton Therapy",,"Recruiting","No Results Available","Lung Cancer|Brain Cancer","Device: Siemens Somatom Definition Edge|Device: Philips Brilliance Big Bore CT/simulator","3D organ-specific distribution of the DECT as measured by proton stopping powers|Patient-specific distributions of the DECT as measured by proton stopping powers|Impact of DECT tissue property mapping as measured by plan quality|Impact of DECT tissue property mapping as measured by dose-delivery accuracy|Impact of DECT tissue property mapping as measured by simulated patient outcomes","Washington University School of Medicine|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201711149|1R01CA212638","June 1, 2018","June 1, 2022","June 1, 2022","January 18, 2018","null","June 25, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03403361"
57,"NCT01473485","ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors",,"Recruiting","No Results Available","Glioma|Metastatic Brain Cancer","Device: ExAblate Transcranial System","Evaluate Safety of ExAblate Transcranial Device","InSightec","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BT003","April 2011","December 2018","December 2018","November 17, 2011","null","March 27, 2018","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01473485"
58,"NCT02693405","Executive and Socio-cognitive Functions in Survivors of Primary Brain Tumor: Impact on Patients' Quality of Life","NEUROCOG-QOL","Recruiting","No Results Available","Primary Brain Tumor|Neurocognition|Quality of Life","Other: Executive functions|Other: social cognition|Other: quality of life","performances in executive tasks and executive questionnaires|performances in social cognition tasks|quality of life questionnaires","University Hospital, Angers","All","8 Years to 59 Years   (Child, Adult)","Not Applicable","160","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHU-P2015-06","February 2016","September 2018","September 2018","February 26, 2016","null","May 3, 2018","CHU Angers, Angers, France","","https://ClinicalTrials.gov/show/NCT02693405"
59,"NCT02423525","Safety Study of Afatinib for Brain Cancer",,"Recruiting","No Results Available","Brain Cancer","Drug: Afatinib","Rate of dose limiting toxicities of pulsatile afatinib|Maximum tolerated dose (MTD) of pulsatile afatinib|Treatment-emergent adverse events|Afatinib levels in cerebrospinal fluid (CSF) and blood|Objective response rate as assessed by the RANO criteria|Best overall response rate|Progression free survival|Overall Survival","Santosh Kesari|Boehringer Ingelheim|John Wayne Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1200.229|20161975","December 2016","December 2019","December 2020","April 22, 2015","null","October 23, 2017","John Wayne Cancer Institute, Santa Monica, California, United States","","https://ClinicalTrials.gov/show/NCT02423525"
60,"NCT03281889","Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation",,"Recruiting","No Results Available","Brain Tumor","Radiation: Proton Beam","Feasibility of cranio-spinal irradiation (CSI) utilizing intensity-modulated proton therapy (IMPT) with pencil beam scanning (PBS) for vertebral body sparing (VBS) in pediatric patients.|Early marrow changes in the vertebral bodies|Vertebral column growth (measured by MRI) over 5 years|Change in sitting height and standing height|Time to abnormality in spinal curvature|Disease Free Survival|Pattern of Disease Relapse|Complete blood counts (CBC) over time|Change in levels of vitamin D, calcium, and growth hormones over time|Weight|BMI","Massachusetts General Hospital|National Cancer Institute (NCI)","All","3 Years to 18 Years   (Child, Adult)","Not Applicable","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-283|U19CA021239-37","January 4, 2018","March 31, 2021","March 31, 2025","September 13, 2017","null","January 19, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03281889"
61,"NCT02796729","CEST- Glucose Enhanced MRI for Metastatic Brain Tumours",,"Recruiting","No Results Available","Brain Neoplasms, Malignant|Metastasis","Procedure: Magnetic resonance imaging|Drug: Gadovist (Gadobutrol)|Drug: 50% dextrose solution","Integral tumour contrast generated by GBCA and glucose experiments will be assessed using Area Under Curve (AUC).|Maximum instantaneous tumour contrast generated by GBCA and glucose experiments will be assessed.","British Columbia Cancer Agency","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","H16-00646","October 2016","January 2018","January 2018","June 13, 2016","null","February 1, 2017","BC Cancer Agency- Vancouver Centre, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02796729"
62,"NCT03264300","Development and Validation of Advanced MRI Methods for Clinical Applications",,"Recruiting","No Results Available","Brain Tumor","Other: MRI","cerebral blood volume|the contrast agent extravasation rate constant (Ktrans, 1/min)|Repeatability coefficient|Intraclass correlation coefficient","St. Joseph's Hospital and Medical Center, Phoenix|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","220","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHXA-16-0235-10-08|1R01CA213158-01A1","June 26, 2017","June 26, 2022","October 26, 2022","August 29, 2017","null","August 29, 2017","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03264300"
63,"NCT02149459","Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy","SMC 0712-13","Recruiting","No Results Available","Brain Neoplasms","Radiation: Partial brain re-irradiation.|Drug: Metformin|Behavioral: low carbohydrate diet","Number of patients with adverse events.|Number of patients completing the trial.|Number of patients whose brain tumors respond on imaging.|Number of patients who demonstrate changes in systemic energy metabolism.","Sheba Medical Center|European Union","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHEBA-13-0712-YL-CTIL","June 2014","July 2018","July 2018","May 29, 2014","null","October 27, 2017","Sheba Medical Center, Ramat Gan, Israel","","https://ClinicalTrials.gov/show/NCT02149459"
64,"NCT02608762","Neurobehavioral Outcomes and Quality of Life in Pediatric Patients With Brain or Head/Neck Tumors Receiving Proton or Photon Radiotherapy",,"Recruiting","No Results Available","Brain Tumor","Radiation: standard adjuvant local radiation therapy or cranial radiation therapy","The change in Intellectual functioning from baseline to 3 months after the start of radiotherapy|Neurobehavioral functions and psychosocial adjustments","Chang Gung Memorial Hospital","All","1 Month to 18 Years   (Child, Adult)","","72","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","102-5729A3","September 2014","December 2018","null","November 20, 2015","null","January 30, 2018","Chang Gung Memorial Hospital, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT02608762"
65,"NCT00659126","Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors",,"Recruiting","No Results Available","Metastatic Malignant Neoplasm in the Brain|Primary Brain Neoplasm","Procedure: 3 Tesla Magnetic Resonance Imaging|Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Drug: Ferumoxytol|Drug: Gadolinium|Procedure: High Field Strength Magnetic Resonance Imaging|Procedure: Susceptibility Weighted Imaging","Contrast to noise ratio (CNR), in terms of normalized signal intensity changes, for T1-weighted MRI signal at 3T and 7T (gadolinium [Gd] T1-weighted magnetic resonance imaging [MRI] data only)|CNR, in terms of normalized signal intensity changes, for dynamic susceptibility contrast (DSC) MRI data sets at 3T and 7T (ferumoxytol only)|Relevant dynamic MRI (dynamic contrast enhancement [DCE] and DSC) signal intensity changes for permeability and perfusion|Change in cerebral blood volume (CBV) measurements, quantified using DSC techniques|Change in tumor microvascularity on susceptibility-weighted images (SWI) before and after ferumoxytol|Presence of iron staining","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00002864|NCI-2015-00225|SOL-06077-L|P30CA069533","November 16, 2006","December 31, 2019","December 31, 2020","April 16, 2008","null","May 7, 2018","OHSU Knight Cancer Institute, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT00659126"
66,"NCT03334162","Playful Sensorimotor Training in Pediatric Brain Tumor Patients","RESET","Not yet recruiting","No Results Available","Pediatric Cancer|Pediatric Brain Tumor|Chemotherapy-induced Peripheral Neuropathy|Sensorimotor Polyneuropathy","Behavioral: Sensorimotor training","Ped-mTNS score (assesses the change in the severity of CIPN symptoms)|Nerve conduction studies|short clinical test battery for CIPN|Postural control|Dorsiflexion function|Knee extension strength|lower limb power|Walk to run transition time:|CIPN-related pain|Participation in PE as well exercise-related leisure activities|Priority of side-effects","University of Basel|University Children's Hospital Basel|Kantonsspital Aarau","All","6 Years to 18 Years   (Child, Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","RESET-study","November 2017","November 2020","November 2020","November 7, 2017","null","November 7, 2017","","","https://ClinicalTrials.gov/show/NCT03334162"
67,"NCT03096431","Impact of Cognitive Rehab and Physical Activity on Cognition in Patients With Metastatic Brain Tumors Undergoing RT",,"Recruiting","No Results Available","Metastatic Brain Tumor|Cerebral Metastases","Behavioral: Physical Activity|Behavioral: Cognitive rehabilitation","Recruitment percentage of eligible subjects.|Retention percentage of participants at end-of-study.|Non-attendance rates of participants. instructions.|Lengths of sessions completed.|Percentage of completion of Physical Activity intervention tasks.|Percentage of Cognitive Therapy intervention tasks.|Change in cognitive abilities.|Change in physical abilities.","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","MCC-16-13082|HM20007924","September 1, 2017","September 1, 2018","September 1, 2018","March 30, 2017","null","September 7, 2017","Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03096431"
68,"NCT02880111","Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa","DMBT1","Recruiting","No Results Available","Malignant Brain Tumor","","measure glycoprotein-like DMBT1 by Elisa|measure MUC5B by Elisa","University Hospital, Lille|Ministry of Health, France","All","6 Years to 35 Years   (Child, Adult)","","60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2012_44|2014-A00259-38|PHRCI-2012","January 2016","January 2020","January 2020","August 26, 2016","null","February 19, 2018","Hôpital Jeanne de Flandre - CHRU de Lille, Lille, France","","https://ClinicalTrials.gov/show/NCT02880111"
69,"NCT03478462","Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma",,"Not yet recruiting","No Results Available","Pediatric Solid Tumor|Pediatric Lymphoma|Pediatric Brain Tumor","Drug: CLR 131","Number of participants with dose limiting toxicities (DLT)|Determination of therapeutic activity of CLR 131 in children and adolescents","Cellectar Biosciences, Inc.","All","2 Years to 21 Years   (Child, Adult)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCL-17-001","July 2018","September 2020","December 2020","March 27, 2018","null","March 27, 2018","University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03478462"
70,"NCT02843230","Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI",,"Recruiting","No Results Available","Glioblastoma","Radiation: Avastin|Radiation: Lomustine|Radiation: Temozolomide|Device: MRI|Device: MRS|Device: DSC","Progression Free Survival For Patients Receiving Advanced MRI and MRS|Overall Survival For Patients Receiving Advanced MRI and MRS|Progression Free Survival For Patient Receiving Dynamic Susceptibility Contrast|Overall Survival Rate For Patient Receiving Dynamic Susceptibility Contrast","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","","85","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","16-147","August 1, 2016","August 31, 2019","August 31, 2021","July 25, 2016","null","June 18, 2018","Massachusetts general Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02843230"
71,"NCT02334722","1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients",,"Recruiting","No Results Available","Brain Neoplasms|Brain Cancer|Brain Tumors|Cancer of the Brain|Cancer of Brain|Seizure","Drug: Levetiracetam extended release","Difference in Neurotoxicity Scale scores","University of Florida","All","18 Years and older   (Adult, Older Adult)","Phase 4","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201400876","August 2015","March 2020","September 2020","January 8, 2015","null","July 6, 2018","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02334722"
72,"NCT01767415","Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection",,"Recruiting","No Results Available","Brain Tumors With Ill-defined Margins","Drug: Indigo carmine","Extent of Resection|Absence of complications after injection","Weill Medical College of Cornell University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1106011772","March 2012","September 2018","December 2018","January 14, 2013","null","January 30, 2018","Weill Cornell Medical College Department of Neurological Surgery, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01767415"
73,"NCT02066220","International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma",,"Recruiting","No Results Available","Brain Tumors","Radiation: Radiotherapy without Carboplatin|Drug: Reduced-intensity maintenance chemotherapy|Radiation: Radiotherapy with Carboplatin|Drug: Maintenance chemotherapy","3-year Event-Free Survival (EFS)|Overall survival|Pattern of relapse|Late effects of therapy on endocrine function|Late effects of therapy on audiology|Late effects of therapy on neurology|Late effects of therapy on quality of survival|Progression-free survival|Feasibility of carboplatin treatment|Residual tumor|Leukoencephalopathy grading","Universitätsklinikum Hamburg-Eppendorf|Deutsche Kinderkrebsstiftung","All","3 Years to 21 Years   (Child, Adult)","Phase 2|Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SIOP PNET 5 MB|2011-004868-30","June 2014","April 2024","April 2024","February 19, 2014","null","May 8, 2017","Medical University of Graz, Graz, Austria|University Hospital Gasthuisberg, Leuven, Belgium|University Hospital Brno, Brno, Czechia|Rigshospitalet, Copenhagen, Denmark|CHU de Grenoble, Grenoble, France|Institute Curie, Paris Cedex 05, France|CHU-TOURS - Hôpital Clocheville, Tours, France|Hôpital NANCY-BRABOIS, Vandoeuvre Les Nancy, France|University Hospital Aachen, Aachen, Germany|Klinikum Augsburg, Augsburg, Germany|Helios Klinikum Berlin-Buch, Berlin, Germany|Charite Campus, University of Berlin, Berlin, Germany|Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany|University Hospital Bonn, Bonn, Germany|Klinikum Braunschweig, Braunschweig, Germany|Klinikum Bremen-Mitte, Bremen, Germany|Klinikum Chemnitz, Chemnitz, Germany|University Hospital Cologne, Cologne, Germany|Carl-Thiem-Klinikum Cottbus, Cottbus, Germany|Vestische Kinder- und Jugendklinik, University Witten/Herdecke, Datteln, Germany|Klinikum Dortmund, Dortmund, Germany|University Hospital Dresden, Dresden, Germany|Klinikum Duisburg, Duisburg, Germany|University Hospital Düsseldorf, Düsseldorf, Germany|HELIOS Klinikum-Erfurt, Erfurt, Germany|University Hospital Erlangen, Erlangen, Germany|University Hospital Essen, Essen, Germany|University Hospital Frankfurt/Main, Frankfurt, Germany|University Hospital Freiburg, Freiburg, Germany|University Hospital Gießen and Marburg, Gießen, Germany|University Hospital Greifswald, Greifswald, Germany|University Hospital Göttingen, Göttingen, Germany|University Hospital Halle/Saale, Halle, Germany|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Angelika-Lautenschläger-Klinik, Heidelberg, Germany|Gemeinschaftskrankenhaus Herdecke, Herdecke, Germany|University Hospital Homburg/Saar, Homburg, Germany|University Hospital Jena, Jena, Germany|Städtisches Klinikum Karlsruhe, Karlsruhe, Germany|Klinikum Kassel, Kassel, Germany|UK-SH Campus Kiel, Kiel, Germany|Gemeinschaftsklinikum Koblenz-Mayen, Koblenz, Germany|HELIOS Klinikum Krefeld, Krefeld, Germany|Kliniken der Stadt Köln, Köln, Germany|University Hospital Leipzig, Leipzig, Germany|University Hospital Lübeck, Lübeck, Germany|University Hospital Magdeburg, Magdeburg, Germany|University Hospital Mainz, Mainz, Germany|University Hospital Mannheim, Mannheim, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|University Hospital München, Dr. von Haunersches Kinderspital, München, Germany|Klinikum Schwabing, Pediatric Hospital of Technical University, München, Germany|University Hospital Münster, Münster, Germany|Cnopf'sche Kinderklinik, Nürnberg, Germany|Klinikum Oldenburg, Oldenburg, Germany|University Hospital Regensburg, Regensburg, Germany|University Hospital Rostock, Rostock, Germany|Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany|HELIOS-Kliniken Schwerin, Schwerin, Germany|Klinikum Stuttgart, Stuttgart, Germany|Mutterhaus der Borromäerinnen, Trier, Germany|University Hospital Tübingen, Tübingen, Germany|University Hospital Ulm, Ulm, Germany|Dr. Horst Schmidt Kliniken, Wiesbaden, Germany|Klinikum der Stadt Wolfsburg, Wolfsburg, Germany|University Hospital Würzburg, Würzburg, Germany|Our Lady's Children's Hospital, Dublin, Ireland|Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy|Erasmus Medical Centre, Rotterdam, Netherlands|Rigshospitalet, Oslo, Norway|The Children's Memorial Health Institute, Warsaw, Poland|University Hospital S.Joao, Porto, Portugal|Oncology Hospital Cruces Bilbao, Baracaldo, Spain|Barncancercentrum Drottning Silvias Barnochungdomssjukhus, Göteburg, Sweden|University Children's Hospital, Zürich, Switzerland|Great Ormond Street Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02066220"
74,"NCT01188096","A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas","Poly-ICLC","Recruiting","No Results Available","Brain Tumors","Drug: Poly ICLC","overall response rate|Progression free survival|Overall survival","Donald Durden, M.D.|Emory University|University of California, San Diego","All","up to 21 Years   (Child, Adult)","Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Poly ICLC|004385","August 2010","July 2019","July 2019","August 25, 2010","null","June 20, 2017","RADY Children's Hospital, San Diego, California, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01188096"
75,"NCT02193568","Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy",,"Recruiting","No Results Available","Adult Brain Tumor","Procedure: Arm I (light sedation)|Procedure: Arm II (intubated general anesthesia)|Other: Arm II (intubated general anesthesia)|Other: Arm I (light sedation)","Compare overall hospital length of stay for patients in each of 2 arms|Compare resource utilization between two groups|Assess the frequency of post-operative delirium|Measure patient perceptions|Track patient complications during hospital stay|Track re-admission and extended hospital stay rates","Ohio State University Comprehensive Cancer Center","All","19 Years and older   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","OSU-12161|NCI-2014-01110","April 2014","August 2018","December 2018","July 17, 2014","null","September 27, 2017","Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02193568"
76,"NCT01535911","Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors","Ketones","Recruiting","No Results Available","Glioblastoma","Other: Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)","MRI imaging will be used to measure changes in brain tumor size.","Michigan State University|Sparrow Health System","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-452FS","April 2012","June 2019","June 2019","February 20, 2012","null","June 14, 2018","Michigan State University/Sparrow Hospital, East Lansing, Michigan, United States","","https://ClinicalTrials.gov/show/NCT01535911"
77,"NCT02617589","An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)","CheckMate 498","Recruiting","No Results Available","Brain Cancer","Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy","Overall survival (OS)|Progression free survival (PFS)|Overall survival","Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 3","550","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209-498|2015-003739-37","February 29, 2016","March 10, 2019","October 1, 2019","December 1, 2015","null","July 3, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph Hospital And Medical Center, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|The University Of Chicago, Chicago, Illinois, United States|University Of Kansas Medical Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Kepler Universitaetsklinikum, Linz, Austria|Medical University Of Vienna, Vienna, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Uz Leuven, Leuven, Belgium|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Odense, Denmark|Local Institution, Bron Cedex, France|Local Institution, Lille Cedex, France|Local Institution, Marseille, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Local Institution, Vandoeuvre Les Nancy, France|Universitaetsklinikum Bonn, Bonn, Germany|Uniklinik Erlangen, Erlangen, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt am Main, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinik Koeln, Koeln, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Bezirksklinikum Regensburg, Regensburg, Germany|Universitasklinikum Tubingen, Tuebingen, Germany|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Rozzano (milano), Italy|Local Institution, Siena, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Onsen-gun, Ehime, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Tokyo, Japan|NKI AVL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Oslo, Norway|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Local Institution, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago De Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|University Hospital Geneva, Geneve, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Universitaetsspital Zuerich, Zuerich, Switzerland|University College Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Found. Trust, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Beaston West of Scotland Cancer Centre, Glasgow, United Kingdom","","https://ClinicalTrials.gov/show/NCT02617589"
78,"NCT02667587","An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)","CheckMate548","Recruiting","No Results Available","Brain Neoplasms","Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy|Other: Nivolumab Placebo","Overall survival (OS) defined as time from the date of randomization to the date of death.|Progression free survival (PFS), defined as the time from randomization to the date of the first documented tumor progression or death to any cause.|Correlation of PFS and OS","Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 3","693","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CA209-548|2015-004722-34","May 5, 2016","February 11, 2022","August 1, 2023","January 29, 2016","null","July 3, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph Hospital And Medical Center, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Local Institution, Chicago, Illinois, United States|University Of Kansas Medical Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Kepler Universitaetsklinikum, Linz, Austria|Medical University Of Vienna, Vienna, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Uz Leuven, Leuven, Belgium|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Odense, Denmark|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 03, France|Local Institution, Marseille, France|Local Institution, Nancy, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Universitaetsklinikum Bonn, Bonn, Germany|Uniklinik Erlangen, Erlangen, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt Am Main, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinik Koeln, Koeln, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Bezirksklinikum Regensburg, Regensburg, Germany|Universitasklinikum Tubingen, Tuebingen, Germany|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Rozzano (milano), Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Kyoto, Japan|NKI AVL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Oslo, Norway|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Nowotworow Glowy i Szyi, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|University Hospital Geneva, Geneve, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitaetsSpital Zurich, Zuerich, Switzerland|University College Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Found. Trust, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Beaston West of Scotland Cancer Centre, Glasgow, United Kingdom","","https://ClinicalTrials.gov/show/NCT02667587"
79,"NCT02392078","Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System","LAANTERN","Recruiting","No Results Available","Metastatic Brain Tumor|Primary Brain Tumor","Device: NeuroBlate System","Procedural Success|Local control Failure Rate|Quality of Life|Safety (Reportable adverse events)","Monteris Medical","All","Child, Adult, Older Adult","","1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","LAANTERN","October 2015","June 2020","September 2020","March 18, 2015","null","May 4, 2018","Barrow Neurological Institute at Dignity Health St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Florida Hospital, Orlando, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Washington University, Saint Louis, Missouri, United States|Ichan School of Medicine at Mount Sinai, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|MD Anderson, Houston, Texas, United States|University of British Columbia, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02392078"
80,"NCT03538587","Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children With High Grade Brain Tumors and Their Caregivers",,"Recruiting","No Results Available","Gliomas|Glioblastomas|Astrocytoma|Brain Neoplasm|Brain Cancer","Behavioral: Enhanced Mindfulness Intervention|Behavioral: Psychoeducation","Feasibility","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","5 Years to 99 Years   (Child, Adult, Older Adult)","Not Applicable","40","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","180080|18-C-0080","July 11, 2018","April 1, 2020","April 1, 2020","May 28, 2018","null","July 6, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03538587"
81,"NCT03163368","Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors",,"Recruiting","No Results Available","Brain Metastases","Radiation: Neoadjuvant stereotactic radiosurgery|Procedure: Neurosurgical resection","Maximum tolerated dose (MTD)|Adverse events|Describe preliminary rates of image-complete resection|Describe preliminary rates of local tumor control|Describe preliminary rates of intracranial control|Describe preliminary rates of progression-free survival|Describe preliminary rates of leptomeningeal spread|Describe preliminary rates of rate of salvage treatment","Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT2016-18-Shiao-NeoAdSRS","May 9, 2017","January 1, 2019","June 1, 2019","May 23, 2017","null","May 25, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03163368"
82,"NCT01668082","An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection",,"Recruiting","No Results Available","Brain Mass","Procedure: surgical resection of a brain tumor","metabolic phenotype correlation to clinical endpoints|baseline imaging data review|molecular profiling","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU 062010-157","August 2009","February 2020","February 2022","August 17, 2012","null","February 13, 2018","University of Texas Southwestern, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01668082"
83,"NCT03347617","Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma",,"Recruiting","No Results Available","Glioblastoma|Malignant Primary Brain Neoplasm|Melanoma|Metastatic Malignant Neoplasm in the Brain","Drug: Ferumoxytol|Other: Laboratory Biomarker Analysis|Procedure: Magnetic Resonance Imaging|Biological: Pembrolizumab","Sensitivity and specificity of rCBV measured by ferumoxytol steady state imaging|Determine the safety and toxicity of pembrolizumab when used in combination with standard of care stereotactic radiation (arm 1) and chemo radiation (arm 2).|Progression free survival|Overall survival|Duration of best response","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00016046|NCI-2017-02008|P30CA069533","December 20, 2017","November 1, 2019","November 1, 2022","November 20, 2017","null","December 22, 2017","OHSU Knight Cancer Institute, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03347617"
84,"NCT01925573","Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)",,"Recruiting","No Results Available","RECURRENT GLIOBLASTOMA|Brain Tumor","Device: Optune(NOVOTTF-100A)","Number of Adverse Events with a grade 3 or high toxicity (Primary Measure)","University of Maryland|NovoCure Ltd.","All","22 Years and older   (Adult, Older Adult)","Not Applicable","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00056719","May 2014","December 2021","December 2026","August 19, 2013","null","January 19, 2018","Ummc Msgcc, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01925573"
85,"NCT03458455","Improved Therapy Response Assessment in Metastatic Brain Tumors","TREATMENT","Recruiting","No Results Available","Brain Metastases","Diagnostic Test: Magnetic Resonance Imaging|Radiation: Stereotactic Radiosurgery|Drug: Ipilimumab, nivolumab or pembrolizumab","Treatment Response|Overall survival","Oslo University Hospital|Hospital of Southern Norway Trust|Ostfold Hospital Trust|St. Olavs Hospital|Massachusetts General Hospital|Dana-Farber Cancer Institute|University Medical Center Groningen|University of Texas Southwestern Medical Center|South-Eastern Norway Regional Health Authority|Norwegian Cancer Society","All","18 Years and older   (Adult, Older Adult)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2013/1033 LOOPS","March 1, 2013","March 1, 2021","March 1, 2021","March 8, 2018","null","March 8, 2018","Oslo University Hospital, Oslo, Norway","","https://ClinicalTrials.gov/show/NCT03458455"
86,"NCT03525080","Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors","GLIROPA","Not yet recruiting","No Results Available","Brain Neoplasms|Adult Brain Tumor","Diagnostic Test: PET imagery","PET pictures and MRI sequences comparison","Center Eugene Marquis","All","18 Years and older   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2017-4-52-010","July 1, 2018","April 30, 2019","May 31, 2019","May 15, 2018","null","May 15, 2018","Centre Eugène Marquis, Rennes, Bretagne, France","","https://ClinicalTrials.gov/show/NCT03525080"
87,"NCT02367482","Tryptophan Metabolism in Human Brain Tumors",,"Recruiting","No Results Available","Glioblastoma","","Interval Changes of Tumoral Metabolism|Interval changes of tumoral tryptophan metabolism","Wayne State University|NovoCure Ltd.","All","22 Years and older   (Adult, Older Adult)","","10","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Novocure rGBM AMT-PET","July 2014","December 2018","December 2018","February 20, 2015","null","December 21, 2017","Wayne State University, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02367482"
88,"NCT03010943","Brain Awake Surgery Using Virtual Reality Headset","CERVO1","Recruiting","No Results Available","Brain Tumor|Virtual Reality","Device: Virtual reality headset","percentage of patients in which assessment of language functions during awake craniotomy, is possible with virtual reality headset.","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2016-A01139-42","February 17, 2017","January 2018","January 2018","January 5, 2017","null","May 8, 2017","CHU Angers, Angers, France","","https://ClinicalTrials.gov/show/NCT03010943"
89,"NCT02693990","A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas",,"Recruiting","No Results Available","Meningioma|Brain Tumor","Radiation: Intensity Modulated Proton Therapy (IMPT)","Assess Safety and Utility of Increased Dose IMPT: Dose-limiting toxicity (DLT) using NCI CTC 4.0|The Absence of Progressive or Recurrent Disease|Overall Survival|Calculate Linear Energy Transfer Using Computer Simulations Based on the Treatment Plan","Massachusetts General Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-542|2U19CA021239-36","February 2016","February 2019","February 2023","February 29, 2016","null","June 14, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02693990"
90,"NCT02783495","Feasibility And Efficacy Of An iPad-Based Cognitive Rehabilitation Program In Brain Tumor Patients",,"Recruiting","No Results Available","Glioma","Behavioral: Device: iPad","Number of subjects who complete the intervention|Patient-reported ease of use|Patient-reported user satisfaction|Change in attention|Change in working memory|Quality of Life|Improvement on neurocognitive testing|Subjective assessment of cognitive symptoms will be assessed","University of California, San Francisco|University of Tilburg","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16106|NCI-2017-01881|15-16366","May 2016","May 2019","December 2019","May 26, 2016","null","June 5, 2018","University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02783495"
91,"NCT02502708","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors",,"Recruiting","No Results Available","Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor|Ependymoma|Medulloblastoma|Diffuse Intrinsic Pontine Glioma|Primary CNS Tumor","Drug: Indoximod|Drug: Temozolomide|Radiation: Conformal Radiation|Drug: Cyclophosphamide|Drug: Etoposide","Incidence of regimen limiting toxicities (RLTs)|Objective Response Rate|Safety and tolerability assessed by development of AEs and laboratory parameters of indoximod in combination with cyclophosphamide and etoposide.|Pharmacokinetics: Serum concentrations (Cmax/Steady State)|Safety and Tolerability of Indoximod combined with Temozolomide as assessed by incidence and severity of adverse events, dose interruptions and dose reductions.|Progression Free Survival (PFS)|Time to Progression|Overall Survival|Safety and Feasibility of Indoximod combined with conformal radiation as assessed by incidence and severity of adverse events, dose interruptions and dose reductions.","NewLink Genetics Corporation","All","3 Years to 21 Years   (Child, Adult)","Phase 1","115","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG2105","October 2015","March 2019","December 2019","July 20, 2015","null","July 2, 2018","Children's Heathcare of Atlanta, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02502708"
92,"NCT02768389","Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioblastoma|Brain Tumor","Drug: Bevacizumab|Behavioral: Modified Atkins Diet","Number of subjects following Modified Atkins Diet|Number of subjects with ketosis|Correlation of blood sugar levels by compliance level|Correlation of ketosis values by compliance level|Correlation of ketosis values by tumor response|Correlation of blood sugar levels by tumor response","Case Comprehensive Cancer Center|University of Cincinnati|OhioHealth Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE10314","September 6, 2016","August 2018","February 2019","May 11, 2016","null","April 18, 2018","University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive cancer Center, Cleveland, Ohio, United States|OhioHealth Research and Innovation Institute, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02768389"
93,"NCT02457845","HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors",,"Recruiting","No Results Available","Supratentorial Neoplasms, Malignant","Biological: G207","Safety and Tolerability as Measured by Frequency of Grade 3 or Above Adverse Events|Immunologic Response|Virologic Shedding|Progression Free Survival|Overall Survival|Change in Performance (Ability to Perform Normal Activities)|Quality of Life (optional)","University of Alabama at Birmingham","All","3 Years to 18 Years   (Child, Adult)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UAB 1472|R01FD005379","May 2016","May 2019","null","May 29, 2015","null","July 6, 2018","Children's of Alabama, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT02457845"
94,"NCT03250520","Application of Palliative Treatment in Children With Brain Stem Glioma and Recurrent High-grade Tumors in the Central Nervous System With the Nanomaterial NPt-Ca",,"Not yet recruiting","No Results Available","Brain Tumor, Pediatric, Brainstem Glioma|Brain Tumor, Pediatric, Recurrent","Drug: Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania","Change in the quality of life using the PedsQL Cancer Module©|Change in tumor size","Hospital Infantil de Mexico Federico Gomez","All","5 Years to 14 Years   (Child)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HIM 2017-072","September 1, 2017","February 28, 2018","February 28, 2019","August 15, 2017","null","August 15, 2017","","","https://ClinicalTrials.gov/show/NCT03250520"
95,"NCT03516162","Linking Digital Smartphone Behaviour With Brain Function","SmartSurgery","Recruiting","No Results Available","Brain Tumor|Hydrocephalus","Other: There is no study-specific intervention","Change in pattern of smartphone-assessed day-to-day behaviour|KPS|NIHSS|MoCA score|Domain-specific z-scores of neuropsychological functioning, age-, sex- and education-adjusted|For patients with a brain tumour, location of the lesion, as determined on MRI imaging|For patients with a brain tumour, the size of the lesion|For patients with a brain tumour, the degree of affected brain tissue as seen on early (within 5 days) or late postoperative MRI (3 months)|For patients with hydrocephalus, ventricular enlargement, as determined on MRI imaging, according to the Evans index (=A/E); Third ventricle index (= C/E); Cella media index (=D/F); Ventricular score (=(A+B+C+D)/E x 100)","University of Zurich","All","18 Years and older   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BASEC 2018-00395","April 20, 2018","April 2020","December 2020","May 4, 2018","null","May 14, 2018","University Hospital Zurich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT03516162"
96,"NCT02451215","Laser Interstitial Thermal Therapy (LITT) for the Treatment of Pediatric Central Nervous System Tumors",,"Recruiting","No Results Available","Brain Tumor","Device: Laser Interstitial Thermotherapy (LITT)","Morbidity of LITT for the treatment of pediatric brain tumors|Efficacy of LITT for the treatment of pediatric brain tumors|Tumor control based on extent of tumor ablation|Characterization of the MRI changes following LITT tumor ablation","Children's Hospitals and Clinics of Minnesota","All","1 Year to 22 Years   (Child, Adult)","Not Applicable","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1504-044","April 2015","April 2025","null","May 21, 2015","null","May 21, 2015","Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02451215"
97,"NCT03068520","Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease Progression?",,"Recruiting","No Results Available","Brain Tumor","Diagnostic Test: PET MR","Distinguish between progressive tumor and treatment related effects","Assuta Medical Center|Rabin Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","022-16-ASMC","March 1, 2017","December 31, 2017","December 31, 2018","March 3, 2017","null","March 21, 2017","Assuta Medical Centers, Tel Aviv, Israel","","https://ClinicalTrials.gov/show/NCT03068520"
98,"NCT03166592","Evaluation of Intra Axial Brain Masses Based on Magnetic Resonance in Adults",,"Recruiting","No Results Available","Brain Tumor","Device: Magnetic resonance imaging with contrast","Number of patients with malignant masses","Assiut University","All","18 Years to 60 Years   (Adult)","","150","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","IAM","July 1, 2017","July 2019","September 2019","May 25, 2017","null","August 16, 2017","Ahmed Abbas, Assiut, Cairo, Egypt|Assiut Faculty of Medicine, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT03166592"
99,"NCT03526822","Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.","MM-Predict","Recruiting","No Results Available","Brain Tumor","Biological: Blood sample|Biological: Tumor sample","correlate the plasma levels of MMP2 and MMP9 to their RNA and protein tissue expression by ELISA","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2017-56|2018-A00740-55","June 1, 2018","December 1, 2021","December 1, 2021","May 16, 2018","null","May 22, 2018","Assistance Publique Hôpitaux de Marseille, Marseille, France","","https://ClinicalTrials.gov/show/NCT03526822"
100,"NCT02713087","Vasopressor Effects in Anesthetized Patients",,"Recruiting","No Results Available","Brain Tumor","Drug: Ephedrine|Drug: Phenylephrine","Capillary Transit Time Heterogeneity|Cerebral Metabolic Rate of Oxygen","University of Aarhus","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Vasobrain01","September 2015","January 2018","August 2021","March 18, 2016","null","December 4, 2017","Aarhus University Hospital, Aarhus, Jylland, Denmark","","https://ClinicalTrials.gov/show/NCT02713087"
101,"NCT02431572","A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy",,"Recruiting","No Results Available","Intracranial Tumors|Glioblastoma|Melanoma","Other: PBR PET|Biological: Cancer Immunotherapy|Radiation: Radiation and chemotherapy","Change in PBR uptake (changes in PBR uptake by PET)","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14-421","May 2015","October 2018","March 2020","May 1, 2015","null","March 5, 2018","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02431572"
102,"NCT01604512","A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression",,"Recruiting","No Results Available","Brain Cancer","Other: MRI perfusion and PET/CT scans","imaging techniques|predicting tumor progression","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-067","May 2012","May 2019","May 2019","May 23, 2012","null","April 3, 2018","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States","","https://ClinicalTrials.gov/show/NCT01604512"
103,"NCT03122197","Study of Letrozole in Recurrent Gliomas",,"Recruiting","No Results Available","Brain Tumor","Drug: Letrozole Oral Tablet","Overall Letrozole AUC in tumor tissue.|Adverse Events|Progression free Survival|Overall Survival","University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UCCI-BN-16-01","May 16, 2017","April 14, 2018","April 14, 2019","April 20, 2017","null","July 24, 2017","University of Cincinnati, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03122197"
104,"NCT02444546","Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors",,"Recruiting","No Results Available","Childhood Astrocytoma|Childhood Atypical Teratoid/Rhabdoid Tumor|Diffuse Intrinsic Pontine Glioma|Glioma|Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Childhood Brain Neoplasm|Recurrent Childhood Glioblastoma|Recurrent Childhood Medulloblastoma|Recurrent Primitive Neuroectodermal Tumor|Refractory Brain Neoplasm","Other: Laboratory Biomarker Analysis|Biological: Sargramostim|Biological: Wild-type Reovirus","MTD, based on the incidence of dose-limiting toxicity (DLT) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0|Adverse event profile|Objective responses|Overall survival|Time to progression|Time to treatment failure|Time until any treatment-related toxicity|Time until treatment-related grade 3+ toxicity|Toxicity profile, assessed by CTCAE v4.0","Mayo Clinic|National Cancer Institute (NCI)","All","10 Years to 21 Years   (Child, Adult)","Phase 1","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1472|NCI-2015-00665|P30CA015083","June 2015","April 2020","April 2020","May 14, 2015","null","March 19, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02444546"
105,"NCT03257631","A Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors",,"Recruiting","No Results Available","Central Nervous System Neoplasms|Medulloblastoma","Drug: Pomalidomide","Objective Response (OR), Long-term Stable Disease (SD) Rate (ORSDR)|Objective Response Rate (ORR)|Long-term stable disease rate|Duration of response|Progression-free survival|Overall Survival|Adverse Events (AEs)","Celgene","All","1 Year to 21 Years   (Child, Adult)","Phase 2","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-BRN-001|U1111-1199-3348|2016-002903-25","August 22, 2017","August 13, 2018","August 13, 2018","August 22, 2017","null","April 5, 2018","Stanford University Cancer Center, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|National Cancer Institute, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Baylor College of Medicine, Houston, Texas, United States|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Hopital d'Enfants de la Timone, Marseille Cedex 01, France|Institut Curie, Paris, France|Hopital des Enfants, Toulouse, France|CHU Nancy Hematology, Vandoeuvre les Nancy, France|Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie, Villejuif Cedex, France|Istituto G. Gaslini Ospedale Pediatrico IRCCS, Genova, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Ospedale Bambin Gesu, Roma, Italy|Hospital Universitario Vall D Hebron, Barcelona, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain|Leeds General Infirmary, Leeds, United Kingdom|Great Ormond Street Hospital, London, United Kingdom|Royal Victoria Infirmary Department of Haematology, Newcastle-upon-Tyne, United Kingdom|The Royal Marsden Hospital, Sutton-Surrey, United Kingdom","","https://ClinicalTrials.gov/show/NCT03257631"
106,"NCT02213536","Investigating the Efficacy of Hair Sparing Radiotherapy Treatment to the Whole Brain.","SPARE","Recruiting","No Results Available","Metastatic Brain Cancer","Radiation: VMAT (Volumetric Modulated Arc Therapy)","To assess hair loss and hair regrowth in patients undergoing WBRT using VMAT via photographic assessment by independent professionals at intervals up to 16 weeks post end of treatment.|To assess patient perceptions of hair loss and hair regrowth in patients undergoing WBRT using VMAT via self assessment at intervals up to 16 weeks post end of treatment.","HCA International Limited","All","18 Years and older   (Adult, Older Adult)","","20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HCA","August 2015","September 2018","February 2019","August 11, 2014","null","February 21, 2018","The Harley Street Clinic, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02213536"
107,"NCT02674945","Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase",,"Recruiting","No Results Available","Brain Tumor","Device: Wireless Activity tracker: Fitbit","Activity measured in steps|Sleep|Quality of Life - SF-36|Quality of Life - Fact- Br","University of Minnesota - Clinical and Translational Science Institute","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","75","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1406M51644|#2014NTLS054","September 2014","September 2018","September 2018","February 5, 2016","null","October 26, 2016","University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02674945"
108,"NCT01592968","A Prospective Phase III Trial to Compare Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy",,"Recruiting","No Results Available","Brain Neoplasms","Radiation: Stereotactic Radiosurgery (SRS)|Radiation: Whole Brain Radiation Therapy (WBRT)|Behavioral: Questionnaires|Behavioral: Cognitive Function Tests","Local Tumor Control|Cognitive Decline","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-0884|NCI-2012-00850","August 2, 2012","August 2019","August 2019","May 7, 2012","null","January 11, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01592968"
109,"NCT02359565","Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma",,"Recruiting","No Results Available","Constitutional Mismatch Repair Deficiency Syndrome|Lynch Syndrome|Malignant Glioma|Progressive Ependymoma|Progressive Medulloblastoma|Recurrent Brain Neoplasm|Recurrent Childhood Ependymoma|Recurrent Diffuse Intrinsic Pontine Glioma|Recurrent Medulloblastoma|Refractory Brain Neoplasm|Refractory Diffuse Intrinsic Pontine Glioma|Refractory Ependymoma|Refractory Medulloblastoma","Procedure: Diffusion Tensor Imaging|Procedure: Diffusion Weighted Imaging|Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Other: Laboratory Biomarker Analysis|Procedure: Magnetic Resonance Spectroscopic Imaging|Biological: Pembrolizumab|Procedure: Perfusion Magnetic Resonance Imaging","Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0|Sustained objective response (partial response [PR] + complete response [CR])|Change in the percentage of CD8+ T cells that are PD-1+ due to treatment with pembrolizumab (Stratum C)|Progression-free survival (PFS)|Event-free survival|Overall survival (OS)|Radiologic response (Stratum C)|Biomarker expression levels|Changes in quantitative imaging parameters","National Cancer Institute (NCI)","All","1 Year to 29 Years   (Child, Adult)","Phase 1","110","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2015-00130|PBTC-045|UM1CA081457","May 22, 2015","April 1, 2020","April 1, 2020","February 10, 2015","null","July 3, 2018","Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02359565"
110,"NCT01847833","Advanced MRI Applications Development",,"Recruiting","No Results Available","Brain Tumors","Other: MRI scan","patients alive and progression free at 6 months","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","","null","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2012p001007","January 2014","December 2023","null","May 7, 2013","null","March 26, 2018","MGH, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01847833"
111,"NCT02795338","Multi-modality Localization of Eloquent Brain Function",,"Not yet recruiting","No Results Available","Brain Neoplasms","Procedure: brain mapping","Location in the brain of the fMRI activations relative to intra-operative brain mapping|Location in the brain of the MEG activations relative to intra-operative brain mapping|Accuracy of fMRI and MEG in pre-operative brain mapping","University of Nebraska","All","19 Years and older   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","176-16-EP","March 2018","October 2020","October 2021","June 10, 2016","null","September 18, 2017","","","https://ClinicalTrials.gov/show/NCT02795338"
112,"NCT02672995","Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial",,"Recruiting","No Results Available","Brain Neoplasm","Radiation: Fractionated stereotactic radiosurgery|Drug: bevacizumab","Maximum tolerated dose|Response rate|Time to progression|The incidence of radiation-induced adverse effects","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201511005MINB","January 2018","December 2018","December 2018","February 3, 2016","null","August 18, 2017","National Taiwan University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT02672995"
113,"NCT02964416","Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery",,"Recruiting","No Results Available","Brain Neoplasm","Drug: Injection Tramadol|Other: placebo","Haemodynamic parameters at the time of emergence and postextubation|Measure the quality of emergence from general anaesthesia by measuring the frequency of cough on cough scale.|Measure the quality of emergence from general anaesthesia by measuring the frequency of laryngospasm and bronchospasm.|Measure the quality of emergence from general anaesthesia by measuring the frequency of episodes of desaturation.|Measure the quality of emergence from general anaesthesia by measuring sedation score|Effect of tramadol on quality of emergence measured by extubation response through monitoring PONV|Effect of tramadol on quality of emergence measured by extubation response through monitoring convulsions|Effect of tramadol on quality of emergence measured by extubation response through monitoring GCS|Effect of tramadol on quality of emergence measured by extubation response through mointoring requirement of analgesia","Aga Khan University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2954-Ane-ERC-14","March 2016","March 2018","December 2018","November 16, 2016","null","November 16, 2016","Aga Khan University, Karachi, Sindh, Pakistan","","https://ClinicalTrials.gov/show/NCT02964416"
114,"NCT01640509","Synchrotron Radiation to the Treatment of Intracranial Tumors","ESRF","Recruiting","No Results Available","Brain Cancer","Radiation: treated by synchrotron radiation","Safety|Survival without limiting adverse events|Acceptability|Treatment efficacy|Quality of life","University Hospital, Grenoble","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCIC 08 06","June 2012","June 2014","June 2019","July 13, 2012","null","November 11, 2013","Esrf / Id17, Grenoble, France","","https://ClinicalTrials.gov/show/NCT01640509"
115,"NCT03542409","Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas",,"Recruiting","No Results Available","Brain Tumor Adult","Other: MR Perfusion Scan|Other: 2HG Spectroscopy Scan","Intraoperative Imaging Completion|Incidence of Patient Complications Following Tumor Resection","University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI77238","February 6, 2017","February 6, 2019","February 6, 2020","May 31, 2018","null","June 26, 2018","Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03542409"
116,"NCT01793714","Presurgical Language Mapping With fMRI: Comparison of BOLD and fASL Techniques","MALTA","Recruiting","No Results Available","Brain Neoplasms","","Qualitative and quantitative comparison of brain activations obtained with both techniques (BOLD fMRI and fASL)|Langage laterality index obtained with both techniques (BOLD fMRI and fASL)and fASL)|Difference of cerebral blood flow maps obtained with ASL and fASL","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2012-A00903-40","January 21, 2014","December 31, 2018","December 31, 2018","February 15, 2013","null","September 25, 2017","Rennes University Hospital, Rennes, France","","https://ClinicalTrials.gov/show/NCT01793714"
117,"NCT03154801","Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX)","NEUROSEX","Recruiting","No Results Available","Low Grade Glioma of Brain|Multiple Sclerosis|Sexual Dysfunctions","Other: Paramedical care","Change of MSISQ15 (Multiple Sclerosis Intimacy and Sexuality Questionnaire)|Change of HAD scale (Hospital Anxiety and Depression)|Change of Rosenberg's Self-esteem Scale|Change of Quality of life scale|Change of QLQ-C30/BM20 scale (Quality of Life Questionnaire - Core Questionnaire / Brain Module)|Change of SEP59 scale (Sclérose En Plaques)|Program satisfaction scale","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P140709","July 26, 2017","January 26, 2020","December 31, 2020","May 16, 2017","null","April 17, 2018","Groupe Hospitalier Pitie Salpetriere, Paris, France","","https://ClinicalTrials.gov/show/NCT03154801"
118,"NCT02600065","Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy","GLIO-CMV-01","Recruiting","No Results Available","Cytomegalovirus Infections","Other: Blood draw and MRI","Change of CMV status during radio(chemo)therapy (RCT)|Change of circulating immune cells of treated patients by deep immunophenotyping.","University of Erlangen-Nürnberg Medical School","All","18 Years and older   (Adult, Older Adult)","","250","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GLIO-CMV-01","November 2014","December 31, 2018","September 30, 2019","November 9, 2015","null","January 26, 2018","Departement of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität erlangen-Nürnberg, Erlangen, Bavaria, Germany","","https://ClinicalTrials.gov/show/NCT02600065"
119,"NCT02940483","Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma","5-AZA","Recruiting","No Results Available","Brain Tumor Recurrent","Drug: 5-Azacytidine","Number of patients with grade 3 through grade 5 new neurological adverse events that are related to study drug, graded according to NCI CTCAE Version 4.0","The University of Texas Health Science Center, Houston","All","1 Year to 21 Years   (Child, Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-16-0739","December 2016","December 2019","January 2020","October 21, 2016","null","August 22, 2017","UTHealth & Children's Memorial Hermann Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02940483"
120,"NCT03194906","Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors",,"Recruiting","No Results Available","Glioma of Brain|Craniopharyngioma|Ependymoma|Germ Cell Tumor","Drug: Memantine|Other: Placebo|Other: Cognitive Assessment","Percent of approached participants who consent to study participation|Percent of participants who complete all 12 weeks of memantine/placebo therapy|Percent of participants who complete at least 3 of 4 cognitive assessments|Change in neurobehavioral outcome|Frequency of memantine side effects","St. Jude Children's Research Hospital|National Cancer Institute (NCI)","All","6 Years to 21 Years   (Child, Adult)","Phase 2","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","MEMCRT|R21CA218625|NCI-2017-01279","November 7, 2017","January 2021","January 2021","June 21, 2017","null","April 17, 2018","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03194906"
121,"NCT02573441","KEYS to Succeed: Cognitive and Academic Intervention Program for Children and Adolescents Surviving Cancer",,"Recruiting","No Results Available","Childhood Brain Tumor","Behavioral: Jump Math|Behavioral: Cogmed|Behavioral: Liaison Services","Woodcock Johnson Academic-Third Edition|Wechsler Intelligence Scale for Children - Fourth Edition Integrated|Wide Range Assessment of Memory and Learning - Second Edition|Automated Working Memory Assessment|Connors' Continuous Performance Test-Second Edition|Behaviour Rating Inventory of Executive Function-Parent Version|Monitoring Basic Skills Progress|SAM|California Verbal Learning Test, Children's Version|CANTAB|Wechsler Abbreviated Scale of Intelligence|Delis-Kaplan Executive Function System","The Hospital for Sick Children|Pediatric Oncology Group of Ontario","All","6 Years to 17 Years   (Child)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1000043747","October 2015","October 2019","December 2019","October 9, 2015","null","April 27, 2018","Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02573441"
122,"NCT02417324","International HIT-MED Registry (I-HIT-MED)",,"Recruiting","No Results Available","Childhood Brain Tumor","","Event free survival|Pattern of relapse|Overall survival","Universitätsklinikum Hamburg-Eppendorf","All","Child, Adult, Older Adult","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","I-HIT-MED Registry","January 2015","December 2019","December 2024","April 15, 2015","null","October 18, 2017","University Hospital Aachen, Aachen, Germany|Klinikum Augsburg, Augsburg, Germany|Helios Klinikum Berlin-Buch, Berlin, Germany|Charite Campus, University of Berlin, Berlin, Germany|Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany|Klinikum Braunschweig, Braunschweig, Germany|Klinikum Bremen-Mitte, Bremen, Germany|Klinikum Chemnitz, Chemnitz, Germany|University Hospital Cologne, Cologne, Germany|Carl-Thiem-Klinikum Cottbus, Cottbus, Germany|Vestische Kinder- und Jugendklinik, University Witten/Herdecke, Datteln, Germany|Klinikum Dortmund, Dortmund, Germany|University Hospital Dresden, Dresden, Germany|Klinikum Duisburg, Duisburg, Germany|Universitäts-Kinderklinik Düsseldorf, Düsseldorf, Germany|HELIOS Klinikum-Erfurt, Erfurt, Germany|University Hospital Erlangen, Erlangen, Germany|University Hospital Essen, Essen, Germany|University Hospital Frankfurt/Main, Frankfurt, Germany|University Hospital Freiburg, Freiburg, Germany|Universitätsklinikum Gießen und Marburg, Gießen, Germany|University Hospital Greifswald, Greifswald, Germany|Georg-August-Universität Göttingen, Göttingen, Germany|University Hospital Halle/Saale, Halle, Germany|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Angelika-Lautenschläger-Klinik, Heidelberg, Germany|SLK-Kliniken, Heilbronn, Germany|Gemeinschaftskrankenhaus Herdecke, Herdecke, Germany|University Hospital Homburg/Saar, Homburg, Germany|University Hopsital Jena, Jena, Germany|Städtisches Klinikum Karlsruhe, Karlsruhe, Germany|Klinikum Kassel, Kassel, Germany|UK-SH Campus Kiel, Kiel, Germany|Gemeinschaftsklinikum Koblenz-Mayen, Koblenz, Germany|HELIOS Klinikum Krefeld, Krefeld, Germany|University Hospital Leipzig, Leipzig, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|University Hospital Magdeburg, Magdeburg, Germany|University Hospital Mainz, Mainz, Germany|University Hospital Mannheim, Mannheim, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Universität München - von Haunersches, München, Germany|Klinikum Schwabing, Pediatric Hospital of Technical University, München, Germany|Universitätsklinikum Münster, Münster, Germany|Cnopf'sche Kinderklinik, Nürnberg, Germany|Klinikum Oldenburg, Oldenburg, Germany|University Hospital Regensburg, Regensburg, Germany|University Hospital Rostock, Rostock, Germany|Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany|Helios Kliniken Schwerin, Schwerin, Germany|Klinikum Stuttgart, Stuttgart, Germany|Universitätsklinik Tübingen, Tübingen, Germany|University Hospital Ulm, Ulm, Germany|Dr. Horst Schmidt Kliniken, Wiesbaden, Germany|Klinikum der Stadt Wolfsburg, Wolfsburg, Germany|Universotätsklinikum Würzburg, Würzburg, Germany","","https://ClinicalTrials.gov/show/NCT02417324"
123,"NCT03454659","Comparison of the Effect of Low and High Fraction of Inspired Oxygen on Postoperative Surgical Field Infection",,"Not yet recruiting","No Results Available","Supratentorial Brain Tumor","Procedure: Craniotomy","the rate of surgical field infection will be evaluated by ASEPSIS score.|The rate of postoperatively pulmonary complications such as pneumonia,respiratory failure will be evaluated.Centers for Disease Control and Prevention criteria will be used for defining nosocomial pneumonia.","Istanbul University","All","18 Years to 70 Years   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","83045809-604.01.02-","April 2018","April 2020","April 2020","March 6, 2018","null","March 6, 2018","","","https://ClinicalTrials.gov/show/NCT03454659"
124,"NCT03185780","Complementary/Integrative Medicine for Brain Cancer Patients",,"Not yet recruiting","No Results Available","Quality of Life|Chemotherapeutic Toxicity|Radiation Toxicity","Other: Acupuncture","Measure Yourself Concerns and Wellbeing (MYCAW) study tool|Functional Assessment of Cancer Therapy, Brain Cancer (FACT-Br) questionnaire|Edmonton Symptom Assessment Scale (ESAS)|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30)|Adverse effects attributed to the complementary/integrative medicine treatments|RDI - relative dose intensity","The Chaim Sheba Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ChaimShebaMC","July 1, 2018","December 31, 2019","December 31, 2019","June 14, 2017","null","March 6, 2018","","","https://ClinicalTrials.gov/show/NCT03185780"
125,"NCT02849171","Assessing 18F-Fluorocholine (18F-FCH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas",,"Recruiting","No Results Available","Brain Cancer","Device: PET scan|Radiation: 18F-Fluorocholine (18F-FCH)","SUV measures","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16-676","July 2016","June 2019","June 2019","July 29, 2016","null","July 3, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02849171"
126,"NCT02271711","Study of Intraventricular Infusions of Autologous ex Vivo-expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol",,"Recruiting","No Results Available","Brain Cancer","Biological: Natural Killer (NK) Cells","Maximum Tolerated Dose (MTD) of Autologous Natural Killer (NK) Cells|Antitumor Activity of Autologous NK Cell Administration","M.D. Anderson Cancer Center","All","up to 21 Years   (Child, Adult)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-0765|NCI-2014-02677","March 2015","March 2020","March 2020","October 22, 2014","null","June 21, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02271711"
127,"NCT03387020","Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors",,"Recruiting","No Results Available","Central Nervous System Embryonal Tumor, Not Otherwise Specified|Malignant Glioma|Recurrent Atypical Teratoid/Rhabdoid Tumor|Recurrent Childhood Ependymoma|Recurrent Diffuse Intrinsic Pontine Glioma|Recurrent Medulloblastoma|Refractory Diffuse Intrinsic Pontine Glioma","Drug: Everolimus|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Ribociclib","Maximum tolerated dose of ribociclib and everolimus|Average Tumor and Plasma Concentrations of Ribociclib for the Surgical Study|Objective responses (complete response + partial response)|Percent reduction in ki67 between archival and post-treatment tissue","Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 1","45","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PBTC-050|NCI-2017-02079|UM1CA081457","January 13, 2018","July 31, 2020","July 31, 2020","December 29, 2017","null","March 13, 2018","Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children Hospital Stanford University, Palo Alto, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children Hospital Medical Center, Cincinnati, Ohio, United States|Children Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States|St. Jude Children Research Hospital, Memphis, Tennessee, United States|Texas Children's Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03387020"
128,"NCT03462914","Comparative Study Between Different Approaches to CPA-petroclival Meningiomas",,"Not yet recruiting","No Results Available","Brain Neoplasms","","The success rate of surgery","Assiut University","All","Child, Adult, Older Adult","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CPA-petroclival meningiomas","March 15, 2018","April 1, 2019","May 1, 2019","March 13, 2018","null","March 13, 2018","","","https://ClinicalTrials.gov/show/NCT03462914"
129,"NCT01528046","Metformin in Children With Relapsed or Refractory Solid Tumors",,"Recruiting","No Results Available","Solid Tumors|Primary Brain Tumors","Drug: Vincristine|Drug: Irinotecan|Drug: Temozolomide|Drug: Metformin","Maximum Tolerated Dose (MTD)|Number of Participants with Antitumor Activity|Pharmacokinetics|Pharmacodynamics|Metformin Concentrations","H. Lee Moffitt Cancer Center and Research Institute|Pediatric Cancer Foundation","All","1 Year to 18 Years   (Child, Adult)","Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-16962|SP003","April 25, 2012","December 2019","December 2020","February 7, 2012","null","June 20, 2018","Connecticut Children's Medical Center, Hartford, Connecticut, United States|Nemours/Alfred I. duPont Hospital for Children, Delaware, Wilmington, Delaware, United States|University of Florida, Gainesville, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Holtz Children's Hospital at the University of Miami, Miami, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|The Children's Hospital at Montefiore, Bronx, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01528046"
130,"NCT01974804","Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis",,"Recruiting","No Results Available","Brain Cancer","Procedure: MRI","feasibility of diffusion and perfusion magnetic resonance imaging (MRI)","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","","36","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","13-094","October 2013","October 2019","October 2019","November 4, 2013","null","November 8, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01974804"
131,"NCT02644291","Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors",,"Recruiting","No Results Available","Medulloblastoma|Astrocytoma, Grade III|Glioblastoma|Anaplastic Astrocytoma|Brain Stem Neoplasms, Malignant|Oligodendroblastoma|Anaplastic Oligodendroglioma|Malignant Glioma","Drug: Mebendazole","Adverse events attributed to mebendazole for patients enrolled in this study|Overall survival for patients enrolled in this study","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","1 Year to 21 Years   (Child, Adult)","Phase 1","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J15211|IRB00072999","May 2016","June 2019","June 2020","December 31, 2015","null","June 1, 2017","Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02644291"
132,"NCT02645487","Stereotactic Radiosurgery (SRS) for Brain Metastasis","SRS","Recruiting","No Results Available","Brain Neoplasms, Adult, Malignant","Radiation: Stereotactic Radiosurgery","Maximal tolerated doses|Overall survival|Time to progression|Local progression rate|Response rate|Health-related quality of life|chronic toxicity","University of Texas Southwestern Medical Center","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 022015-106","December 18, 2015","December 2020","December 2020","January 1, 2016","null","January 24, 2018","University of Texas Southwestern Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02645487"
133,"NCT02303678","D2C7 for Adult Patients With Recurrent Malignant Glioma",,"Recruiting","No Results Available","Malignant Glioma|Brain Tumor, Recurrent","Drug: D2C7-IT","Maximum tolerated dose (MTD) of D2C7-IT|Overall survival (OS)|Association between EGFRvIII and EGFRwt expression and PFS and OS.","Darell D. Bigner, MD, PhD|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1","75","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00053325","May 5, 2015","December 2018","December 2019","December 1, 2014","null","December 2, 2017","Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02303678"
134,"NCT02684071","Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors",,"Recruiting","No Results Available","Recurrent Childhood Medulloblastoma|Recurrent Childhood Ependymoma|Childhood Atypical Teratoid/Rhabdoid Tumor|Embryonal Tumor With Abundant Neuropil and True Rosettes|Metastatic Malignant Neoplasm to the Leptomeninges","Drug: Intra thecal methotrexate|Drug: topotecan|Drug: cyclophosphamide","Tumor response|Toxicity of chemotherapy regimen (topotecan and cyclophosphamide)","Nicklaus Children's Hospital f/k/a Miami Children's Hospital","All","up to 22 Years   (Child, Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCH-CNS-1601","February 2016","December 2018","February 2020","February 17, 2016","null","March 2, 2018","Nicklaus Children's Hospital, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT02684071"
135,"NCT02372409","Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors",,"Recruiting","No Results Available","Glioma|Pilocytic Astrocytoma|Anaplastic Astrocytoma|Glioblastoma|Mixed Oligoastrocytoma|Mixed Glioma|Oligodendroglioma|Optic Glioma|Astrocytoma","Device: MRI-guided laser ablation|Drug: Doxorubicin|Drug: Etoposide|Device: Dynamic contrast-enhanced (DCE) MRI|Device: Dynamic susceptibility contrast (DSC) MRI","Arm A only: Progression-free survival (PFS)|Arm A only: Overall survival (OS)|Arm B only: Progression-free survival (PFS)|Arm B only: Quality of life (QOL)|Correlation of MR imaging with peritumoral BBB disruption|Serum biomarkers of peritumoral BBB disruption|Predictive value of the peritumoral permeability score for patient outcome as measured by PFS","Washington University School of Medicine","All","3 Years to 21 Years   (Child, Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201502062","August 14, 2015","October 30, 2019","October 30, 2019","February 26, 2015","null","May 11, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02372409"
136,"NCT03033693","Study of the Depth of Anesthesia on Postoperative Clinical Outcome in Patients With Supratentorial Tumor","DEPTH","Recruiting","No Results Available","Anesthesia, Brain Tumor, Supratentorial,Outcome","Other: Bispectral index will be targeted at 50|Other: Bispectral index will be targeted at 35","Disability-free survival rate","Beijing Tiantan Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","3004","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","2016-1-20410","February 1, 2017","October 31, 2019","December 31, 2019","January 27, 2017","null","June 14, 2017","Beijing TianTan Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT03033693"
137,"NCT03425292","A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer",,"Recruiting","No Results Available","Newly Diagnosed Glioblastoma","Drug: Temozolomide|Radiation: conformal brain radiation therapy|Drug: Nivolumab|Drug: Ipilimumab","Rate of dose limiting toxicities|Treatment-related adverse events|Tumor response rates|Progression free survival (PFS)|Overall survival (OS)|Levels of nivolumab and ipilimumab in specimens|Change in clinical molecular profile of tumor tissue after treatment","John Wayne Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JWCI-17-0801","March 1, 2018","February 1, 2019","February 1, 2020","February 7, 2018","null","May 11, 2018","John Wayne Cancer Institute, Santa Monica, California, United States","","https://ClinicalTrials.gov/show/NCT03425292"
138,"NCT02343549","A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)",,"Recruiting","No Results Available","Cancer of Brain and Nervous System","Device: bevacizumab, NovoTTF100A, temozolomide","Survival at 12 months","Ashley Love Sumrall|NovoCure Ltd.|Carolinas Healthcare System","All","22 Years and older   (Adult, Older Adult)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCI-NEU-NOV-001|00010270","January 2015","June 2018","June 2019","January 22, 2015","null","January 23, 2018","Levine Cancer Institute, Charlotte, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02343549"
139,"NCT00870129","Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors",,"Recruiting","No Results Available","Brain Cancer|Glioma","Procedure: MRI and advanced MRI sequences","To assess the utility of baseline advanced MRI & changes between baseline & follow up advanced MRI in predicting high risk areas that are likely to develop progressive glioma despite chemoradiotherapy.|To compare radiation therapy simulations in patients with gliomas using conventional and baseline advanced MRI data.|feasibility of 2HG spectroscopy","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","190","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","09-009","March 2009","March 2019","March 2019","March 27, 2009","null","April 5, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00870129"
140,"NCT01116661","Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain","ALA","Recruiting","No Results Available","Glioma","Drug: 5-Aminolevuline Acid","To determine if the use of 5-aminolevulinic acid (ALA) helps distinguish tumor cells|Determine the safety of 5-aminolevulinic acid (ALA)","University of California, San Francisco","All","18 Years to 72 Years   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10101","August 2010","July 2018","July 2018","May 5, 2010","null","July 25, 2017","UCSF Department of Neurosurgery, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT01116661"
141,"NCT01048060","Consent for Obtaining Additional Bone Marrow Specimens at Time of Diagnostic Bone Marrow Procedure",,"Recruiting","No Results Available","Brain Cancer|Cancer","Procedure: Bone marrow specimen banking","Cancer Research in Future","Stanford University","All","up to 21 Years   (Child, Adult)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BANKPEDSBMS0001|78014|SU-11022007-789","February 2002","February 2060","February 2060","January 13, 2010","null","November 9, 2016","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT01048060"
142,"NCT02696993","Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer",,"Recruiting","No Results Available","Metastatic Brain Cancer","Drug: Nivolumab|Drug: Ipilimumab|Radiation: Stereotactic Radiosurgery (SRS)|Radiation: Whole Brain Radiation Therapy (WBRT)|Behavioral: Neurocognitive Exam","Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Stereotactic Radiosurgery (SRS)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Whole Brain Radiation Therapy (WBRT)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Ipilimumab and Stereotactic Radiosurgery (SRS)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Ipilimumab and Whole Brain Radiation Therapy (WBRT)|Intracranial Progression Free Survival|Neurocognitive Changes","M.D. Anderson Cancer Center|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0883|NCI-2016-00661","December 2016","December 2020","December 2020","March 2, 2016","null","May 31, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02696993"
143,"NCT02259218","Longitudinal Metabolomic and Epigenetic Profiling of Bodyfluids From Patients With Lung and Brain Cancer Receiving Radiation Therapy",,"Recruiting","No Results Available","Adult Brain Tumor|Lung Cancer|Radiation Toxicity","Other: laboratory biomarker analysis","Potential predictive biomarkers for the development of radiation pneumonitis for lung cancer patients|Potential predictive biomarkers for the development of radiation necrosis for brain cancer patients|Biomarkers that are prognostically significant on disease free or overall survival, identified using the survival analysis","Ohio State University Comprehensive Cancer Center","All","19 Years and older   (Adult, Older Adult)","","360","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","OSU-11108|NCI-2014-01575","October 4, 2012","December 30, 2017","December 30, 2017","October 8, 2014","null","April 13, 2017","Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02259218"
144,"NCT03402425","The Diagnostic Value of 18F-FET PET/MRI for CNS Tumors in Children and Adolescents","BUF","Recruiting","No Results Available","Positron-Emission Tomography|Brain Neoplasms, Childhood","Diagnostic Test: 18F-FET PET","Change of treatment|Sensitivity and specificity|Recurrence free survival time","Rigshospitalet, Denmark|Børnecancerfonden","All","Child, Adult, Older Adult","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","327-15","February 24, 2015","December 31, 2020","December 31, 2020","January 18, 2018","null","January 18, 2018","Copenhagen University Hospital Rigshospitalet, Copenhagen, Copenhagen O, Denmark","","https://ClinicalTrials.gov/show/NCT03402425"
145,"NCT01434602","Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas",,"Recruiting","No Results Available","Brain Tumor|Glioblastoma|Anaplastic Glioma","Drug: everolimus|Drug: sorafenib","Maximum tolerated dose and safety of everolimus in combination with sorafenib for patients with recurrent malignant gliomas|Median Rate of subject survival without disease progression after treatment for glioblastoma patients with no prior bevacizumab exposure|Median Rate of subject survival without disease progression after treatment for glioblastoma patients with prior bevacizumab exposure|Median Rate of subject survival without disease progression after treatment for AG patients with no prior bevacizumab exposure|Median amount of time subject survives without disease progression and the median amount of time a subject survives after therapy|Proportion of subject with tumor size reduction|Rate of patient's symptom severity and interference with function","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","118","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160011|16-C-0011","November 5, 2015","December 1, 2018","July 1, 2020","September 15, 2011","null","June 13, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01434602"
146,"NCT02655536","Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial","BRILLIANT","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Brain Neoplasms","Drug: Bevacizumab plus erlotinib|Drug: Erlotinib","Progression-free survival|overall survival|overall response rate|Time-to-central nervous system (CNS) progression|Time to extra-CNS progression|The PFS-2 in patients in patients with CNS progression only|Time to neurological symptom progression|Number of participants with treatment-related adverse events as assessed by CTCAE version 4.03","National Taiwan University Hospital","All","20 Years to 99 Years   (Adult, Older Adult)","Phase 2","109","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201510073MIPB","July 2016","December 2018","December 2019","January 14, 2016","null","September 21, 2016","Department of Oncology, Nationa Taiwan University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT02655536"
147,"NCT03434262","SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors",,"Recruiting","No Results Available","Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Ganglioglioma|Anaplastic Meningioma|Anaplastic Oligodendroglioma|Pleomorphic Xanthoastrocytoma, Anaplastic|Atypical Teratoid/Rhabdoid Tumor|Brain Cancer|Brain Tumor|Central Nervous System Neoplasms|Choroid Plexus Carcinoma|CNS Embryonal Tumor With Rhabdoid Features|Ganglioneuroblastoma of Central Nervous System|CNS Tumor|Embryonal Tumor of CNS|Ependymoma|Glioblastoma|Glioma|Glioma, Malignant|Medulloblastoma|Medulloblastoma; Unspecified Site|Medulloepithelioma|Neuroepithelial Tumor|Neoplasms|Neoplasms, Neuroepithelial|Papillary Tumor of the Pineal Region (High-grade Only)|Pediatric Brain Tumor|Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)|Pineoblastoma|Primitive Neuroectodermal Tumor|Recurrent Medulloblastoma|Refractory Brain Tumor|Neuroblastoma. CNS|Glioblastoma, IDH-mutant|Glioblastoma, IDH-wildtype|Medulloblastoma, Group 3|Medulloblastoma, Group 4|Glioma, High Grade|Neuroepithelial Tumor, High Grade|Medulloblastoma, SHH-activated and TP53 Mutant|Medulloblastoma, SHH-activated and TP53 Wildtype|Medulloblastoma, Chromosome 9q Loss|Medulloblastoma, Non-WNT Non-SHH, NOS|Medulloblastoma, Non-WNT/Non-SHH|Medulloblastoma, PTCH1 Mutation|Medulloblastoma, WNT-activated|Ependymoma, Recurrent|Glioma, Recurrent High Grade|Glioma, Recurrent Malignant|Embryonal Tumor, NOS|Glioma, Diffuse Midline, H3K27M-mutant|Embryonal Tumor With Multilayered Rosettes (ETMR)|Ependymoma, NOS, WHO Grade III|Ependymoma, NOS, WHO Grade II|Medulloblastoma, G3/G4|Ependymoma, RELA Fusion Positive","Drug: Gemcitabine|Drug: ribociclib|Drug: sonidegib|Drug: trametinib|Biological: filgrastim|Biological: pegfilgrastim","Estimate the Maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) of each doublet by stratum|Pharmacokinetics of combination treatment: Stratum A|Pharmacokinetics of combination treatment: Stratum B|Pharmacokinetics of combination treatment: Stratum C|Response rate by stratum|Duration of objective response by stratum","St. Jude Children's Research Hospital|Novartis Pharmaceuticals","All","1 Year to 39 Years   (Child, Adult)","Phase 1","108","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SJDAWN|NCI-2018-00284","March 5, 2018","February 2025","March 2025","February 15, 2018","null","April 10, 2018","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03434262"
148,"NCT02375841","Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers",,"Recruiting","No Results Available","Brain Cancer|Glioblastoma","Behavioral: psychometric tests, questionnaires and neurocognitive assessments","number of responses from patients, to 3 yes/no questions|number of responses from caregivers to 3 yes/no questions|number of responses from physicians to 3 yes/no questions","Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15-034","February 2015","February 2019","February 2019","March 3, 2015","null","March 8, 2018","Henry Ford Hospital, Detroit, Michigan, United States|Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering West Harrison, Harrison, New York, United States|Memoral Sloan Kettering Cancer Center, New York, New York, United States|University of Vermont Medical Center, Burlington, Vermont, United States","","https://ClinicalTrials.gov/show/NCT02375841"
149,"NCT03294486","Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients","ONCOVIRAC","Recruiting","No Results Available","Glioblastoma|Brain Cancer","Drug: Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)","Number of Participant with Dose Limiting Toxicities defined as Any of the following treatment-related adverse events (AEs) is evaluated and reported from Day 1 through Day 26; as assessed by NCI-CTCAE, version 4.03|Number of patients without documented tumor progression at 6 months from date of first TG6002 infusion according to Response Assessment Neuro-Oncology Criteria (Wen et al., 2010, JCO, PMID:20231676)|TG6002 recommended dose prior to the Phase 2a part of the study (RP2D) in combination with 5-FC (Maximum Plasma Concentration [Cmax])|Overall Survival (OS)|Relative quantification of circulating viral DNA|Blood pharmacokinetics of 5-FC|Blood pharmacokinetics of 5-Fluorouraril (5-FU)|Blood pharmacokinetics of final metabolite a-fluoro-B-alanine(FBAL)|Viral shedding in saliva, urine and feces|Humoral response|Isolation of peripheral blood mononuclear cells (PBMC);|Metabolic Response|Safety and tolerability : Incidence of Treatment; evaluation of treatement-releated adverse events","Assistance Publique - Hôpitaux de Paris|Transgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","78","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P150936|2015-004452-21","October 12, 2017","May 2019","September 2021","September 27, 2017","null","November 6, 2017","Groupe Hospitalier Pitié-Salpêtrière, Paris, France","","https://ClinicalTrials.gov/show/NCT03294486"
150,"NCT02878707","The Neuroprotective Effects of Dexmedetomidine During Brain Surgery",,"Recruiting","No Results Available","Brain Tumor|Cerebrovascular Disorders","Drug: Dexmedetomidine","Number of participants with postoperative complications|Serum biomarkers changes","National Taiwan University Hospital","All","20 Years to 75 Years   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","201605056MIFA","August 2016","September 2018","null","August 25, 2016","null","August 25, 2016","National Taiwan University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT02878707"
151,"NCT02731521","Clinical Development of MR Spectroscopy and Imaging in Brain Cancers",,"Recruiting","No Results Available","Malignant Gliomas|Astrocytomas|Oligodendrogliomas","Device: 3 Tesla Scanning|Device: 7 Tesla Scanning","Amount of 2-hydroxyglutarate (2HG) bio-marker in 170 patients with clinically‐proven brain metastasis, multiple sclerosis, epilepsy, stroke, or encephalitis using magnetic resonance spectroscopy (MRS).","University of Texas Southwestern Medical Center|Cancer Prevention Research Institute of Texas","All","18 Years and older   (Adult, Older Adult)","","175","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","STU 122013-077","January 2014","December 2019","December 2019","April 7, 2016","null","March 22, 2018","UT Southwestern Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02731521"
152,"NCT02846038","Understanding Communication in Healthcare to Achieve Trust (U-CHAT)",,"Recruiting","No Results Available","Brain Tumors|Solid Tumor","","Number of communication styles employed","St. Jude Children's Research Hospital","All","Child, Adult, Older Adult","","175","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","U-CHAT","September 9, 2016","July 31, 2023","July 31, 2028","July 27, 2016","null","May 18, 2018","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02846038"
153,"NCT00303849","Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors",,"Recruiting","No Results Available","Adult Anaplastic Oligodendroglioma|Adult Mixed Glioma|Adult Oligodendroglioma|Oligoastrocytoma|Recurrent Adult Brain Neoplasm","Drug: Carboplatin|Drug: Etoposide Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mannitol|Drug: Melphalan|Other: Quality-of-Life Assessment|Drug: Sodium Thiosulfate","MTD of melphalan, defined as one dose level below the dose that produces grade 4 toxicity in 33% of patients, graded in accordance with National Cancer Institute Common Toxicity Criteria (NCI CTC) (version 3.0) (Phase I)|Overall survival|Progression free survival (Phase II)|Response rate|Time to best response|Functional outcomes|Incidence of severe neutropenia (specifically febrile neutropenia or sepsis) in accordance with NCI CTC (version 3.0)|Rates of 2YPFS for specific tumor types","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","43","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00002868|NCI-2013-00786|CR00002456|2868|P30CA069533","September 2005","December 2020","December 2021","March 17, 2006","null","May 3, 2018","University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT00303849"
154,"NCT03423628","A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer",,"Recruiting","No Results Available","Recurrent Glioblastoma Multiforme|Primary Glioblastoma Multiforme|Brain Neoplasms, Malignant|Leptomeningeal Disease (LMD)","Radiation: Radiation Therapy|Drug: AZD1390","Incidence of dose-limiting toxicities (DLTs)|Incidence of adverse events (AEs) and serious adverse events (SAEs)|Event free survival (EFS) for Arms A and C only|Objective response rate defined by RANO criteria for Arms A and C only|Objective response rate defined by RANO-BM criteria for Arm B only|Objective response rate defined by RECIST 1.1 criteria for Arm B only|Maximum Observed Plasma Concentration (Cmax) of AZD1390|Time to observed Cmax (Tmax) for AZD1390|Area under the plasma concentration-time curve (AUC) for AZD1390|Renal clearance (CLR) for AZD1390","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 1","132","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D6940C00002|2017-002451-28|135803","April 2, 2018","April 5, 2021","April 5, 2021","February 6, 2018","null","May 30, 2018","Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Richmond, Virginia, United States|Research Site, Cambridge, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Leeds, United Kingdom","","https://ClinicalTrials.gov/show/NCT03423628"
155,"NCT01502917","Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy",,"Recruiting","No Results Available","Brain Cancer|Brain Stem Glioma","Radiation: Radioactive iodine-labeled monoclonal antibody 8H9","maximum tolerated dose|safety|overall survival","Y-mAbs Therapeutics|Weill Medical College of Cornell University|Johns Hopkins University","All","2 Years to 21 Years   (Child, Adult)","Phase 1","64","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-011","December 2011","December 2018","December 2018","January 2, 2012","null","June 20, 2018","Weill Medical College of Cornell University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01502917"
156,"NCT02500459","Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection",,"Recruiting","No Results Available","Brain Tumor|High Grade Glioma","Drug: topotecan|Device: Cleveland Multiport Catheter","Summary of number of adverse events by grade - A measure of treatment safety|The number of patients with abnormal hematology lab reports|The number of patients with abnormal clinical chemistry lab reports|The number of patients with abnormal coagulation lab reports","Michael Vogelbaum, MD, PhD|Infuseon Therapeutics, Inc.|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INFT1315","July 6, 2015","December 2018","December 2019","July 16, 2015","null","January 25, 2018","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02500459"
157,"NCT01954576","NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme",,"Recruiting","No Results Available","Glioblastoma|Brain Neoplasms","Device: NovoTTF-100A|Procedure: Quality-of-life assessment|Genetic: Laboratory biomarker analysis","ORR (CR + PR + SD) (bevacizumab-naive)|ORR (CR + PR + SD) (bevacizumab-refractory)|Genetic signature of response (CR + PR + SD)|Genetic signature of response (CR + PR) and SD|Progression-free survival in bevacizumab-naïve and bevacizumab-refractory glioblastoma patients|Quality of Life","University of Florida|Washington University School of Medicine|NovoCure Inc.","All","22 Years and older   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201500287|09-27-2013|201306042","October 10, 2013","December 2019","March 2021","October 7, 2013","null","May 9, 2018","University of Florida, Gainesville, Florida, United States|Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01954576"
158,"NCT02639325","Tumor Related Epilepsy",,"Recruiting","No Results Available","Epilepsy|Cancer|Brain Neoplasm","","Change in seizure frequency, as measured by the Engel scale|Mean Engel Class stratified by the type of brain tumor and location|Extent of tumor and peri-tumoral resection as seen on MRI imaging and correlation with seizure outcome|Changes in neuropsychological assessment following surgical resection stratified by location and type of tumor and extent of resection|Longitudinal changes in symptom burden and interference scores using established instruments in brain tumor patients|Changes in structural imaging following surgical resection|Change in the use of anti-epileptic medication|Percentage of patients with permanent neurological side-effects from surgical treatment","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","8 Years and older   (Child, Adult, Older Adult)","","100","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","160041|16-N-0041","December 23, 2015","September 1, 2020","September 1, 2020","December 24, 2015","null","June 25, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02639325"
159,"NCT01811498","Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM",,"Recruiting","No Results Available","Glioblastoma Multiforme|Brain Tumor","Drug: Bevacizumab","Composite overall response rate (CORR)|Progression-free survival (PFS) and Overall survival (OS)|Toxicities","Northwell Health|Feinstein Institute for Medical Research","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-352","February 2013","January 2020","January 2020","March 14, 2013","null","March 1, 2018","Lenox Hill Brain Tumor Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01811498"
160,"NCT02575027","Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme",,"Recruiting","No Results Available","Glioblastoma|Recurrent Brain Neoplasm","Radiation: Palliative Radiation Therapy|Other: Questionnaire Administration|Radiation: Radiation Therapy Treatment Planning and Simulation","Accuracy of dose delivery|Normal tissue dose volume|Patient comfort with treatment time, determined by a patient-completed questionnaire completed at the end of each fraction","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-001086|NCI-2015-01449|P30CA016042","November 12, 2014","November 30, 2018","November 30, 2019","October 14, 2015","null","January 9, 2018","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02575027"
161,"NCT02020720","18F-DOPA-PET in Planning Surgery in Patients With Gliomas",,"Recruiting","No Results Available","Malignant Glioma|Recurrent Brain Neoplasm","Procedure: Biopsy|Procedure: Computed Tomography|Procedure: Diffusion Weighted Imaging|Drug: Fluorine F 18 Fluorodopa|Other: Laboratory Biomarker Analysis|Procedure: Perfusion Magnetic Resonance Imaging|Procedure: Positron Emission Tomography|Procedure: Therapeutic Conventional Surgery","Ratios of maximum tumor standardized uptake value (SUVmax) normalized to mean SUV (SUVmean) of T/N|Differences in volumes generated from biopsy-validated thresholds evaluated by 18F-DOPA-PET, pMRI, and DTI|Histologic grade of the specimen defined as HGG, LGG, or non-malignant brain tissue|MRI contrast enhancement values|Progression free survival|Proportion of patients whose maximum 18F-DOPA uptake samples are in agreement with the final diagnostic grade","Mayo Clinic|National Cancer Institute (NCI)","All","7 Years and older   (Child, Adult, Older Adult)","Not Applicable","90","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MC1373|NCI-2013-02373|P30CA015083","January 2014","November 2018","November 2018","December 25, 2013","null","March 15, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02020720"
162,"NCT02808416","Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)","PerCellVac3","Recruiting","No Results Available","Brain Cancer|Neoplasm Metastases","Biological: Personalized cellular vaccine","Incidence of treatment-emergent adverse events and severe adverse events (safety and tolerability)|Progression-free survival|Overall survival|Antitumor specific T cell response","Guangdong 999 Brain Hospital|Beijing Tricision Biotherapeutics Inc|Guangzhou Trinomab Biotech Co., Ltd.|Jinan University Guangzhou","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ag-mRNA-Cell-BM-999Brain","June 2016","June 2018","September 2019","June 21, 2016","null","June 21, 2016","Guangdong 999 Brain Hospital, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02808416"
163,"NCT02260531","Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases",,"Recruiting","No Results Available","Breast Cancer|Brain Tumor - Metastatic","Drug: Cabozantinib|Drug: Trastuzumab","CNS Objective Response Rate|ORR in non-CNS|Progression Free Survival Rate|Clinical benefit rate|First Progression Rate (CNS versus non-CNS)|Overall Survival (OS) Rate|Participants will be grouped as to whether or not their tumor has amplified Met|To evaluate the incidence of c-Met amplified circulating tumor cells at baseline|To evaluate potential plasma biomarkers of cabozantinib when given in combination with trastuzumab|To assess vascularity of CNS tumors, through descriptive analysis as a composite of tumor vessel size, cerebral blood volume, cerebral blood flow, perfusion, and diffusion before and after exposure to cabozantinib by research MRIs|To assess the number of participants with Adverse Events","Dana-Farber Cancer Institute|Exelixis|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-359","October 2014","June 2018","February 2022","October 9, 2014","null","February 1, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02260531"
164,"NCT03086421","Social Emotional Development in Young Children With Cancer",,"Recruiting","No Results Available","Solid Tumor, Childhood|Brain Tumor, Pediatric","Behavioral: Questionnaires","Social functioning as assessed by parent-completed measures and child-completed measures","St. Jude Children's Research Hospital|American Cancer Society, Inc.","All","4 Years to 6 Years   (Child)","","64","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SEDYC","July 11, 2017","September 2024","September 2024","March 22, 2017","null","November 21, 2017","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03086421"
165,"NCT03510208","Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery",,"Recruiting","No Results Available","Malignant Brain Neoplasm|Malignant Glioma","Procedure: Near-Infrared Fluorescence Imaging|Biological: Panitumumab|Drug: Panitumumab-IRDye800|Other: Pharmacokinetic Study|Procedure: Surgical Procedure","Number of grade 2 or higher adverse events which have been determined to be clinically significant and definitely, probably, or possibly related to the study treatment, graded according to Common Terminology Criteria for Adverse Effects (CTCAE) v. 4.0|Tumor to background ratio (TBR)|Panitumumab Loading Dose|Optimal Timing of Surgical Procedure","Eben Rosenthal|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","22","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BRNCNS0009|NCI-2018-00536|43179","May 14, 2018","May 14, 2021","May 14, 2022","April 27, 2018","null","May 21, 2018","Stanford University School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03510208"
166,"NCT00267865","Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma",,"Recruiting","No Results Available","Lymphoma-AIDS-Related|Brain Neoplasm","Drug: Methotrexate|Drug: Rituximab|Drug: Leucovorin","Survival; without recurrent lymphoma or severe cognitive problems at two years","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","28","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","060051|06-C-0051","December 16, 2005","July 31, 2019","July 31, 2021","December 21, 2005","null","June 28, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00267865"
167,"NCT02505165","Illness Management and Parental Adjustment to Cancer Treatment","IMPACT","Recruiting","No Results Available","Solid Tumor|Leukemia|Lymphoma|Brain Tumor","Behavioral: IMPACT|Other: ESO","Psychosocial Functioning as assessed by the global severity index of the symptom checklist 90.|Post-Traumatic Stress Symptoms as assessed by the Impact of Events Scale-Revised (IES-R)","Children's Hospital Medical Center, Cincinnati|University of Oklahoma|Oklahoma State University|Dayton Children's Hospital","All","up to 18 Years   (Child, Adult)","Not Applicable","296","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","NR014248","November 2015","March 2020","March 2020","July 22, 2015","null","January 3, 2018","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States","","https://ClinicalTrials.gov/show/NCT02505165"
168,"NCT03299309","PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma","PRiME","Recruiting","No Results Available","Recurrent Medulloblastoma|Recurrent Brain Tumor, Childhood|Malignant Glioma","Drug: PEP-CMV","Proportion of patients with unacceptable toxicity|Mean or median change from baseline at each follow-up assessment in ELISPOT (IFN-γ)|Mean or median change from baseline at each follow-up assessment in ELISA (gB-KLH)","Gary Archer Ph.D.|Pediatric Brain Tumor Foundation|Annias Immunotherapeutics, Inc.|Duke University","All","3 Years to 17 Years   (Child)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00079843","June 2018","June 2019","June 2022","October 3, 2017","null","June 12, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03299309"
169,"NCT02644460","Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors","AflacST1501","Recruiting","No Results Available","Diffuse Intrinsic Pontine Glioma|Brain Tumor, Recurrent|Solid Tumor, Recurrent|Neuroblastoma, Recurrent, Refractory|Ewing Sarcoma, Recurrent, Refractory|Rhabdomyosarcoma, Recurrent, Refractory|Osteosarcoma, Recurrent, Refractory|Rhabdoid Tumor, Recurrent, Refractory","Drug: Abemaciclib","Abemaciclib Maximum Tolerated Dose (MTD) for Diffuse Intrinsic Pontine Glioma (DIPG)|Abemaciclib Maximum Tolerated Dose (MTD) for Recurrent/Refractory Solid Tumors|Pharmacokinetics (PK): Predose Concentration (Cmin) of Abemaciclib|Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib|Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Abemaciclib|Number of participants with adverse events|Number of hematological toxicities|Number of non-hematological toxicities","Emory University","All","2 Years to 25 Years   (Child, Adult)","Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00083793","February 2016","October 2018","October 2020","December 31, 2015","null","July 17, 2017","Children's Hospital colorado, Aurora, Colorado, United States|Children's Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02644460"
170,"NCT02851706","Natural History of and Specimen Banking for People With Tumors of the Central Nervous System",,"Recruiting","No Results Available","Brain Cancer|Brain Tumor|Spine Cancer|Spine Tumor|Neoplasm","","To evaluate patients with tumors of the central nervous system (CNS) who are probable future candidates for NCI Phase I and II protocols","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","","10000","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","160151|16-C-0151","July 29, 2016","June 6, 2066","April 5, 2100","August 2, 2016","null","June 27, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02851706"
171,"NCT02193347","IDH1 Peptide Vaccine for Recurrent Grade II Glioma","RESIST","Recruiting","No Results Available","Brain Cancer|Brain Neoplasm, Primary|Brain Neoplasms, Recurrent|Brain Tumor|Cancer of the Brain","Biological: PEPIDH1M vaccine|Biological: Tetanus-Diphtheria Toxoid (Td)|Drug: Temozolomide","The percentage of patients with an unacceptable toxicity will be estimated.|IFNγ ELIspot Measurements","Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00054746","December 2015","June 2019","June 2019","July 17, 2014","null","March 23, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02193347"
172,"NCT02909777","Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",,"Recruiting","No Results Available","Lymphoma|Neuroblastoma|Brain Tumor|Solid Tumor","Drug: CUDC-907","Dose Limiting Toxicity|Progression Free Survival|Peak plasma concentration of CUDC-907 in Pediatrics|Exposure (AUC) of CUDC-907 in Pediatrics|Duration of Response|Adverse Events per CTCAE Version 4|Objective Response","Dana-Farber Cancer Institute|Curis, Inc.","All","1 Year to 21 Years   (Child, Adult)","Phase 1","44","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-371","October 2016","October 2019","October 2022","September 21, 2016","null","January 16, 2018","University of California, San Francisco, Benioff Children's Hospital, San Francisco, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Texas Children's, Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02909777"
173,"NCT01894061","NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma",,"Recruiting","No Results Available","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor","Biological: Bevacizumab|Device: NovoTTF-l00A|Other: Quality of Life Assessment","Progression Free Survival (PFS)|Objective response rate based on RANO Criteria|Number of patients that experience toxicities with this combination of therapies|Median overall survival|To assess time-to-progression|Neurocognitive function (NCF)|Quality of Life (QOL)","Case Comprehensive Cancer Center|NovoCure Ltd.|National Cancer Institute (NCI)","All","22 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE3313|P30CA043703","June 12, 2013","December 2018","December 2018","July 9, 2013","null","February 27, 2018","University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01894061"
174,"NCT03052738","Medical Marijuana in the Pediatric Central Nervous System Tumor Population",,"Recruiting","No Results Available","Central Nervous System Tumor|Brain Tumor|Spinal Tumor","","Overall Quality of Life","University of Colorado, Denver","All","2 Years to 18 Years   (Child, Adult)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15-0404.cc","January 15, 2016","December 2019","December 2019","February 14, 2017","null","June 4, 2018","Chilsdren's Hospital Colorado, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT03052738"
175,"NCT03426891","Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma",,"Recruiting","No Results Available","Glioblastoma|Brain Tumor|GBM","Drug: Pembrolizumab|Drug: Vorinostat|Drug: Temozolomide|Radiation: Radiotherapy","Maximum Tolerated Dose (MTD)|Overall Survival (OS)","H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-19342","March 16, 2018","April 2021","April 2022","February 8, 2018","null","March 20, 2018","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03426891"
176,"NCT02256137","A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Brain Tumor|Hodgkin Lymphoma","","Change in proportion of participants who are frail from baseline to 5 years later|Association between frailty at baseline and worsening of chronic health conditions 5 years later|Association between demographic and treatment factors and lifestyle on prevalent frailty.|Effects of physical activity, diet and smoking on prevalent frailty","St. Jude Children's Research Hospital|National Cancer Institute (NCI)","All","18 Years to 45 Years   (Adult)","","1493","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","FRAILTY|R01CA174851","October 8, 2014","June 2021","June 2021","October 3, 2014","null","November 14, 2017","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02256137"
177,"NCT01228448","In-Room PET in Proton Radiation Therapy",,"Recruiting","No Results Available","Brain Tumor|Head and Neck Tumor|Skull Base Tumor","Procedure: PET scan","Effectiveness|Optimize the in-room PET acquisition length","Massachusetts General Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","39","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10-241","October 2010","December 2018","December 2018","October 26, 2010","null","March 8, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01228448"
178,"NCT02658981","Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioblastoma|Gliosarcoma|Recurrent Brain Neoplasm","Biological: Anti-LAG-3 Monoclonal Antibody BMS 986016|Biological: Anti-PD-1|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis|Biological: Anti-CD137","Maximum tolerated dose (MTD) of anti-LAG-3 monoclonal antibody BMS-986016 as monotherapy as determined by frequency of toxicity|Maximum tolerated dose (MTD) of anti-CD137 as monotherapy as determined by frequency of toxicity|MTD of Anti-LAG-3 + Anti-PD-1 as determined by frequency of toxicity|MTD of Anti-CD137 + Anti-PD-1 as determined by frequency of toxicity|Overall Survival|Progression-free survival rate|Overall Response, assessed by RANO and iRANO|Overall Response to anti-LAG-3 monoclonal antibody BMS-98601, assessed by RANO and iRANO|Overall Response to anti-CD137 as monotherapy, assessed by RANO and iRANO|Overall Response to Anti-LAG-3 + Anti-PD-1, assessed by RANO and iRANO","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABTC 1501|IRB00095527|UM1CA137443","August 2016","August 2019","December 2020","January 20, 2016","null","May 28, 2018","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02658981"
179,"NCT03323580","Effects of Intraoperative GDFT on the Postoperative Brain Edema",,"Recruiting","No Results Available","Fluid Therapy|Brain Edema|Brain Tumor","Other: SVV-based GDFT|Other: traditional fluid therapy","Quantitative analysis of brain edema","Beijing Tiantan Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","2017-10-24","December 20, 2017","October 2019","November 2019","October 27, 2017","null","March 20, 2018","Beijing Tiantan Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03323580"
180,"NCT03436433","Phase II Trial of Seizure Prophylaxis in Suspected Primary Glioma Patients Undergoing Craniotomy",,"Not yet recruiting","No Results Available","Glioma|Glioma of Brain|Brain Tumor","Drug: Lacosamide|Drug: Levetiracetam","Percentage of patients with an ED visit/hospital readmission within 30 days of craniotomy|Adverse event within first 30 days after craniotomy","Duke University","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00081334","June 25, 2018","September 1, 2020","September 1, 2020","February 16, 2018","null","June 1, 2018","Duke Comprehensive Cancer Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03436433"
181,"NCT03190967","T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery",,"Recruiting","No Results Available","Breast Cancer|Brain Metastasis|Brain Cancer","Drug: T-DM1|Drug: TMZ","MTD of temozolomide when used with TDM1|Median amount of time subject survives without disease progression after treatment|adverse event frequency|Number of patients with DLTs at each dose level|Time to whole brain irradiation|Median amount of time subject survives after therapy","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","125","NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170115|17-C-0115","April 18, 2018","June 30, 2022","June 30, 2023","June 19, 2017","null","May 23, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03190967"
182,"NCT02253212","Safety of BBB Opening With the SonoCloud","SONOCLOUD","Recruiting","No Results Available","Glioblastoma|Glioma|Brain Tumor","Device: SonoCloud|Drug: Carboplatin","Safety of transient disruption of the blood-brain barrier using the SonoCloud system in patients with recurrent glioblastoma.|Maximum tolerated dose of ultrasound with the SonoCloud system for transient disruption of the BBB.|Quantification of the disruption of the BBB by the SonoCloud system using dynamic T1 contrast-enhanced MRI.|Progression-free survival in patients treated with the SonoCloud system in combination with carboplatin chemotherapy.|Overall survival in patients treated with the SonoCloud system in combination with carboplatin chemotherapy.","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P120905","July 2014","July 2018","December 2018","October 1, 2014","null","August 29, 2017","Groupe Hospitalier Pitié Salpetriere - Neurosurgery Department, Paris, France","","https://ClinicalTrials.gov/show/NCT02253212"
183,"NCT02409121","A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers",,"Recruiting","No Results Available","Leukemia|Lymphoma|Brain Tumor","Behavioral: Education information system","Number of subjects who participate in the health information technology educational intervention","Sung Choi, M.D.|Agency for Healthcare Research and Quality (AHRQ)|University of Michigan Cancer Center","All","10 Years to 75 Years   (Child, Adult, Older Adult)","Not Applicable","20","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HUM00100126","September 2015","November 2018","December 2018","April 6, 2015","null","June 14, 2018","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02409121"
184,"NCT03371004","DM-CHOC-PEN Plus Radiation for Brain Tumors",,"Recruiting","No Results Available","Advanced Cancer","Drug: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Imaging studies","DEKK-TEC, Inc.","All","21 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DTI-025|5R43CA213545-02","February 5, 2016","December 31, 2018","December 31, 2018","December 13, 2017","null","December 13, 2017","Tulane University Medical Center, New Orleans, Louisiana, United States|Tulane University Medical School, New Orleans, Louisiana, United States|Detroit Clinical Research Centers, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03371004"
185,"NCT00897286","Study of Stored Tumor Samples in Young Patients With Brain Tumors",,"Recruiting","No Results Available","Brain and Central Nervous System Tumors","","Relationship between molecular abnormalities and tumor histologic and clinical characteristics","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","","500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NBTP01","November 30, 2004","February 2026","February 2026","May 12, 2009","null","September 11, 2017","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00897286"
186,"NCT03025893","A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme","STELLAR","Not yet recruiting","No Results Available","Glioblastoma Multiforme|Glioblastoma, Adult|Glioblastoma|Recurrent Brain Tumor|GBM","Drug: Sunitinib|Drug: Lomustine","Six-month progression-free survival (PFS-6)|Overall survival (OS)|Objective radiological response rate|Adverse events (AEs)|Health-related quality of life (HRQoL)|Blood markers (TEP: tumor educated platelets, and miRNA)|MGMT promoter methylation status","VU University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016.221","August 2017","January 2020","January 2020","January 20, 2017","null","August 1, 2017","VU University Medical Center, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT03025893"
187,"NCT03213002","Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM","CAPTEM","Recruiting","No Results Available","Glioblastoma Multiforme (GBM)|Glioblastoma|Glioma of Brain|Glioblastoma, Adult|Brain Tumor|Brain Tumor, Primary|Brain Tumor Adult|Cancer|Brain Cancer","Drug: Capecitabine|Drug: Temozolomide","Progression-free survival (PFS)|Overall Survival (OS)|Composite overall response rate (CORR) through the Response Evaluation Criteria In Solid Tumors (RECIST)|Toxicities will be tabulated and graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03.","Northwell Health","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 1|Phase 2","67","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-0312","June 13, 2017","June 2021","June 2021","July 11, 2017","null","July 11, 2017","Lenox Hill Brain Tumor Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03213002"
188,"NCT02300766","Cerebellar Mutism Syndrome Study",,"Recruiting","No Results Available","Infratentorial Neoplasms|Mutism","","Development and progress of Cerebellar Mutism Syndrome|Development and progress of reduced speech output","Rigshospitalet, Denmark|Odense University Hospital|Aarhus University Hospital|Aalborg Universitetshospital|Technical University of Denmark|Karolinska University Hospital|Skane University Hospital|University Hospital, Linkoeping|Uppsala University Hospital|Sahlgrenska University Hospital, Sweden|University Hospital, Umeå|Oslo University Hospital|Trondheim University Hospital|Haukeland University Hospital|University Hospital of North Norway|Helsinki University Central Hospital|Tampere University Hospital|Kuopio University Hospital|Turku University Hospital|Oulu University Hospital|Radboud University","All","up to 18 Years   (Child, Adult)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-6-2014-002","October 2014","March 2021","March 2022","November 25, 2014","null","December 21, 2017","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Kuopio University Hospital, Kuopio, Finland|Oulu University Hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland|Semmelweis University, 2nd Dept of Pediatrics, Budapest, Hungary|Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas, Lithuania|Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands|UMC Groningen, Groningen, Netherlands|UMC Utrecht, Utrecht, Netherlands|Haukeland University Hospital, Bergen, Norway|Oslo University Hospital, Oslo, Norway|University Hospital of North Norway, Tromsø, Norway|St. Olav's Hospital, Trondheim, Norway|Sahlgrenska University Hospital, Gothenburg, Sweden|Linköping University Hospital, Linköping, Sweden|Skåne University Hospital, Skåne, Sweden|Karolinska University Hospital, Stockholm, Sweden|University Hospital of Umeå, Umeå, Sweden|Uppsala University Hospital, Uppsala, Sweden|Alder Hey Childrens NHS Foundation Trust, Liverpool, United Kingdom","","https://ClinicalTrials.gov/show/NCT02300766"
189,"NCT03463733","Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)","HUTMZ","Recruiting","No Results Available","Glioma|Glioblastoma","Drug: Hydroxyurea|Drug: Temozolomide","Maximal tolerated dose (MTD) hydroxyurea in combination with dose intense temozolomide","M.E. van Linde|Massachusetts General Hospital|VU University Medical Center","All","Child, Adult, Older Adult","Phase 1","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro-16/11","March 12, 2018","June 1, 2019","June 2020","March 13, 2018","null","March 13, 2018","VU University Medical Center, Amsterdam, Noord-Holland, Netherlands","","https://ClinicalTrials.gov/show/NCT03463733"
190,"NCT02885324","Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children",,"Recruiting","No Results Available","Glioblastoma Multiforme|Anaplastic Astrocytoma|Malignant Brain Tumor|High Grade Glioma","Drug: Cabozantinib","Disease response","Indiana University","All","2 Years to 21 Years   (Child, Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IUSCC-0601","May 18, 2017","July 2019","January 2020","August 31, 2016","null","May 28, 2018","Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT02885324"
191,"NCT02942264","TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma",,"Recruiting","No Results Available","Brain Tumor|Astrocytoma|Astroglioma|Glioblastoma|Gliosarcoma","Drug: TG02|Drug: TMZ","Phase I: maximum tolerated dose (MTD) of TG02 plus TMZ using both the dd and mn TMZ schedules in adult patients with recurrent anaplastic astrocytoma or glioblastoma/gliosarcoma.|Phase II: progression free survival in subjects taking TG02 plus TMZ versus TMZ alone in patients with recurrent WHO grade III or IV astrocytoma.|The treatment regimen with better PFS4 between TG02 plus dd TMZ or mn TMZ at each of the MTDs following cohort expansion.|Objective response rate, PFS at 6 months (PFS6) and overall survival(OS) in the treatment arms.|Relationship between symptoms and disease progression and treatment tolerance|Patient's symptom severity and interference with function rating error bar graphs for each symptom severity|Mean core symptom severity, mean severity of the MDASI, and mean symptom interference|Estimates of differences in the mean symptom severity and mean symptom interference between responders and non-responders will be estimated in the intent to treat population","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","152","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170009|17-C-0009","October 21, 2016","August 2, 2021","August 2, 2022","October 24, 2016","null","July 6, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02942264"
192,"NCT02208362","Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma",,"Recruiting","No Results Available","Malignant Glioma|Refractory Brain Neoplasm|Recurrent Brain Neoplasm|Glioblastoma","Biological: IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing Autologous T lymphocytes|Other: laboratory biomarker analysis|Other: quality-of-life assessment|Procedure: Magnetic Resonance Imaging|Procedure: Magnetic Resonance Spectroscopic Imaging|Biological: Vaccine Therapy|Other: Laboratory Biomarker Analysis|Other: Quality of Life Assessment","Incidence of grade 3 toxicity, graded using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0, the revised cytokine release syndrome grading system as well as the modified neurological grading system|Incidence of DLT, graded using NCI CTCAE version 4.0|Incidence of toxicities, graded using NCI CTCAE version 4.0 as well as the modified neurological grading system|Changes in largest length of tumor|Changes in cytokine levels|Changes in CAR T cell levels|Progression free survival|Disease response by the Response Assessment in Neuro-Oncology criteria|Overall survival (OS)|Changes in quality of life|T cell detection in tumor|IL13Ra2 antigen expression levels|Disease response from intraventricular infusion following progression after intracranial infusion (stratum 1 and 2)","City of Hope Medical Center|National Cancer Institute (NCI)|Gateway for Cancer Research|Mustang Bio, Inc.","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1","92","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13384|NCI-2014-01488|R01FD005129","May 18, 2015","May 2020","May 2020","August 5, 2014","null","May 1, 2018","City of Hope Medical Center, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT02208362"
193,"NCT02919332","Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma",,"Recruiting","No Results Available","Glioblastoma|Glioma","Procedure: Computed Tomography|Radiation: Fludeoxyglucose F-18|Procedure: Positron Emission Tomography","Tumor-to-background ratio on delayed scans (240 min after injection)|Tumor-to-background ratio on standard scans (60 min after injection)|Standard uptake value comparison","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 99 Years   (Adult, Older Adult)","","100","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","16-000600|NCI-2016-01214|16-000600 JCCCID655|P30CA016042","June 8, 2016","June 2021","June 2022","September 29, 2016","null","October 13, 2017","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02919332"
194,"NCT02343406","Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas","INTELLANCE 2","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: Lomustine|Drug: ABT-414|Drug: Temozolomide","Pediatric study: Maximum observed serum concentration (Cmax) for ABT-414|Adult study: Progression Free Survival (PFS)|Pediatric study: AUC for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414)|Pediatric study: Half-life (t1/2) observed for ABT-414|Pediatric study: Area Under the Concentration-time Curve (AUC) observed for ABT-414|Pediatric study: Maximum observed plasma concentration (Cmax) for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414)|Pediatric study: t1/2 for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414)|Adult study: Overall Survival (OS)|Pediatric study: Safety including toxicities according to CTCAE criteria|Pediatric study: Objective response rate, best response rate and duration of response based on RANO criteria|Pediatric study: Overall survival, Time to progression and Time to progression-free survival|Adult study: Overall Response Rate (ORR)|Pediatric study: Changes in neurological status and function (including PedsQL cancer module)|Adult study: Overall Survival in the subgroup with Epithelial Growth Factor Receptor (EGFRvIII) mutation","AbbVie|European Organisation for Research and Treatment of Cancer - EORTC","All","up to 99 Years   (Child, Adult, Older Adult)","Phase 2","260","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-483|2014-004438-24|EORTC 1410-BTG","February 11, 2015","December 27, 2019","June 11, 2020","January 22, 2015","null","May 16, 2018","Lucile Packard Children's Hosp, Palo Alto, California, United States|Univ California, San Francisco, San Francisco, California, United States|Univ of Colorado Cancer Center, Aurora, Colorado, United States|Univ of Colorado Cancer Center, Aurora, Colorado, United States|Rush University Medical Center, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pittsburgh MC, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology-Sarah Cannon Research Institute, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Sydney Children's Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, Saint Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Southern Medical Day Care Ctr, Wollongong, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Barwon Health, Univ Hosp Geelo, Geelong, Victoria, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|University Hospital St. Polten, St. Pölten, Niederosterreich, Austria|LKH-Univ. Klinikum Graz, Graz, Austria|Kepler Universitatskliniken, Linz, Austria|Cliniques Universitaires Saint Luc, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Grand Hôpital de Charleroi, Charleroi, Hainaut, Belgium|UZ Gent, Gent, Oost-Vlaanderen, Belgium|AZ St-Jan Brugge-Oostende AV, Brugge, West-Vlaanderen, Belgium|ZNA Middelheim, Antwerp, Belgium|UZ Leuven, Leuven, Belgium|Hospital for Sick Children, Toronto, Ontario, Canada|Montreal Neurological Institut, Montreal, Quebec, Canada|Masarykuv onkologikcy ustav, Brno, Czechia|FN Hradec Kralove, Hradec Kralove, Czechia|Univ Hosp Ostrava-Poruba, Ostrava, Czechia|Fakultni Nemocnice v Motole, Prague, Czechia|Helsinki Univ Central Hospital, Helsinki, Finland|Helsinki Univ Central Hospital, Helsinki, Finland|Turku University Hospital, Turku, Finland|CHRU Lille - Hôpital Claude Huriez, Lille CEDEX, Hauts-de-France, France|Centre Oscar Lambret, Lille, Hauts-de-France, France|CHU-Hopital Avicenne, Bobigny, Ile-de-France, France|Institut Gustave Roussy, Villejuif, Ile-de-France, France|Institut de Cancer de l'Ouest, St Herblain CEDEX, Loire-Atlantique, France|Hopital de la Timone, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|CHU de Nice, Nice CEDEX 1, Provence-Alpes-Cote-d Azur, France|Centre Leon Berard, Lyon CEDEX 08, Rhone, France|Institut de Cancer de l'Ouest, Angers, France|Hospices Civils de Lyon, Bron, France|Hopital Pitie Salpetriere, Paris, France|Universitaetsklinik Heidelberg, Heidelberg, Baden-Wurttemberg, Germany|Universitatsklinik Regensburg, Ratisbon, Bayern, Germany|Univ Klinik Eppendorf Hamburg, Hamburg, Germany|Klinikum der Univ Munich, Munich, Germany|Universitatsklinikum Tubingen, Tuebingen, Germany|Pecsi Tudomanyegyetem, Pécs, Pecs, Hungary|Semmelweis Egyetem, Budapest, Hungary|National Institute of Oncology, Budapest, Hungary|Orszagos Klinikai Idegtudomany, Budapest, Hungary|Debreceni Egyetem Klinikai Koz, Debrecen, Hungary|Cork University Hospital, Cork, Ireland|Beaumont Hospital, Dublin, Ireland|Istituto delle Scienze Neurolo, Bologna, Italy|Ospedale Generale di Bolzano, Bolzano, Italy|Fondazione IRCCS Istituto Neur, Milan, Italy|Istituto Oncologico Veneto, Padua, Italy|Azienda Ospedaliera Sant' Andr, Rome, Italy|Seoul National Univ Bundang ho, Seongnam, Gyeonggido, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Vrije Univ Medisch Centrum, Amsterdam, Netherlands|Univ Med Center Groningen, Groningen, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|MC Haaglanden - Westeinde, The Hague, Netherlands|UMC Utrecht, Utrecht, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdańsk, Mazowieckie, Poland|Wojewodzkie Wielospecjalistycz, Lodz, Poland|National University Hospital, Singapore, Singapore|National Cancer Ctr Singapore, Singapore, Singapore|KK Women's & Children Hospital, Singapore, Singapore|Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Clinica Universitar de Navarra, Pamplona, Navarra, Comunidad, Spain|Hospital Universitario Nino, Madrid, Spain|Hosp Univ 12 de Octubre, Madrid, Spain|Centre Hospitalier Univ Vaudoi, Lausanne, Switzerland|University Hospital Zurich, Zurich, Switzerland|China Medical University Hosp, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp, Taipei City, Taipei, Taiwan|Taichung Veterans General Hosp, Taichung City, Taiwan|Taipei Veterans General Hosp, Taipei City, Taiwan|Linkou Chang Gung Memorial Ho, Taoyuan City, Taiwan|Guy's and St Thomas' NHS Found, London, London, City Of, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust, Birmingham, United Kingdom|Gartnavel General Hospital, Glasgow, United Kingdom|Hull and East Yorkshire NHS, Hull, United Kingdom|University College Hospitals, London, United Kingdom|Great Ormond St Hospital NHS, London, United Kingdom|Christie NHS Foundation Trust, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT02343406"
195,"NCT02747407","Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors",,"Recruiting","No Results Available","Astrocytoma|Glioma|Oligodendroglioma","Biological: Hepatitis A Vaccine|Other: Laboratory Biomarker Analysis|Biological: Tetanus Toxoid Vaccine|Biological: Trivalent Influenza Vaccine","Proliferative ability of lymphocytes by carboxyfluorescein diacetate succinimidyl ester assay|The quantity of cells determined by flow cytometry|Response of the tetanus toxoid vaccine-specific IgG antibody|Vaccine-specific total antibody response after hepatitis A vaccination. In hepatitis A exposed patients, hepatitis B will be used.","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00037250|NCI-2016-00472|CCCWFU 01316|P30CA012197","May 2016","August 2018","August 2018","April 21, 2016","null","July 2, 2018","Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02747407"
196,"NCT00075387","Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors",,"Recruiting","No Results Available","Glioma","Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Etoposide Phosphate|Other: Quality-of-Life Assessment|Drug: Sodium Thiosulfate","Rate of platelet toxicities (i.e. platelet count less than 20,000), graded according to the National Cancer Institute Common Toxicity Criteria version 3.0|Change in hearing levels, if any, at the higher frequencies in the standard testing range (4000 and 8000 Hz), and at higher frequencies above standard testing (9000 to 16000 Hz) based on American Speech-Language-Hearing Association criteria|Erythrocyte counts|Granulocyte count|Number of dose reductions and transfusions due to platelet toxicity|Quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and Quality of Life Questionnaire-Brain Module-20|Time to disease progression|Time to response|Tumor response (complete response + partial response + stable disease) assessed by neurologic exams, radiographic studies, and steroid dose","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IRB00000922|NCI-2013-00781|MR00041590|CR00023930|eIRB #922|CR00018679|ONC-02019-L|CR00021317|CR00022743|P30CA069533","March 7, 2003","April 30, 2020","April 30, 2021","January 12, 2004","null","May 7, 2018","University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT00075387"
197,"NCT03496181","Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently",,"Recruiting","No Results Available","Glioma|Glioma of Brain|Glioma of Spinal Cord","Behavioral: Multilingual Aphasia Examination|Diagnostic Test: Language paradigms + RS fMRI|Diagnostic Test: Language paradigms + RS fMRI + one anatomical sequence","Comparison of RS fMRI and overall TB fMRI","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18-121","March 30, 2018","March 2019","March 2019","April 12, 2018","null","June 12, 2018","Memorial Sloan - Kettering Cancer Center, New York, New York, United States|City College of New York, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03496181"
198,"NCT03050736","Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression",,"Recruiting","No Results Available","Glioma|Glioblastoma|Glioblastoma Multiforme|GBM|Brain Cancer","Drug: VAL-083 (Dianhydrogalactitol)","Efficacy evaluation of tumor response in patients, as measured by magnetic resonance imaging|Safety evaluation of VAL-083 in combination with a standard radiation therapy, as determined by incidence of patient adverse events and changes in laboratory results, ECG and vital signs|Ctrough|Cmax|Tmax|AUClast|AUCinf|CL/F|Mean Residence Time|Vz|Lambda z|T½|Pharmacokinetic profile and dose-exposure relationship of VAL-083 in Cerebral Spinal Fluid (CSF)","DelMar Pharmaceuticals, Inc.|Sun Yat-sen University","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 2","30","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DLM-14-001","February 2018","February 2019","August 2019","February 13, 2017","null","January 17, 2018","Sun Yat-Sen University Cancer Center, Guangzhou, China","","https://ClinicalTrials.gov/show/NCT03050736"
199,"NCT02717962","Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioma|Glioblastoma|Glioblastoma Multiforme|GBM|Brain Cancer","Drug: VAL-083, Dianhydrogalactitol","Overall Survival|Estimate Progression-free Survival|Estimate Median Progression-Free Survival|Estimate Median Overall Survival|Estimate Overall Response Rate|Estimate Duration of Response|Safety evaluation of VAL-083 in patients|Quality of Life|Plasma Pharmacokinetics","DelMar Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DLM-16-001","January 20, 2017","September 2020","June 2021","March 24, 2016","null","January 18, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02717962"
200,"NCT02756312","The Perioperative Anesthetic Management and the Prognosis of Patients Undergoing Brain Malignant Glioma Resection",,"Recruiting","No Results Available","Anesthesia, Prognosis, Malignant Glioma","Other: IV Anesthesia|Other: IH anesthesia","progression free survival rate","Beijing Tiantan Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ChiECRCT-2016008","July 15, 2017","October 31, 2018","December 31, 2018","April 29, 2016","null","July 17, 2017","Beijing Tiantan Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02756312"
201,"NCT03466762","Resilience and Quality of Life Among Cancer Survivors",,"Not yet recruiting","No Results Available","Mental Health Wellness 1","Other: Non applicable","Resilience|Quality of life","Aga Khan University","All","18 Years and older   (Adult, Older Adult)","","500","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","5154-Sur-ERC-17","April 1, 2018","November 30, 2018","March 31, 2019","March 15, 2018","null","March 16, 2018","Aga Khan University, Karachi, Sindh, Pakistan","","https://ClinicalTrials.gov/show/NCT03466762"
202,"NCT02391246","Radionecrosis and FDG PET","DTPI FDG-PET","Recruiting","No Results Available","Malignant Glioma","Other: Positron Emission Tomography Imaging","sensitivity and specificity percentages|Cost efficiency analysis","Ottawa Hospital Research Institute","All","18 Years and older   (Adult, Older Adult)","","62","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20150094-01H","June 2015","March 2018","March 2018","March 18, 2015","null","April 13, 2017","The Ottawa Hospital, Ottawa, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02391246"
203,"NCT03565367","Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors",,"Not yet recruiting","No Results Available","Malignant Central Nervous System Neoplasm|Metastatic Malignant Neoplasm in the Central Nervous System","Other: Gadolinium|Drug: Hyperpolarized Carbon C 13 Pyruvate|Procedure: Magnetic Resonance Imaging|Procedure: Magnetic Resonance Spectroscopic Imaging","Incidence of Grade 2 or Higher Toxicities|Lactate and Bicarbonate Production in Tumor and Normal Brain Tissue","Daniel M. Spielman|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BRN0036|NCI-2018-01122|39845","November 14, 2018","November 14, 2019","November 14, 2019","June 21, 2018","null","June 21, 2018","Stanford University School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03565367"
204,"NCT01454596","CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII",,"Recruiting","No Results Available","Malignant Glioma|Glioblastoma|Brain Cancer|Gliosarcoma","Biological: Anti-EGFRvIII CAR transduced PBL|Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide","Frequency of treatment related adverse events|Progression-free survival|Radiographic changes|Engineered cell survival","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","107","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110266|11-C-0266","September 29, 2011","December 29, 2028","December 28, 2029","October 19, 2011","null","July 6, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01454596"
205,"NCT01904123","Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma",,"Not yet recruiting","No Results Available","Brain Cancer|Central Nervous System Neoplasms|Melanoma|Solid Tumors","Drug: WP1066|Procedure: Advanced Brain Tumor Imaging (ABTI)|Procedure: Surgical Resection","Maximum Tolerated Dose (MTD) of WP1066|Overall Response Rate (ORR)|Progression Free Survival (PFS)","M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0358|P50CA093459|P50CA127001|NCI-2015-00163","July 2018","July 2021","July 2022","July 22, 2013","null","May 4, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01904123"
206,"NCT02849743","Intranasal Oxytocin in Hypothalamic Obesity",,"Recruiting","No Results Available","Craniopharyngioma|Hypothalamic Obesity","Drug: Syntocinon|Drug: Placebo (for Syntocinon)","Weight loss|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Peripheral oxytocin area under the curve (AUC)","Shana McCormack, MD|Children's Hospital of Philadelphia","All","10 Years to 35 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16-012730","October 2016","July 2019","July 2020","July 29, 2016","null","May 15, 2018","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02849743"
207,"NCT03543020","Radiation- Induced Alopecia in Patients Undergoing Radiation Therapy to the Brain",,"Recruiting","No Results Available","Alopecia; X-Rays","Radiation: radiation therapy to brain","To record the degree of alopecia at the conclusion of radiotherapy compared to pre- radiotherapy status with use of scalp sparing radiotherapy technique.|radiation dose range levels that causes alopecia|in vivo dosimetry values for scalp doses in modern radiotherapy treatment","Fortis Memorial Research Institute","All","Child, Adult, Older Adult","","50","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017-008IP-20","July 17, 2017","December 17, 2018","January 30, 2019","June 1, 2018","null","June 14, 2018","Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon, Haryana, India","","https://ClinicalTrials.gov/show/NCT03543020"
208,"NCT01817751","Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma",,"Recruiting","No Results Available","Glioblastoma|Recurrent Adult Brain Neoplasm|Malignant Glioma|WHO Grade III Glioma","Drug: sorafenib tosylate|Drug: valproic acid|Drug: sildenafil citrate","PFS|Overall best response rate (complete response + partial response) using RANO or Macdonald criteria.|Overall survival|Incidence of adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0","Virginia Commonwealth University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-14816|HM14816|NCI-2013-00705|P30CA016059","April 11, 2013","December 31, 2018","March 31, 2019","March 25, 2013","null","March 21, 2018","Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01817751"
209,"NCT03389802","Phase I Study of APX005M in Pediatric CNS Tumors",,"Recruiting","No Results Available","Glioblastoma Multiforme|High-grade Astrocytoma NOS|CNS Primary Tumor, Nos|Ependymoma, NOS|Diffuse Intrinsic Pontine Gliomas (DIPG)|Medulloblastoma","Biological: APX005M treatment for recurrent or refractory primary malignant CNS tumor patients|Biological: APX005M treatment for newly diagnosed DIPG patients","The incidence of APX005M treatment-emergent adverse events in children with central nervous system tumors.|The maximum tolerated dose and/or the recommended phase II dose of APX005M.|The pharmacokinetics of APX005M.|The overall response rate.|The duration of response.|The progression-free survival.|The overall survival for DIPG patients.","Pediatric Brain Tumor Consortium|St. Jude Children's Research Hospital|American Lebanese Syrian Associated Charities|The Cancer Therapy Evaluation Program of the National Cancer Institute|Apexigen, Inc.|Solving Kids’ Cancer|Ty Louis Campbell Foundation|A Kids Brain Tumor Cure","All","1 Year to 21 Years   (Child, Adult)","Phase 1","45","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PBTC-051","February 2, 2018","September 30, 2019","September 30, 2022","January 4, 2018","null","February 6, 2018","Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children Hospital Stanford University, Palo Alto, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Childrens National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Lurie Childrens Hospital-Chicago, Chicago, Illinois, United States|National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children Hospital Medical Center, Cincinnati, Ohio, United States|Children Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03389802"
210,"NCT03343873","The Effects of Different Anesthetics on Functional Connectivity and (EEG)","ACTION","Not yet recruiting","No Results Available","Sedation","Drug: Midazolam|Drug: Propofol|Drug: Ketamine|Drug: Dexmedetomidine|Drug: Saline","Amplitude of Low Frequency Fluctuations（ALLF）and Regional Homogeneity（ReHo)","Beijing Tiantan Hospital","Male","18 Years to 45 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","2017-7-17","January 1, 2018","December 31, 2019","December 31, 2020","November 17, 2017","null","November 17, 2017","","","https://ClinicalTrials.gov/show/NCT03343873"
211,"NCT02861898","Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma",,"Recruiting","No Results Available","Glioblastoma|Brain Cancer|Brain Neoplasm|Brain Tumor|Brain Neoplasm, Malignant|EGFR Gene Overexpression|GBM","Drug: Intra-arterial Cetuximab|Drug: Intra-arterial Mannitol","Progression Free Survival (PFS)|Overall Survival (OS)|Composite overall response rate (CORR) through the Response Assessment in Neuro-Oncology (RANO)|Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS16-0257","June 2016","June 2019","June 2019","August 10, 2016","null","March 1, 2018","Lenox Hill Brain Tumor Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02861898"
212,"NCT03152318","A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2","rQNestin","Recruiting","No Results Available","Malignant Glioma of Brain|Astrocytoma|Malignant Astrocytoma|Oligodendroglioma|Anaplastic Oligodendroglioma of Brain (Diagnosis)|Mixed Oligo-Astrocytoma|Ependymoma|Ganglioglioma|Pylocytic/Pylomyxoid Astrocytoma|Brain Tumor|Glioma|Brain Cancer|Glioblastoma|Glioblastoma Multiforme","Drug: rQNestin|Drug: Cyclophosphamide|Procedure: Stereotactic biopsy","Maximum Tolerated Dose|MRI Changes in Permeability|MRI Changes in Volume|MRI Changes in Flow|Viral Shedding in Saliva|HSV1 Viremia|HSV1 Antibody Response","Dana-Farber Cancer Institute|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Phase 1","108","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-557","July 18, 2017","July 2021","July 2022","May 15, 2017","null","April 10, 2018","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03152318"
213,"NCT03126266","Re-Irradiation of Progressive or Recurrent DIPG",,"Recruiting","No Results Available","Recurrent or Progressive Diffuse Intrinsic Pontine Glioma","Radiation: re-irradiation","second progression-free survival|overall survival","University of Calgary|Meagan's Walk|Janeway Child Health Centre|IWK Health Centre|St. Justine's Hospital|Montreal Children's Hospital of the MUHC|CHU de Quebec-Universite Laval|Children's Hospital of Eastern Ontario|The Hospital for Sick Children|McMaster Children's Hospital|Children's Hospital Medical Center, Cincinnati|CancerCare Manitoba|Stollery Children's Hospital|Alberta Children's Hospital|British Columbia Children's Hospital","All","up to 17 Years   (Child)","Not Applicable","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HREBA.CC16-0143","April 15, 2017","October 2021","October 2021","April 24, 2017","null","October 26, 2017","Alberta Children's Hospital, Calgary, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT03126266"
214,"NCT01674582","Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters",,"Recruiting","No Results Available","Intracranial Tumor","Other: MRI, neuropsychological evaluation, blood sampling","Early prediction of treatment response based on MRI parameters.|Neuropsychological function.","Lund University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Version1.0","October 2012","February 2019","February 2019","August 29, 2012","null","March 12, 2018","Lund University Hospital, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT01674582"
215,"NCT01748149","Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas",,"Recruiting","No Results Available","Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas","Drug: Vemurafenib","Maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D)|Toxicity Profile (dose limiting toxicities)|Concentrations of vemurafenib in the blood found through pharmacokinetic samples|Objective Response|Intra-tumoral drug concentration Comparison|Progression-free survival","Theodore Nicolaides MD|Genentech, Inc.|University of California, San Francisco","All","up to 25 Years   (Child, Adult)","Early Phase 1","54","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC #120819|NCI-2014-00387","February 2014","January 2019","June 2020","December 12, 2012","null","June 1, 2018","Children's Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota/Masonic Children's Hospital, Minneapolis, Minnesota, United States|Saint Louis Children's Hospital, Saint Louis, Missouri, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01748149"
216,"NCT02768337","Cambridge Brain Mets Trial 1","CamBMT1","Recruiting","No Results Available","Lung Cancer|Breast Cancer|Brain Cancer|Advanced Breast Cancer|Advanced Lung Cancer","Drug: Afatinib|Radiation: 2 Gy targeted radiotherapy|Radiation: 4 Gy targeted radiotherapy","Ratio of afatinib concentration in: [resected brain metastases] / [plasma] - each measured in (ng/mL) on day 12|Safety of afatinib alone and combined with targeted low-dose radiotherapy - assessed by number of participants with treatment- related adverse events as assessed by CTCAE v4.0","Cambridge University Hospitals NHS Foundation Trust|Boehringer Ingelheim|Cancer Research UK|University of Cambridge|The Brain Tumour Charity","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CamBMT1|2013-002398-23|1200.206|146009","February 2015","October 2019","December 2019","May 11, 2016","null","February 23, 2017","Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT02768337"
217,"NCT02903069","Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer",,"Recruiting","No Results Available","Glioblastoma|Malignant Glioma","Drug: MRZ|Drug: TMZ|Radiation: RT|Device: Optune","Determine MRZ maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for both concomitant treatment (MRZ + TMZ + RT) and adjuvant treatment (MRZ + TMZ)|To assess adverse events during the adjuvant treatment|To confirm the MRZ RP2D for concomitant and adjuvant treatment in an expanded group of patients|Assess adverse events during concomitant and adjuvant treatment|Evaluate the activity (overall survival [OS]) of MRZ + TMZ + RT|Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + RT|MRZ pharmacokinetics - Maximum Serum Concentration (Cmax)|MRZ pharmacokinetics - Elimination Half-Life (t1/2)|MRZ pharmacokinetics - Area Under the Blood Concentration-Time Curve (AUC0-t, AUC0-inf)|MRZ pharmacokinetics - Clearance (CL)|MRZ pharmacokinetics - Volume of Distribution (Vd)|TMZ serum concentration|Assess neurological coordination using the Scale for the Assessment and Rating for Ataxia (SARA)|Evaluate the activity (overall survival [OS]) of MRZ + TMZ + Optune|Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + Optune","Celgene|Triphase","All","18 Years and older   (Adult, Older Adult)","Phase 1","72","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRZ-112","April 15, 2016","June 18, 2019","May 31, 2020","September 16, 2016","null","April 27, 2018","University of California, Irvine Medical Center Comprehensive Brain Tumor Program, Irvine, California, United States|University of California, San Diego Moores Cancer Center, La Jolla, California, United States|John Wayne Cancer Institute at the Providence Saint John's Health Center, Santa Monica, California, United States|Northwestern Brain Tumor Institute at Northwestern University, Chicago, Illinois, United States|Duke University Medical Center, Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Princess Margaret Hospital, Gerry and Nancy Pencer Brain Tumour Centre, Toronto, Ontario, Canada|University Hospital Zurich Brain Tumor Center, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT02903069"
218,"NCT03503110","Bridging Brain Structure and Function by Correlating Structural Connectivity, Cortico-Cortical Transmission and Direct Electro-Stimulation",,"Not yet recruiting","No Results Available","Tumor, Brain","Other: electrocorticography with electrostimulation|Other: dRMI","Descriptive activity of brain with dMRI results|Descriptive functional responses elicited by the direct electrostimulation of the cortex.","Centre Hospitalier Universitaire de Nice|INRIA sophia antipolis","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","17-PP-15","April 2018","July 2019","July 2019","April 19, 2018","null","April 20, 2018","","","https://ClinicalTrials.gov/show/NCT03503110"
219,"NCT03076255","Head and Neck Maskless Immobilization Device in Immobilizing Patients With Intracranial Tumors Undergoing Radiation Therapy",,"Recruiting","No Results Available","Brain and Nervous System|Intracranial Neoplasm","Procedure: Computed Tomography|Device: Medical Device|Procedure: Cone-Beam Computed Tomography","Accuracy measured by quantifying the difference in translational shifts from the daily setup to planning CT scan digitally reconstructed radiograph","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","16D.557","February 24, 2017","February 2021","February 2022","March 10, 2017","null","May 24, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03076255"
220,"NCT00736749","Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Brain Neoplasm|Hodgkin Lymphoma|Rhabdomyosarcoma","Procedure: Assessment of Therapy Complications|Other: Questionnaire Administration","Collection of cumulative therapeutic exposure data|Collection of protocol-specific outcome data|Percentage of eligible patients located who were lost to follow-up|Percentage of located patients enrolled|Percentage of patients enrolled|Percentage of patients in which long-term (20+ years) contact is maintained","Children's Oncology Group|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","","4485","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ALTE05N1|NCI-2009-00382|PALTE05N1_A06PAMDREVW01|CDR0000590123|U10CA180886|U10CA098543","May 2008","January 2100","null","August 18, 2008","null","October 23, 2017","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|University of South Alabama, Mobile, Alabama, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Southern California Permanente Medical Group, Downey, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, D.C., District of Columbia, United States|Children's National Medical Center, Washington, D.C., District of Columbia, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Lee Memorial Health System, Fort Myers, Florida, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida, Gainesville, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Florida Hospital Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Columbia Regional, Columbia, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|The Childrens Mercy Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Children's Specialty Center of Nevada II, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Montefiore Medical Center - Moses Campus, The Bronx, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospital-Memorial Campus, Asheville, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Medical Center-Fargo, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Mercy Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Palmetto Health Richland, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Greenville Cancer Treatment Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|T C Thompson Children's Hospital, Chattanooga, Tennessee, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont College of Medicine, Burlington, Vermont, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Childrens Hospital-King's Daughters, Norfolk, Virginia, United States|Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, United States|West Virginia University Charleston, Charleston, West Virginia, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|San Jorge Children's Hospital, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00736749"
221,"NCT01677741","A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects",,"Recruiting","No Results Available","Neoplasms, Brain","Drug: Dabrafenib","Safety and tolerability of dabrafenib dose that achieves similar exposures to the dabrafenib adult dose as assessed by number of subjects with adverse events (AEs)|Safety and tolerability of dabrafenib dose that achieves similar exposures to the dabrafenib adult dose as assessed by change from Baseline in ECG readings|Safety and tolerability of dabrafenib dose that achieves similar exposures to the dabrafenib adult dose as assessed by change from Baseline in ECHO findings|Safety and tolerability of dabrafenib dose that achieves similar exposures to the dabrafenib adult dose as assessed by change from Baseline in laboratory values|Safety and tolerability of dabrafenib dose that achieves similar exposures to the dabrafenib adult dose as assessed by change from Baseline in vital signs|Maximum concentration (Cmax) of dabrafenib dose(s)|Area under the concentration-time curve over the dosing interval (AUC(0-τ)) and AUC from zero to infinity (AUC(0-inf)) of dabrafenib dose(s)|Pre-dose (trough) concentration (C tau) of dabrafenib and its metabolites|The AUC(0-t) and AUC(0-tau) of dabrafenib and its metabolites|Apparent clearance following oral dosing (CL/F) of dabrafenib|Cmax of dabrafenib, and its metabolites|Time from administration to Cmax (tmax) of dabrafenib and its metabolites|Elimination half life (t½) of dabrafenib and its metabolites|Longer term safety and tolerability of dabrafenib as assessed by number of subjects with AEs|Longer term safety and tolerability of dabrafenib as assessed by change from Baseline in ECG readings|Longer term safety and tolerability of dabrafenib as assessed by change from Baseline in laboratory values|Longer term safety and tolerability of dabrafenib as assessed by change from Baseline in vital signs|Overall tumor response of dabrafenib|Effect of age and weight on CL/F of dabrafenib|Effect of age and weight on volume of distribution (V/F) of dabrafenib|Effect of age and weight on absorption rate (ka) of dabrafenib|Effect of age and weight on coefficients for significant covariates of dabrafenib","Novartis Pharmaceuticals|Novartis","All","12 Months to 17 Years   (Child)","Phase 1","86","Industry","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","116013","February 27, 2013","September 2, 2019","September 2, 2019","September 3, 2012","null","May 14, 2018","Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Subiaco, Western Australia, Australia|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Marseille Cedex 5, France|Novartis Investigative Site, Paris cedex 05, France|Novartis Investigative Site, Paris cedex 12, France|Novartis Investigative Site, Toulouse cedex 9, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Ramat-Gan, Israel|Novartis Investigative Site, Milan, Italy|Novartis Investigative Site, Esplugues De Llobregat. Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01677741"
222,"NCT03244995","An Online Dyadic Mind-Body Intervention for Glioma Patients and Their Partners",,"Recruiting","No Results Available","Malignant Neoplasms of Eye|High Grade Glioma|Malignant Neoplasms of Brain|Malignant Neoplasms of Central Nervous System","Behavioral: Questionnaires|Behavioral: Mind-Body Intervention|Other: Compact Discs (CD's) + Printed Materials|Behavioral: Phone Calls","Feasibility of Couple-Based Mind-Body (CBMB) Program in Patients with High Grade Glioma (HGG) and Their Partners Determined by Overall Accrual|Feasibility of Couple-Based Mind-Body (CBMB) Program in Patients with High Grade Glioma (HGG) and Their Partners Determined by Attrition|Feasibility of Couple-Based Mind-Body (CBMB) Program in Patients with High Grade Glioma (HGG) and Their Partners Determined by Adherence|Feasibility of Couple-Based Mind-Body (CBMB) Program in Patients with High Grade Glioma (HGG) and Their Partners Determined by Acceptability|Efficacy of Couple-Based Mind-Body (CBMB) Program in Patients with High Grade Glioma (HGG) and Their Partners","M.D. Anderson Cancer Center|Hackett Family Foundation Award","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2017-0290","August 6, 2017","July 2019","July 2020","August 10, 2017","null","May 9, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03244995"
223,"NCT03177252","Scalp Block: Hemodynamic Stability and Patient Comfort In Craniotomy Patients","Scalp block","Not yet recruiting","No Results Available","Tumor, Brain|Anesthesia, Local","Drug: Lidocaine|Drug: Sodium chloride|Drug: Bupivacaine","Overall perioperative comfort of the patient as measured by hemodynamic fluctuations|Overall perioperative comfort as measured by opioid requirements|Cost-effectiveness of scalp block","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","201701037","June 30, 2018","June 30, 2019","June 30, 2019","June 6, 2017","null","May 10, 2018","Washington University in St Louis School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03177252"
224,"NCT03028246","A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects",,"Recruiting","No Results Available","Benign Centrally-Located Intracranial Tumors","Device: ExAblate 4000 System","Incidence of Treatment-Emergent Adverse Events Safety and Tolerability|Measurement of Tumor Volume|Changes in the General Physical Exam|Changes in the Neurological Exam|Confrontational Visual Field Testing|Global Impression of Change-Clinician|Patient Global Impression of Change","InSightec","All","8 Years to 22 Years   (Child, Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BT005","February 28, 2017","March 31, 2020","December 31, 2021","January 23, 2017","null","June 27, 2018","Miami Children's Research Institute - Nicklaus Children's Hospital, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT03028246"
225,"NCT00840047","Methionine PET/CT Studies In Patients With Cancer",,"Recruiting","No Results Available","Brain Tumors and/or Solid Tumors Including|Brain Stem Glioma|High Grade CNS Tumors|Ependymoma|Medulloblastoma|Craniopharyngioma|Low Grade CNS Tumors|Hodgkin Lymphoma|Non Hodgkin Lymphoma|Ewing Sarcoma|Osteosarcoma|Rhabdomyosarcoma|Neuroblastoma|Other","Drug: Methionine","Success rate of methionine (MET) for visualizing tumors|Association of methionine uptake with tumor grade|Bio-distribution of MET in organs","St. Jude Children's Research Hospital","All","Child, Adult, Older Adult","Phase 2","650","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","METPET|NCI-2011-02414","July 20, 2009","May 31, 2020","May 31, 2023","February 10, 2009","null","June 18, 2018","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00840047"
226,"NCT02800486","Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",,"Recruiting","No Results Available","Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Glioma|Brain Neoplasm|Brain Cancer|Brain Tumor|Brain Tumor, Recurrent|Brain Neoplasm, Malignant","Drug: Intra-arterial Cetuximab|Drug: Intra-arterial Mannitol|Radiation: Hypofractionated re-irradiation","Progression Free Survival (PFS)|Overall Survival (OS)|Composite overall response rate (CORR) through the Response Evaluation Criteria In Solid Tumors (RECIST)|Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS16-0181","May 2016","May 2020","May 2021","June 15, 2016","null","March 1, 2018","Lenox Hill Brain Tumor Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02800486"
227,"NCT03115398","A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery",,"Recruiting","No Results Available","Brain Cancer|Head and Neck Cancer|Lung Cancer|Gastrointestinal Cancer|Cervical Cancer","Behavioral: Pedometer-based Walking Program","Number of Missed Scheduled Radiotherapy Treatments|Daily Step Counts|Treatment-related Toxicities|Patient-reported Quality of Life Scores|Number of Emergency Room Visits|Number of Hospitalizations|Modified Glasgow Prognostic Scores|Disease Progression or Recurrence|Survival Status","Albert Einstein College of Medicine, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","166","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2017-7472","February 16, 2017","February 16, 2021","February 16, 2023","April 14, 2017","null","May 30, 2018","Montefiore Medical Center, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT03115398"
228,"NCT01849952","Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas",,"Recruiting","No Results Available","Astrocytoma|Oligodendroglioma|Oligoastrocytoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma|Brain Tumors|Brain Cancer","","Overall Survival|Progression-Free Survival","Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Older Adult)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","D12160","May 2013","May 2018","May 2018","May 9, 2013","null","August 19, 2016","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT01849952"
229,"NCT02584400","Tumor Hypoxia With HX4 PET in Several Diseases","HX4 SD","Recruiting","No Results Available","Prostatic Neoplasms|Esophageal Neoplasms|Neoplasm Metastases, Brain|Rectal Neoplasms|Brain Neoplasm, Primary","Drug: Injection with the hypoxia tracer [18F]HX4,","Visualization of tumor hypoxia with [18F] HX4 PET imaging, valuated by the measurement of a tumor-to-background (T/B) ratio on the [18F]HX4 PET/CT|Quantification of tumor hypoxia with [18F] HX4 PET imaging, evaluated by the measurement of a tumor-to-background (T/B) ratio on the [18F]HX4 PET/CT|Time between [18F] HX4 uptake with local and locoregional tumor recurrence and survival|Correlation of hypoxia imaging with blood hypoxia markers will be measured by the Pearson or Spearman correlation coefficient|Correlation of hypoxia imaging with tumor tissue biomarkers will be measured by the Pearson or Spearman correlation coefficient|Evaluation of tumor hypoxia changes during treatment by comparison of the PET uptake values in the tumor, measured before and during treatment|Spatial correlation of [18F] HX4-PET with imaging pre-treatment using a correlation coefficient|Spatial correlation of [18F] HX4-PET with imaging three months after treatment using a correlation coefficient","Maastricht Radiation Oncology","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NL50833.068","May 2016","December 2019","June 2020","October 22, 2015","null","May 24, 2016","MAASTRO Clinic, Maastricht, Limburg, Netherlands","","https://ClinicalTrials.gov/show/NCT02584400"
230,"NCT02576522","Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor",,"Recruiting","No Results Available","Brain Metastases","Radiation: brain metastatic patients","Local control rate|Distant brain failure|Overall survival, statistical|Morbidity/mortality after surgery|Radionecrosis after treatments|Neuropsycological alterations after treatments, questionnaire","Istituto Clinico Humanitas","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1408","June 2015","June 2017","June 2019","October 15, 2015","null","October 15, 2015","Istituto Clinico Humanitas, Rozzano, Milano, Italy","","https://ClinicalTrials.gov/show/NCT02576522"
231,"NCT03561896","Hypofractionated Brain Radiationcavity",,"Recruiting","No Results Available","Brain Metastases, Adult|Cancer Brain","Radiation: IGRT|Radiation: SRS","Relapse rate|Overall survival|Time to systemic progression|Time to neurological progression|Quality of life assessment","Oncology Institute of Southern Switzerland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IOSI-RTO-001","January 2015","December 2020","December 2020","June 19, 2018","null","June 19, 2018","A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy|Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Ticino, Switzerland|Universitätsspital Basel, Basel, Switzerland|Inselspital, Bern, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Klinik Hirslanden, Zürich, Switzerland","","https://ClinicalTrials.gov/show/NCT03561896"
232,"NCT03409549","Multi-parametric MRI/Fluorine-18 Fluciclovine PET-CT in Glioblastoma",,"Not yet recruiting","No Results Available","Tumor, Brain","Radiation: Fluciclovine PET/CT","Measurment od tumour volumes following scans","The Leeds Teaching Hospitals NHS Trust","All","18 Years to 100 Years   (Adult, Older Adult)","","12","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RD17/101925","January 31, 2018","June 28, 2019","June 28, 2019","January 24, 2018","null","January 24, 2018","","","https://ClinicalTrials.gov/show/NCT03409549"
233,"NCT02433171","Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery",,"Recruiting","No Results Available","Brain Metastasis","Procedure: Standard of Care FDG-PET Imaging","Change in Regrowing Tumor Rate from Radiation Effect","Yale University","All","18 Years to 80 Years   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1401013294","January 2015","December 2019","December 2019","May 4, 2015","null","December 16, 2016","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02433171"
234,"NCT03366376","Hippocampus-sparing WBRT and Simultaneous Integrated Boost for Multiple Brain Metastases From NSCLC","KROG17-06","Recruiting","No Results Available","Brain Metastases","Radiation: WBRT with hippocampus-sparing and SIB","Intracranial progression free survival|Verbal neurocognitive function (Seoul Verbal Learning Test-Elderly, SVLT-E)|Overall survival|Adverse events|Quality of life","Samsung Medical Center|Korean Radiation Oncology Group","All","55 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-08-070","December 11, 2017","December 1, 2019","December 1, 2019","December 8, 2017","null","December 8, 2017","Samsung Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03366376"
235,"NCT03091803","QSM and Regional DCE MRI Permeability Using GOCART Technique",,"Recruiting","No Results Available","Intracranial Neoplasm","Device: Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Drug: Gadobenate Dimeglumine|Drug: Gadoterate Meglumine|Device: Magnetic Resonance Imaging","Change in QSM score|Change in T1WI signal intensity ratio|kTrans and Ve signal using GOCART 3D MRI","University of Southern California|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","6B-16-1|NCI-2017-00499|P30CA014089","April 4, 2017","April 4, 2019","April 4, 2020","March 27, 2017","null","September 6, 2017","USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03091803"
236,"NCT02386241","Identification of Genomic Changes in Families Having Multiple Members With Tumors",,"Recruiting","No Results Available","Glioma","Other: saliva or blood sample collection","Total genomic sequencing","St. Joseph's Hospital and Medical Center, Phoenix|Translational Genomics Research Institute","All","18 Years and older   (Adult, Older Adult)","","60","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","14BN108","March 2015","December 2019","January 2020","March 11, 2015","null","January 6, 2017","Barrow Neurological Institute at St. Joseph's Hospital Medical Center, Phoenix, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02386241"
237,"NCT03412812","A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases","RAD1705","Not yet recruiting","No Results Available","Brain Metastases","Radiation: Dose Escalated Five Fraction Stereotactic Radiosurgery","Maximum tolerated dose of five fraction stereotactic radiotherapy|Acute toxicity of five fraction stereotactic radiotherapy using Adverse Event questionnaire|Late toxicity of five fraction stereotactic radiotherapy using Adverse Event questionnaire|Rate of local tumor control with five fraction stereotactic radiotherapy using Adverse Event questionnaire","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300001065","July 2018","January 2020","February 2020","January 26, 2018","null","June 25, 2018","","","https://ClinicalTrials.gov/show/NCT03412812"
238,"NCT03550391","Stereotactic Radiosurgery Compared With Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases",,"Not yet recruiting","No Results Available","Brain Metastases","Drug: Memantine|Radiation: Whole Brain Radiotherapy (WBRT)|Procedure: Stereotactic Radiosurgery (SRS)","Overall Survival|Neurocognitive progression-free survival|Time to central nervous system (CNS) failure (local, distant, and leptomeningeal) in patients who receive SRS compared to patients who receive WBRT|Difference in CNS failure patterns (local, distant, or leptomeningeal) in patients who receive SRS compared to patients who receive WBRT|Number of salvage procedures following SRS in comparison to WBRT|Neurocognitive progression-free survival in patients who receive SRS compared to WBRT|Tabulate and descriptively compare the post-treatment adverse events associated with the interventions.|Time delay to (re-)initiation of systemic therapy in patients receiving SRS in comparison to WBRT|Prospectively validate a predictive nomogram for distant brain failure in patients who receive SRS|Compare the estimated cost of brain-related therapies in patients who receive SRS compared to patients who receive WBRT.|Quality of life, as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) with brain cancer module (BN20)|Quality of life assessed by ECOG performance status|Quality of life, as assessed by EQ-5D|Collect plasma to evaluate whether detectable somatic mutations in liquid biopsy can enhance prediction of the overall survival and development of new brain metastases.|Analysis of serum samples for inflammatory biomarker C-reactive protein and brain-derived-neurotrophic factor (BDNF) to elucidate molecular/genomic mechanisms of neurocognitive decline and associated radiographic changes|Collect whole-brain dosimetry in SRS patients to be prospectively correlated with cognitive toxicity, intracranial control and radiation necrosis|Evaluate serial changes in imaging features found in routine MRI images (T2w changes, morphometry) that may predict tumour control and/or neurocognitive outcomes","Canadian Cancer Trials Group|Alliance for Clinical Trials in Oncology","All","18 Years and older   (Adult, Older Adult)","Phase 3","206","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CE7","June 2018","December 2021","June 2022","June 8, 2018","null","June 12, 2018","","","https://ClinicalTrials.gov/show/NCT03550391"
239,"NCT03401866","Multi-site Validation and Application of a Consensus DSC-MRI Protocol",,"Not yet recruiting","No Results Available","Glioblastoma Multiforme|Gliosarcoma","Diagnostic Test: DSC-MRI","Histologic measures of tumor fraction|Determine the repeatability of rCBV measured with the consensus DSC-MRI protocol.|Determine overall survival (OS) in recurrent GBM patients.","St. Joseph's Hospital and Medical Center, Phoenix","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17-DSC-MRI-Quarles","February 2018","January 2021","July 2021","January 17, 2018","null","January 17, 2018","Mayo Clinic, Scottsdale, Arizona, United States|Brown University, Providence, Rhode Island, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03401866"
240,"NCT03508752","Neurocognitive Decline in Patients With Brain Metastases",,"Recruiting","No Results Available","Brain Metastases","Radiation: Stereotactic Radiosurgery","Phase I: To determine the toxicity within 90 days from the date of SRS, in patients with a greater intracranial disease burden, defined as 6 or more metastases.|Phase II: Determine the cognitive deterioration (HVLT delayed recall) in patients treated with SRS for multiple metastases (from baseline to 4 months)|To determine the optimal dose which will provide local control in patients with a greater intracranial disease burden, defined as 6 or more metastases|To determine quality of life|To detemine overall survival|To determine the time to distant brain recurrence","University of Texas Southwestern Medical Center","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1|Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 122016-064","December 5, 2017","December 31, 2023","December 31, 2023","April 26, 2018","null","April 26, 2018","University of Texas Southwestern Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03508752"
241,"NCT03346655","Brain Metastases in Norway",,"Recruiting","No Results Available","Brain Metastases","","Overall survival after diagnosis of brain metastases|Treatment offered to patients diagnosed with brain metastases|Quality of life","Oslo University Hospital|Norwegian Cancer Society|South-Eastern Norway Regional Health Authority","All","18 Years and older   (Adult, Older Adult)","","3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017/1358","January 1, 2018","January 1, 2022","January 1, 2023","November 17, 2017","null","January 17, 2018","Oslo University Hospital, Oslo, Norway","","https://ClinicalTrials.gov/show/NCT03346655"
242,"NCT03278249","Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma",,"Recruiting","No Results Available","Glioblastoma","Other: Modified Atkins Ketogenic Diet","Assessment of inducing ketosis|Assessment of progression free survival|Assessment of survival","University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCCI-BRAIN-16-01","September 2017","January 2021","January 2021","September 11, 2017","null","September 11, 2017","UC Health, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03278249"
243,"NCT03189381","Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases",,"Recruiting","No Results Available","Brain Metastases","Radiation: Cohort A|Radiation: Cohort B","In-brain distant failure rate|Treated lesion control|Overall survival|Change in neurocognitive function|Change in health-related quality of life|Change in performance status|Incidence of early and late adverse effects","Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IUSCC-0605","July 6, 2017","March 31, 2019","March 31, 2020","June 16, 2017","null","January 10, 2018","Indiana University Health Hospital, Indianapolis, Indiana, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Methodist Hospital, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT03189381"
244,"NCT02798406","Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects","CAPTIVE","Recruiting","No Results Available","Brain Cancer|Brain Neoplasm|Glioma|Glioblastoma|Gliosarcoma|Malignant Brain Tumor|Neoplasm, Neuroepithelial|Neuroectodermal Tumors|Neoplasm by Histologic Type|Neoplasm, Nerve Tissue|Nervous System Diseases","Biological: DNX-2401|Biological: pembrolizumab","Objective response rate (ORR)|Overall survival (OS)|Time to tumor response|Duration of response","DNAtrix, Inc.|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2401BT-002P","June 2016","December 2019","June 2020","June 14, 2016","null","June 21, 2018","University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States|UCLA Medical Center, Los Angeles, California, United States|Northwestern University, Chicago, Illinois, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill-Cornell Medicine New York-Presbyterian, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University James Cancer Center, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Texas Oncology Austin-Midtown, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Health Network, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02798406"
245,"NCT03398694","Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With Brain Metastases",,"Recruiting","No Results Available","Brain Metastases","Procedure: Radiosurgery","Rate of local control of any new, recurrent, or progressing tumors within the planning target volume|Rate of overall survival|Rate of in-brain progression free survival|Proportion of patients with distant in-brain failure (any new parenchymal lesion outside of the planning target volume)|Proportion of patients with radiation necrosis (radiographic or biopsy-positive diagnosis of radiation necrosis)|Proportion of patients with leptomeningeal spread (radiographic or CSF diagnosis of leptomeningeal disease)","Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IUSCC-0627|1707314702","May 1, 2018","February 28, 2021","February 28, 2021","January 12, 2018","null","June 20, 2018","Indiana University Health Hospital, Indianapolis, Indiana, United States|Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT03398694"
246,"NCT03223922","Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases",,"Recruiting","No Results Available","Brain Metastases","Radiation: whole brain radiation therapy","Rate of change of cognitive function|Rate of change of white matter microstructure|Rate of change of cognition|Time to brain metastasis|Rate of change in QoL|Rate of change in other frontally-mediated functions","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J-1737|IRB00128471","July 19, 2017","July 21, 2022","July 21, 2024","July 21, 2017","null","November 6, 2017","Sibley Memorial Hospital, Washington, District of Columbia, United States|The SKCCC at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03223922"
247,"NCT03368625","A Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases","NASRS","Recruiting","No Results Available","Brain Metastases","Radiation: Stereotactic Radiosurgery","Radiation toxicity|local control|leptomeningeal disease|Survival|progression-free survival|overall survival","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-5689","March 19, 2018","January 1, 2022","January 1, 2022","December 11, 2017","null","April 24, 2018","University Health Network, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03368625"
248,"NCT03285932","Stereotactic Radiotherapy of the Resection Cavity of Brain Metastases vs. Post-operative Whole-brain Radiotherapy","ESTRON","Recruiting","No Results Available","Brain Metastases, Adult","Radiation: post-operative stereotactic radiosurgery (SRS)|Radiation: Whole brain radiotherapy (WBRT)","neurological progression-free survival (PFS)|Overall survival (OS)|Local PFS|Quality of life (QLQ-C30)|Loco-regional recurrence|Quality of life (BN20)|Local recurrence|Loco-regional PFS","Juergen Debus|Heidelberg University|University Hospital Heidelberg","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S-451/2017","February 1, 2018","November 2020","November 2021","September 18, 2017","null","March 5, 2018","Department of Radiotherapy, University of Heidelberg, Heidelberg, Germany","","https://ClinicalTrials.gov/show/NCT03285932"
249,"NCT03247127","Memory Preservation of Hippocampal Avoidance Whole Brain Radiotherapy",,"Recruiting","No Results Available","Brain Metastases|Neurocognitive Function","Radiation: Hippocampal avoidance whole brain radiotherapy","Changes of Memory immediate recall and delayed recall|Changes of general cognitive function|Changes of Quality of life","Kaohsiung Medical University Chung-Ho Memorial Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","KMUHIRB-E(II)20170081","March 27, 2017","December 31, 2020","December 31, 2020","August 11, 2017","null","August 11, 2017","Fang, Pen-Tzu, Kaohsiung, Taiwan","","https://ClinicalTrials.gov/show/NCT03247127"
250,"NCT03113799","A Study Evaluate Aqueduct's Smart External Drain","SED","Recruiting","No Results Available","Hydrocephalus|Hydrocephalus in Children|Tumor, Brain","Device: Smart External Drain - SED","Staff interactions|Staff Time|Safety","Aqueduct Critical Care","All","5 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASSESSED SED1","April 12, 2017","December 2018","December 2018","April 14, 2017","null","January 11, 2018","Seattle Children's Hospital, Seattle, Washington, United States|University of Washington School of Medicine / Harborview Medical Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03113799"
251,"NCT02798029","Frameless Fractionated Stereotactic Radiation Therapy (FSRT) for Brain Mets Study",,"Recruiting","No Results Available","Brain Metastases","Radiation: Frameless Fractionated Stereotactic Radiation Therapy (FFSRT)","Incidence of lesion failure based on imaging assessments for each lesion","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0874|NCI-2016-01180","August 2016","August 2019","August 2020","June 14, 2016","null","March 7, 2018","MD Anderson Radiation Treatment Center at Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|MD Anderson Radiation Treatment Center at Cancer Center At Presbyterian, Rio Rancho, New Mexico, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02798029"
252,"NCT03539731","[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers",,"Recruiting","No Results Available","Healthy Subject|Intracranial Neoplasm|Recurrent Glioblastoma","Drug: Fluorine F 18 DASA-23|Procedure: Positron Emission Tomography","Change in [18F]DASA-23 PET scan signal in patients with suspected recurrent glioblastoma|Sensitivity of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Specificity of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Accuracy of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Progression-free survival in patients with suspected recurrent glioblastoma|Overall survival in patients with suspected recurrent glioblastoma","Sanjiv Sam Gambhir|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BRN0038|NCI-2018-00826|44597","April 23, 2018","April 23, 2020","April 23, 2020","May 28, 2018","null","May 28, 2018","Stanford University, School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03539731"
253,"NCT02882984","Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)","Hybrid","Recruiting","No Results Available","Stage IV EGFR Mutated NSCL With Brain Metastases","Drug: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib|Radiation: WBRT|Radiation: HFSRS","iPFS|cognitive function|Overall survival (OS)","Sichuan Provincial People's Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","325","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hybrid","March 2015","March 2020","December 2020","August 30, 2016","null","August 30, 2016","Sichuan PPH, Cancer Center, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT02882984"
254,"NCT03223675","Neurocognitive Impact and Dose-Effect Relationship of Hippocampal Avoidance During Whole Brain Radiotherapy Plus Simultaneous Integrated Boost - A Prospective Follow-up Study",,"Recruiting","No Results Available","Brain Metastasis|Brain Metastases","Radiation: hippocampal-sparing WBRT","The primary endpoint is delayed recall, as determined by the change/decline in verbal memory (WMS III- Word List score) from the baseline assessment to 4 months after the start of HS-WBRT.|The primary endpoint is delayed recall, as determined by the change/decline in non-verbal memory (WMS III- Visual Reproduction score) from the baseline assessment to 4 months after the start of HS-WBRT|Overall survival time, indicated by the time from the date of recruitment to the date of expiring|The time from the date of recruitment to that of intracranial progression/failure noted on brain MRI or CT","Chang Gung Memorial Hospital","All","20 Years to 84 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","104-9176A3","April 1, 2016","December 31, 2019","December 31, 2021","July 21, 2017","null","July 21, 2017","Chang Gung Memorial Hospital, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT03223675"
255,"NCT02390518","Stereotactic Radiosurgery Dose Escalation for Brain Metastases",,"Recruiting","No Results Available","Brain Metastases","Radiation: Stereotactic Radiosurgery","Maximum Tolerated Dose of stereotactic radiosurgery","University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI71940","May 5, 2015","May 2019","May 2019","March 17, 2015","null","May 24, 2018","Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02390518"
256,"NCT02886572","SIMT Stereotactic Radiosurgery Outcomes Study","SIMT","Recruiting","No Results Available","Brain Metastases, Adult","Radiation: Stereotactic radiosurgery","Proportion of patients who live longer than predicted according to the Graded Prognostic Assessment (GPA) score|Proportion of patients that experience local brain recurrence within 1 year of SIMT SRS treatment.|Proportion of patients who are dead within 1 year of SIMT SRS treatment due to neurologic reasons|Proportion of patients that experience a new brain metastasis at a site different from the original brain metastasis site 1 year after SIMT SRS treatment|Proportion of patients who experience grade 3, 4, or 5 neurologic adverse events attributable to SIMT SRS","Duke University|Varian Medical Systems","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00075429","May 12, 2017","May 2019","May 2019","September 1, 2016","null","November 6, 2017","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02886572"
257,"NCT02504788","A Prospective Study of the Impact of Hippocampal Avoidance During Whole Brain Radiotherapy on Neurocognitive Function Decline",,"Recruiting","No Results Available","Brain Metastasis|Brain Metastases","Radiation: hippocampal-sparing WBRT","The primary endpoint is delayed recall, as determined by the change/decline in verbal memory (WMS III- Word List score) from the baseline assessment to 4 months after the start of HS-WBRT.|The primary endpoint is delayed recall, as determined by the change/decline in non-verbal memory (WMS III- Visual Reproduction score) from the baseline assessment to 4 months after the start of HS-WBRT.|Overall survival time, indicated by the time from the date of recruitment to the date of expiring|The time from the date of recruitment to that of intracranial progression/failure noted on brain MRI or CT","Chang Gung Memorial Hospital","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101-4151B","January 18, 2013","December 31, 2019","December 31, 2019","July 22, 2015","null","September 7, 2017","Chang Gung Memorial Hospital, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT02504788"
258,"NCT02490878","Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases",,"Recruiting","No Results Available","Radionecrosis|Brain Metastases","Drug: bevacizumab|Drug: corticosteroids|Other: placebo","Patient-reported outcome (symptoms) of radionecrosis|Toxicities associated with bevacizumab and corticosteroids in patients with radionecrosis using CTCAE Version 4.0 and DSQ-C.|Quality of life measure using the Single Item Linear Analogue Scale (LASA)|Quality of life measure using the Dexamethasone Symptoms Questionnaire - Chronic (DSQ-C)|Quality of life measure using the The M. D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) score.|Progression free survival|Corticosteroid dose over time|Maximum radiographic response|Time to stopping corticosteroids","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","A221208|NCI-2015-01348","April 2016","April 2020","null","July 7, 2015","null","June 12, 2018","Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|PCR Oncology, Arroyo Grande, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Halifax Health Medical Center-Centers for Oncology, Daytona Beach, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|University Cancer and Blood Center LLC, Athens, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Summit Cancer Care-Memorial, Savannah, Georgia, United States|Low Country Cancer Care Associates PC, Savannah, Georgia, United States|Summit Cancer Care-Candler, Savannah, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Chancellor Center for Oncology, Newburgh, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Alliance for Clinical Trials in Oncology, Boston, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Beaumont Hospital - Farmington Hills, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Lymphoma Clinic of Michigan, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|William Beaumont Hospital-Grosse Point, Grosse Pointe, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Assarian Cancer Center, Novi, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Huron Medical Center PC, Port Huron, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Michigan Cancer Specialists, Roseville, Michigan, United States|Oakland Colon and Rectal Association, Royal Oak, Michigan, United States|Cancer Care Associates PC, Royal Oak, Michigan, United States|Comprehensive Medical Center PLLC, Royal Oak, Michigan, United States|Hematology Oncology Consultants PC, Royal Oak, Michigan, United States|Oakland Medical Group, Royal Oak, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Providence Hospital-Southfield Cancer Center, Southfield, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Premier Hematology Oncology Care, Sterling Heights, Michigan, United States|Mitchell Folbe MD PC, Sterling Heights, Michigan, United States|Saint Joseph Health System-Tawas City, Tawas City, Michigan, United States|Michigan Institute of Urology-Town Center, Troy, Michigan, United States|Claudia BR Herke MD PC, Troy, Michigan, United States|Hematology Oncology Consultants PC-Troy, Troy, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Bhadresh Nayak MD PC-Warren, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|Nevada Cancer Specialists-Saint Rose, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|Nevada Cancer Specialists?Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Nevada Cancer Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Nevada Cancer Specialists-Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Wilson, Wilson, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physicians LLC-Samaritan North, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Dayton Physicians LLC-Signal Point, Middletown, Ohio, United States|Dayton Physicians LLC-Wilson, Sidney, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Roper Hospital, Charleston, South Carolina, United States|Charleston Hematology Oncology Associates-Roper, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-North Charleston, Charleston, South Carolina, United States|Bon Secours Saint Francis Hospital, Charleston, South Carolina, United States|Charleston Hematology Oncology Associates PA-Saint Francis, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-West Ashley, Charleston, South Carolina, United States|Greenville Health System Cancer Institute-Laurens, Clinton, South Carolina, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Lowcountry Hematology Oncology PA-Mount Pleasant, Mount Pleasant, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Vanderbilt-Ingram Cancer Center Cool Springs, Franklin, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|M D Anderson Cancer Center, Houston, Texas, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Rockwood North Cancer Treatment Center, Spokane, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|United Hospital Center, Bridgeport, West Virginia, United States|WVUH-East City Hospital, Martinsburg, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Camden-Clark Memorial Hospital, Parkersburg, West Virginia, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario, Canada|Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02490878"
259,"NCT02328300","FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions",,"Recruiting","No Results Available","Brain Lesions|Brain Metastasis|Brain Metastases","Drug: FLT PET/MR","Sensitivity and specificity of FLT-PET-MRI in distinguishing between recurrence and radiation necrosis, with surgical biopsy as gold standard","UNC Lineberger Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","","15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LCCC1327","May 7, 2014","June 2018","June 2018","December 31, 2014","null","October 4, 2017","University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02328300"
260,"NCT01850563","A Proof-of-principle Study of Hyperbaric Oxygen as a Radiosensitizer Prior to Stereotactic Radiosurgery for Brain Metastases",,"Recruiting","No Results Available","Brain Metastases","Other: Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO","Statistical Methods for the primary outcome variable of feasibility","Dartmouth-Hitchcock Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D12129","July 1, 2013","August 2018","December 2018","May 9, 2013","null","May 15, 2018","Dartmouth-Hitchcock, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT01850563"
261,"NCT02608307","Medical Treatment Decision Making Using Adaptive Conjoint Analysis",,"Recruiting","No Results Available","Cancer|Brain Tumor|Solid Tumor|Leukemia|Lymphoma","","Percentage of responses","St. Jude Children's Research Hospital","All","13 Years and older   (Child, Adult, Older Adult)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AYACA","February 9, 2016","June 2019","June 2024","November 18, 2015","null","September 28, 2017","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02608307"
262,"NCT02478346","Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions","Fluoescein","Recruiting","No Results Available","Cerebrovascular Disorders|Intracranial Neoplasms","Drug: Fluorescein Sodium","Incidence of Intracerebral lesion","Florida Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","684812","May 2015","December 2018","April 2019","June 23, 2015","null","February 14, 2017","Florida Hospital, Orlando, Florida, United States","","https://ClinicalTrials.gov/show/NCT02478346"
263,"NCT02775136","An Evaluation of a Non-invasive Brain Monitor",,"Recruiting","No Results Available","Brain Injuries|Subarachnoid Hemorrhage|Vasospasm, Intracranial|Hydrocephalus|Brain Neoplasms","Device: HS-1000 recording","Number of recordings that correlate to neuropathology|Incidence of adverse events|Rate of ear infections/irritations graded by none/mild/moderate and severe","HeadSense Medical|Klinikum Stuttgart|Klinikum Darmstadt|University Medical Center Goettingen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","160","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HS-011","October 2014","June 2017","December 2017","May 17, 2016","null","December 23, 2016","Klinikum Darmstadt, Darmstadt, Germany|University Hospital Erlangen, Erlangen, Germany|Universitätsklinik Göttingen, Gottingen, Germany|Klinikum Stuttgart, Stuttgart, Germany","","https://ClinicalTrials.gov/show/NCT02775136"
264,"NCT02323880","Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas",,"Recruiting","No Results Available","Childhood Central Nervous System Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Malignant Glioma|Recurrent Brain Neoplasm","Other: Pharmacological Study|Drug: Selinexor","Incidence of adverse events graded according to NCI CTCAE version 4.0|Pharmacokinetics (PK) of selinexor|RP2D or MTD of selinexor|Antitumor effect of selinexor|Penetration, pharmacodynamic effects, and biologic effects of selinexor in tumor tissue of patients with recurrent/refractory HGG requiring resection|PFS (surgical patients)|Pharmacodynamics of selinexor|Rate of objective radiographic response (medical patients)","Children's Oncology Group|National Cancer Institute (NCI)|COG Phase 1 Consortium","All","12 Months to 21 Years   (Child, Adult)","Phase 1","81","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADVL1414|NCI-2014-02410|UM1CA097452","October 2015","March 2021","March 2021","December 24, 2014","null","September 12, 2017","Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, D.C., District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02323880"
265,"NCT02568267","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","STARTRK-2","Recruiting","No Results Available","Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Sarcomas|Salivary Gland Cancers|Adult Solid Tumor","Drug: Entrectinib","Objective Response Rate|Duration of Response|Time to Response|Clinical Benefit Rate|Intracranial Tumor Response|CNS Progression-free Survival|Progression-free Survival|Overall Survival","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RXDX-101-02|2015‐003385‐84|GO40782","November 19, 2015","October 31, 2019","October 31, 2020","October 5, 2015","null","June 15, 2018","Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States|Cancer Treatment Centers of America, Goodyear, Arizona, United States|Dignity Health St Joseph's Hospital and Medical Center (Barrow Neurology), Phoenix, Arizona, United States|Mayo Clinic Hospital, Scottsdale, Arizona, United States|Contact Ignyta, Little Rock, Arkansas, United States|City of Hope Cancer Center, Duarte, California, United States|Scripps Clinic Medical Group, La Jolla, California, United States|University of California San Diego Moores Cancer Center, La Jolla, California, United States|University of Southern California - Keck School of Medicine, Los Angeles, California, United States|University of California, Irvine College of Medicine, Orange, California, United States|Southern California Kaiser Permanente - All So. California Locations, Panorama City, California, United States|UCSF Mount Zion Medical Center, San Francisco, California, United States|Sarcoma Oncology Research Center LLC, Santa Monica, California, United States|St. Joseph Heritage Healthcare, Santa Rosa, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Contact Ignyta, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Contact Ignyta, Dover, Delaware, United States|Georgetown University - Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Weinberg Cancer Institute at Franklin Square, Washington, District of Columbia, United States|Florida Cancer Specialists, Sarasota, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States|Cleveland Clinic Florida - Maroone Cancer Center, Weston, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Cancer Treatment Centers of America, Newnan, Georgia, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Contact Ignyta, Boise, Idaho, United States|Northwestern University Memorial Hospital, Chicago, Illinois, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Cancer Treatment Centers of America, Zion, Illinois, United States|Baptist Health Cancer Center, New Albany, Indiana, United States|Contact Ignyta, Des Moines, Iowa, United States|Contact Ignyta, Topeka, Kansas, United States|Contact Ignyta, Frankfort, Kentucky, United States|Hematology/Oncology Clinic, LLP, Baton Rouge, Louisiana, United States|Contact Ignyta, Augusta, Maine, United States|Contact Ignyta, Annapolis, Maryland, United States|Massachusetts General Hospital / Beth Israel Deaconess Med Ctr / Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Health Partners Institute - Park Nicollet Institute, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Contact Ignyta, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Contact Ignyta, Helena, Montana, United States|Contact Ignyta, Lincoln, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Contact Ignyta, Trenton, New Jersey, United States|Contact Ignyta, Santa Fe, New Mexico, United States|North Shore Hematology Oncology Associates, PC, East Setauket, New York, United States|Northern Westchester Hospital Association, Mount Kisco, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center/ Duke Cancer Center, Durham, North Carolina, United States|Contact Ignyta, Bismarck, North Dakota, United States|Cleveland Clinic, Cleveland, Ohio, United States|OSU - James Comprehensive Cancer Center, Columbus, Ohio, United States|Cancer Treatment Centers of America, Tulsa, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Cancer Treatment Centers of America, Philadelphia, Pennsylvania, United States|Contact Ignyta, Providence, Rhode Island, United States|Contact Ignyta, Columbia, South Carolina, United States|Contact Ignyta, Pierre, South Dakota, United States|Contact Ignyta, Nashville, Tennessee, United States|Mary Crowley Cancer Research Center, Dallas, Texas, United States|University of Texas Southwestern Hospital - Medical Oncology Clinic, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Contact Ignyta, Montpelier, Vermont, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|Contact Ignyta, Charleston, West Virginia, United States|Wheaton Franciscan Cancer Care-All Saints, Franklin, Wisconsin, United States|Contact Ignyta, Cheyenne, Wyoming, United States|Flinders Medical Centre, Bedford Park, Australia|Austin Hospital, Heidelberg, Australia|Liverpool Hospital, Liverpool, Australia|Newcastle Private Hospital, New Lambton Heights, Australia|Border Medical Oncology, Wodonga, Australia|Antwerp University Hospital, Edegem, Belgium|Institut Bergonié, Bordeaux cedex, Gironde, France|Institut de Cancerologie de l'Ouest - Centre Rene Gauducheau, Saint-Herblain, Loire Atlantique, France|Centre Oscar Lambret, Lille Cedex, Nord, France|Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris, Paris Cedex 05, Paris, France|Centre Léon Bérard, Lyon, Rhone, France|Institut de Recherche en Cancérologie de Montpellier, Montpellier, Rhone, France|Institut Gustave Roussy, Villejuif cedex, Val De Marne, France|Institut de Cancerologie de l'Ouest - Centre Paul Papin, Angers, France|Hôpital De La Timone - AP-HM Marseille, Marseille, France|Hôpital Nord - AP-HM Marseille, Marseille, France|Hôpital Européen Georges Pompidou, Paris, France|Institut Claudius Regaud-Oncopole, Toulouse, France|Evangelische Lungenklinik Berlin, Berlin, Germany|Medizinische Fakultät Carl Gustav Carus Medizinische Klinik und Poliklinik I, Dresden, Germany|Asklepios Fachkliniken Muenchen-Gauting, Gauting, Germany|Universitaetsmedizin Goettingen, Goettingen, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Hong Kong Integrated Oncology Centre, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Kowloon, Hong Kong|Queen Mary Hospital, Kowloon, Hong Kong|Princess Margaret Hospital, Lai Chi Kok, Hong Kong|The Chinese University of Hong Kong, Shatin, Hong Kong|SCDU Oncologia Medica - Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, Torino, Italy|Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Italy|IRCCS AOU San Martino IST, Genova, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda), Milano, Italy|Azienda Ospedaliera Universitaria Seconda Università di Napoli, Napoli, Italy|Oncologia Medica 1, Istituto Oncologico Veneto, Padova, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Italy|U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Policlinico Universitario Campus Bio-Medico, Roma, Italy|Città della Salute e della Scienza di Torino. Presidio Molinette, Torino, Italy|National Cancer Center Hospital, Chūō, Japan|National Cancer Center Hospital East, Kashiwa, Japan|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Centre, Seoul, Korea, Republic of|Samsung Medical Centre, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|NKI The Netherlands Cancer Institute, Amsterdam, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radioterapii, Gdansk, Poland|Centrum Onkologii-Instytut im.M.Sklodowskiej Curie, Gliwice, Poland|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Poland|Szpital Kliniczny Przemienienia Panskiego UM im. Karola Marcinkowskiego w Poznaniu, Oddzial Chemiote, Poznań, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, Poland|National University Hospital, Kent Ridge, Singapore|National Cancer Centre, Singapore, Singapore|Hospital Vall D' Hebron, Barcelona, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Changhua Christian Hospital, Shanghua, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans Hospital, Taipei, Taiwan|Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT02568267"
266,"NCT03072134","Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma",,"Recruiting","No Results Available","Glioma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma Multiforme|Astrocytoma, Grade III|Astrocytoma, Grade IV|Brain Cancer","Biological: Neural stem cells loaded with an oncolytic adenovirus","Determine the maximum number of neural stem cells loaded with the oncolytic adenovirus.|Assessment of tumor response or progression to treatment on MRI.","Northwestern University","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU00203933","April 24, 2017","March 30, 2019","April 1, 2019","March 7, 2017","null","April 25, 2017","Northwestern Memorial Hospital, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03072134"
267,"NCT03328143","Feasibility of Aromatherapy in an Awake Craniotomy Environment",,"Not yet recruiting","No Results Available","Intracranial Pathology","Drug: Lavender (Lavandula angustifolia)","Number of consented patients|Protocol completion|Validation of Visual Analogue Scale for Anxiety (VAS-A)|Validation of Visual Analogue Scale for Pain (VAS-P)|Patient Opinion of Pain Management (POPM) survey|Analgesic and anxiolytic dosage","Aurora Health Care","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","17.101","July 7, 2018","February 7, 2019","February 7, 2019","November 1, 2017","null","May 2, 2018","","","https://ClinicalTrials.gov/show/NCT03328143"
268,"NCT02686229","Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas","LoG-Glio","Recruiting","No Results Available","Glioma","Other: no interventions","Progression-free survival (PFS)|Overall survival (OS)|Extent of tumor resection|Quality of life (QoL) assessed by the EORTC QLQ C-30/BN-20. (European Organisation for Research and Treatment of Cancer Quality of Life Questionaire C-30","University of Ulm|Institute for Epidemiology and Medical Biometrics, University of Ulm|Charite University, Berlin, Germany|Department of Internal Medicine III, University of Ulm","All","18 Years and older   (Adult, Older Adult)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LoG-Glio","December 2015","December 2020","December 2030","February 19, 2016","null","March 11, 2016","University of Ulm, Ulm, Germany","","https://ClinicalTrials.gov/show/NCT02686229"
269,"NCT03449238","Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients",,"Not yet recruiting","No Results Available","Metastatic Breast Cancer|Brain Metastases","Drug: Pembrolizumab","Tumor response for non-irradiated brain lesions at 8 weeks according to RECIST1.1|Correlation of abscopal responses with the radiation dose received|Overall survival - assessed from the start of study drug until death in non-irradiation metastases in the rest of the body by routine imaging.","Weill Medical College of Cornell University","Female","19 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1710018694","June 30, 2018","December 30, 2024","December 30, 2026","February 28, 2018","null","May 1, 2018","","","https://ClinicalTrials.gov/show/NCT03449238"
270,"NCT02581839","Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate",,"Recruiting","No Results Available","Metastatic Breast Cancer|Brain Metastases","Drug: Eribulin Mesylate|Device: MRI|Drug: Pre-Medication: Zofran|Drug: Pre-Medication: Decadron","Proportion of subjects with Central Nervous System (CNS) Progression free survival (PFS)|Objective Response Rate (RR)|Average duration of CNS response|Toxicity|Number of patients with CBR|Systemic Disease Response Rate|Average overall survival (OS)","Case Comprehensive Cancer Center","Female","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE7113","November 17, 2015","September 2018","January 2020","October 21, 2015","null","May 17, 2018","University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02581839"
271,"NCT01724606","Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)",,"Recruiting","No Results Available","Breast Cancer|Brain Metastases","Radiation: Whole Brain Radiotherapy (WBRT)|Drug: Sorafenib","Maximum Tolerated Dose|assessing toxicity by the number of adverse events|CNS progression-free survival","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-046","November 2012","November 2018","November 2018","November 12, 2012","null","December 5, 2017","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States","","https://ClinicalTrials.gov/show/NCT01724606"
272,"NCT02993146","Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases",,"Recruiting","No Results Available","Metastatic Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain","Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Quality-of-Life Assessment|Drug: Ropidoxuridine|Radiation: Whole-Brain Radiotherapy","Maximum tolerated dose of ropidoxuridine defined as defined as the highest dose that has fewer than 3 (out of 6) patients experiencing dose-limiting toxicity assessed by National Cancer Institute's Common Toxicity Criteria version 4|Tumor response assessed by Response Evaluation Criteria in Solid Tumors 1.1|Pharmacokinetic parameters of daily oral dosing of ropidoxuridine|Biomarkers|Intracranial progression free survival (icPFS)|Overall survival|Incidence of delayed neurological toxicity including delayed-recall assessed by Hopkins Verbal Learning Test Revised (HVLT-R) and quality of life assessed by Functional Assessment of Cancer Therapy-Brain (FACT-BR)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","47","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2016-01909|HP-00067789|9979|UM1CA186686","December 7, 2016","August 1, 2019","null","December 15, 2016","null","July 3, 2018","UC San Diego Moores Cancer Center, La Jolla, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02993146"
273,"NCT03203616","Kadcyla In pAtients With bRAin Metastasis","KIARA","Not yet recruiting","No Results Available","Metastatic HER2-positive Breast Cancer With Brain Metastasis","Drug: Kadcyla 160Mg Powder for Injection","Clinical Benefit (CB)|CB in the brain RECIST 1.1|CB in the brain RANO|General and cardiac-specific safety|CB: Systemic|CB: bi-compartmental|Overall Response (OR) in the brain|Overall Response (OR) systemic|Overall Response (OR) bi-compartmental|Best Response (BR) in the brain|Best Response (BR) systemic|Best Response (BR) bi-compartmental|Brain Progression free survival (PFS)|Systemic PFS|Bi-compartmental PFS|Duration of response in the brain|Duration of response systemic|Duration of response bi-compartmental|Duration of Clinical Benefit (DCB) in the brain|Duration of Clinical Benefit (DCB) systemic|Duration of Clinical Benefit (DCB) bi-compartmental|Overall survival|Quality of life","Jules Bordet Institute","Female","18 Years and older   (Adult, Older Adult)","Phase 2","97","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IJB‐BC‐TDM1BM‐2016","July 1, 2017","July 1, 2020","July 1, 2020","June 29, 2017","null","June 29, 2017","","","https://ClinicalTrials.gov/show/NCT03203616"
274,"NCT03303365","Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence","CYBER-SPACE","Recruiting","No Results Available","Brain Metastases|Adult Solid Tumor","Radiation: stereotactic radiosurgery (SRS)","Ineligibility for further cerebral SRS|Overall survival (OS)|cognitive function|quality of life","Juergen Debus|Heidelberg University|University Hospital Heidelberg","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S-448/2017","February 1, 2018","November 1, 2019","November 1, 2020","October 6, 2017","null","March 5, 2018","University Hospital of Heidelberg, Department of Radiation Oncology, Heidelberg, Germany","","https://ClinicalTrials.gov/show/NCT03303365"
275,"NCT03184038","Assessment of Neurocognitive Function in Patients With Multiple Brain Metastases Undergoing Stereotactic Radiosurgery or Stereotactic Body Radiation Therapy",,"Recruiting","No Results Available","Metastatic Malignant Neoplasm in the Brain|Solid Neoplasm","Procedure: Cognitive Assessment|Radiation: Stereotactic Radiosurgery|Radiation: Stereotactic Body Radiation Therapy","Neurocognitive function as measured by neurocognitive decline on a Hopkins Verbal Learning Test-Revised (HVLT-R) for Total Recall|Neurocognitive function as measured by neurocognitive decline on a Hopkins Verbal Learning Test-Revised (HVLT-R) for Delayed Recall|Neurocognitive function as measured by neurocognitive decline on a Hopkins Verbal Learning Test-Revised (HVLT-R) for Delayed Recognition|Neurocognitive function as measured by neurocognitive decline on a Hopkins Verbal Learning Test-Revised (HVLT-R) for Trail Making Test (TMT) Parts A|Change in neurocognitive function as measured by neurocognitive decline on a battery of tests conducted by the primary investigator or a trained member of the clinical team","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","16D.651","February 21, 2017","May 2021","May 2022","June 12, 2017","null","July 4, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Aria Health, Philadelphia, Pennsylvania, United States|Reading Hospital, Reading, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03184038"
276,"NCT03403803","Prognosis and Therapeutic Biomarkers for Glioblastoma Patients",,"Recruiting","No Results Available","Glioblastoma","Device: Optune","Primary Outcome - CD44 expression in cerebrospinal fluid (CSF), blood and saliva","Baylor Research Institute","All","22 Years and older   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","160280","September 1, 2017","September 1, 2019","September 1, 2019","January 19, 2018","null","February 22, 2018","Baylor Scott and White Medical Center, Temple, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03403803/Prot_000.pdf|""Informed Consent Form: Main Consent"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03403803/ICF_001.pdf|""Informed Consent Form: Control Consent"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03403803/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03403803"
277,"NCT01445483","Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases",,"Recruiting","No Results Available","Brain Metastasis|Cancer","","To identify the neuropsychological test scores which detect significant change in neuropsychological functioning in patients receiving radiation therapy for brain metastases.|To examine the relationship between neuropsychological function and survival in patients receiving radiation therapy for brain metastases|To further examine whether other measures from the following battery detect significant change in neuropsychological function or predict prognosis in this patient population.|To examine the relationship between the RTOG RPA classification for brain metastasis survival and baseline neuropsychological functioning.|To examine the strengths and weaknesses in neuropsychological functioning of patients with brain metastases after radiation therapy.|To explore the neuropsychological functioning of patients with brain metastases treated with different therapies (e.g. chemotherapy, corticosteroids, complete surgical resection).|To investigate the relationship between neuropsychological functioning, brain lesions (e.g., number and volume), MRI abnormalities, biomarkers, and disease progression or recurrence.|To investigate the role of biomarkers, including neuron specific enolase (NSE), S100B, MMPs and VEGF as potential markers of brain injury and disease progression in the serum, plasma and urine of patients with brain metastases.|To gather baseline neuropsychological data on patients with brain metastases for use as a reference in the development of new clinical trials involving this patient population in the ROB.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 90 Years   (Adult, Older Adult)","","60","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","080214|08-C-0214","September 15, 2008","null","null","October 3, 2011","null","April 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01445483"
278,"NCT03297788","Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases","ENCEPHALON","Recruiting","No Results Available","SCLC|Brain Metastases","Radiation: SRS|Radiation: WBRT","Neurocognition|Intracranial progression|Overall survival (OS)|Death due to brain metastases|Locally progression-free survival|Progression-free survival (PFS)|Changes in other cognitive performance measures|Quality of life","Juergen Debus|Heidelberg University|University Hospital Heidelberg","All","18 Years and older   (Adult, Older Adult)","Phase 2","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S-470/2017","December 1, 2017","October 2019","October 2020","September 29, 2017","null","March 5, 2018","University Hospital of Heidelberg, Department of Radiation Oncology, Heidelberg, Germany","","https://ClinicalTrials.gov/show/NCT03297788"
279,"NCT02992964","Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers",,"Recruiting","No Results Available","Refractory or Recurrent Hypermutated Malignancies|Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients","Drug: Nivolumab","To evaluate the objective response rate to Nivolumab in bMMRD positive pediatric patients with refractory hypermutated malignancies|To evaluate the objective response rate to Nivolumab in bMMRD positive pediatric patients with recurrent hypermutated malignancies.|Estimating the feasibility of using Nivolumab as a treatment in bMMRD positive, pediatric patients with refractory or recurrent hypermutated malignancies.|The progression free survival (PFS) of pediatric patients with progressive or recurrent hypermutated malignancies including bMMRD patients treated with Nivolumab.|Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment","The Hospital for Sick Children","All","12 Months to 18 Years   (Child, Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OZM-075","April 2017","September 2021","September 2021","December 14, 2016","null","April 6, 2017","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|The Hospital for Sick Children, Toronto, Ontario, Canada|Institut Gustave Roussy, Villejuif, France|Tel Aviv Sourasky Medical Centre, Tel Aviv-Yafo, Israel","","https://ClinicalTrials.gov/show/NCT02992964"
280,"NCT03414944","Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases","SMART-Brain","Recruiting","No Results Available","Brain Metastases","Radiation: SMART-Brain","AE|iPFS","Shandong Cancer Hospital and Institute|Shandong Provincial Hospital|Qilu Hospital of Shandong University|The Affiliated Hospital of Xuzhou Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRTOG1602","December 2, 2016","May 30, 2018","September 30, 2018","January 30, 2018","null","January 30, 2018","Shandong Cancer Hospital, Jin'an, Shandong, China","","https://ClinicalTrials.gov/show/NCT03414944"
281,"NCT02972333","Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M",,"Not yet recruiting","No Results Available","EGFR-TKI Resistant Mutation|Nonsmall Cell Lung Cancer|AZD9291|Brain Metastases","Drug: AZD9291 80mg oral each day|Radiation: Radiation therapy","PFSo (overall progression free survival)|PFSe (extracranial progression-free survival)|PFSi (intracranial progression-free survival)|ORRo (overall objective response rate)|ORRe (extracranial objective response rate)|ORRi (intracranial objective response rate)|DCRo (overall disease control rate)|DCRe (extracranial disease control rate)|DCRi (intracranial disease control rate)|DoRo (overall duration of response)|DoRe (extracranial duration of response)|DoRi (intracranial duration of response)|OS(overall survival)|Adverse events/Serious adverse events|QoL|Cognitive function","Shandong Cancer Hospital and Institute|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APOLLO","December 2016","September 2019","December 2019","November 23, 2016","null","November 23, 2016","","","https://ClinicalTrials.gov/show/NCT02972333"
282,"NCT03075072","Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-20 Brain Metastases: A Phase III, Randomized Clinical Trial",,"Recruiting","No Results Available","Brain Metastases","Radiation: Whole brain radiation|Radiation: Stereotactic radiation (SRS)","Quality of Life|Overall survival|Neurologic survival|Incidence and time to detection of new brain metastases|Incidence and time to local recurrence of treated brain tumor(s)|Incidence and time to development of radiation necrosis|Incidence and time to development of leptomeningeal disease|Incidence and time to salvage craniotomy|Incidence and time to additional radiotherapeutic treatments|Incidence and time to the development of seizures|Incidence and time to neurocognitive decline|Performance status","Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","196","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-305","April 10, 2017","March 30, 2021","March 30, 2022","March 9, 2017","null","December 22, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03075072"
283,"NCT03226483","Intraoperative Radiotherapy After the Resection of Brain Metastases","INTRAMET","Recruiting","No Results Available","Brain Metastases","Radiation: Intraoperative Radiotherapy","Median local progression-free-survival|Overall-survival|Time to further therapy|Patients cognitive performance|Patients quality of life|Global progression-free-survival|Regional progression-free-survival|Intraoperative radiotherapy caused dose-limiting toxicities","Universitätsmedizin Mannheim","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-638N-MA","March 28, 2017","April 1, 2019","April 1, 2021","July 21, 2017","null","July 21, 2017","Universitätsmedizin Mannheim, Mannheim, Germany","","https://ClinicalTrials.gov/show/NCT03226483"
284,"NCT02052778","A Study of TAS-120 in Patients With Advanced Solid Tumors",,"Recruiting","No Results Available","Cholangiocarcinoma|Brain Tumor|Urothelial Cancer|Other Tumor Types With FGFR2 Gene Fusions|Activating Mutations|FGFR2 Amplification","Drug: TAS-120","Phase 1 - Overall Response Rate (ORR)|Phase 1 - Early Progression Rate (EPR) for GBM or grade III glioma|Phase 2 - Overall Response Rate (ORR)|Duration of Response (DOR)|Disease Control Rate (DCR)|Progression free survival (PFS)|Patient Reported Outcome (PRO)|Overall Survival (OS)","Taiho Oncology, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","371","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TPU-TAS-120-101|2013-004810-16","July 2014","March 2019","September 2019","February 3, 2014","null","May 31, 2018","Mayo Clinic (AZ), Scottsdale, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|UCSF - Helen Diller, San Francisco, California, United States|Mayo Clinic (Jacksonville), Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic (MN), Rochester, Minnesota, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Sidney Kimmel Cancer Center at Jefferson, Philadelphia, Pennsylvania, United States|Greenville Health System ITOR, Greenville, South Carolina, United States|Mary Crowley, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Virginia Mason Cancer Center, Seattle, Washington, United States|Royal Melbourne Hospital, Melbourne, Australia|Scientia Clinical Research University of New South Wales, Randwick, Australia|Institut Bergonie, Bordeaux, France|Hospices Civils de Lyon, Bron, France|Centre Léon Bérard Bât, Lyon, France|Pitié-Salpêtrière Hospital, Paris, France|Institute Goustave-Roussy, Paris, France|Rennes, Centre Eugène Marquis, Rennes cedex, France|Prince of Wales Hospital, Shatin, Hong Kong|Val D'Hebron University Hospital, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona,, Barcelona, Spain|University Hospital Ramón y Cajal, Madrid, Spain|Centro Integral Oncológico Clara Campal - Hospital Universitario Madrid Sanchinarro, Madrid, Spain|University College London Hospital, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02052778"
285,"NCT03027544","Tomotherapy for Refractory Brain Metastases","TRBM","Recruiting","No Results Available","Brain Metastases","Radiation: tomotherapy","Objective response rate|Overall survival rate|progress free survival rate|local control rate|intracranial progress free survival rate|adverse event|cause of death","Chinese Academy of Medical Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCC2014 YZ-14","September 1, 2014","September 1, 2018","September 1, 2018","January 23, 2017","null","January 23, 2017","Chinese Academy of Medical Sciences, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03027544"
286,"NCT03525301","Short Course Radiation Therapy in Palliative Treatment of Brain Metastases",,"Recruiting","No Results Available","Brain Metastases|Radiotherapy|Palliative Care","Radiation: standard treatment|Radiation: short course treatment","Efficacy of palliation using the short course scheme compared with the standard scheme|Acute toxicity in the two treatment groups|Late toxicity in the two treatment groups|Quality of Life (QoL) assessment in the two groups","Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi","All","18 Years and older   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RT-15-02 SHARON BRAIN","November 8, 2017","November 8, 2022","November 8, 2023","May 15, 2018","null","May 18, 2018","Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, BO, Italy","","https://ClinicalTrials.gov/show/NCT03525301"
287,"NCT02747303","Frameless Stereotactic Radiosurgery for Intact Brain Metastases",,"Recruiting","No Results Available","Brain Metastases","Procedure: Stereotactic Radiosurgery","Progression free survival (PFS) rates estimated by the Kaplan-Meier method at 6 months|Progression free survival (PFS) rates estimated by the Kaplan-Meier method|Overall survival rates|Rates of radiation necrosis|Rates of pseudoprogression|Local failure rates|Rate of acute central nervous system (CNS) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 2 and higher toxicities|Rate of late central nervous system (CNS) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 2 and higher toxicities|Rates of distant intracranial failure|Rates of salvage therapy|Association between dose and risk of radionecrosis or pseudoprogression","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 2","166","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB15-1476","June 2016","May 2020","May 2026","April 21, 2016","null","April 25, 2018","University of Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02747303"
288,"NCT03430947","Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases","RadioCoBRIM","Recruiting","No Results Available","Malignant Melanoma Stage IV|BRAF V600 Mutation|Brain Metastases","Drug: Vemurafenib|Drug: Cobimetinib","Best overall response rate in the brain|Extracranial best overall response rate|Best overall response rate calculated for the whole body tumor sites|Intracranial duration of response|Extracranial duration of response|Progression-free survival|Overall survival|Incidence of adverse events|Radiomics for long-term control of brain metastases|Radiomics for intracranial Treatment-related toxicity","Technische Universität Dresden","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TUD-CoBRIM-67|2017-000768-13","March 7, 2018","August 31, 2019","August 31, 2021","February 13, 2018","null","March 7, 2018","Technische Universität Dresden, Dresden, Germany|Ruprecht-Karls-University of Heidelberg, Faculty of Medicine, Heidelberg, Germany|Eberhard Karls University of Tübingen, University Medical Center, Tuebingen, Germany","","https://ClinicalTrials.gov/show/NCT03430947"
289,"NCT02974803","Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases",,"Recruiting","No Results Available","Melanoma|Brain Metastases","Drug: Dabrafenib|Drug: Trametinib","Intracranial objective response rate to concurrent dabrafenib and trametinib with stereotactic radiation in patients with BRAF mutation-positive malignant melanoma and brain metastases|Extra-cranial objective response rate|Duration of response|Intracranial progression free survival|Overall progression free survival|Number and severity of adverse events","Canadian Cancer Trials Group|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I224","November 23, 2016","December 2019","June 2020","November 28, 2016","null","June 13, 2018","QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada","","https://ClinicalTrials.gov/show/NCT02974803"
290,"NCT02563288","Esmolol Versus Dexmedetomidine During Intracranial Procedures",,"Recruiting","No Results Available","Intracranial Aneurysm|Intracranial Neoplasms","Drug: Esmolol|Drug: Dexmedetomidine","Systolic arterial pressure- mean arterial pressure (mmHg)","George Papanicolaou Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GeorgePapanikolaouHospital","August 2016","August 2017","October 2017","September 30, 2015","null","July 27, 2017","George Papanikolaou General Hospital, Thessaloniki, Greece","","https://ClinicalTrials.gov/show/NCT02563288"
291,"NCT03336931","PRecISion Medicine for Children With Cancer","PRISM","Recruiting","No Results Available","Childhood Cancer|Childhood Solid Tumor|Childhood Brain Tumor|Childhood Leukemia|Refractory Cancer|Relapsed Cancer","Diagnostic Test: Molecular profiling and drug testing","Personalized medicine recommendation|Tumor samples with actionable molecular alterations|Successfully conducted in vitro high throughput drug screening and in vivo drug sensitivity testing|Identification of potential treatment by in vitro or in vivo drug screening|Reporting turnaround time|Patients receiving the recommended personalized therapy|Barriers or reasons for patients not receiving the recommended personalized therapy","Sydney Children's Hospitals Network|Children's Cancer Institute Australia|Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG)|Garvan Institute of Medical Research|German Cancer Research Center","All","up to 21 Years   (Child, Adult)","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRISM","September 5, 2017","September 2020","September 2027","November 8, 2017","null","November 8, 2017","John Hunter Children's Hospital, Newcastle, New South Wales, Australia|Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia|The Children's Hospital at Westmead, Sydney, New South Wales, Australia|Lady Cilento Children's Hospital, Brisbane, Queensland, Australia|Women's and Children's Hospital, Adelaide, South Australia, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|Monash Children's Hospital, Melbourne, Victoria, Australia|Perth Children's Hospital, Perth, Western Australia, Australia","","https://ClinicalTrials.gov/show/NCT03336931"
292,"NCT03500991","HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors",,"Recruiting","No Results Available","Central Nervous System Tumor, Pediatric","Biological: HER2-specific chimeric antigen receptor (CAR) T cell","Establish the safety, defined by the adverse events, of HER2-specific CAR T cell infusions delivered by a central nervous system (CNS) catheter into the tumor resection cavity or ventricular system|Establish the feasibility, defined by the ability to produce and administer CAR T cell product, of HER2-specific CAR T cell product infusions delivered by a central nervous system (CNS) catheter into the tumor resection cavity or ventricular system|Assess the distribution of CNS-delivered HER2-specific CAR T cells within the cerebrospinal fluid (CSF) and peripheral blood|Assessment of whether HER2 expression changes in relapsed CNS tumors that were HER2 positive prior to treatment with CAR T cells|Assessment of disease response of HER2-expressing refractory or recurrent central nervous system (CNS) tumors to HER2 specific CAR T cell therapy delivered directly into the CNS","Seattle Children's Hospital","All","1 Year to 26 Years   (Child, Adult)","Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BrainChild-01","June 15, 2018","June 15, 2021","June 15, 2036","April 17, 2018","null","June 20, 2018","Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03500991"
293,"NCT02900248","CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice","N1","Recruiting","No Results Available","Neoplasms|Lung Neoplasms|Colon Neoplasms|Breast Neoplasms|Pancreatic Neoplasms|Prostate Neoplasms|Kidney Neoplasms|Liver Neoplasms|Rectal Neoplasms|Hematologic Neoplasms|Multiple Myeloma|Myelodysplastic Syndromes|Ovarian Neoplasms|Bladder Neoplasms|Testicular Neoplasms|Endometrial Neoplasms|Brain Neoplasms|Biliary Tract Neoplasms|Head and Neck Neoplasms|Uterine Cervical Neoplasms|Skin Neoplasms|Melanoma|Gastric Neoplasms|Anal Neoplasms|Sarcoma","Other: Provider determined","Best Overall Response|Time to Treatment Progression|Overall Survival|Establish stable estimates of biomarker prevalence in patients with advanced malignancies in a large population.|To determine rate of enrollment into existing and future therapeutic clinical trials.","CureOne","All","18 Years and older   (Adult, Older Adult)","","100000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","N1OR","October 2, 2017","October 2021","October 2024","September 14, 2016","null","October 4, 2017","Teton Cancer Institute, Idaho Falls, Idaho, United States","","https://ClinicalTrials.gov/show/NCT02900248"
294,"NCT02624388","Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)","UVA-Gen001","Recruiting","No Results Available","Lymphoma|Childhood Lymphoma|Solid Tumor|Childhood Solid Tumor|Neuroblastoma|Ewing Sarcoma|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Rhabdomyosarcoma|Soft Tissue Sarcoma|Medulloblastoma|Germ Cell Tumor|Wilms Tumor|Brain Neoplasms|Medulloblastoma, Childhood|Neuroectodermal Tumors, Primitive","Drug: Genistein|Drug: Placebo","Time to neutrophil count recovery following myelosuppressive chemotherapy|Serum marker levels of inflammation during cycles of chemotherapy|Number of days that participants experience adverse events that are commonly caused by chemotherapy treatment|Number of participants who experience adverse events that are commonly caused by chemotherapy treatment|Number of times per participant that adverse events that are commonly caused by chemotherapy treatment occur|Severity of adverse events that are commonly caused by chemotherapy treatment|Number of days that participants are hospitalized or have prolonged hospitalization due to an adverse event|Number of days that planned cancer treatment is delayed due to an adverse event|Percent that planned cancer treatment doses are reduced due to an adverse event|Number of days that antimicrobial treatment is administered|Number of participants who are administered granulocyte-colony stimulating factor (G-CSF)|Number of times per participant that granulocyte-colony stimulating factor (G-CSF) is administered|Number of participants who are administered a blood product|Number of times per participant that a blood product is administered|Number of times that a blood product is administered for anemia, decreased platelets, abnormal bleeding, or the subject's best interest","University of Virginia","All","1 Year to 21 Years   (Child, Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","17588","August 2016","August 2018","June 2019","December 8, 2015","null","June 21, 2017","University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02624388"
295,"NCT02881957","Hypovitaminosis D in Neurocritical Patients",,"Recruiting","No Results Available","Craniocerebral Trauma|Intracranial Aneurysm|Brain Neoplasms|Spinal Cord Injuries|Seizures|Meningitis|Stroke|Intracranial Hemorrhages|Critical Illness|Vitamin d Deficiency","Drug: Cholecalciferol|Other: Placebo","Hospital length-of-stay|In-hospital mortality|ICU length-of-stay|Glasgow Outcome Score|Hospital complications|SF-36 quality-of-life metric|Study drug adverse events|Glasgow Outcome Score followup|SF-36 quality-of-life metric followup","University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","436","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB_00091541","October 2016","October 2017","March 2018","August 29, 2016","null","November 17, 2016","University of Utah Hospital, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02881957"
296,"NCT02576431","Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)",,"Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Thyroid Neoplasms|Sarcoma|Colorectal Neoplasms|Salivary Gland Neoplasms|Biliary Tract Neoplasms|Brain Neoplasm, Primary|Carcinoma, Ductal, Breast|Melanoma|Solid Tumors|Glioblastoma|Bile Duct Neoplasms|Astrocytoma|Head and Neck Squamous Cell Carcinoma|Pontine Glioma|Pancreatic Neoplasms|Ovarian Neoplasms|Carcinoma, Renal Cell|Cholangiocarcinoma|Carcinoma|Carcinoma, Bronchogenic|Bronchial Neoplasms|Lung Neoplasms|Respiratory Tract Neoplasms|Thoracic Neoplasms|Neoplasms, Nerve Tissue|Nevi and Melanomas","Drug: LOXO-101","Overall Response Rate of confirmed CR or PR as determined by an Independent Radiology Committee using RECIST 1.1 or RANO criteria|Overall Response Rate of confirmed CR or PR as determined by the treating investigator using RECIST 1.1 or RANO criteria|Duration of response for subjects with best overall response of confirmed CR or PR by Independent Radiology Committee|Duration of response for subjects with best overall response of confirmed CR or PR by the treating investigator|Progression Free Survival|Overall Survival (OS)|Comparison of Progression Free Survival following initiation of Loxo-101 to that following the line of therapy immediately preceding Loxo-101|Incidence of Adverse Events|Severity of Adverse Events|Duration of Adverse Events|Changes from baseline in clinical safety laboratory values|Changes from baseline in vital signs","Loxo Oncology, Inc.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","151","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LOXO-TRK-15002","October 2015","April 2018","December 2019","October 15, 2015","null","September 7, 2017","University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Medstar Hospital Washington, Washington, D.C., District of Columbia, United States|Memorial Hospital, Pembroke Pines, Florida, United States|University of Chicago, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|John Theurer Cancer Center at Hackensack, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina (UNC), Chapel Hill, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Vanderbilt University, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Inova Health System, Fairfax, Virginia, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Copenhagen University Hospital, Copenhagen, Denmark|Institut Bergonie, Bordeaux Cedex, France|St. Vincent's University Hospital, Dublin, Ireland|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal|National Cancer Centre, Outram, Singapore|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|Barts Health NHS Trust Royal London Hospital, London, United Kingdom|University College Hospital, London, United Kingdom|University Hospital Southampton (UHS), Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT02576431"
297,"NCT03215511","Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers",,"Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Thyroid Neoplasms|Sarcoma|Colorectal Neoplasms|Salivary Gland Neoplasms|Biliary Tract Neoplasms|Brain Neoplasm, Primary|Melanoma|Glioblastoma|Bile Duct Neoplasms|Astrocytoma|Head and Neck Squamous Cell Carcinoma|Pontine Glioma|Pancreatic Neoplasms|Ovarian Neoplasms|Carcinoma, Renal Cell|Cholangiocarcinoma|Skin Carcinoma|Carcinoma, Bronchogenic|Bronchial Neoplasms|Lung Neoplasms|Respiratory Tract Neoplasms|Thoracic Neoplasms|Neoplasms, Nerve Tissue|Nevi and Melanomas|Intestinal Neoplasms|Thyroid Cancer|GIST|Malignant Peripheral Nerve Sheath Tumors|Breast Secretory Carcinoma|Uterine Neoplasms|Fibrosarcoma|Infantile Fibrosarcoma|Congenital Mesoblastic Nephroma|Central Nervous System Neoplasms","Drug: LOXO-195","Maximum Tolerated Dose (MTD)|Recommended dose for further study in patients age 12 and older and age <12|Best overall response of confirmed PR or CR by independent radiology review in patients age 12 and older and age <12 in NTRK fusion cancer patients previously treated with TRK inhibitor who have progressed|Incidence of AEs|Severity of AEs|Duration of AEs|Changes in clinical laboratory results compared to baseline|Changes in vital signs compared to baseline|Best overall response of confirmed PR or CR by independent radiology review in NTRK fusion cancer patients previously treated with TRK inhibitor|Best overall response of confirmed CR or PR as determined by treating investigators using RANO in patients with primary CNS malignancies.|Characterize PK properties of Loxo-195|Best overall response of confirmed PR or CR using RECIST v1.1 or RANO criteria as appropriate in patients with documented NTRK fusion cancers, who discontinued previous TRK inhibitor due to intolerance|Duration or response (DOR) for patients with best overall response of confirmed CR or PR by an independent radiology review committee|Duration or response (DOR) for patients with best overall response of confirmed CR or PR by the treating Investigator|Progression-free survival (PFS)|Overall survival (OS)|Clinical benefit rate (CBR)","Loxo Oncology, Inc.|Bayer","All","1 Month and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","93","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LOXO-EXT-17005","July 10, 2017","August 2019","December 2019","July 12, 2017","null","May 31, 2018","Stanford Cancer Center, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas, Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Righospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT03215511"
298,"NCT01505569","Auto Transplant for High Risk or Relapsed Solid or CNS Tumors",,"Recruiting","No Results Available","Ewing's Family Tumors|Renal Tumors|Hepatoblastoma|Rhabdomyosarcoma|Soft Tissue Sarcoma|Primary Malignant Brain Neoplasms|Retinoblastoma|Medulloblastoma|Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)|Atypical Teratoid/Rhabdoid Tumor (AT/RT)|CNS Tumors|Germ Cell Tumors","Drug: Ifosfamide|Drug: Etoposide|Drug: Mesna|Biological: G-CSF|Drug: Busulfan|Drug: Melphalan|Drug: Thiotepa|Biological: Autologous stem cell infusion|Radiation: Radiation|Drug: Carboplatin|Drug: Paclitaxel|Procedure: Leukapheresis|Drug: Anti-seizure prophylaxis|Drug: Ursodiol","Overall Survival|Number of Patients Who Achieved Transplant Engraftment|Disease Free Survival|Treatment-Related Mortality","Masonic Cancer Center, University of Minnesota","All","up to 70 Years   (Child, Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011OC057|MT2011-09C","October 20, 2011","January 2019","January 2021","January 6, 2012","null","April 26, 2018","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01505569"
299,"NCT03002532","Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer",,"Recruiting","No Results Available","Breast Cancer Metastatic|Brain Metastases","Radiation: whole brain radiotherapy","neurocognitive function|quality of life|patient-reported quality of life|time to intracranial progression|overall survival after brain metastases","Affiliated Hospital to Academy of Military Medical Sciences","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ky-2016-9-37","August 2015","August 2017","August 2017","December 23, 2016","null","December 23, 2016","Affiliated Hospital of Academy of Military Medical Sciences, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03002532"
300,"NCT03488472","Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain","RAD 1704","Not yet recruiting","No Results Available","Brain Metastases|Small Cell Lung Cancer","Device: NovoTTF-200A|Radiation: Stereotactic Radiosurgery (SRS)","Rate of Distant Metastases|Overall Survival|Local Recurrence|Distant CNS Progression","Drexell Hunter Boggs|NovoCure Ltd.|University of Alabama at Birmingham","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300001201","June 2018","April 2021","April 2021","April 5, 2018","null","May 10, 2018","University of Alabama at Birmingham (UAB), Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03488472"
301,"NCT02185352","Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain Metastases","A-Plus","Recruiting","No Results Available","Breast Cancer|Brain Metastases","Drug: BEEP regimen","The Brain-specific progression free survival (BS-PFS)|The 2-month brain-specific objective response rate (BS-ORR)","National Taiwan University Hospital","Female","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201402059MIPD","September 2014","July 2017","July 2017","July 9, 2014","null","January 19, 2017","Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Shuang Ho Hospital, New Taipei City, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital-LinKou, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT02185352"
302,"NCT02101905","Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma",,"Recruiting","No Results Available","Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Oligodendroglioma|Gliosarcoma|Mixed Glioma|Recurrent Adult Brain Neoplasm|Recurrent Glioblastoma","Other: Laboratory Biomarker Analysis|Drug: Lapatinib Ditosylate|Other: Pharmacological Study|Procedure: Therapeutic Conventional Surgery","Lapatinib ditosylate intratumoral concentration (pharmacokinetics)|Ratio of phosphorylated (p)EGFR/total EGFR (PD) in tumor tissue|Incidence of adverse events (AEs)|Inhibition of tumor cell proliferation (KI-67)|Ex-vivo sensitivity of tumor sphere cultures to lapatinib ditosylate|Objective response rate|OS|Progression-free survival","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","33","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2014-00634|ABTC-1302|U01CA137443|UM1CA137443","March 13, 2014","June 30, 2018","null","April 2, 2014","null","May 24, 2018","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02101905"
303,"NCT02058953","CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases","13-052","Recruiting","No Results Available","Melanoma|Brain Metastases","Procedure: Craniotomy scheduled|Procedure: Collection for non-craniotomy","Collection of blood, tumor tissue samples and adjacent uninvolved tissue and Cerebrospinal Fluid","University of Pittsburgh|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","","50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","UPCI 13-052 (IMWG-01)","August 2014","August 31, 2018","August 31, 2019","February 11, 2014","null","September 11, 2017","University of Pittsburgh Medical Center- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|The University of Texas- MD Anderson Cancer Center, Houston, Texas, United States|Melanoma Institute Australia- Westmead Institute for Cancer Research, Sydney, Australia","","https://ClinicalTrials.gov/show/NCT02058953"
304,"NCT02541370","Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133",,"Recruiting","No Results Available","Liver Cancer|Pancreatic Cancer|Brain Tumor|Breast Cancer|Ovarian Tumor|Colorectal Cancer|Acute Myeloid and Lymphoid Leukemias","Biological: anti-CD133-CAR vector-transduced T cells","Occurrence of study related adverse events|Anti-tumor responses to CART-133 cell infusions","Chinese PLA General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s2015-080-03","September 2015","October 2017","October 2018","September 4, 2015","null","September 4, 2015","Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02541370"
305,"NCT03257735","A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain Metastases",,"Recruiting","No Results Available","Lung Cancer|Brain Metastases|Cerebrospinal Fluid|Next-generation Sequencing","Diagnostic Test: next-generation sequencing","Change from baseline gene mutation status at 2 months|Change from second line gene mutation status at 6 months|PFS|OS","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A2017-003","May 1, 2017","December 31, 2018","May 31, 2019","August 22, 2017","null","August 22, 2017","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03257735"
306,"NCT03356600","Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer",,"Not yet recruiting","No Results Available","Brain Metastases","Combination Product: Apatinib plus radiotherapy","The intracranial disease progression free survival time|Progression free survival time|Overall survival|Disease control rate|Objective response rate|Dosage changes of dexamethasone|Volume change rate of cerebral edema|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Cognitive function screening ：Mini-mental state examination (MMSE)|Executive function testing：trail marking test（TMT）|Language function detection ：Hopkins verbal learning test-revised（HVLT-R）|Verbal learning and memory:Hopkins verbal learning test-revised（HVLT-R）","Shanxi Province Cancer Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ahead-SXZL 7","December 2017","January 2019","October 2019","November 29, 2017","null","December 11, 2017","","","https://ClinicalTrials.gov/show/NCT03356600"
307,"NCT03251989","Outcomes and Risk in People With Ependymoma",,"Recruiting","No Results Available","Ependymoma","","Relationship between health status and disease and treatment characteristics as well as clinicaL and demographic risk factors as self reported by adult participants with rare CNS tumors; and the relationship of genomic susceptibility of the popu...","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","","1650","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999917141|17-C-N141","July 11, 2018","February 1, 2022","February 26, 2022","August 16, 2017","null","July 6, 2018","National Cancer Institute (NCI), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03251989"
308,"NCT01951469","Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer",,"Recruiting","No Results Available","Non-small Cell Lung Cancer|Brain Metastases|EGFR Mutation","Drug: Gefitinib and Pemetrexed/cisplatin|Drug: Gefitinib mono-therapy","comparing the difference of iPFS(intracranial progression free survival) in two arms|comparing the difference of Response rate(CR&PR) and in two arms","Sun Yat-sen University|Wu Jieping Medical Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSCLC brain metastasis 01","June 2013","June 2018","June 2019","September 26, 2013","null","October 26, 2017","Sun Yat-sen University of Cancer Center, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT01951469"
309,"NCT01951482","Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer",,"Recruiting","No Results Available","Non Squamous Non-small Cell Lung Cancer|Brain Metastases|Bevacizumab","Drug: Pemetrexed/cisplatin|Drug: Bevacizumab and Pemetrexed/cisplatin","Compare iPFS(intracranial progression free survival) in two arms|Response rate(CR&PR)","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSCLC brain metastasis 02","June 2013","December 2019","June 2020","September 26, 2013","null","October 26, 2017","Sun Yat-sen University of Cancer Center, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT01951482"
310,"NCT02978677","Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas","PANAMA","Not yet recruiting","No Results Available","Meningioma","Radiation: Radiotherapy 68 Gy(RBE)|Radiation: Radiotherapy 72 Gy(RBE)|Radiation: Radiotherapy 60 Gy(RBE)","progression-free survival|late toxicity|acute toxicity|overall survival|patterns of recurrence using MRI|quality of life by validated quality of life questionnaires","Technische Universität Dresden|German Cancer Research Center|Radiation Oncology Working Group of the German Cancer Society","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STR-PANAMA-2015","January 2018","December 2027","December 2028","December 1, 2016","null","June 20, 2017","","","https://ClinicalTrials.gov/show/NCT02978677"
311,"NCT02896335","Palbociclib In Progressive Brain Metastases",,"Recruiting","No Results Available","Metastatic Malignant Neoplasm to Brain","Drug: Palbociclib","Clinical Benefit Rate (Intracranial)|Clinical Benefit Rate (Extracranial)|Intracranial disease progression rate|Extracranial disease progression rate|Overall Survival Rate|Number of Participants with Grade 3 or more hematologic toxicity; grade 3 or more neurologic toxicity","Massachusetts General Hospital|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-254","November 2016","August 2018","August 2022","September 12, 2016","null","March 8, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02896335"
312,"NCT03277638","Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioblastoma, Adult","Drug: Pembrolizumab at 7 days prior|Drug: Pembrolizumab at 14 days post|Drug: Pembrolizumab at 35 days post|Procedure: Laser Interstitial Thermotherapy","Phase I Objective: Optimal timing of LITT with pembrolizumab|Phase II Objective: Tumor Response|Progression free survival|overall survival|The proportion of patients who achieve progression free survival at 6 months (PFS6)|The proportion of patients who achieve progression free survival at 12 months (PFS12)|The proportion of patients who achieve progression free survival at 24 months (PFS24)","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE3316","November 29, 2017","February 2019","February 2020","September 11, 2017","null","December 20, 2017","University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03277638"
313,"NCT02393131","Neurocognitive Outcome of Conformal WBRT w/wo Hippocampal Avoidance for Brain Metastases",,"Recruiting","No Results Available","Metastatic Malignant Neoplasm to Brain","Radiation: Hippocampal avoidance WBRT|Radiation: Conformal WBRT","Hopkins Verbal Learning Test-Revised (HVTL-R) delayed recall score|Neurocognitive function by a standardized neurocognitive battery|Patient reported outcome (Quality of Life questionnaire)|Acute toxicity (Common Toxicity Criteria for Adverse Events version 4)|Late toxicity (Common Toxicity Criteria for Adverse Events version 4)|Intracranial progression (Number of participant with intracranial progression on MRI of brain)|Overall survival","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","201412029RINB","February 2015","August 2018","December 2018","March 19, 2015","null","March 29, 2017","National Taiwan University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT02393131"
314,"NCT02970448","Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas",,"Recruiting","No Results Available","High Grade Glioma","Procedure: LITT|Radiation: Radiation therapy|Drug: Temozolomide","Study safety as determined by the number of patients who experience pre-specified adverse events|Number of patients with adjustments to radiation plan to account for post-LITT tissue distortion","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE4316","May 18, 2017","January 2020","January 2020","November 22, 2016","null","August 24, 2017","Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02970448"
315,"NCT02285439","Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors",,"Recruiting","No Results Available","Low-Grade Gliomas|Malignant Neoplasms, Brain|Soft Tissue Neoplasms","Drug: MEK162","Response rate|Survival","Children's Hospital Los Angeles|Dana-Farber Cancer Institute","All","1 Year to 18 Years   (Child, Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ChildrenHLA","April 2016","December 2019","June 2020","November 7, 2014","null","February 2, 2018","Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Colorado, Aurora, Colorado, United States|Children's National Heath Systems, Washington, District of Columbia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Children's Hospitals and Clinics of Minnesota-Minneapolis, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New York University, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Texas Southwestern Medical, Dallas, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02285439"
316,"NCT03222258","Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients",,"Recruiting","No Results Available","Stage IV Breast Cancer|Stage IV Pancreatic Cancer|Stage IV Colon Cancer|Stage IV Gastric Cancer|Stage IV Lung Cancer|Stage IV Liver Cancer|Malignant Hematologic Neoplasm|Biliary Cancer Metastatic|Pediatric Leukemia|Pediatric Lymphoma|Pediatric Brain Tumor|Pediatric Solid Tumor","Behavioral: Early palliative care|Behavioral: Routine hospice care","Quality of Life Questionnaire - Core 15 items|Mcgill Quality of Life|Pediatric Quality of Life Inventory|Patients survival and Physicians Orders for Life Sustaining Treatment (POLST) documentation|Depression|Level of decision conflict|Understanding the illness|Recognition of health status|Crisis overcoming capability|Daily functional skills in elderly|Medical cost in KRW/person/month|Utilization of healthcare services|Preference of Advance care and Palliative care|M.D. Anderson Symptom Inventory","Seoul National University Hospital|Seoul National University Bundang Hospital|National Cancer Center, Korea|Kyunghee University Medical Center|Severance Hospital|Gyeongsang National University Hospital|Chungnam National University Hospital|Chonbuk National University Hospital|Ewha Womans University Mokdong Hospital|Daegu Fatima Hospital, South Korea|Chonnam National University Hospital|Keimyung University Dongsan Medical Center|Hallym University Medical Center|Asan Medical Center|National Evidence-Based Healthcare Collaborating Agency|National Institute of Health, Korea|National Clinical Research Coordination Center, Seoul, Korea|Ulsan University Hospital","All","Child, Adult, Older Adult","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HC15C1391-2","December 17, 2016","June 30, 2019","June 30, 2019","July 19, 2017","null","September 8, 2017","National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gyeongsang National University Hospital, Jinju-si, Gyeongsangnam-do, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Korea, Republic of|Daegu Fatima Hospital, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Kyunghee University Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03222258"
317,"NCT02716948","SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine",,"Recruiting","No Results Available","Metastatic Malignant Neoplasm in the Brain|Metastatic Malignant Neoplasm in the Spine|Stage IV Skin Melanoma","Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Radiation: Stereotactic Radiosurgery","Incidence of serious adverse events (SAE) graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 4.0|Changes in the immune profile of peripheral blood during and after treatment with nivolumab in combination with stereotactic radiosurgery (immune response)|Incidence of toxicity graded according to the NCI CTC 4.0|Local control rate in brain defined as no change in number of lesions at initial treatment in the brain and change on size of targeted lesion is =< 25% from initial measurement|Progression-free survival according to Response Evaluation Criteria in Solid Tumors criteria 1.1|Systematic control rate in spine defined as no change in number of lesions at initial treatment in the spine and change on size of targeted lesion is =< 25% from initial measurement","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Phase 1","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J15214|NCI-2016-00370|IRB00086553","March 2016","April 2019","March 2021","March 23, 2016","null","January 23, 2018","Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02716948"
318,"NCT01793168","Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford","CoRDS","Recruiting","No Results Available","Rare Disorders|Undiagnosed Disorders|Disorders of Unknown Prevalence|Cornelia De Lange Syndrome|Prenatal Benign Hypophosphatasia|Perinatal Lethal Hypophosphatasia|Odontohypophosphatasia|Adult Hypophosphatasia|Childhood-onset Hypophosphatasia|Infantile Hypophosphatasia|Hypophosphatasia|Kabuki Syndrome|Bohring-Opitz Syndrome|Narcolepsy Without Cataplexy|Narcolepsy-cataplexy|Hypersomnolence Disorder|Idiopathic Hypersomnia Without Long Sleep Time|Idiopathic Hypersomnia With Long Sleep Time|Idiopathic Hypersomnia|Kleine-Levin Syndrome|Kawasaki Disease|Leiomyosarcoma|Leiomyosarcoma of the Corpus Uteri|Leiomyosarcoma of the Cervix Uteri|Leiomyosarcoma of Small Intestine|Acquired Myasthenia Gravis|Addison Disease|Hyperacusis (Hyperacousis)|Juvenile Myasthenia Gravis|Transient Neonatal Myasthenia Gravis|Williams Syndrome|Lyme Disease|Myasthenia Gravis|Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome)|Isolated Klippel-Feil Syndrome|Frasier Syndrome|Denys-Drash Syndrome|Beckwith-Wiedemann Syndrome|Emanuel Syndrome|Isolated Aniridia|Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11|Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15|Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion|Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication|Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion|Axenfeld-Rieger Syndrome|Aniridia-intellectual Disability Syndrome|Aniridia - Renal Agenesis - Psychomotor Retardation|Aniridia - Ptosis - Intellectual Disability - Familial Obesity|Aniridia - Cerebellar Ataxia - Intellectual Disability|Aniridia - Absent Patella|Aniridia|Peters Anomaly - Cataract|Peters Anomaly|Potocki-Shaffer Syndrome|Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11|Silver-Russell Syndrome Due to Imprinting Defect of 11p15|Silver-Russell Syndrome Due to 11p15 Microduplication|Syndromic Aniridia|WAGR Syndrome|Wolf-Hirschhorn Syndrome|4p16.3 Microduplication Syndrome|4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome|Autosomal Recessive Stickler Syndrome|Stickler Syndrome Type 2|Stickler Syndrome Type 1|Stickler Syndrome|Mucolipidosis Type 4|X-linked Spinocerebellar Ataxia Type 4|X-linked Spinocerebellar Ataxia Type 3|X-linked Intellectual Disability - Ataxia - Apraxia|X-linked Progressive Cerebellar Ataxia|X-linked Non Progressive Cerebellar Ataxia|X-linked Cerebellar Ataxia|Vitamin B12 Deficiency Ataxia|Toxic Exposure Ataxia|Unclassified Autosomal Dominant Spinocerebellar Ataxia|Thyroid Antibody Ataxia|Sporadic Adult-onset Ataxia of Unknown Etiology|Spinocerebellar Ataxia With Oculomotor Anomaly|Spinocerebellar Ataxia With Epilepsy|Spinocerebellar Ataxia With Axonal Neuropathy Type 2|Spinocerebellar Ataxia Type 8|Spinocerebellar Ataxia Type 7|Spinocerebellar Ataxia Type 6|Spinocerebellar Ataxia Type 5|Spinocerebellar Ataxia Type 4|Spinocerebellar Ataxia Type 37|Spinocerebellar Ataxia Type 36|Spinocerebellar Ataxia Type 35|Spinocerebellar Ataxia Type 34|Spinocerebellar Ataxia Type 32|Spinocerebellar Ataxia Type 31|Spinocerebellar Ataxia Type 30|Spinocerebellar Ataxia Type 3|Spinocerebellar Ataxia Type 29|Spinocerebellar Ataxia Type 28|Spinocerebellar Ataxia Type 27|Spinocerebellar Ataxia Type 26|Spinocerebellar Ataxia Type 25|Spinocerebellar Ataxia Type 23|Spinocerebellar Ataxia Type 22|Spinocerebellar Ataxia Type 21|Spinocerebellar Ataxia Type 20|Spinocerebellar Ataxia Type 2|Spinocerebellar Ataxia Type 19/22|Spinocerebellar Ataxia Type 18|Spinocerebellar Ataxia Type 17|Spinocerebellar Ataxia Type 16|Spinocerebellar Ataxia Type 15/16|Spinocerebellar Ataxia Type 14|Spinocerebellar Ataxia Type 13|Spinocerebellar Ataxia Type 12|Spinocerebellar Ataxia Type 11|Spinocerebellar Ataxia Type 10|Spinocerebellar Ataxia Type 1 With Axonal Neuropathy|Spinocerebellar Ataxia Type 1|Spinocerebellar Ataxia - Unknown|Spinocerebellar Ataxia - Dysmorphism|Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature|Spectrin-associated Autosomal Recessive Cerebellar Ataxia|Spasticity-ataxia-gait Anomalies Syndrome|Spastic Ataxia With Congenital Miosis|Spastic Ataxia - Corneal Dystrophy|Spastic Ataxia|Rare Hereditary Ataxia|Rare Ataxia|Recessive Mitochondrial Ataxia Syndrome|Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature|Posterior Column Ataxia - Retinitis Pigmentosa|Post-Stroke Ataxia|Post-Head Injury Ataxia|Post Vaccination Ataxia|Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract|Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus|Non-progressive Cerebellar Ataxia With Intellectual Disability|Non-hereditary Degenerative Ataxia|Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity|Olivopontocerebellar Atrophy - Deafness|NARP Syndrome|Myoclonus - Cerebellar Ataxia - Deafness|Multiple System Atrophy, Parkinsonian Type|Multiple System Atrophy, Cerebellar Type|Multiple System Atrophy|Maternally-inherited Leigh Syndrome|Machado-Joseph Disease Type 3|Machado-Joseph Disease Type 2|Machado-Joseph Disease Type 1|Lethal Ataxia With Deafness and Optic Atrophy|Leigh Syndrome|Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema|Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination|Leigh Syndrome With Nephrotic Syndrome|Leigh Syndrome With Leukodystrophy|Leigh Syndrome With Cardiomyopathy|Late-onset Ataxia With Dementia|Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome|Infection or Post Infection Ataxia|Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia|Infantile Onset Spinocerebellar Ataxia|GAD Ataxia|Hereditary Episodic Ataxia|Gliadin/Gluten Ataxia|Friedreich Ataxia|Fragile X-associated Tremor/Ataxia Syndrome|Familial Paroxysmal Ataxia|Exposure to Medications Ataxia|Episodic Ataxia With Slurred Speech|Episodic Ataxia Unknown Type|Episodic Ataxia Type 7|Episodic Ataxia Type 6|Episodic Ataxia Type 5|Episodic Ataxia Type 4|Episodic Ataxia Type 3|Episodic Ataxia Type 1|Epilepsy and/or Ataxia With Myoclonus as Major Feature|Early-onset Spastic Ataxia-neuropathy Syndrome|Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity|Early-onset Cerebellar Ataxia With Retained Tendon Reflexes|Early-onset Ataxia With Dementia|Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia|Dilated Cardiomyopathy With Ataxia|Cataract - Ataxia - Deafness|Cerebellar Ataxia, Cayman Type|Cerebellar Ataxia With Peripheral Neuropathy|Cerebellar Ataxia - Hypogonadism|Cerebellar Ataxia - Ectodermal Dysplasia|Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss|Brain Tumor Ataxia|Brachydactyly - Nystagmus - Cerebellar Ataxia|Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia|Autosomal Recessive Syndromic Cerebellar Ataxia|Autosomal Recessive Spastic Ataxia With Leukoencephalopathy|Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay|Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria|Autosomal Recessive Spastic Ataxia|Autosomal Recessive Metabolic Cerebellar Ataxia|Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine|Autosomal Recessive Ataxia, Beauce Type|Autosomal Recessive Ataxia Due to Ubiquinone Deficiency|Autosomal Recessive Ataxia Due to PEX10 Deficiency|Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia|Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency|Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency|Autosomal Recessive Congenital Cerebellar Ataxia|Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome|Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency|Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency|Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency|Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome|Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity|Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency|Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect|Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion|Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation|Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness|Autosomal Recessive Cerebellar Ataxia|Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly|Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation|Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy|Autosomal Dominant Spastic Ataxia Type 1|Autosomal Dominant Spastic Ataxia|Autosomal Dominant Optic Atrophy|Ataxia-telangiectasia Variant|Ataxia-telangiectasia|Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy|Autosomal Dominant Cerebellar Ataxia Type 4|Autosomal Dominant Cerebellar Ataxia Type 3|Autosomal Dominant Cerebellar Ataxia Type 2|Autosomal Dominant Cerebellar Ataxia Type 1|Autosomal Dominant Cerebellar Ataxia|Ataxia-telangiectasia-like Disorder|Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome|Ataxia-deafness-intellectual Disability Syndrome|Ataxia With Vitamin E Deficiency|Ataxia With Dementia|Ataxia Neuropathy Spectrum|Ataxia - Tapetoretinal Degeneration|Ataxia - Photosensitivity - Short Stature|Ataxia - Pancytopenia|Ataxia - Oculomotor Apraxia Type 1|Ataxia - Hypogonadism - Choroidal Dystrophy|Ataxia - Other|Ataxia - Genetic Diagnosis - Unknown|Acquired Ataxia|Adult-onset Autosomal Recessive Cerebellar Ataxia|Alcohol Related Ataxia|Multiple Endocrine Neoplasia|Multiple Endocrine Neoplasia Type II|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2|Multiple Endocrine Neoplasia, Type IV|Multiple Endocrine Neoplasia, Type 3|Multiple Endocrine Neoplasia (MEN) Syndrome|Multiple Endocrine Neoplasia Type 2B|Multiple Endocrine Neoplasia Type 2A|Atypical Hemolytic Uremic Syndrome|Atypical HUS|Wiedemann-Steiner Syndrome|Breast Implant-Associated Anaplastic Large Cell Lymphoma|Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)|Hemophagocytic Lymphohistiocytosis|Behcet's Disease","","To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.","Sanford Health|National Ataxia Foundation|International WAGR Syndrome Association|4p- Support Group|ML4 Foundation|Cornelia de Lange Syndrome Foundation|Stickler Involved People|Kawasaki Disease Foundation|Klippel-Feil Syndrome Alliance|Klippel-Feil Syndrome Freedom|Hyperacusis Research Limited|Hypersomnia Foundation|Kabuki Syndrome Network|Kleine-Levin Syndrome Foundation|Leiomyosarcoma Direct Research Foundation|Marinesco-Sjogren Syndrome Support Group|Mucolipidosis Type IV (ML4) Foundation|People with Narcolepsy 4 People with Narcolepsy (PWN4PWN)|Soft Bones Incorporated|American Multiple Endocrine Neoplasia Support|Atypical Hemolytic Uremic Syndrome Foundation|All Things Kabuki|Wiedemann-Steiner Syndrome Foundation|Breast Implant Victim Advocates|PROS Foundation|American Behcet's Disease Association","All","Child, Adult, Older Adult","","20000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","03-10-014|Hypersomnia Foundation|National Ataxia Foundation|4p- Support Group|CdLS Foundation|Hyperacusis Research Limited|Kabuki Syndrome Network|Kawasaki Disease Foundation|Klippel-Feil Syndrome Freedom|Leiomyosarcoma Direct Research|MSS Support Group|ML4 Foundation|Stickler Involved People|IWSA|Soft Bones|PWN4PWN|aHUS|Klippel-Feil Syndrome Alliance|American MEN Support|Kleine-Levin Syndrome|All Things Kabuki|WSS Foundation|BIVA|ABDA|PROS Foundation (HLH)","July 2010","December 2100","December 2100","February 15, 2013","null","October 2, 2017","Sanford Health, Sioux Falls, South Dakota, United States","","https://ClinicalTrials.gov/show/NCT01793168"
319,"NCT02774291","Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1",,"Recruiting","No Results Available","HLA-A2 Positive Cells Present|Metastatic Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain","Biological: Aldesleukin|Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis","Incidence of toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|In vivo survival of TCR gene-engineered cells|Objective response rate, graded according to RECIST criteria","Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI)","All","18 Years to 66 Years   (Adult, Older Adult)","Not Applicable","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-5254|NCI-2015-01781|P30CA013330","August 2016","January 2018","January 2018","May 17, 2016","null","January 10, 2018","Albert Einstein College of Medicine, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT02774291"
320,"NCT03089749","Characterization of Human Autoantibody Titers After Central Nervous System Insult","CHAT CNS","Recruiting","No Results Available","Brain Injuries, Traumatic|Spinal Cord Trauma|Intracranial Neoplasm","","Quantitate Autoantibodies|Autoantibody Correlation|Autoantibody Production and History","University of Utah","All","18 Years and older   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHAT-00081214","May 2015","August 2018","May 2022","March 24, 2017","null","October 26, 2017","University of Utah Hospital, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03089749"
321,"NCT02460068","A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis","NIBIT-M2","Recruiting","No Results Available","Brain Metastases","Drug: Fotemustine|Drug: Fotemustine and Ipilimumab|Drug: Ipilimumab and nivolumab","Overall Survival (OS)|safety (adverse events)|m-WHO and immune-related Disease Control Rate (DCR) in and outside the brain|Immune-related Progression-free Survival (irPFS)|m-WHO Progression-free Survival (irPFS)|Objective Response Rate (ORR)|Immune-related Objective Response Rate (irORR)|Time to Response (TTR)|Immune-related Time to Response (irTTR)|Duration of Response (DoR)|Immune-related Duration of Response (irDoR)|Brain progression-free survival (Brain-PFS)","Italian Network for Tumor Biotherapy Foundation|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","168","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIBIT-M2","December 2012","January 2018","January 2020","June 2, 2015","null","June 2, 2015","Medical Oncology, Cancer Institute ""Giovanni Paolo II"", Bari, Italy|Medical Oncology, Pope Giovanni XXIII Hospital, Bergamo, Italy|National Institute for Cancer Research, Genoa, Italy|Immunotherapy and Somatic Cell Therapy Unit, Scientific Institute of Romagna, Meldola, Italy|Surgical Oncology, National Cancer Institute, Milan, Italy|European Institute of Oncology, Milan, Italy|Medical Oncology and Innovative Therapy, National Cancer Institute, Naples, Italy|esophageal and melanoma oncology, Istituto Oncologico Veneto, Padua, Italy|Medical Oncology, National Cancer Institute ""Regina Elena"", Rome, Italy|Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, Italy|S C Dermatology, A.O.U. City of Health and Science of Turin, Turin, Italy","","https://ClinicalTrials.gov/show/NCT02460068"
322,"NCT02621515","Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases","CA209-322","Recruiting","No Results Available","Melanoma|Brain Metastasis","Drug: Nivolumab","The best overall response rate (BORR) of brain metastases to nivolumab will be assessed on Magnetic Resonance Imaging (MRI) using the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.|The difference in BORR will be assessed between previously treated and previously untreated brain metastases using the RANO-BM criteria.|The difference in BORR will be assessed between intracranial metastases on and extra-cranial metastases within the same patient, using the RANO-BM criteria and the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria respectively.|Duration of response (DOR)|Time to development of new brain metastases in responding patients|Progression free survival|Overall survival|The number of patients with treatment related adverse events as assessed by CTCAE v4.0.","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201500776","August 2016","August 2018","August 2018","December 3, 2015","null","April 27, 2018","Dutch Cancer Institute/ A v. Leeuwenhoek Hospital, Amsterdam, Netherlands|VU Medical Center, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT02621515"
323,"NCT02192359","Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas",,"Recruiting","No Results Available","Adult Anaplastic Astrocytoma|Adult Anaplastic Oligoastrocytoma|Adult Anaplastic Oligodendroglioma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor|Glioma","Biological: carboxylesterase-expressing allogeneic neural stem cells|Drug: irinotecan hydrochloride|Other: laboratory biomarker analysis|Other: pharmacological study","Incidence of dose limiting toxicities (DLTs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence of all attributable toxicities graded according to the NCI CTCAE version 4.0|Pharmacokinetics parameters, including maximum concentration and area under the curve of irinotecan and SN-38 in dialysate and plasma|Development of NSC immunogenicity after first and repeat exposures|Clinical benefit, defined by tumor response based on MRI results|Fate of the NSCs, defined by NSC persistence","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 1","53","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14108|NCI-2014-01463|R01CA198076","March 7, 2016","March 2019","March 2019","July 16, 2014","null","June 18, 2018","City of Hope Medical Center, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT02192359"
324,"NCT03471702","A Secondary Study Evaluating Aqueduct's Smart External Drain (SED)",,"Recruiting","No Results Available","Hydrocephalus|Hydrocephalus in Children|Tumor, Brain|Subarachnoid Hemorrhage","Device: Smart External Drain - SED","The number of subjects which require switching to a standard of care external drain.|Subject transport while on the SED system.|Evaluating SED system control throughout duration of study.","Aqueduct Critical Care","All","up to 80 Years   (Child, Adult, Older Adult)","Not Applicable","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASSESSED SED2","February 28, 2018","June 1, 2019","June 1, 2019","March 21, 2018","null","March 21, 2018","Texas Children's Hospital, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|University of Washington School of Medicine, Harborview Medical Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03471702"
325,"NCT02831959","Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)",,"Recruiting","No Results Available","Brain Metastases From Non-small Cell Lung Cancer (NSCLC)","Device: NovoTTF-100M device|Other: Best Standard of Care","Time to intracranial progression|Time to neurocognitive failure|Overall survival|Radiological response in the brain|Time to second intracranial progression|Time to first and second intracranial progression evaluated in two cohorts, 1-4 brain metastases and 5-10 brain metastases.|Rate of intracranial progression at 2, 4, 6, 8, 10, 12 months|Time to distant progression|Rate of decline in cognitive function at 2, 4, 6, 8, 10, 12 months|Neurocognitive failure-free survival|Quality of Life using the EORTC QLQ C30 with BN20 addendum|Toxicity during NovoTTF-100M treatment based on incidence and severity of treatment emergent adverse events as evaluated using the CTCAE version 4.0","NovoCure Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EF-25","July 2016","July 2019","July 2019","July 13, 2016","null","June 26, 2018","University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Mayo Clinic Phoenix, Phoenix, Arizona, United States|Mayo Clinic - Phoenix, Phoenix, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|MemorialCare Cancer Institute, Long Beach, California, United States|Keck Medical Center of USC, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Redwood City, Redwood City, California, United States|Dignity Health - Mercy Cancer Centers, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Associated Neurologists of Southern CT, Fairfield, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|UF Health Cancer Center, Orlando, Florida, United States|Piedmont Brain Tumor Center, Atlanta, Georgia, United States|Robert H. Lurie Comprehensive Cancer Center - Northwestern University, Chicago, Illinois, United States|The University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|CDH-Delnor Health System, Warrenville, Illinois, United States|St. Elizabeth Healthcare Cancer Care Center, Edgewood, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Tulane Cancer Center, New Orleans, Louisiana, United States|Ochsner Health System, New Orleans, Louisiana, United States|Willis-Knighton Cancer Center, Shreveport, Louisiana, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|21st Century Oncology, Troy, Michigan, United States|John Nasseff Neuroscience Institute ANW Brain Tumor Center, Minneapolis, Minnesota, United States|Masonic Cancer Clinic, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center, University of Missouri Healthcare, Columbia, Missouri, United States|Weil Cornell Medical College/New York Presbyterian Hospital, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Nyph/Cumc, New York, New York, United States|UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Wake Forest Health, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Alleghany Health Network, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Chattanooga Center for Neurologic Research, Chattanooga, Tennessee, United States|West Cancer Center, Germantown, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology - Austin, Austin, Texas, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Texas Oncology, McKinney, Texas, United States|Texas Oncology, Plano, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|University of VA Health Sciences Center, Charlottesville, Virginia, United States|Sentara Health, Norfolk, Virginia, United States|Aurora Research Institute - St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Froedtert and Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States|Medizinische Universität Innsbruck, Innsbruck, Austria|Cancercare Manitoba, Winnipeg, Manitoba, Canada|London Health Sciences Centre, London, Ontario, Canada|Notre-Dame Hospital CHUM, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Le CIUSSS de I'Est-de-L'ile de Montreal, Montréal, Quebec, Canada|Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada|University Hospital Lille, Lille, France|Clairval Hospital Center, Marseille, France|Sheba Medical Center, Ramat Gan, Israel|A.O.S.G. Moscati Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialità, Avellino, Italy|Azienda Socio Sanitaria Territoriale di Lecco, Lecco, Italy|Marek Harat Private Practice, Neurosurgery and Radiation Oncology, Bydgoszcz, Poland|University Clinical Center, Gdańsk, Poland|Catalan Institute of Oncology, Barcelona, Spain|Clinica Universidad de Navarra, Pamplona, Spain","","https://ClinicalTrials.gov/show/NCT02831959"
326,"NCT03391362","Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-6 Brain Metastases",,"Not yet recruiting","No Results Available","Brain Metastases|Small Cell Lung Cancer","Radiation: Stereotactic Radiation","Death due to progressive neurologic disease|All-cause mortality|Quality of life|Neurocognitive function: Verbal learning and memory|Neurocognitive function: Visual attention and task switching|Neurocognitive function: Verbal fluency|Neurocognitive function: Cognitive impairment|Ability to complete activities of daily living|Performance status|Incidence and time to detection of new brain metastases|Incidence and time to local recurrence of existing brain metastases|Incidence and time to development of radiation necrosis|Incidence and time to development of leptomeningeal disease|Incidence and time to progressive intracranial disease|Incidence and time to salvage craniotomy|Incidence and time to additional CNS-directed radiotherapeutic treatments (stereotactic or WBRT) after the initial course|Incidence and time to the development of seizures","Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","111","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-550","January 31, 2018","June 30, 2021","June 30, 2025","January 5, 2018","null","January 18, 2018","Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03391362"
327,"NCT00752323","Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma",,"Recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: aminolevulinic acid","Assess 2 doses of 5-ALA|Correlation between intensity of in vivo fluorescence and the pathologist's quantification of tumor in biopsy specimens (e.g., percentage of tumor present) as measured by PpIX concentration and intra-operative fluorescence intensity|Correlation between the amount and location of residual tumor detected intraoperatively by fluorescence imaging and frameless stereotaxy after maximal resection and the post-operative image enhancement on CT scan and/or MRI","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","CASE1305|P30CA043703","August 18, 2008","September 2018","September 2018","September 15, 2008","null","March 6, 2018","University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00752323"
328,"NCT02681549","Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer",,"Recruiting","No Results Available","Melanoma|Non-small Cell Lung Cancer|Brain Metastasis","Drug: Pembrolizumab plus Bevacizumab","brain metastasis response rate (BMRR) using modified RECIST (mRECIST) criteria|Proportion of patients using steroids to control of cerebral edema for greater than 96 hours|best overall response rate (ORR) by mRECIST criteria in the brain or RECIST criteria in the body|progression-free survival by mRECIST criteria in the brain or RECIST criteria in the body|Safety and toxicity of combination pembrolizumab and bevacizumab assessed using common terminology criteria for adverse events v. 4.","Yale University","All","18 Years and older   (Adult, Older Adult)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1512016953","May 2016","May 2019","May 2019","February 12, 2016","null","March 21, 2018","Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02681549"
329,"NCT03475186","Testing Ramipril to Prevent Memory Loss in People With Glioblastoma",,"Not yet recruiting","No Results Available","Glioblastoma|Radiotherapy; Complications|Cognitive Decline|Chemoradiation","Drug: Ramipril","Change from Baseline Neurocognitive Function at 10 weeks - Hopkins Verbal Learning Test-Revised (HVLT-R)|Change from Baseline Neurocognitive Function at 10 weeks - Trail Making Test Part A and B (TMT A & B)|Change from Baseline Neurocognitive Function at 10 weeks - Controlled Oral Word Association Test (COWA)|Efficacy of Ramipril of Neurocognitive Function at 10 weeks - Shipley Institute of Living Scale-Version 2 Vocabulary|Retention Rate at 10 weeks|Efficacy of Ramipril on Non-Memory Cognitive Functions- M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)|Efficacy of Ramipril on Non-Memory Cognitive Functions-EORTC Quality of Life Questionnaire-Core 30/Brain Cancer Module-20 (EORTCQLQ30/BN20)|Estimate Time of Neurocognitive Decline- HVLT-R|Estimate Time of Neurocognitive Decline- TMT A & B|Estimate Time of Neurocognitive Decline- COWA|Determine Presence of Apolipoprotein Epsilon (ApoE)|Efficacy of neurocognitive function in surviving patients- HVLT-R|Efficacy of neurocognitive function in surviving patients- TMT A & B|Efficacy of neurocognitive function in surviving patients- COWA|Efficacy of neurocognitive function in surviving patients- MDASI-BT|Efficacy of neurocognitive function in surviving patients- EORTCQLQ30/BN20","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","REBAWF1801|3UG1CA189824-04S1|WF-1801","August 2018","May 2020","April 2021","March 23, 2018","null","June 26, 2018","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03475186"
330,"NCT03128047","HUMC 1612: Optune NovoTTF-200A System",,"Recruiting","No Results Available","High Grade Glioma","Device: Optune NovoTTF-200A System|Drug: Bevacizumab|Drug: Temozolomide","Safety and tolerability of the Optune NovoTTF-200A System when used alone in pediatric patients with recurrent high-grade gliomas.|Safety and tolerability of the Optune NovoTTF-200A System when used in combination with temozolomide and bevacizumab in pediatric patients with newly diagnosed or recurrent high-grade gliomas.|Assess the event-free and overall survival of patients treated on this study protocol to aid in the future development of pediatric phase II/III studies using the Optune NovoTTF-200A System.|Survival of patients with recurrent high-grade glioma receiving treatment with the Optune NovoTTF-200A System.|2-year event-free survival (EFS) and overall survival (OS) of patients with recurrent high-grade glioma treated with the Optune NovoTTF-200A System monotherapy and in combination with temozolomide and bevacizumab|Survival of patients with high-grade glioma receiving treatment with the Optune NovoTTF-200A System in combination with temozolomide and bevacizumab","Hackensack University Medical Center|NovoCure Ltd.","All","1 Year to 17 Years   (Child)","Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2016-0583","April 6, 2017","February 2019","February 2019","April 25, 2017","null","February 12, 2018","Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT03128047"
331,"NCT03027388","Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma",,"Not yet recruiting","No Results Available","Astrocytoma, Grade IV|Glioblastoma Multiforme|Giant Cell Glioblastoma","Drug: LB-100","Drug Level in tumor tissue","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","20","NIH","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","170037|17-C-0037","January 5, 2017","August 30, 2020","August 30, 2020","January 23, 2017","null","July 6, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03027388"
332,"NCT03535350","Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma",,"Not yet recruiting","No Results Available","Glioblastoma","Drug: Ibrutinib|Radiation: Radiation|Drug: Temozolomide (TMZ)","Maximum tolerated dose (MTD) of ibrutinib|Number of patients who experience adverse events|Number of patients with Progression Free Survival (PFS)|Length of time of overall survival","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE2317","July 9, 2018","December 2019","December 2020","May 24, 2018","null","May 24, 2018","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03535350"
333,"NCT02709226","Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma",,"Recruiting","No Results Available","Astrocytoma, Grade IV|Giant Cell Glioblastoma|Glioblastoma Multiforme|Gliosarcoma","Radiation: Radiation","To determine maximum tolerated re-irradiation dose (MTD)|To determine progression free survival and overall survival|To determine late toxicity secondary to re-irradiation|To determine QOL and impact on neurocognition in the settingof re-irradiation of recurrent glioblastoma","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","24","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160081|16-C-0081","March 4, 2016","October 30, 2020","October 30, 2025","March 16, 2016","null","July 2, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02709226"
334,"NCT02978404","Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases",,"Recruiting","No Results Available","Clear-Cell Metastatic Renal Cell Carcinoma|Non Small Cell Lung Cancer Metastatic|Brain Metastases, Adult","Drug: Nivolumab|Radiation: Radiosurgery","Intracranial progression-free survival|Treated brain lesions control rate|Overall survival after receiving Nivolumab.|Maximum response rate of distant non-irradiated disease|Progression-free survival|Correlation between tumor PD-L1 expression and clinical outcomes|Patient quality of life|Neurocognitive function, as measured by the HVLT-R|Neurocognitive function, as measured by TMT|Neurocognitive function, as measured by COWA|Acute and late toxicity of SRS + Nivolumab|Imaging indicators of response","Centre hospitalier de l'Université de Montréal (CHUM)|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16.206|OZM-080","January 2017","June 2020","June 2020","December 1, 2016","null","July 12, 2017","Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02978404"
335,"NCT01622868","Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer",,"Recruiting","No Results Available","ERBB2 Gene Amplification|HER2 Positive Breast Carcinoma|Invasive Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7","Other: Laboratory Biomarker Analysis|Drug: Lapatinib Ditosylate|Radiation: Stereotactic Radiosurgery|Radiation: Whole-Brain Radiotherapy","Complete response (CR) rate in the measurable brain metastases measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on magnetic resonance imaging (MRI) scan of the brain|CR rate of measurable brain metastases measured using revised RECIST version 1.1 based on MRI scan of the brain|Objective response rate (ORR) (CR + partial response [PR]) of measurable brain metastases measured using RECIST version 1.1 based on MRI scan of the brain|ORR (CR + PR) of measurable brain metastases measured using RECIST version 1.1 based on MRI scan of the brain|Central nervous system (CNS) progressive disease outside the targeted measurable disease|Targeted lesion-specific progression|Incidence of treatment-related toxicity as measured by Common Terminology Criteria for Adverse Events version 4|Overall CNS complete response|Overall CNS progressive disease|Overall survival (OS)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","143","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-01977|RTOG-1119|CDR0000735353|U10CA180868|U10CA021661","July 26, 2012","August 31, 2019","null","June 19, 2012","null","July 4, 2018","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|The Kirklin Clinic at Acton Road, Birmingham, Alabama, United States|University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Mercy San Juan Medical Center, Carmichael, California, United States|Sutter Davis Hospital, Davis, California, United States|Memorial Medical Center, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Mercy General Hospital Radiation Oncology Center, Sacramento, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Gynecologic Oncology LLC, Newark, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Northside Hospital-Forsyth, Cumming, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Presence Saint Joseph Hospital-Chicago, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Elkhart Clinic, Elkhart, Indiana, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Radiation Oncology Associates PC, Fort Wayne, Indiana, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|Saint Luke's Hospital, Cedar Rapids, Iowa, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Norton Hospital Pavilion and Medical Campus, Louisville, Kentucky, United States|Norton Suburban Hospital and Medical Campus, Louisville, Kentucky, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Spectrum Health Big Rapids Hospital, Big Rapids, Michigan, United States|Henry Ford Cancer Institute¿Downriver, Brownstown, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Cancer Research Consortium of West Michigan NCORP, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Singing River Hospital, Pascagoula, Mississippi, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Cape Radiation Oncology, Cape Girardeau, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Saint Louis-Cape Girardeau CCOP, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Cancer Research for the Ozarks NCORP, Springfield, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Renown Regional Medical Center, Reno, Nevada, United States|Elliot Hospital, Manchester, New Hampshire, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Virtua Memorial, Mount Holly, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|Mount Sinai Hospital, New York, New York, United States|Highland Hospital, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Park Ridge Health, Hendersonville, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Southeast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem, North Carolina, United States|Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Radiation Oncology Center, Alliance, Ohio, United States|Summa Barberton Hospital, Barberton, Ohio, United States|Cleveland Clinic Cancer Center Beachwood, Beachwood, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|Mercy Medical Center, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physicians LLC-Samaritan North, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Cleveland Clinic Cancer Center Independence, Independence, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|Summa Health Center at Lake Medina, Medina, Ohio, United States|Lake University Ireland Cancer Center, Mentor, Ohio, United States|Southwest General Health Center Ireland Cancer Center, Middleburg Heights, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|University Hospitals Parma Medical Center, Parma, Ohio, United States|Robinson Radiation Oncology, Ravenna, Ohio, United States|University Hospitals Portage Medical Center, Ravenna, Ohio, United States|UH Seidman Cancer Center at Salem Regional Medical Center, Salem, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Cancer Treatment Center, Wooster, Ohio, United States|Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio, United States|Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma, United States|Warren Clinic Oncology-Tulsa, Tulsa, Oklahoma, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Covenant Medical Center-Lakeside, Lubbock, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Vermont College of Medicine, Burlington, Vermont, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Wheeling Hospital/Schiffler Cancer Center, Wheeling, West Virginia, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|UW Cancer Center Johnson Creek, Johnson Creek, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Columbia Saint Mary's Hospital - Ozaukee, Mequon, Wisconsin, United States|Columbia Saint Mary's Water Tower Medical Commons, Milwaukee, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Keimyung University-Dongsan Medical Center, Jung-Ku, Daegu, Korea, Republic of|National Cancer Center-Korea, Goyang-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam City, Kyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Yonsei University Health System-Severance Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01622868"
336,"NCT01906385","Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioblastoma|Astrocytoma","Drug: Rhenium Liposome Treatment","Maximum Tolerated Dose|Dose Distribution|Response rate|Survival","Andrew Brenner|The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTRC 12-02|14-450X","March 2015","August 2018","December 2018","July 24, 2013","null","May 4, 2018","The Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT01906385"
337,"NCT03520842","Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer",,"Not yet recruiting","No Results Available","KRAS Gene Mutation|Metastatic Malignant Neoplasm in the Brain|Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer AJCC v7","Drug: Methotrexate|Other: Pharmacokinetic Study|Drug: Regorafenib","Progression free survival (PFS), measured from time of first study treatment until objective tumor progression as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria or death from any cause, whichever occurs earlier.|Objective response rate (ORR)|Disease control rate (DCR)|Incidence of adverse events|Dose-limiting toxicities (DLTs)|Trough Serum Concentration of Methotrexate|Maximum Serum Concentration (Cmax) of Methotrexate","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LUN0097|NCI-2018-00413|43398","June 1, 2018","September 1, 2019","June 1, 2020","May 10, 2018","null","May 21, 2018","Stanford University School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03520842"
338,"NCT02885272","Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma",,"Recruiting","No Results Available","Malignant Neoplasms, Eye|Glioblastoma|Malignant Neoplasms, Brain|Malignant Neoplasms, Central Nervous System","Drug: FDG|Procedure: PET/CT|Procedure: MRI","Optimal FDG Positron Emission Tomography-Magnetic Resonance (PET-MR) Imaging Time Point","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016-0261|NCI-2016-01971","October 2016","October 2019","October 2020","August 31, 2016","null","January 29, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02885272"
339,"NCT03418961","S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer",,"Recruiting","No Results Available","Cardiotoxicity|HER2/Neu Positive|Metastatic Malignant Neoplasm in the Brain|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7","Drug: Carvedilol|Other: Laboratory Biomarker Analysis|Other: Patient Observation","Time to the first identification of cardiac dysfunction|Incidence of adverse events associated with beta blocker treatment|Rate of first interruption of trastuzumab|Rate of death|Time to first occurrence of cardiac event|Drug adherence","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","817","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","S1501|NCI-2016-01047|SWOG-S1501|UG1CA189974","September 15, 2017","February 1, 2023","February 1, 2023","February 1, 2018","null","June 28, 2018","Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Enloe Medical Center, Chico, California, United States|Epic Care-Dublin, Dublin, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Fresno Cancer Center, Fresno, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser San Rafael-Gallinas, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Kaiser Permanente-Franklin, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Kaiser Permanente-Rock Creek, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Kaiser Permanente-Lone Tree, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|Middlesex Hospital, Middletown, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Low Country Cancer Care Associates PC, Savannah, Georgia, United States|Summit Cancer Care-Candler, Savannah, Georgia, United States|Hawaii Oncology Inc-Pali Momi, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Hawaii Oncology Inc-POB I, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Memorial and Saint Elizabeth's Health Care Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Franciscan Health Mooresville, Mooresville, Indiana, United States|Reid Health, Richmond, Indiana, United States|Union Hospital, Terre Haute, Indiana, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Coffeyville Regional Medical Center, Coffeyville, Kansas, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Saint Catherine Hospital, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Hays Medical Center, Hays, Kansas, United States|University of Kansas Cancer Center-West, Kansas City, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Olathe Medical Center, Olathe, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Via Christi Hospital-Pittsburg, Pittsburg, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Saint Francis Hospital and Medical Center - Topeka, Topeka, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States|Medical Center of Baton Rouge, Baton Rouge, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Upper Chesapeake Medical Center, Bel Air, Maryland, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Winchester Hospital, Winchester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|McLaren Cancer Institute-Bloomfield, Bloomfield, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|Henry Ford Cancer Institute?Downriver, Brownstown, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|McLaren Cancer Institute-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|McLaren Cancer Institute-Flint, Flint, Michigan, United States|Singh and Arora Hematology Oncology PC, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Lymphoma Clinic of Michigan, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|McLaren-Greater Lansing, Lansing, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|McLaren Cancer Institute-Macomb, Mount Clemens, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Assarian Cancer Center, Novi, Michigan, United States|Henry Ford Medical Center-Columbus, Novi, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Providence Hospital-Southfield Cancer Center, Southfield, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Saint Joseph Health System-Tawas City, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi, United States|Baptist Cancer Center-Grenada, Grenada, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi, United States|Singing River Hospital, Pascagoula, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-North, Kansas City, Missouri, United States|The University of Kansas Cancer Center-Lee's Summit, Lee's Summit, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Morristown Medical Center, Morristown, New Jersey, United States|Newton Memorial Hospital, Newton, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Nyack Hospital, Nyack, New York, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Wilson, Wilson, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physicians LLC-Samaritan North, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Lake University Ireland Cancer Center, Mentor, Ohio, United States|Southwest General Health Center Ireland Cancer Center, Middleburg Heights, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|SWOG, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Riddle Memorial Hospital, Media, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Phoenixville Hospital, Phoenixville, Pennsylvania, United States|Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Health System Cancer Institute-Laurens, Clinton, South Carolina, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Collierville, Collierville, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States|Baptist Memorial Hospital for Women, Memphis, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|University Hospital, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|MultiCare Auburn Medical Center, Auburn, Washington, United States|Virginia Mason Bainbridge Island Medical Center, Bainbridge Island, Washington, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Virginia Mason Federal Way Medical Center, Federal Way, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Gig Harbor, Gig Harbor, Washington, United States|MultiCare Gig Harbor Medical Park, Gig Harbor, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Northwest Cancer Clinic, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Virginia Mason Lynnwood Medical Center, Lynnwood, Washington, United States|Jefferson Healthcare, Port Townsend, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Peninsula Cancer Center, Poulsbo, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Puyallup, Puyallup, Washington, United States|Valley Medical Center, Renton, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Rockwood North Cancer Treatment Center, Spokane, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Jackson Hall, Tacoma, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Saint Joe's, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, United States|Mercy Health System, Janesville, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Advance Oncology Center, Aguadilla, Puerto Rico|Doctor's Cancer Center-Arecibo, Arecibo, Puerto Rico|Cancer Center-Metro Medical Center Bayamon, Bayamon, Puerto Rico|Hematologia Oncologia San Pablo, Bayamon, Puerto Rico|HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico|Doctors Cancer Center, Manati, Puerto Rico|Instituto Oncologia Moderna Ponce, Ponce, Puerto Rico|San Juan Community Oncology Group, San Juan, Puerto Rico|Primary Care Physician Group, San Juan, Puerto Rico|San Juan City Hospital, San Juan, Puerto Rico|Centro de Hematologia y Oncologia del Sur, Santa Isabel, Puerto Rico","","https://ClinicalTrials.gov/show/NCT03418961"
340,"NCT02460874","Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)",,"Recruiting","No Results Available","Cerebral Edema|Brain Metastases","Drug: Glyburide|Other: Placebo","Pilot Portion: Occurrence of Dose Limiting Toxicities (DLTs)|Randomized Portion: Occurrence of edema increase and initiation of dexamethasone (or any corticosteroid administration with the purpose of treating cerebral edema)|ktrans change|FLAIR ratio change|Time until dexamethasone initiation (or any corticosteroid administration with the purpose of treating cerebral edema)|Incidence of CTCAE version 4.0 reportable toxicities of grades 2-5.|Incidence of CTCAE version 4.0 reportable toxicities of grades 1-2 Cardiac Disorders or Hepatobiliary Disorders.|Cerebral edema increase as measured on FLAIR volumetric imaging|Absolute volume change of index tumor(s)","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","F16063003","August 16, 2017","March 2020","October 2020","June 3, 2015","null","June 13, 2018","University of Alabama at Birmingham (UAB) Department of Radiation Oncology, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT02460874"
341,"NCT02997228","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer",,"Recruiting","No Results Available","Colorectal Adenocarcinoma|Mismatch Repair Deficiency|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7","Drug: Atezolizumab|Biological: Bevacizumab|Drug: Fluorouracil|Drug: Leucovorin Calcium|Drug: Oxaliplatin|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Progression free survival (PFS)|Overall survival (OS)|Objective response rate (ORR) (complete response [CR] or partial response [PR]) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|Incidence of adverse events as defined by Common Terminology Criteria for Adverse Events (CTCAE) version 4|Surgical conversion rate defined as the proportion of patients that have surgery with curative intent|Disease control rate (CR + PR + stable disease [SD]) assessed by RECIST 1.1|Duration of overall response (CR or PR) as assessed by RECIST 1.1|PFS","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","347","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2016-01961|NRG-GI004/S1610|NRG-GI004|U10CA180868","November 7, 2017","April 30, 2022","April 30, 2022","December 20, 2016","null","July 4, 2018","Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|John Muir Medical Center-Concord Campus, Concord, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Comprehensive Cancer Care and Research Institute of Colorado LLC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Danbury Hospital, Danbury, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|Midstate Medical Center, Meriden, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|William Backus Hospital, Norwich, Connecticut, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Franciscan Health Mooresville, Mooresville, Indiana, United States|Union Hospital, Terre Haute, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Olathe Medical Center, Olathe, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Lowell General Hospital, Lowell, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Saint Joseph Health System-Tawas City, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Renown Regional Medical Center, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Arnot Ogden Medical Center/Falck Cancer Center, Elmira, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|University of Rochester, Rochester, New York, United States|Dickstein Cancer Treatment Center, White Plains, New York, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|NRG Oncology, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Wellmont Medical Associates Oncology and Hematology-Johnson City, Johnson City, Tennessee, United States|Wellmont Medical Associates Oncology and Hematology-Kingsport, Kingsport, Tennessee, United States|M D Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Wellmont Medical Associates-Bristol, Bristol, Virginia, United States|Augusta Health Cancer Center, Fishersville, Virginia, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Ascension Saint Elizabeth Hospital, Appleton, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Ascension Mercy Hospital, Oshkosh, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States","","https://ClinicalTrials.gov/show/NCT02997228"
342,"NCT02308020","A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",,"Recruiting","No Results Available","Breast Cancer|Non-small Cell Lung Cancer|Melanoma|Brain Metastases","Drug: Abemaciclib","Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)|Percentage of Participants with CR, PR, Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE): Best Overall Intracranial Response (BOIR)|Duration of CR and PR: Duration of Intracranial Response (DOIR)|Proportion of Participants with BOIR of CR, PR, or SD: Intracranial Disease Control Rate (IDCR)|Proportion of Participants with BOIR of CR, PR, or SD with Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR)|Overall Survival|Percentage of Participants with a Best Response of CR or PR: Objective Response Rate (ORR)|Proportion of Participants with a Best Overall Response of CR, PR, or SD: Disease Control Rate (DCR)|Progression Free Survival|Change from Baseline to End of Study in Neurologic Symptoms on the MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Scale|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Abemaciclib and its Metabolites","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","247","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15450|I3Y-MC-JPBO|2014-004010-28","April 2015","November 2018","November 2018","December 4, 2014","null","May 16, 2018","City of Hope National Medical Center, Duarte, California, United States|University of California - San Diego, La Jolla, California, United States|Univ of California San Francisco, San Francisco, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|University of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Kaiser Permanente Center for Health Research, Honolulu, Hawaii, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Providence Health and Services, Portland, Oregon, United States|SMO Sarah Cannon Research Inst., Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southport, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woolloongabba, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussel, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liege, Belgium|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ottawa, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon Cedex 08, France|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris Cedex 05, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint-Brieuc, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse cedex 9, France|Hadassah Medical Center - Ein Karem, Jerusalem, Israel|Sheba Medical Center, Tel Hashomer, Israel|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Cona, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain","","https://ClinicalTrials.gov/show/NCT02308020"
343,"NCT02672241","Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children",,"Recruiting","No Results Available","Childhood Brain Stem Neoplasm","Drug: Nimotuzumab|Drug: Temozolomide","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Progression free survival(PFS)|Overall survival (OS)|Objective response rate (ORR)","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","3 Years to 12 Years   (Child)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","sanghaixinhua-002","January 2016","January 2017","August 2017","February 3, 2016","null","September 13, 2016","he Department of Radiation Oncology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02672241"
344,"NCT02858869","Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases",,"Recruiting","No Results Available","Metastatic Malignant Neoplasm in the Brain|Metastatic Melanoma|Mucosal Melanoma|Ocular Melanoma|Stage IV Non-Small Cell Lung Cancer|Stage IV Skin Melanoma","Biological: Pembrolizumab|Radiation: Stereotactic Radiosurgery","Proportion of dose limiting toxicities defined as Radiation Therapy Oncology Group grade 3 central nervous system toxicities which are irreversible severe neurological symptoms requiring medications|Frequency and absolute cell counts for pre and post treatment serum immune biomarkers|Overall response (intra-cranial and extra-cranial) assessed using RECIST and immune RECIST Criteria|Overall survival|Rate of anywhere intra-cranial failure (also called distant brain failure, DBR)|Rate of leptomeningeal disease|Rate of local recurrence|Rate of symptomatic radiation necrosis defined as evidence of necrosis on MRI images (radiographic evidence or radionecrosis) and a patient having neurological symptoms attributed to the location where the radiosurgery was done (symptomatic)","Emory University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00086461|NCI-2016-00718|RAD3179-16","October 4, 2016","October 2019","October 2020","August 8, 2016","null","January 16, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02858869"
345,"NCT03444519","The Therapeutic Time Window of Mannitol During Craniotomy for Optimal Brain Relaxation in Patients With Supratentorial Tumours",,"Recruiting","No Results Available","Supratentorial Tumors","Drug: Mannitol","brain relaxation score|Blood sodium levels|Blood potassium levels|Blood chlorine levels|Blood lactate levels|Fluid balance during operation","Huashan Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KY2017-306","June 21, 2017","March 30, 2018","April 30, 2018","February 23, 2018","null","February 23, 2018","Fudan University affiliated Huashan Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03444519"
346,"NCT02792582","A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection",,"Recruiting","No Results Available","Craniopharyngioma","Radiation: Proton Therapy|Procedure: Surgery","Progression-free survival (PFS)|Overall survival (OS)|Compare incidence of first cystic intervention with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital|Compare event-free survival (EFS) with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital|Compare survival distributions with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital|Compare survival distributions between groups","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","140","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RT3CR|NCI-2016-00813","June 22, 2016","June 2025","June 2027","June 7, 2016","null","September 28, 2017","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02792582"
347,"NCT03173950","Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers",,"Recruiting","No Results Available","Ependymoma|Meningioma|Chordoma","Drug: Nivolumab","objective response|progression free survival rate","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","180","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170102|17-C-0102","July 13, 2017","December 31, 2019","December 1, 2021","June 2, 2017","null","July 4, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03173950"
348,"NCT02669173","Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma",,"Recruiting","No Results Available","Glioblastoma","Drug: Capecitabine|Drug: Bevacizumab","Change of concentration in circulating MDSCs after treatment with low dose capecitabine|Concentration of MDSCs in resected glioblastoma after treatment with low dose capecitabine|Concentration of T-regulatory cells after treatment with low dose capecitabine|Number of participants with adverse events relating to treatment with low-dose capecitabine alone as assessed by CTCAE v4.0|Number of participants with adverse events relating to treatment with low-dose capecitabine combined with bevacizumab as assessed by CTCAE v4.0","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE7315","April 20, 2016","December 2018","December 2018","February 1, 2016","null","March 15, 2018","Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02669173"
349,"NCT03493932","Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade",,"Recruiting","No Results Available","Glioblastoma","Drug: Nivolumab|Drug: BMS-986016","The primary outcome measure is the proportion of patients that have a rise in interferon gamma levels within the tumor microenvironment of 4 pg/ml or higher before the first dose of Nivolumab as compared to after the first dose, the safety of th...|1)change in IFNg in body 2)response of immune environment of brain tumor tissue to Nivolumab 3)To evaluate clinical response of pts 4)the difference in survival between responders and non-responders 5)differences in the immune cells and secreted...","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","22 Years and older   (Adult, Older Adult)","Phase 1","15","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","180077|18-N-0077","July 11, 2018","June 1, 2021","June 1, 2021","April 11, 2018","null","July 6, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03493932"
350,"NCT01295944","Carboplatin and Bevacizumab for Recurrent Ependymoma",,"Recruiting","No Results Available","Ependymoma|Anaplastic Ependymoma","Drug: Carboplatin|Drug: Bevacizumab","progression-free survival (PFS) at one year|To evaluate response rates to this chemotherapy.|To evaluate overall survival in this population.|To evaluate toxicity profile of this combination.|To evaluate the occurrence of symptoms and correlate to disease progression and tolerance to treatment using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT or MDASI-SP) selfreporting tool.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","35","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160009|16-C-0009","October 21, 2015","July 1, 2018","July 1, 2020","February 15, 2011","null","November 24, 2017","Harvard Cancer Center, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01295944"
351,"NCT02796261","Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients","STELLAR","Recruiting","No Results Available","Anaplastic Astrocytoma|Recurrent Anaplastic Astrocytoma","Drug: Eflornithine|Drug: Lomustine","Overall survival|Progression-free survival (PFS)|Objective response rate (ORR)","Orbus Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OT-15-001","July 2016","June 2019","August 2019","June 10, 2016","null","April 18, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Kaiser Permanente, Los Angeles, California, United States|University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|University of California Irvine Medical Center, Orange, California, United States|Kaiser Permanente Center, Redwood City, California, United States|Kaiser Permanente, Sacramento, California, United States|UCSD Moores Cancer Center, San Diego, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Boca Raton Regional Hospital, Eugene M. & Christine E. Lynn Cancer Institute, Boca Raton, Florida, United States|The University of Florida Health System - UF Health Neurosurgery, Gainesville, Florida, United States|University of South Florida (USF) - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Piedmont Physicians Neuro-Oncology, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Northwestern Medicine CDH Cancer Center, Warrenville, Illinois, United States|The University of Iowa, Iowa City, Iowa, United States|University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|Norton Cancer Institute - Louisville, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center New Orleans, New Orleans, Louisiana, United States|Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic Minnesota, Rochester, Minnesota, United States|HCA Midwest Division, Kansas City, Missouri, United States|Dent Neurologic Institute, Buffalo, New York, United States|Columbia University Medical Center, The Neurological Institute, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|The Cleveland Clinic, Richard E. Jacobs Health Center, Cleveland, Ohio, United States|OhioHealth Research and Innovation Institute, Columbus, Ohio, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Texas Oncology Austin Brain Tumor Center, Austin, Texas, United States|Neuro-Oncology Associates, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Swedish Health Services, Seattle, Washington, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Universitair Ziekenhuis Antwerpen, Edegem, Antwerpen, Belgium|Universitair Ziekenhuis Leuven, Leuven, Flemish Brabant, Belgium|Cliniques Universitaires UCL De Mont-Godinne, Yvoir, Namur, Belgium|Onze Lieve Vrouwziekenhuis Aalst, Aalst, Oost-Vlaanderen, Belgium|Cross Cancer Institute, Calgary, Alberta, Canada|Tom Baker Cancer Center, Calgary, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada|Universtaetsklinikum Heidelberg - Neurologische Klinik, Heidelberg, Baden-Wuerttemberg, Germany|Universtaetsklinikum Erlangen - Neurologische Klinik, Erlangen, Bayern, Germany|Klinik und Poliklinik fur Neurologie der Universitat Regensburg, Regensburg, Bayern, Germany|Johnn-Wofgang-Goethe-Universitat Frankfurt, Frankfurt, Hessen, Germany|Universitaetsklinikum Bonn - Zentrum fuer Innere Medizin - Medizinische Klinik und Poliklink III, Bonn, Nordrhein-Westfalen, Germany|Heinrich-Heine-Universitat Duesseldorf, Düsseldorf, Nordrhein-Westfalen, Germany|Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|Universtatsklinikum Koln Klinik und Poliklinik fur Neurologie, Köln, Nordrhein-Westfalen, Germany|Charite Universitätsmedizin Berlin, Berlin, Germany|Ruhr-Universitaet Bochum - Knappschaftskrankenhaus Bochum-Langendreer - Neurologische, Bochum, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universtaetsklinikum Giessen und Marburg GmbH - Marburg - Neurologische Klinik, Marburg, Germany|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Oncohematology IRST Cesena, Cesena, Italy|Fondazione IRCCS - Instituto Neurologico Carlo Besta, Milano, Italy|Istituto Oncologico Veneto, Padova, Italy|Istituto Nazionale dei Tumori Regina Elena - IRE, Roma, Italy|Azienda Ospedaliera Universitaria Senese - Policlinico S. Maria alle Scotte, Siena, Italy|Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino - Ospedale Molinette, Torino, Italy|Sint Elisabeth Ziekenhuis, Tilburg, Noord-Brabant, Netherlands|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Noord-Holland, Netherlands|Erasmus Medisch Centrum Daniel den Hoed, Rotterdam, Zuid-Holland, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands","","https://ClinicalTrials.gov/show/NCT02796261"
352,"NCT01878617","A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma",,"Recruiting","No Results Available","Medulloblastoma","Radiation: Craniospinal Irradiation with boost to the primary tumor site|Drug: Cyclophosphamide|Drug: Cisplatin|Drug: Vincristine|Drug: Vismodegib|Drug: Pemetrexed|Drug: Gemcitabine|Other: Aerobic Training|Other: Neurocognitive Remediation","Progression-free survival distribution (Stratum W1)|Progression free survival distribution (Stratum N1)|Change in VO2 peak values|Change in spatial span backward standard score|Compare progression-free survival by strata with prior St. Jude SJMB03 study participants|Compare overall survival by strata with prior St. Jude SJMB03 study participants|Proportion of patients able to complete protocol therapy|Number of patients who go off treatment for reasons other than progressive disease|Number of local failures|Change in hand grip strength|Change in range of motion|Change in overall flexibility|Change in motor proficiency|Change in quality of life (QOL) score|Change in fatigue score|Change in measure of memory function|Change in measure of attention|Change in executive function score|Change in sleep|Association between baseline cognitive performance and sleep quality|Association between baseline cognitive performance and sleep quantity|Association between baseline cognitive performance and fatigue|Longitudinal change in measure of intellectual function|Association of demographic and clinical factors with change in intellectual function|Longitudinal change in measure of academic ability|Association of demographic and clinical factors with change in academic ability|Longitudinal change in measure of attention|Association of demographic and clinical factors with change in attention|Longitudinal change in measure of memory|Association of demographic and clinical factors with change in memory|Longitudinal change in measure of cognitive processing speed function|Association of demographic and clinical factors with change in cognitive processing speed|Longitudinal change in measure of neurocognitive executive function|Association of demographic and clinical factors with change in neurocognitive executive function|Change in measure of processing speed|Change in measure of executive function ability|Change in measure of attention among 3 groups (working memory intervention + physical exercise intervention VS. working memory intervention alone VS. physical training intervention alone)|Change in measure of processing speed among 3 groups (working memory intervention + physical exercise intervention VS. working memory intervention alone VS. physical training intervention alone)|Change in measure of executive function among 3 groups (working memory intervention + physical exercise intervention VS. working memory intervention alone VS. physical training intervention alone)|Change in measure of attention between participants who received computer-based intervention VS. those who did not|Change in measure of working memory between participants who received computer-based intervention VS. those who did not|Change in measure of processing speed between participants who received computer-based intervention VS. those who did not|Change in measure of executive function between participants who received computer-based intervention VS. those who did not","St. Jude Children's Research Hospital|Genentech, Inc.|National Cancer Institute (NCI)","All","3 Years to 39 Years   (Child, Adult)","Phase 2","440","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SJMB12|NCI-2013-01125|R01CA187079","June 23, 2013","June 2023","December 2026","June 17, 2013","null","February 6, 2018","Lucille Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States|Rady Children's Hospital, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota, United States|Duke Children's Hospital and Health Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Texas Children's Cancer Center, Houston, Texas, United States|Sydney Children's Hospital, Randwick, New South Wales, Australia|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Lady Cilento Children's Hospital, Brisbane, Brisbane, Queensland, Australia|Royal Children's Hospital, Melbourne, Melbourne, Victoria, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada|Starship Children's Hospital, Auckland, New Zealand","","https://ClinicalTrials.gov/show/NCT01878617"
353,"NCT02573324","A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification ( Intellance1 )","Intellance1","Recruiting","No Results Available","Glioblastoma Multiforme|Gliosarcoma","Drug: Temozolomide|Drug: ABT-414|Radiation: Radiation|Drug: Placebo for ABT-414","Overall Survival (OS)|OS for the O6-methylguaninemethlytransferese (MGMT) methylated subgroup|Number of days to deterioration in symptom severity score M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)|OS for the EGFRvIII-mutated tumor subgroup|Number of days to deterioration in neurocognitive functioning on the Hopkins Verbal Learning Test Revised (HVLT-R)|Progression Free Survival (PFS)|Number of days to deterioration in symptom interference score (MDASI-BT)|PFS for EGFRvIII-mutated tumor subgroup","AbbVie|Radiation Therapy Oncology Group","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","640","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M13-813|2015-001166-26","December 7, 2015","March 18, 2020","February 13, 2021","October 9, 2015","null","June 21, 2018","St. Josephs Hosp and Med Ctr /ID# 144149, Phoenix, Arizona, United States|Highlands Oncology Group /ID# 142050, Fayetteville, Arkansas, United States|Usc /Id# 147543, Los Angeles, California, United States|Cedars-Sinai Medical Ctr /ID# 148472, Los Angeles, California, United States|University of California, Los Angeles /ID# 149239, Los Angeles, California, United States|Sharp Memorial Hospital /ID# 148193, San Diego, California, United States|Univ California, San Francisco /ID# 145889, San Francisco, California, United States|St. John's Health Center /ID# 148192, Santa Monica, California, United States|Univ of Colorado Cancer Center /ID# 148194, Aurora, Colorado, United States|Associated Neurologists of Sou /ID# 147701, Fairfield, Connecticut, United States|Yale University /ID# 144170, New Haven, Connecticut, United States|Christiana Care Health Service /ID# 144127, Newark, Delaware, United States|Boca Raton Regional Hospital /ID# 163659, Boca Raton, Florida, United States|Holy Cross Hospital /ID# 156764, Fort Lauderdale, Florida, United States|Baptist Hospital Miami /ID# 152451, Miami, Florida, United States|Florida Hospital /ID# 144128, Orlando, Florida, United States|Moffitt Cancer Center /ID# 144130, Tampa, Florida, United States|Piedmont Hospital /ID# 145892, Atlanta, Georgia, United States|Emory University Hospital /ID# 144015, Atlanta, Georgia, United States|Northwestern University /ID# 147895, Chicago, Illinois, United States|University of Chicago /ID# 144158, Chicago, Illinois, United States|NorthShore Univ HealthSystem /ID# 144017, Evanston, Illinois, United States|NW Medical Cancer Ctr, Geneva /ID# 151568, Geneva, Illinois, United States|NW Medical Cancer Ctr, Warrenv /ID# 148476, Warrenville, Illinois, United States|Parkview Research Ctr, Hosp /ID# 144150, Fort Wayne, Indiana, United States|Univ Kansas Cancer Ctr - Overl /ID# 145895, Westwood, Kansas, United States|Maine Medical Partners Neurolo /ID# 160864, Scarborough, Maine, United States|Tufts Medical Center /ID# 145897, Boston, Massachusetts, United States|Massachusetts General Hospital /ID# 144145, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 148475, Boston, Massachusetts, United States|Wayne State University /ID# 145890, Detroit, Michigan, United States|Henry Ford Health System /ID# 145896, Detroit, Michigan, United States|St. Joseph Mercy Hospital /ID# 144143, Ypsilanti, Michigan, United States|Mmcorc /Id# 144146, Saint Louis Park, Minnesota, United States|Washington University-School of Medicine /ID# 144174, Saint Louis, Missouri, United States|Nebraska Methodist Hospital /ID# 144140, Omaha, Nebraska, United States|Univ Nebraska Med Ctr /ID# 145899, Omaha, Nebraska, United States|MD Anderson Cancer Center at Cooper /ID# 145891, Camden, New Jersey, United States|Rutgers Cancer Institute of NJ /ID# 148190, New Brunswick, New Jersey, United States|Columbia Univ Medical Center /ID# 144020, New York, New York, United States|Univ Rochester Med Ctr /ID# 144166, Rochester, New York, United States|Levine Cancer Ins, Carolina Me /ID# 144124, Charlotte, North Carolina, United States|University of Cincinnati /ID# 144164, Cincinnati, Ohio, United States|Univ Hosp Cleveland /ID# 144153, Cleveland, Ohio, United States|Cleveland Clinic Foundation /ID# 144023, Cleveland, Ohio, United States|The Ohio State University - Columbus /ID# 144016, Columbus, Ohio, United States|University of Toledo /ID# 156763, Toledo, Ohio, United States|Univ Oklahoma HSC /ID# 144161, Oklahoma City, Oklahoma, United States|St. Luke's Hospital /ID# 148191, Bethlehem, Pennsylvania, United States|Penn State University and Milton S. Hershey Medical Center /ID# 147525, Hershey, Pennsylvania, United States|University of Pennsylvania /ID# 157623, Philadelphia, Pennsylvania, United States|Thomas Jefferson University /ID# 144191, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center /ID# 145893, Philadelphia, Pennsylvania, United States|Allegheny General Hospital /ID# 144126, Pittsburgh, Pennsylvania, United States|UPMC - Shadyside /ID# 144159, Pittsburgh, Pennsylvania, United States|Med Univ of South Carolina /ID# 144141, Charleston, South Carolina, United States|Austin Cancer Centers /ID# 151061, Austin, Texas, United States|Baylor Sammons Cancer Center /ID# 155542, Dallas, Texas, United States|Univ TX, MD Anderson /ID# 144013, Houston, Texas, United States|Univ TX, MD Anderson /ID# 144018, Houston, Texas, United States|Scott and White Medical Center /ID# 160743, Temple, Texas, United States|Intermountain Medical Center /ID# 144142, Murray, Utah, United States|University of Utah /ID# 144160, Salt Lake City, Utah, United States|Inova Health System /ID# 152956, Falls Church, Virginia, United States|Virginia Commonwealth Univ /ID# 149014, Richmond, Virginia, United States|Virginia Mason Medical Center /ID# 144022, Seattle, Washington, United States|University of Washington /ID# 144162, Seattle, Washington, United States|Univ of Wisconsin Hosp/Clinics /ID# 144167, Madison, Wisconsin, United States|Froedtert and Medical College /ID# 144139, Milwaukee, Wisconsin, United States|Instituto Med Alex Flem /ID# 142884, Buenos Aires, Argentina|Sanatorio Parque S.A. - Grupo /ID# 142825, Rosario, Santa FE, Argentina|Liverpool Hospital /ID# 144392, Liverpool, New South Wales, Australia|The Prince of Wales Hospital /ID# 144882, Randwick, New South Wales, Australia|Royal North Shore Hospital /ID# 143870, Saint Leonards, New South Wales, Australia|Calvary Mater Newcastle /ID# 143860, Waratah, New South Wales, Australia|Southern Medical Day Care Ctr /ID# 143868, Wollongong, New South Wales, Australia|Princess Alexandra Hospital /ID# 143857, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital /ID# 143867, Adelaide, South Australia, Australia|Calvary North Adelaide Hospita /ID# 143866, Adelaide, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 143858, Fitzroy, Victoria, Australia|Austin Hospital /ID# 143859, Heidelberg, Victoria, Australia|St. John of God Subiaco Hosp /ID# 143869, Subiaco, Western Australia, Australia|AKH Wien /ID# 141981, Vienna, Wien, Austria|LKH-Univ. Klinikum Graz /ID# 141982, Graz, Austria|Medical University Innsbruck /ID# 141984, Innsbruck, Austria|Kepler Universitatskliniken /ID# 141983, Linz, Austria|Cliniques Universitaires Saint Luc /ID# 141648, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Grand Hôpital de Charleroi /ID# 141645, Charleroi, Hainaut, Belgium|CHU de Liege /ID# 162860, Liège, Liege, Belgium|UZ Gent /ID# 141647, Gent, Oost-Vlaanderen, Belgium|Centre Hospitalier Jolimont /ID# 143873, La Louvière, Belgium|UZ Leuven /ID# 143872, Leuven, Belgium|UCL Mont Godinne /ID# 141644, Yvoir, Belgium|Liga Norte Rigrandese Contra o /ID# 143878, Natal, Rio Grande Do Norte, Brazil|Hospital Sao Lucas da PUCRS /ID# 143879, Porto Alegre, Rio Grande Do Sul, Brazil|Icesp /Id# 144031, São Paulo, Sao Paulo, Brazil|Inca /Id# 143877, Rio de Janeiro, Brazil|Hospital de Cancer de Barretos /ID# 143876, Sao Paulo, Brazil|Cancer Care Manitoba /ID# 149253, Winnipeg, Manitoba, Canada|Qe Ii Hsc /Id# 151600, Halifax, Nova Scotia, Canada|Juravinski Cancer Clinic /ID# 152117, Hamilton, Ontario, Canada|Victoria Hospital /ID# 144184, London, Ontario, Canada|The Ottawa Hospital /ID# 150120, Ottawa, Ontario, Canada|Princess Margaret Cancer Centr /ID# 166277, Toronto, Ontario, Canada|Hospital Maisonneuve-Rosemont /ID# 149315, Montreal, Quebec, Canada|McGill Univ HC /ID# 144187, Montreal, Quebec, Canada|Jewish General Hospital /ID# 144029, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 144027, Montréal, Quebec, Canada|CHU de Quebec-Universite Laval /ID# 144189, Quebec City, Quebec, Canada|CHUS - Hopital Fleurimont /ID# 149771, Sherbrooke, Quebec, Canada|Anhui Provincial Hospital /ID# 166320, Hefei, Anhui, China|Huashan Hospital affiliated to Fudan University /ID# 159999, Shanghai, Shanghai, China|Shanghai Changhai Hospital /ID# 164120, Shanghai, Shanghai, China|The Second Affiliated Hospital /ID# 165593, Hangzhou, Zhejiang, China|Beijing Shijitan Hospital /ID# 164038, Beijing, China|Sanbo Brain Hospital Capital M /ID# 166422, Beijing, China|Beijing Tian Tan Hospital /ID# 167160, Beijing, China|Peking Union Medical College H /ID# 157430, Beijing, China|Xiangya Hosp Central South Uni /ID# 166791, Changsha, China|1st Affiliated Hosp Fujian Med /ID# 159166, Fuzhou, China|Sun Yat-Sen Uni Cancer Center /ID# 143919, Guangzhou, Guangdong, China|Shengjing Hosp China Med Univ /ID# 167016, Shenyang, China|1st Affil Hosp Soochow Univ /ID# 165596, Suzhou, China|Tianjin Med Univ General Hosp /ID# 143923, Tianjin, China|Tongji Hosp Tongji Med College /ID# 163820, Wuhan, China|Fourth Military Medical Univ. /ID# 143920, Xi'an, China|Administradora del Country_S.A-Clinica Del Country /ID# 143881, Bogota, Cundinamarca, Colombia|Centro Medico Imbanaco de Cali /ID# 143882, Cali, Colombia|Hospital Pablo Tobon Uribe /ID# 143780, Medellín, Colombia|Inst Med Alta Tec Onc (IMAT) /ID# 147223, Monteria, Colombia|Oncologos de Occidente SA /ID# 147713, Pereira, Colombia|Masarykuv onkologikcy ustav /ID# 143884, Brno, Czechia|FN Hradec Kralove /ID# 143885, Hradec Kralove, Czechia|Krajska nemocnice Liberec a.s. /ID# 142024, Liberec, Czechia|Univ Hosp Ostrava-Poruba /ID# 143883, Ostrava, Czechia|Fakultni Nemocnice v Motole /ID# 142023, Prague, Czechia|CHRU Lille - Hôpital Claude Huriez /ID# 143915, Lille CEDEX, Hauts-de-France, France|CHU-Hopital Avicenne /ID# 143910, Bobigny, Ile-de-France, France|Institut Gustave Roussy /ID# 143912, Villejuif, Ile-de-France, France|Institut de Cancer de l'Ouest /ID# 143914, St Herblain CEDEX, Loire-Atlantique, France|Hopital de la Timone /ID# 143911, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|CHU de Nice /ID# 143916, Nice CEDEX 1, Provence-Alpes-Cote-d Azur, France|Insititut de Cancerologie /ID# 143908, Angers, France|Hopital Pitie Salpetriere /ID# 143917, Paris, France|Universitaetsklinik Heidelberg /ID# 143927, Heidelberg, Baden-Wuerttemberg, Germany|Universitaetsklinikum Leipzig /ID# 143962, Leipzig, Sachsen, Germany|Knappschaftskrankenhaus /ID# 143961, Bochum, Germany|Universitatsklinikum Tubingen /ID# 143926, Tuebingen, Germany|Prince of Wales Hospital /ID# 143952, Sha Tin, Nt, Hong Kong|Beaumont Hospital /ID# 142969, Dublin, Ireland|Rabin Medical Center /ID# 143957, Petakh Tikva, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Ctr /ID# 143956, Tel Aviv-Yafo, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 143959, Haifa, Israel|Hadassah University Hospital /ID# 143958, Jerusalem, Israel|Sheba Medical Center /ID# 143960, Ramat Gan, Israel|AOU Citta della Salute Scienza /ID# 141801, Turin, Piemonte, Italy|Fondazione IRCCS Istituto Neur /ID# 141800, Milan, Italy|Istituto Oncologico Veneto /ID# 143821, Padua, Italy|Regina Elena National Cancer I /ID# 141795, Rome, Italy|National Cancer Center /ID# 141845, Goyang, Gyeonggido, Korea, Republic of|Seoul National University Hospital /ID# 143886, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 141846, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 143887, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 141844, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Hospital Zambrano Hellion /ID# 143845, San Pedro Garza García, Mexico|Vrije Univ Medisch Centrum /ID# 143889, Amsterdam, Netherlands|Univ Med Center Groningen /ID# 141408, Groningen, Netherlands|Maastricht University Med Ctr /ID# 143585, Maastricht, Netherlands|MC Haaglanden - Westeinde /ID# 141405, The Hague, Netherlands|UMC Utrecht /ID# 141406, Utrecht, Netherlands|Canterbury District Health Boa /ID# 143861, Christchurch, New Zealand|Wellington Hospital /ID# 143890, Wellington, New Zealand|CCA Braga - Hospital de Braga /ID# 141940, Braga, Portugal|Centro Hospitalar do Algarve /ID# 141939, Faro, Portugal|IPO Lisboa FG, EPE /ID# 141938, Lisboa, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 141941, Lisboa, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 142830, Porto, Portugal|Interregional clin.diagnostic cntr /ID# 141702, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|State budgetary healthcare institution Republican Clinical Oncology Dispensary /ID# 141706, UFA, Republic Of Bashkortosta, Kirovskaya Oblast, Russian Federation|GEMC - European Medical Center /ID# 141703, Moscow, Moskovskaya Oblast, Russian Federation|NN Blokhin Russian Cancer /ID# 141707, Moscow, Moskva, Russian Federation|Scientific and Research Inst. /ID# 141701, Moscow, Moskva, Russian Federation|Federal State Treatment and rehabilitation center /ID# 141704, Moscow, Moskva, Russian Federation|Sverdlovsk Regional Oncology Center /ID# 141700, Ekaterinburg, Sverdlovskaya Oblast, Russian Federation|National University Hospital /ID# 143933, Singapore, Singapore|National Cancer Ctr Singapore /ID# 143932, Singapore, Singapore|Universitas Annexe /ID# 144064, Bloemfontein, Free State, South Africa|Unitas Hospital /ID# 152936, Centurion, Gauteng, South Africa|The Oncology Centre /ID# 143950, Durban, Kwazulu-Natal, South Africa|Netcare Oncology Intervent Ctr /ID# 143951, Cape Town, Western Cape, South Africa|Cape Town Oncology Trials /ID# 143948, Cape Town, Western Cape, South Africa|GVI Rondebosch Oncology Centre /ID# 143949, Cape Town, Western Cape, South Africa|Hospital Regional de Malaga /ID# 143902, Málaga, Malaga, Spain|Hosp Santa Creu i Sant Pau /ID# 143900, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 143906, Barcelona, Spain|Hospital Clin Univ San Carlos /ID# 143901, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 143930, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 143496, Madrid, Spain|Hosp General Univ de Valencia /ID# 143903, Valencia, Spain|Kantonsspital Aarau /ID# 141885, Aarau, Switzerland|Ente Ospedaliero Cantonale /ID# 143936, Bellinzona, Switzerland|Inselspital, Universitaetsklin /ID# 141886, Bern, Switzerland|University Hospital Zurich /ID# 141887, Zurich, Switzerland|National Taiwan Univ Hosp /ID# 143940, Taipei City, Taipei, Taiwan|Taipei Veterans General Hosp /ID# 143955, Taipei City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 143941, Taoyuan City, Taiwan|Guy's and St Thomas' NHS Found /ID# 142652, London, London, City Of, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 154592, Birmingham, United Kingdom|Velindre Cancer Centre /ID# 141996, Cardiff, United Kingdom|Ninewells Hospital /ID# 141651, Dundee, United Kingdom|Western General Hospital /ID# 141802, Edinburgh, United Kingdom|St. James University Hospital /ID# 141653, Leeds, United Kingdom|University College Hospitals /ID# 142658, London, United Kingdom|Freeman Hospital /ID# 141999, Newcastle Upon Tyne, United Kingdom|Royal Marsden Hospital /ID# 142827, Sutton, United Kingdom","","https://ClinicalTrials.gov/show/NCT02573324"
354,"NCT02933749","Effects of the Prone and the Sitting Positions on the Brain Oxygenation in Posterior Fossa Surgery",,"Not yet recruiting","No Results Available","Infratentorial Neoplasms","Device: SctO2|Device: BIS","Cerebral oxygen saturation","Istanbul University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Istanbul","November 2016","October 2018","October 2018","October 14, 2016","null","October 14, 2016","Ozlem Korkmaz Dilmen, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT02933749"
355,"NCT03194971","NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy",,"Recruiting","No Results Available","Glioblastoma","Other: Tumor samples from patients treated with TTFields at initial diagnosis.|Other: Tumor samples from patients treated with TTFields at tumor recurrence.","Underlying pathological signatures of TTField therapy compared to patients naïve to TTField therapy using pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells .|Differences in the pathological pattern of failure when patients are treated with TTFields at initial diagnosis (up-front) compared to those treated at tumor recurrence using pathological assessment.","Medical College of Wisconsin","All","18 Years and older   (Adult, Older Adult)","","20","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","PRO00017446","June 1, 2017","May 31, 2021","May 31, 2022","June 21, 2017","null","April 17, 2018","Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03194971"
356,"NCT03087591","APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery",,"Recruiting","No Results Available","Metastatic Malignant Neoplasm in the Brain|Metastatic Solid Neoplasm|Recurrent Colorectal Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Solid Neoplasm|Stage IV Colorectal Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVA Pancreatic Cancer|Stage IVB Colorectal Cancer|Stage IVB Pancreatic Cancer|Unresectable Solid Neoplasm","Other: Laboratory Biomarker Analysis|Biological: siRNA-transfected Peripheral Blood Mononuclear Cells APN401","Incidence of adverse events Common Terminology Criteria for Adverse Events version 4.0|Clinical response as assessed by RECIST|Immune response as measured by frequency of immune cells|Immune response as measured by interferon production|Immune response as measured by neutrophil to lymphocyte ratio|Overall survival (OS)|Progression-free survival (PFS)|Survival as assessed by RECIST","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00041173|NCI-2017-00050|CCCWFU 03716|P30CA012197","April 28, 2017","October 2018","October 2018","March 22, 2017","null","July 2, 2018","Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03087591"
357,"NCT03150862","A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma",,"Recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: BGB-290|Drug: TMZ|Radiation: Radiation","Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE|Incidence, nature and severity of adverse events as assessed by CTCAE|Number of treatment cycles, dose intensity of components of each treatment regimen, and changes in vital signs and clinical laboratory tests during and following treatment|Phase 2: Arm A [BGB-290 + RT] and Arm B [BGB-290 + RT + TMZ]|Phase 2 Arm C [BGB-290 + TMZ]|Pharmacokinetic (PK) parameters of BGB-290 of steady state Ctrough|Modified disease control rate (DCR). (Arms A and B)|Disease control rate (Arm C)|Objective response rate (ORR)|Clinical benefit rate (CBR).|Duration of response (DOR).|Progression free survival (PFS).|Overall survival (OS)|Objective response rate (ORR).|Clinical benefit rate (CBR)|Duration of response (DOR)|Progression free survival (PFS)|PK parameter of BGB-290 of steady state Ctrough|PK parameter of BGB-290 (Cmax)|Disease control rate (DCR).","BeiGene USA, Inc.|BeiGene","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BGB-290-104","June 30, 2017","June 30, 2021","October 31, 2021","May 12, 2017","null","June 29, 2018","Center for Neurosciences, Tucson, Arizona, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health Systems, Detroit, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center (Stephenson Cancer Center), Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|SCRI / Tennessee Oncology, Nashville, Tennessee, United States|Huntsman Cancer Center, Salt Lake City, Utah, United States|University of Virginia Health Systems, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03150862"
358,"NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry",,"Recruiting","No Results Available","Cancer, Metastatic|Cancer|Cancer of Pancreas|Cancer of Liver|Cancer of Stomach|Cancer Liver|Cancer of Rectum|Cancer of Kidney|Cancer of Esophagus|Cancer of Cervix|Cancer of Colon|Cancer of Larynx|Cancer, Lung|Cancer, Breast|Cancer, Advanced|Cancer Prostate|Cancer of Neck|Cancer of Skin|Neuroendocrine Tumors|Carcinoma|Mismatch Repair Deficiency|BRCA Gene Rearrangement|Non Hodgkin Lymphoma|Leukemia|Non Small Cell Lung Cancer|Cholangiocarcinoma|Glioblastoma|Central Nervous System Tumor|Melanoma|Urothelial Carcinoma|Bladder Cancer|Ovarian Cancer|Endometrial Cancer|Testicular Cancer|Breast Cancer","Other: Clinical Trial Matching","Proportion of patients Eligible for CTE versus Actual CTE|Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis|Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis|Identification of Barriers to CTE|Real World Data Analytics|Virtual Tumor Board Utilization|Time from Intervention to Actual CTE (months)","Massive Bio, Inc.","All","Child, Adult, Older Adult","","1500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","SYNERGY-AI","January 1, 2018","December 2021","December 2022","March 2, 2018","null","March 2, 2018","Massive Bio, Inc, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03452774"
359,"NCT03050268","Familial Investigations of Childhood Cancer Predisposition","SJFAMILY","Recruiting","No Results Available","Acute Leukemia|Adenomatous Polyposis|Adrenocortical Carcinoma|AML|BAP1 Tumor Predisposition Syndrome|Carney Complex|Choroid Plexus Carcinoma|Constitutional Mismatch Repair Deficiency Syndrome|Diamond-Blackfan Anemia|DICER1 Syndrome|Dyskeratosis Congenita|Emberger Syndrome|Familial Acute Myeloid Leukemia|Familial Adenomatous Polyposis|Fanconi Anemia|Familial Cancer|Familial Wilms Tumor|Familial Neuroblastoma|GIST|Hereditary Breast and Ovarian Cancer|Hereditary Paraganglioma-Pheochromocytoma Syndrome|Hodgkin Lymphoma|Juvenile Polyposis|Li-Fraumeni Syndrome|Lynch Syndrome|MDS|Melanoma Syndrome|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2|Neuroblastoma|Neurofibromatosis Type 1|Neurofibromatosis Type II|Nevoid Basal Cell Carcinoma Syndrome|Non Hodgkin Lymphoma|Noonan Syndrome and Other Rasopathy|Overgrowth Syndromes|Pancreatic Cancer|Peutz-Jeghers Syndrome|Pheochromocytoma/Paraganglioma|PTEN Hamartoma Tumor Syndrome|Retinoblastoma|Rhabdoid Tumor Predisposition Syndrome|Rhabdomyosarcoma|Rothmund-Thomson Syndrome|Tuberous Sclerosis|Von Hippel-Lindau Disease","","Identification of novel cancer predisposing genes","St. Jude Children's Research Hospital","All","Child, Adult, Older Adult","","3000","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","SJFAMILY","April 6, 2017","March 31, 2037","March 31, 2037","February 10, 2017","null","January 5, 2018","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03050268"
360,"NCT02858895","Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma",,"Recruiting","No Results Available","Glioblastoma|Grade IV Astrocytoma|Glioblastoma Multiforme|Grade IV Glioma","Drug: MDNA55","Objective Response Rate (ORR)|Overall Survival (OS)|Progression Free Survival (PFS)","Medicenna Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDNA55-05","October 2016","October 2018","July 2019","August 8, 2016","null","May 18, 2018","University of California San Francisco, San Francisco, California, United States|John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Weill Cornell Medical Center - New York Presbyterian, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Mazovian Brodnowski Hospital, Warsaw, Poland","","https://ClinicalTrials.gov/show/NCT02858895"
361,"NCT01986348","A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas","KING","Recruiting","No Results Available","Glioblastoma|Glioma","Drug: Selinexor","Determine the efficacy of selinexor in adults with recurrent GBM|Response to therapy|Safety and tolerability of Selinexor","Karyopharm Therapeutics Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KCP-330-004","March 2014","December 2018","December 2018","November 18, 2013","null","June 8, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Center for Neuro-Oncology, Boston, Massachusetts, United States|Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States|The Phase I Unit, Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark|University of Groningen Faculty of Medical Sciences, Medical Oncology, Groningen, Netherlands|Erasmus MC-Daniel den Hoed Cancer Center- Neuro-Oncology Unit, Rotterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT01986348"
362,"NCT03390569","Exercise in Patients With Glioblastoma",,"Recruiting","No Results Available","Glioblastoma","Behavioral: Exercise","Progression-Free Survival|Cognitive Decline|Cognitive Complaints|Overall survival|Personality Changes|Quality of Life|Mood|Interference with valued activities and interests|Sleep Quality|Physical Function","University Health Network, Toronto|Canadian Cancer Society Research Institute (CCSRI)|University of Toronto|McMaster University|University of British Columbia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","16-5922","August 29, 2017","June 2019","December 2020","January 4, 2018","null","January 4, 2018","Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03390569"
363,"NCT02100891","Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors","STIR","Recruiting","No Results Available","Ewing Sarcoma|Neuroblastoma|Rhabdomyosarcoma|Osteosarcoma|CNS Tumors","Procedure: Allogeneic HCT|Drug: Donor NK Cell Infusion","Disease-control rate|Overall survival","Monica Thakar|Medical College of Wisconsin","All","Child, Adult, Older Adult","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STIR Trial","March 2014","December 2019","December 2019","April 1, 2014","null","June 1, 2018","Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02100891"
364,"NCT02780804","Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors",,"Recruiting","No Results Available","Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm","Drug: Entinostat|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Maximum tolerated dose defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity during cycle 1 of therapy|Incidence of adverse events as described and graded using CTCAE version 5.0|Changes in pharmacokinetic (PK) parameters|Antitumor activity of entinostat|Change in histone H3 and H4 acetylation assessed in peripheral blood mononuclear cells","National Cancer Institute (NCI)","All","12 Months to 21 Years   (Child, Adult)","Phase 1","36","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2016-00708|ADVL1513|UM1CA097452","December 26, 2016","April 30, 2022","null","May 24, 2016","null","July 6, 2018","Children's Hospital of Alabama, Birmingham, Alabama, United States|COG Phase I Consortium, Arcadia, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02780804"
365,"NCT02255461","Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors",,"Recruiting","No Results Available","Childhood Choroid Plexus Tumor|Childhood Ependymoblastoma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Recurrent Childhood Anaplastic Astrocytoma|Recurrent Childhood Anaplastic Oligoastrocytoma|Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Giant Cell Glioblastoma|Recurrent Childhood Glioblastoma|Recurrent Childhood Gliomatosis Cerebri|Recurrent Childhood Gliosarcoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor","Drug: palbociclib isethionate|Other: pharmacological study|Other: laboratory biomarker analysis","MTD of palbociclib isethionate defined as the highest dose level at which six patients have been treated with at most one patient experiencing a dose limiting toxicity and the next higher dose level has been determined to be too toxic|Incidence of adverse events|Objective responses (partial response + complete response)|Individual pharmacokinetic parameters of interest, such as apparent volume of the central compartment (Vc/F), elimination rate constant (Ke), half-life (t1/2), apparent oral clearance (CL/F), and area under the plasma concentration time curve (AUC)|Population pharmacokinetic parameters","Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)","All","4 Years to 21 Years   (Child, Adult)","Phase 1","55","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PBTC-042|U01CA081457","October 2014","December 31, 2018","December 31, 2018","October 2, 2014","null","September 28, 2017","Childrens Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children Hospital Stanford University, Palo Alto, California, United States|Childrens National Medical Center, Washington, D.C., District of Columbia, United States|Lurie Childrens Hospital-Chicago, Chicago, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children Hospital Medical Center, Cincinnati, Ohio, United States|Children Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children Research Hospital, Memphis, Tennessee, United States|Texas Childrens Hospital, Houston, Texas, United States|Seattle Children Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02255461"
366,"NCT02929147","Comparison of Efficacy and Safety of the Postoperative Analgesia Methods",,"Not yet recruiting","No Results Available","Supratentorial Neoplasms","Drug: Morphine|Drug: Dexketoprofen|Drug: Placebo","Integrated Pulmonary Index (IPI)|Pain intensity measured by Visual Analog Score|Sedation level measured by Ramsay score|Cumulative Morphine consumption","Istanbul University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Istanbul U","November 2016","November 2017","November 2017","October 11, 2016","null","October 11, 2016","Ozlem Korkmaz Dilmen, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT02929147"
367,"NCT03465423","Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia",,"Recruiting","No Results Available","Pituitary Tumor","Procedure: Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)","effect site concentration of propofol","Yonsei University","All","19 Years and older   (Adult, Older Adult)","","62","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","4-2017-1241","March 20, 2018","February 10, 2019","February 11, 2019","March 14, 2018","null","May 16, 2018","Associate Professor Department of Anesthesiology and Pain Medicine, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03465423"
368,"NCT03132259","Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach",,"Recruiting","No Results Available","Pituitary Tumor","Drug: high dose dexmedethomidine|Drug: low dose dexmedethomidine","Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach|Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor","Mahidol University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","116/2559","May 2016","May 2017","June 2018","April 27, 2017","null","May 30, 2017","Faculy of Medicine Siriraj hospital Mahidol University, Bangkok, Thailand","","https://ClinicalTrials.gov/show/NCT03132259"
369,"NCT02749227","Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors","PASSILCORT","Recruiting","No Results Available","Pituitary Tumor|ACTH-producing Pituitary Tumour","Drug: Pasireotide LAR","Change in plasma Proopiomelanocortin (POMC) levels|Change in pituitary tumor volume","Columbia University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAQ6255|CSOM230GUS44T","July 10, 2017","May 2018","May 2018","April 22, 2016","null","April 12, 2018","Neuroendocrine Unit and Pituitary Center, Columbia University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02749227"
370,"NCT02854228","PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon","PITUICARE-Lyon","Recruiting","No Results Available","Pituitary Tumor","","Progression free survival after pituitary surgery according to the clinicopathological classification (HYPOPRONOS)|Correlation between percentage of SSTR expression of the pituitary tumor and somatostatine analogs efficacy.|Correlation between percentage of MGMT expression of the pituitary tumor and tumor response to temozolomide.","Hospices Civils de Lyon","All","Child, Adult, Older Adult","","1300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL16_0506","February 2007","December 2015","December 2020","August 3, 2016","null","August 3, 2016","Groupement Hospitalier Est, Lyon, France, Bron, France","","https://ClinicalTrials.gov/show/NCT02854228"
371,"NCT02419664","Ga-68-DOTATOC -PET in the Management of Pituitary Tumours",,"Recruiting","No Results Available","Pituitary Tumours","Procedure: Gallium-68 DOTATOC PET","SUV max in GA-68 DOTATOC in pituitary tumours in comparison to normal pituitary|Ga-PET uptake in correlation to sst expression in pituitary tumours, measured as SUVmax which is then used to establish statistical relationship with a cell membrane-based sst-immunohistochemistry (IHC) score""|Adverse event registration in association to Ga-68 PET|Detection of tumour recurrence with Ga-PET","Göteborg University|Sahlgrenska University Hospital, Sweden|Uppsala University","All","18 Years and older   (Adult, Older Adult)","Phase 3","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Ga-PET version 8 (141017)|2010-020482-24","January 2015","May 2018","December 2019","April 17, 2015","null","February 21, 2018","Center of Endocrinology and Metabolism, Sahlgrenska university Hospital, Göteborg, Sweden","","https://ClinicalTrials.gov/show/NCT02419664"
372,"NCT02813044","Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor",,"Recruiting","No Results Available","Pituitary Tumor","Drug: total intravenous anesthesia (TIVA)|Drug: inhalation anesthesia group","QoR-40 score","Yonsei University","All","19 Years and older   (Adult, Older Adult)","Not Applicable","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","4-2016-0344","June 16, 2016","June 2018","June 2018","June 24, 2016","null","June 20, 2018","Associate Professor Department of Anesthesiology and Pain Medicine,, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02813044"
373,"NCT00089245","Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer",,"Recruiting","No Results Available","Brain and Central Nervous System Tumors|Neuroblastoma|Sarcoma","Radiation: iodine I 131 monoclonal antibody 8H9","Number of patients that have treatment related toxicities","Y-mAbs Therapeutics|National Cancer Institute (NCI)|New York University School of Medicine","All","Child, Adult, Older Adult","Phase 1","120","Industry|NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","03-133|P30CA008748|MSKCC-03133","July 2004","July 2018","July 2018","August 5, 2004","null","April 17, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00089245"
374,"NCT03471026","Advanced MRI for Posterior Fossa Tumours",,"Not yet recruiting","No Results Available","Cerebellar Mutism|Posterior Fossa Syndrome","Diagnostic Test: Advanced MRI sequences","Diffusion MRI tractography|Arterial Spin Labeling Perfusion MRI|Clinical measure of severity of pCMS","Great Ormond Street Hospital for Children NHS Foundation Trust","All","up to 18 Years   (Child, Adult)","","60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","17NI17","March 2018","March 2020","March 2020","March 20, 2018","null","March 21, 2018","","","https://ClinicalTrials.gov/show/NCT03471026"
375,"NCT02834013","Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",,"Recruiting","No Results Available","Acinar Cell Carcinoma|Adenoid Cystic Carcinoma|Adrenal Cortex Carcinoma|Adrenal Gland Pheochromocytoma|Anal Canal Neuroendocrine Carcinoma|Anal Canal Undifferentiated Carcinoma|Appendix Mucinous Adenocarcinoma|Bartholin Gland Transitional Cell Carcinoma|Bladder Adenocarcinoma|Cervical Adenocarcinoma|Cholangiocarcinoma|Chordoma|Colorectal Squamous Cell Carcinoma|Desmoid-Type Fibromatosis|Endometrial Transitional Cell Carcinoma|Endometrioid Adenocarcinoma|Esophageal Neuroendocrine Carcinoma|Esophageal Undifferentiated Carcinoma|Extrahepatic Bile Duct Carcinoma|Fallopian Tube Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fibromyxoid Tumor|Gastric Neuroendocrine Carcinoma|Gastric Squamous Cell Carcinoma|Gastrointestinal Stromal Tumor|Giant Cell Carcinoma|Intestinal Neuroendocrine Carcinoma|Intrahepatic Cholangiocarcinoma|Lung Carcinoid Tumor|Lung Sarcomatoid Carcinoma|Major Salivary Gland Carcinoma|Malignant Odontogenic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Testicular Sex Cord-Stromal Tumor|Metaplastic Breast Carcinoma|Metastatic Malignant Neoplasm of Unknown Primary Origin|Minimally Invasive Lung Adenocarcinoma|Mixed Mesodermal (Mullerian) Tumor|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Nasal Cavity Adenocarcinoma|Nasal Cavity Carcinoma|Nasopharyngeal Carcinoma|Nasopharyngeal Papillary Adenocarcinoma|Nasopharyngeal Undifferentiated Carcinoma|Oral Cavity Carcinoma|Oropharyngeal Undifferentiated Carcinoma|Ovarian Adenocarcinoma|Ovarian Germ Cell Tumor|Ovarian Mucinous Adenocarcinoma|Ovarian Squamous Cell Carcinoma|Ovarian Transitional Cell Carcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Neuroendocrine Carcinoma|Paraganglioma|Paranasal Sinus Adenocarcinoma|Paranasal Sinus Carcinoma|Parathyroid Gland Carcinoma|Pituitary Gland Carcinoma|Placental Choriocarcinoma|Placental-Site Gestational Trophoblastic Tumor|Primary Peritoneal High Grade Serous Adenocarcinoma|Pseudomyxoma Peritonei|Rare Disorder|Scrotal Squamous Cell Carcinoma|Seminal Vesicle Adenocarcinoma|Seminoma|Serous Cystadenocarcinoma|Small Intestinal Adenocarcinoma|Small Intestinal Squamous Cell Carcinoma|Spindle Cell Neoplasm|Squamous Cell Carcinoma of the Penis|Teratoma With Malignant Transformation|Testicular Non-Seminomatous Germ Cell Tumor|Thyroid Gland Carcinoma|Tracheal Carcinoma|Transitional Cell Carcinoma|Undifferentiated Gastric Carcinoma|Ureter Adenocarcinoma|Ureter Squamous Cell Carcinoma|Urethral Adenocarcinoma|Urethral Squamous Cell Carcinoma|Vaginal Adenocarcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified|Vulvar Carcinoma","Procedure: Biospecimen Collection|Biological: Ipilimumab|Biological: Nivolumab","Overall response rate (ORR) defined as confirmed and unconfirmed complete and partial response|Incidence of adverse events graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Best response calculated from the sequence of RECIST 1.1 and immune-related response criteria (irRC) objectives|Clinical benefit rate defined as complete response, partial response, or stable disease, estimated using both RECIST and irRC|Overall survival (OS), estimated using both RECIST and irRC|Progression free survival (PFS), estimated using both RECIST and irRC","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","707","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2016-01041|S1609|U10CA180888","January 13, 2017","August 31, 2020","null","July 15, 2016","null","July 2, 2018","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|University of Arizona Cancer Center at Saint Joseph's, Phoenix, Arizona, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Highlands Oncology Group-Rogers, Rogers, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|PCR Oncology, Arroyo Grande, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States|Sutter Davis Hospital, Davis, California, United States|Epic Care-Dublin, Dublin, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Palo Alto Medical Foundation-Fremont, Fremont, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Ontario, Ontario, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Desert Regional Medical Center, Palm Springs, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Eisenhower Medical Center, Rancho Mirage, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Kaiser Permanente Downtown Commons, Sacramento, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser San Rafael-Gallinas, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|Kaiser Permanente-Franklin, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Comprehensive Cancer Care and Research Institute of Colorado LLC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Valley View Hospital Cancer Center, Glenwood Springs, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Grand Valley Oncology, Grand Junction, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Kaiser Permanente-Rock Creek, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Kaiser Permanente-Lone Tree, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Yale-New Haven Shoreline Medical Center, Guilford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Florida Hospital Cancer Institute Altamonte, Altamonte Springs, Florida, United States|Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Florida Hospital Kissimmee, Kissimmee, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Hospital Orlando, Orlando, Florida, United States|Florida Urology Associates-Orlando, Orlando, Florida, United States|Florida Hospital East Orlando, Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Florida Hospital Cancer Institute Winter Park, Winter Park, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Harbin Clinic Medical Oncology and Clinical Research, Rome, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Low Country Cancer Care Associates PC, Savannah, Georgia, United States|Summit Cancer Care-Candler, Savannah, Georgia, United States|Hawaii Oncology Inc-Pali Momi, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Hawaii Oncology Inc-POB I, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Mount Sinai Hospital Medical Center, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Advocate Illinois Masonic Medical Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Presence Saint Mary's Hospital, Kankakee, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Marjorie Weinberg Cancer Center at Loyola-Gottlieb, Melrose Park, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Memorial and Saint Elizabeth's Health Care Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|IU Health West Hospital, Avon, Indiana, United States|IU Health North Hospital, Carmel, Indiana, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Springmill Medical Center, Indianapolis, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Chancellor Center for Oncology, Newburgh, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Coffeyville Regional Medical Center, Coffeyville, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Saint Catherine Hospital, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Hays Medical Center, Hays, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|University of Kansas Cancer Center-West, Kansas City, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Olathe Medical Center, Olathe, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Via Christi Hospital-Pittsburg, Pittsburg, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Saint Francis Hospital and Medical Center - Topeka, Topeka, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States|Hematology/Oncology Clinic LLP, Baton Rouge, Louisiana, United States|Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States|Medical Center of Baton Rouge, Baton Rouge, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Western Maryland Regional Medical Center, Cumberland, Maryland, United States|Frederick Memorial Hospital, Frederick, Maryland, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|Henry Ford Cancer Institute¿Downriver, Brownstown, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Lymphoma Clinic of Michigan, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Green Bay Oncology-Manistique, Manistique, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Monroe Cancer Center, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Assarian Cancer Center, Novi, Michigan, United States|Henry Ford Medical Center-Columbus, Novi, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Huron Medical Center PC, Port Huron, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Providence Hospital-Southfield Cancer Center, Southfield, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Saint Joseph Health System-Tawas City, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Bhadresh Nayak MD PC-Warren, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi, United States|Baptist Cancer Center-Grenada, Grenada, Mississippi, United States|Hattiesburg Clinic - Hematology/Oncology Clinic, Hattiesburg, Mississippi, United States|Forrest General Hospital / Cancer Center, Hattiesburg, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Saint Luke's Hospital, Chesterfield, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-South, Kansas City, Missouri, United States|The University of Kansas Cancer Center-North, Kansas City, Missouri, United States|The University of Kansas Cancer Center-Lee's Summit, Lee's Summit, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|Nevada Cancer Specialists-Saint Rose, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|Nevada Cancer Specialists?Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Nevada Cancer Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Nevada Cancer Specialists-Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Manchester, Manchester, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Morristown Medical Center, Morristown, New Jersey, United States|Chilton Memorial Hospital, Pompton, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Inspira Medical Center Vineland, Vineland, New Jersey, United States|Lovelace Medical Center-Saint Joseph Square, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, United States|Christus Saint Vincent Regional Cancer Center, Santa Fe, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Arnot Ogden Medical Center/Falck Cancer Center, Elmira, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Asheville Hematology-Oncology Associates, Asheville, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Haywood Infusion Center, Clyde, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Park Ridge Health, Hendersonville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Wilson, Wilson, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Mercy Medical Center, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physicians LLC-Samaritan North, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Dayton Physicians LLC-Signal Point, Middletown, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Dayton Physicians LLC-Wilson, Sidney, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|UPMC-Heritage Valley Health System Beaver, Beaver, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|UPMC-Johnstown/John P. Murtha Regional Cancer Center, Johnstown, Pennsylvania, United States|UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania, United States|UPMC-Coraopolis/Heritage Valley Radiation Oncology, Moon, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Margaret, Pittsburgh, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Passavant Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania, United States|Pottstown Hospital, Pottstown, Pennsylvania, United States|UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania, United States|UPMC Uniontown Hospital Radiation Oncology, Uniontown, Pennsylvania, United States|UPMC Washington Hospital Radiation Oncology, Washington, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Health System Cancer Institute-Laurens, Clinton, South Carolina, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Georgetown Hospital System, Georgetown, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|MGC Hematology Oncology-Union, Union, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Collierville, Collierville, Tennessee, United States|Vanderbilt-Ingram Cancer Center Cool Springs, Franklin, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|University Hospital, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, United States|Farmington Health Center, Farmington, Utah, United States|Logan Regional Hospital, Logan, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Riverton Hospital, Riverton, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|South Jordan Health Center, South Jordan, Utah, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Vermont College of Medicine, Burlington, Vermont, United States|Norris Cotton Cancer Center-North, Saint Johnsbury, Vermont, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|MultiCare Auburn Medical Center, Auburn, Washington, United States|Virginia Mason Bainbridge Island Medical Center, Bainbridge Island, Washington, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Virginia Mason Federal Way Medical Center, Federal Way, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Gig Harbor, Gig Harbor, Washington, United States|MultiCare Gig Harbor Medical Park, Gig Harbor, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Northwest Cancer Clinic, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Virginia Mason Lynnwood Medical Center, Lynnwood, Washington, United States|Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, Washington, United States|Skagit Valley Hospital, Mount Vernon, Washington, United States|Jefferson Healthcare, Port Townsend, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Peninsula Cancer Center, Poulsbo, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Puyallup, Puyallup, Washington, United States|Valley Medical Center, Renton, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Spokane Valley Cancer Center-Mayfair, Spokane, Washington, United States|Spokane Valley Cancer Center-Mission, Spokane, Washington, United States|Rockwood North Cancer Treatment Center, Spokane, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Jackson Hall, Tacoma, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Saint Joe's, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center - Eau Claire, Eau Claire, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Marinette, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States|Marshfield Clinic-Rice Lake Center, Rice Lake, Wisconsin, United States|HSHS Saint Nicholas Hospital, Sheboygan, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States","","https://ClinicalTrials.gov/show/NCT02834013"
376,"NCT02549768","Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery",,"Recruiting","No Results Available","Pituitary Neoplasms","Drug: Dexmedetomidine|Drug: Sodium Chloride 0.9%","Cortisol plasmatic levels|Adrenocorticotropin hormone|Hemodynamics|Nausea and vomiting|Pain|Patient comfort|Diabetes insipidus incidence|Cerebrospinal fluid fistula","Pontificia Universidad Catolica de Chile","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","15-095","September 2015","July 2017","August 2017","September 15, 2015","null","October 12, 2016","Division de Anestesia - Pontificia Universidad Catolica de Chile, Santiago, Region Metropolitana, Chile","","https://ClinicalTrials.gov/show/NCT02549768"
377,"NCT03309319","A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas",,"Recruiting","No Results Available","Pituitary Tumor","Drug: Rosiglitazone","Growth hormone(GH)|insulin like factor 1(IGF-1)|tumor volume","Zhaoyun Zhang|Huashan Hospital","All","20 Years to 60 Years   (Adult)","Not Applicable","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY2016-360","October 16, 2016","December 31, 2018","December 31, 2018","October 13, 2017","null","October 13, 2017","Huashan Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03309319"
378,"NCT02162732","Molecular-Guided Therapy for Childhood Cancer",,"Recruiting","No Results Available","Neuroblastoma|Medulloblastoma|Glioma|Ependymoma|Choroid Plexus Neoplasms|Craniopharyngioma|Dysembryoplastic Neuroepithelial Tumor|Meningioma|Primitive Neuroectodermal Tumors (PNETs)|Germ Cell Tumors|Rhabdomyosarcoma|Non-rhabdomyosarcoma|Ewings Sarcoma|Osteosarcoma|Wilms Tumor|Renal Cell Carcinoma|Malignant Rhabdoid Tumor|Clear Cell Sarcoma|Liver Tumors","Device: Guided Therapy","Days to treatment will be used in order to determine feasibility of using tumor samples to assess genomic sequencing using predictive modeling to make real-time treatment decisions for children with relapsed/refractory cancers.|Number of Participants with Adverse Events as a Measure of Safety|Overall Response Rate (ORR) of Participants by the presence of radiologically assessable disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans.|Duration of response will be objectively documented|Biology studies to include: genomic analysis of cells pre- and post- treatment, correlation of in vitro response to in vivo response, sub analysis examination of disease types, and biomarker development.|Progression Free Survival (PFS) interval will be measured by days and compared to the PFS of previous chemotherapy regimens since relapse for each patient.","Giselle Sholler|Translational Genomics Research Institute|Dell, Inc.|Spectrum Health Hospitals","All","13 Months to 21 Years   (Child, Adult)","Not Applicable","200","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NMTRC009","June 2014","June 2020","June 2021","June 13, 2014","null","July 11, 2017","Arkansas Children's Hospital, Little Rock, Arkansas, United States|Rady Children's Hospital, San Diego, California, United States|Connecticut Children's Hospital, Hartford, Connecticut, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital and Clinics on Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|The Children's Hospital at Montefiore, The Bronx, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Randall Children's Hospital, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Monroe Carrell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Blood and Cancer Center, Austin, Texas, United States|Texas Children's Cancer and Hematology Centers, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|American University of Beirut Medical Center, Beirut, Lebanon","","https://ClinicalTrials.gov/show/NCT02162732"
379,"NCT02743442","Da Vinci Transoral Robotic-assisted Surgery of Pituitary Gland","ROBOPHYSE","Recruiting","No Results Available","Pituitary Neoplasms","Device: da Vinci® Si™","Number of patients in which the entire sella turcica (including its anterior face) is seen during surgery and reached by the robotic arms.","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCT-2015-043","March 2016","March 2018","September 2018","April 19, 2016","null","February 8, 2018","Fondation Ophtalmologique Adolphe de Rothschild, Paris, France","","https://ClinicalTrials.gov/show/NCT02743442"
380,"NCT03457389","Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma",,"Not yet recruiting","No Results Available","Pituitary Adenoma|Prolactinoma|Pituitary Tumor|Recurrence Tumor","Drug: Cabergoline","Recurrence rate within 1 year after cabergoline withdrawal|Time to normalization of serum prolactin level|Change from baseline on tumor volume measured by pituitary MRI|Change from baseline of visual field defect","Seoul National University Hospital","All","19 Years and older   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1711-119-901","May 1, 2018","December 31, 2024","December 31, 2024","March 7, 2018","null","April 18, 2018","Seoul National University Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03457389"
381,"NCT02769533","A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma",,"Recruiting","No Results Available","Patients With Suspected Malignancies of the Pituitary Gland","Drug: OTL0038|Drug: Benadryl|Device: intraoperative imaging","Number of Adverse Events|Number of pituitary adenomas are detected by intraoperative imaging","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UPCC 18315","September 2015","September 2020","null","May 11, 2016","null","July 31, 2017","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02769533"
382,"NCT03382158","International PPB Registry for PPB, DICER1 and Associated Conditions",,"Recruiting","No Results Available","Pleuropulmonary Blastoma|Sertoli-Leydig Cell Tumor|DICER1 Syndrome|Cystic Nephroma|Wilms Tumor|Pineoblastoma|Renal Sarcoma|Nodular Hyperplasia of Thyroid|Nasal Chondromesenchymal Hamartoma|Ciliary Body Medulloepithelioma|Neuroblastoma|Pituitary Cancer|Embryonal Rhabdomyosarcoma","","Event-free survival|Overall response to chemotherapy|Overall survival|Quality of life outcomes in individuals diagnosed with PPB.|Cardiac outcomes in individuals diagnosed with PPB.|Pulmonary function testing results in individuals diagnosed with PPB|Incidence of neoplasms in individuals with DICER1-related conditions or germline DICER1 variants. mutation.","Children's Hospitals and Clinics of Minnesota|Children's Research Institute|Washington University School of Medicine","All","Child, Adult, Older Adult","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","FDAAA","December 6, 2016","December 6, 2023","December 6, 2026","December 22, 2017","null","December 22, 2017","Children;s Minnesota, Minneapolis, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03382158/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03382158/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03382158"
383,"NCT02288962","Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas",,"Recruiting","No Results Available","Pituitary Neoplasms|Adenoma","Drug: cabergoline","change in tumour volume during the main study of two years|need for surgical and/or radiation treatment|changed pituitary function|change in tumour's distance to chiasma opticum in mm|development of cardiac valvulopathy|impulse control disorder","St. Olavs Hospital|Norwegian University of Science and Technology","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2012/677|2012-001338-32","November 2014","May 2021","May 2025","November 13, 2014","null","December 21, 2017","Department of Endocrinology, Akershus University hospital, Oslo, Norway|Department of Endocrinology, St. Olavs Hospital, Trondheim, Norway|Sahlgrenska University Hospital, Gøteborg, Sweden","","https://ClinicalTrials.gov/show/NCT02288962"
384,"NCT03474601","Seoul National University Pituitary Disease Cohort Study","SNU-PIT","Recruiting","No Results Available","Pituitary Disease|Pituitary Incidentaloma|Acromegaly|Central Diabetes Insipidus|Pituitary Stalk Compression Hyperprolactinaemia|Cushing's Disease|Pituitary Tumor|Prolactinoma","Other: Dynamic hormone study and Magnetic resonance imaging","Treatment outcome of pituitary diseases|Complications of pituitary disease","Seoul National University Hospital","All","18 Years and older   (Adult, Older Adult)","","1600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1503-040-654","March 15, 2015","February 14, 2025","February 14, 2025","March 22, 2018","null","March 22, 2018","Seoul National University Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03474601"
385,"NCT02357498","Transsphenoidal Extent of Resection Study","TRANSSPHER","Recruiting","No Results Available","Pituitary Adenoma","Procedure: transsphenoidal surgery","percentage of patients who have complete tumor removal (gross total resection) based on MRI .|volume of residual tumor|percentage of tumor removed|postoperative cerebral-spinal fluid (CSF) leak|postoperative meningitis|hypopituitarism|diabetes insipidus (DI)|visual outcomes|hypothyroidism|hypogonadism|growth hormone deficiency|adrenal insufficiency","St. Joseph's Hospital and Medical Center, Phoenix|John Wayne Cancer Institute|Swedish Medical Center|Northwestern University|Ohio State University|Washington University School of Medicine|Brigham and Women's Hospital|University of California, Los Angeles|University of California, San Francisco|Rutgers University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","700","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14BN151","February 2015","February 2019","February 2020","February 6, 2015","null","October 4, 2016","Barrow Neurological Institute/St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCSF Medical Center, San Francisco, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|Northwestern University, Chicago, Illinois, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Rutgers University Health Services, New Brunswick, New Jersey, United States|Ohio State University Medical Center, Colombus, Ohio, United States|Swedish Neuroscience Institute, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02357498"
386,"NCT01556230","Prospective Study of Clinically Nonfunctioning Pituitary Adenomas","PAPS","Recruiting","No Results Available","Pituitary Adenoma|Pituitary Tumor","Procedure: Surgical intervention for CNFA|Radiation: Radiotherapy for CNFA","Number of patients with pituitary tumor enlargement|Change in neurocognitive function test score","Columbia University|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years and older   (Adult, Older Adult)","","350","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAE1260|R01NS070600","November 2010","December 2018","December 2018","March 16, 2012","null","February 1, 2017","Columbia University College of Physicians & Surgeons, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01556230"
387,"NCT03515603","Endocrine Outcome of Surgery for Pituitary Adenoma",,"Recruiting","No Results Available","Pituitary Adenoma","Procedure: Endoscopic resection|Procedure: Microsurgical resection","endocrine function|Extent of resection|Quality of Life","University of Ulm","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","EndOSPA","May 2018","May 2020","May 2021","May 3, 2018","null","May 3, 2018","Department of Neurosurgery, Günzburg, Germany","","https://ClinicalTrials.gov/show/NCT03515603"
388,"NCT03404414","Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT",,"Recruiting","No Results Available","Pituitary Adenoma","Drug: 18F-FDG","Standardized uptake value of 18F-FDG in pituitary adenoma|Adverse events collection","Peking Union Medical College Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PekingUMCH-NM017","February 2013","November 2018","November 2018","January 19, 2018","null","January 19, 2018","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03404414"
389,"NCT02684058","Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG",,"Recruiting","No Results Available","Diffuse Astrocytoma|Anaplastic Astrocytoma|Astrocytoma|Oligodendroglioma, Childhood|Anaplastic Oligodendroglioma|Glioblastoma|Pilocytic Astrocytoma|Giant Cell Astrocytoma|Pleomorphic Xanthoastrocytoma|Anaplastic Pleomorphic Xanthoastrocytoma|Angiocentric Glioma|Chordoid Glioma of Third Ventricle|Gangliocytoma|Ganglioglioma|Anaplastic Ganglioglioma|Dysplastic Gangliocytoma of Cerebrellum|Desmoplastic Infantile Astrocytoma and Ganglioglioma|Papillary Glioneuronal Tumor|Rosette-forming Glioneurona Tumor|Central Neurocytoma|Extraventricular Neurocytoma|Cerebellar Iponeurocytoma","Drug: dabrafenib|Drug: trametinib|Drug: Carboplatin with vincristine","HGG cohort: Overall response rate (ORR)|LGG cohort: Overall response rate (ORR)|HGG and LGG cohorts: Duration of response (DOR)|HGG and LGG cohorts: Time to response (TTR)|HGG and LGG cohorts: Overall survival (OS)|HGG and LGG cohorts: Progression free survival (PFS)|Patients on DRB+TMT: Area under the curve (AUClast)|Patients on DRB+TMT: Area under the curve (AUCtau)|Patients on DRB+TMT: Maximum Plasma Concentration (Cmax)|Patients on DRB+TMT: Time to reach maximum concentration (Tmax)|Patients on DRB+TMT: Elimination half-life (T1/2)|Patients on DRB+TMT: Predose plasma concentration (Ctrough)|HGG and LGG cohorts: Adverse events|HGG and LGG cohorts: Vital signs|HGG and LGG cohorts: Abnormal lab values|HGG and LGG cohorts: Changes in Electrocardiogram (ECG)|HGG and LGG cohorts: ECHO|HGG and LGG cohort: Palatability of pediatric formulations|LGG cohort: PROMIS Parent Proxy scale|HGG and LGG Cohorts: Clinical benefit rate (CBR)|LGG cohort: 2 year Overall survival (OS)","Novartis Pharmaceuticals|Novartis","All","6 Years to 17 Years   (Child)","Phase 2","142","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDRB436G2201|2015-004015-20","December 28, 2017","February 11, 2021","September 13, 2024","February 17, 2016","null","July 2, 2018","Children's Hospital Colorado, Aurora, Colorado, United States|Childrens National Hospital, Washington, District of Columbia, United States|Johns Hopkins University IDS Pharmacy John Hopkins Hospital, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Memorial Sloan Kettering Cancer Center PC-2, New York, New York, United States|Cincinnati Children's Hospital Medical Center Cancer & Blood Disease Inst., Cincinnati, Ohio, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|UT Southwestern Medical Center UTSW/Children's Medical Center, Dallas, Texas, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Praha 5, Czechia|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Goettingen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Setagaya-ku, Tokyo, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Zürich, Switzerland|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02684058"
390,"NCT00939523","Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy",,"Recruiting","No Results Available","Pituitary Adenomas|Prolactinomas","Drug: Lapatinib","Primary outcome in nonfunctioning adenomas: stabilization of tumor volume and mean tumor diameter on MRI. Stabilization is defined as < 2 mm change in any dimension. MRIs will be performed at baseline and at 3 and 6 months.|Primary outcome in prolactinomas: normalization of prolactin levels. Prolactin levels will be measured at baseline and monthly.|Secondary outcomes: measurement of pituitary hormones|Secondary outcome: visual field testing","Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18129","July 2009","December 2018","December 2019","July 15, 2009","null","January 26, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00939523"
391,"NCT03284775","Intraoperative Ultrasound in Patients Undergoing Transsphenoidal Surgery for Pituitary Adenoma",,"Not yet recruiting","No Results Available","Pituitary Adenoma","Device: Intraoperative ultrasound","Technical feasibility|Device safety|Radiological resection|Endocrinological remission|Postoperative complications|Operating time (minutes)|Length of stay (days)","University College, London","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17/0310","August 2018","August 2020","August 2021","September 15, 2017","null","October 12, 2017","","","https://ClinicalTrials.gov/show/NCT03284775"
392,"NCT03164148","Heart Rate Variability (HRV) in Pituitary Adenoma",,"Recruiting","No Results Available","Pituitary Adenoma","Device: T-REX TRI00A","Changes in Heart rate variability according to the types of pituitary adenoma","Seoul St. Mary's Hospital","All","19 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","KC17OESI0205","May 17, 2017","October 16, 2017","May 16, 2018","May 23, 2017","null","May 23, 2017","Seoul St. Mary's hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03164148"
393,"NCT03346954","Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease","IMPEC","Not yet recruiting","No Results Available","Cushing's Disease","Other: [11C]-Methionine PET/MRI","Sensitivity of [11C]-Methionine PET/MRI|False negatives and false positives description|Description of identified microadenomas|Comparison of [11C]-Methionine PET/MRI and pituitary MRI","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","69HCL17_0167","December 1, 2017","April 1, 2018","January 1, 2019","November 20, 2017","null","November 21, 2017","Service de Médecine Nucléaire - Hospices Civils de Lyon, Bron, France","","https://ClinicalTrials.gov/show/NCT03346954"
394,"NCT03439709","Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma","MERGE","Not yet recruiting","No Results Available","Acromegaly Due to Pituitary Adenoma","Radiation: Gamma knife radiosurgery|Drug: Lanreotide 60Mg Solution for Injection","endocrinologic remission|tumor size|drug requirement dosage|side effect|performance status","Samsung Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMC 2017-11-091-002","March 1, 2018","June 30, 2022","December 31, 2022","February 20, 2018","null","March 1, 2018","Samsung Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03439709"
395,"NCT03014687","Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions","POET","Recruiting","No Results Available","Antibiotics|Pituitary Adenoma","Drug: Placebo|Drug: Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole","Change in quality of life from baseline - Anterior Skull Base Nasal Inventory 12 (ASK Nasal-12)|Change in quality of life from baseline - Sino-Nasal Outcome Test (SNOT-22)|Incidence of Acute Bacterial Sinusitis|Changes in endoscopic appearances using Postoperative Debridement Scoring Sheet (modified Lund-Kennedy score)|Sinusitis and antibiotic resistance as evidenced by nasal congestion|Sinusitis and antibiotic resistance as evidenced by purulent discharge|Sinusitis and antibiotic resistance as evidenced by pressure|Sinusitis and antibiotic resistance as evidenced by pain|Sinusitis and antibiotic resistance as evidenced headache","St. Joseph's Hospital and Medical Center, Phoenix|Thomas Jefferson University|The Cleveland Clinic","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 4","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PHX-16-0134-30-12","January 2017","January 2019","March 2019","January 9, 2017","null","January 10, 2017","Barrow Brain and Spine, Phoenix, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03014687"
396,"NCT02803697","Predictive Factors of Recurrence of Non Functioning Pituitary Adenomas : a Retrospective Study of 220 Patients in the Reims University Hospital, France",,"Recruiting","No Results Available","Pituitary Adenomas","Other: Patients","Recurrence rate / predictive factors of recurrence","CHU de Reims","All","18 Years and older   (Adult, Older Adult)","","220","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PA13045","November 2015","March 2017","November 2017","June 17, 2016","null","December 28, 2016","Chu de Reims, Reims, France","","https://ClinicalTrials.gov/show/NCT02803697"
397,"NCT02750371","Effect of Irradiation of the Cavernous Sinus and the Sellar Region on Autobiographical Memory","ISOMAB","Recruiting","No Results Available","Cavernous Sinus Meningioma|Pituitary Adenoma","Other: Evaluation of autobiographical memory","Autobiographical memory test (TEMPau) score|Revised Self Consciousness Scale (RSCS) score|Quality of life questionnaire (QLQC-30/BN20) score|California Verbal Learning Test (CVLT) score","University Hospital, Bordeaux","All","35 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CHUBX 2015/03","July 2016","January 2021","January 2021","April 25, 2016","null","August 24, 2017","University Hospital Bordeaux, Bordeaux, France","","https://ClinicalTrials.gov/show/NCT02750371"
398,"NCT02727686","Post-Operative Water Load Following Transsphenoidal Pituitary Surgery",,"Recruiting","No Results Available","Hyponatremia|Pituitary Adenoma","Other: Water Load (WL) Post-Operative Day 1","POD1 Response Serum Sodium|POD1 Response Serum Osmolality|POD1 Response Urine Output|POD1 Response Vasopressin|Post-Discharge Response","St. Joseph's Hospital and Medical Center, Phoenix|Barrow Brain and Spine|Barrow Neurological Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PHX1600103012","April 2016","December 2017","January 2018","April 5, 2016","null","October 12, 2016","Barrow Brain and Spine, Phoenix, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02727686"
399,"NCT01794793","Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.",,"Recruiting","No Results Available","Cushing's Disease|Acromegaly|Neuroendocrine Tumors|Pituitary Tumors|Ectopic ACTH Secreting (EAS) Tumors|Dumping Syndrome|Prostate Cancer|Melanoma Negative for bRAF|Melanoma Negative for nRAS","Drug: Pasireotide","Number of patients receiving pasireotide|Frequency and nature of serious adverse events (SAEs)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSOM230B2412","January 14, 2013","June 9, 2023","June 12, 2023","February 20, 2013","null","May 22, 2018","Ximed Research SC - SOM230B2412, La Jolla, California, United States|Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States|Stanford University Medical Center Stanford Hospital & Clinics, Stanford, California, United States|University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States|Icahn School of Medicine at Mount Sinai Cardiology, New York, New York, United States|Memorial Sloan-Kettering Cancer Center SC, New York, New York, United States|Virginia Endocrinology Research SC, Chesapeake, Virginia, United States|Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, Botucatu, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Toulouse, Cedex 9, France|Novartis Investigative Site, Angers cedex 09, France|Novartis Investigative Site, Bron Cedex, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Pierre-Benite Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wurzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Nankoku-city, Kochi, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Miraflores, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey","","https://ClinicalTrials.gov/show/NCT01794793"
400,"NCT00565903","Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome","PPB","Recruiting","No Results Available","Pleuropulmonary Blastoma|Cystic Nephroma|Sertoli-Leydig Cell Tumor of Ovary|Medulloepithelioma|Embryonal Rhabdomyosarcoma of Cervix|Goiter|Sarcoma|Pineoblastoma|Pituitary Tumors|Wilms Tumor","","Identify the genetic factors which contribute to the development or progression of pleuropulmonary blastoma|Define the clinical features of the pleuropulmonary blastoma (PPB) familial cancer syndrome.","D. Ashley Hill, M.D.|Children's Research Institute","All","up to 95 Years   (Child, Adult, Older Adult)","","2000","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","05-0192 / 201012830","March 2005","December 2018","December 2020","November 30, 2007","null","July 19, 2017","Children's National Medical Center, Washington, D.C., District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT00565903"
401,"NCT00461188","Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA",,"Recruiting","No Results Available","Acromegaly|Gigantism|Familial Isolated Pituitary Adenoma|FIPA|Pituitary Adenoma Predisposition|PAP","","","Barts & The London NHS Trust","All","6 Years and older   (Child, Adult, Older Adult)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","004842","March 2007","April 2099","April 2099","April 17, 2007","null","January 18, 2018","Barts and the London medical School, London, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom","","https://ClinicalTrials.gov/show/NCT00461188"
402,"NCT02596828","Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma",,"Recruiting","No Results Available","Pineoblastoma","Drug: Temozolomide|Drug: Irinotecan|Drug: Dasatinib|Drug: Rapamycin","The primary endpoint is progression-free survival (PFS)|Overall survival (OS)|Response to the investigational treatment after 4 and 8 courses of I/T and 1-year-follow-up in the RIST treatment arm|Duration until adequate response to this treatment regimen|Assessment of quality of life (Lansky and Karnofsky Scores)|Toxicity of this combination of drugs in children, adolescents and young adults with rNB - Assessment according to the latest version of the CTC criteria|Safety and tolerability of the investigational treatment - Assessment according to the latest version of the CTC criteria","University of Regensburg","All","up to 25 Years   (Child, Adult)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RIST-rPB-2015-P","April 2016","April 2019","April 2020","November 4, 2015","null","December 30, 2016","University Hospital of Regensburg, Regensburg, Germany","","https://ClinicalTrials.gov/show/NCT02596828"
403,"NCT00392327","Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma",,"Recruiting","No Results Available","Untreated Childhood Medulloblastoma|Untreated Childhood Pineoblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Radiation: Radiation Therapy|Drug: Vincristine Sulfate|Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Isotretinoin|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment","Event-free survival (EFS) percentage|Tumor response to radiation therapy with or without carboplatin|Time to death","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 3","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACNS0332|NCI-2009-00336|COG-ACNS0332|CDR0000511991|R01CA114567|U10CA180886|U10CA098543","March 2007","June 2018","null","October 26, 2006","null","August 31, 2017","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Childrens Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, D.C., District of Columbia, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, D.C., District of Columbia, United States|Lee Memorial Health System, Fort Myers, Florida, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|Memorial Healthcare System - Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic-Jacksonville South, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Florida Hospital Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph Children's Hospital of Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Memorial University Medical Center, Savannah, Georgia, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States|Advocate Children's Hospital-Park Ridge, Park Ridge, Illinois, United States|Advocate Lutheran General Hospital., Park Ridge, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Services, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Michigan State University Clinical Center, East Lansing, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|The Childrens Mercy Hospital, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Children's Specialty Center of Nevada II, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|UMDNJ - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|New York University Langone Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Montefiore Medical Center - Moses Campus, The Bronx, New York, United States|New York Medical College, Valhalla, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Medical Center-Fargo, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Mercy Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Palmetto Health Richland, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Greenville Cancer Treatment Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|T C Thompson Children's Hospital, Chattanooga, Tennessee, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Tech University Health Science Center-Amarillo, Amarillo, Texas, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont College of Medicine, Burlington, Vermont, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Childrens Hospital-King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Carilion Clinic Children's Hospital, Roanoke, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Charleston, Charleston, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Women's and Children's Hospital-Adelaide, North Adelaide, South Australia, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|University of Alberta Hospital, Edmonton, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Ste-Foy, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Dutch Childhood Oncology Group, Den Haag, Netherlands|San Jorge Children's Hospital, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00392327"
404,"NCT00001595","An Investigation of Pituitary Tumors and Related Hypothalmic Disorders",,"Recruiting","No Results Available","Abnormalities|Craniopharyngioma|Cushing's Syndrome|Endocrine Disease|Pituitary Neoplasm","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","3 Years to 70 Years   (Child, Adult, Older Adult)","","1500","NIH","Observational","","970076|97-CH-0076","February 13, 1997","null","null","November 4, 1999","null","July 2, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001595"
405,"NCT02574728","Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors","AflacST1502","Recruiting","No Results Available","Cancer","Drug: Sirolimus|Drug: Celecoxib|Drug: Etoposide|Drug: Cyclophosphamide","Change in radiographic response to treatment for solid tumors|Change in radiographic response to treatment for central nervous system (CNS) tumors|Number of adverse events","Emory University","All","12 Months to 30 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00082488","June 2015","June 2020","June 2020","October 14, 2015","null","June 8, 2018","Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02574728"
406,"NCT00005664","Evaluation of Patients With Endocrine-Related Conditions",,"Recruiting","No Results Available","Adrenal Insufficiency|Pituitary Neoplasm|Obesity","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","","2000","NIH","Observational","Observational Model: Other|Time Perspective: Prospective","000127|00-CH-0127","May 16, 2000","null","null","May 18, 2000","null","June 26, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00005664"
407,"NCT01445288","Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors",,"Recruiting","No Results Available","Diffuse Intrinsic Pontine Glioma|PNET|Ependymoma|Germinoma|Medulloblastoma","","Measure changes in antiogenesis, blood brain barrier permability and neurotoxicity re to radiation of the CNS|Describe changes in imaging, endocrine function after xrt to the brain|Monitor changes in serum proteome and germline polymorphisms","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","up to 21 Years   (Child, Adult)","","150","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","060219|06-C-0219","August 1, 2006","null","null","October 3, 2011","null","June 27, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01445288"
408,"NCT03243461","International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)","HIT-HGG-2013","Not yet recruiting","No Results Available","Glioblastoma WHO Grade IV|Diffuse Midline Glioma Histone 3 K27M WHO Grade IV|Anaplastic Astrocytoma WHO Grade III|Diffuse Intrinsic Pontine Glioma|Gliomatosis Cerebri","Drug: Temozolomide + Valproic Acid|Drug: Temozolomide + Chloroquine","Comparison of effects of valproine acid and chloroquine.|Comparison of effects of valproine acid with respect to historical control group.|Comparison of effects of chloroquine with respect to historical control group.","University of Göttingen|Deutsche Kinderkrebsstiftung|Hannover Clinical Trial Center GmbH","All","3 Years to 17 Years   (Child)","Phase 3","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01153|2013-004187-56","February 19, 2018","August 1, 2021","January 1, 2023","August 9, 2017","null","February 7, 2018","","","https://ClinicalTrials.gov/show/NCT03243461"
409,"NCT02650401","Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions",,"Recruiting","No Results Available","Solid Tumors|CNS Tumors|Neuroblastoma","Drug: Entrectinib","Maximum Tolerated Dose (MTD)|Recommended Phase 2 Dose (RP2D)|Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03|Maximum observed plasma drug concentration (Cmax)|Time to Cmax, by inspection (Tmax)|Css|Terminal half life (t½)|Area under the drug concentration by time curve (AUC)|Objective Response Rate (ORR)|Progression-free Survival (PFS)","Hoffmann-La Roche","All","2 Years to 22 Years   (Child, Adult)","Phase 1","190","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RXDX-101-03|CO40778","May 3, 2016","September 30, 2018","March 31, 2019","January 8, 2016","null","June 18, 2018","Children'S Hospital of Orange County, Orange, California, United States|Rady Childrens Hospital, San Diego, California, United States|UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology, San Francisco, California, United States|Children's Hospital Colorado; Center For Cancer/Blood Disorder, Aurora, Colorado, United States|Children's National Medical Center; Department of Pediatrics, Washington, District of Columbia, United States|Egleston Children's Hospital at Emory University Atlanta; Pediatric Hematology/Oncology, Atlanta, Georgia, United States|University of Chicago; Comer Children's Hospital/Department of Pediatrics, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota Childrens' Hospital, Minneapolis, Minnesota, United States|Washington University,St. Louis Children's Hospital; Neurology, Movement Disorder, Saint Louis, Missouri, United States|Morgan Stanley Children's Hospital; Herbert Irving Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center; Pediatrics, New York, New York, United States|Nationwide Children's Hospital; Dept. of Pulmonology, Columbus, Ohio, United States|Oregon Health & Science Uni, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children'S Research Hospital, Memphis, Tennessee, United States|Cook Childrens Medical Center, Fort Worth, Texas, United States|Texas Children's Cancer and Hematology Center, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02650401"
410,"NCT02661282","Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients",,"Recruiting","No Results Available","Glioblastoma|Gliosarcoma","Drug: Temozolomide|Biological: T Cell Infusion|Procedure: Surgery|Behavioral: Phone Calls","Maximum Tolerated Dose (MTD) of CMV-T Cells|Immunological Effects in Tumor Tissue|Tumor-Mediated Immune Suppression at the Effector Location|Overall Survival (OS)","M.D. Anderson Cancer Center|Marnie Rose Foundation|Gateway for Cancer Research","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0899|NCI-2016-00183","June 2016","June 2020","June 2021","January 22, 2016","null","March 14, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02661282"
411,"NCT02920580","The NEUROlogically-impaired Extubation Timing Trial","NEURO-ETT","Recruiting","No Results Available","Acute Brain Injury","Procedure: Extubation|Procedure: Usual Care","ICU Free Days|Mortality,|Ventilator-Free Days|Airway Complications|Nutrition Intake|Antibiotic Days|Delirium|Rate of Tracheostomy Insertion|Rate of ICU Readmission|Hospital Discharge Destination|Extended Glasgow Outcome Score|EQ-5D","Sunnybrook Health Sciences Centre|Canadian Institutes of Health Research (CIHR)","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","410","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","NEURO-ETT","February 1, 2017","March 2021","September 2021","September 30, 2016","null","April 19, 2018","University of Alberta Hospital, Edmonton, Alberta, Canada|Royal Columbian Hospital, New Westminster, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada|Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada|L'Hôpital de l'Enfant-Jésus, Quebec City, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02920580"
412,"NCT03363217","Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.",,"Not yet recruiting","No Results Available","Low-grade Glioma|Plexiform Neurofibroma|Central Nervous System Glioma","Drug: Trametinib","Objective Response Rate|Time to Progression (time from registration to progression)|Progression Free Survival (time from registration to the earlier of progression or death).|Overall Survival (time from registration to death)|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability).|Determination of the Serum Level of Trametinib.|Evaluation of the Quality of Life During Treatment.","St. Justine's Hospital|Montreal Children's Hospital of the MUHC|CHU de Québec","All","1 Month to 25 Years   (Child, Adult)","Phase 1|Phase 2","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Trametinib study (ID TBD)","May 15, 2018","June 1, 2026","December 1, 2026","December 6, 2017","null","April 17, 2018","CHU Sainte-Justine, Montreal, Quebec, Canada|Montreal Children's Hospital, Montreal, Quebec, Canada|CHU de Québec, Quebec City, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03363217"
413,"NCT01804634","A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors",,"Recruiting","No Results Available","Refractory and/or Relapsed Metastatic Solid Tumors","Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: low dose total body irradiation|Drug: Melphalan|Drug: Sirolimus","Donor cell engraftment|Overall survival|Relapse|Non-Relapse Mortality","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","up to 40 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J12106","February 2013","December 2017","December 2018","March 5, 2013","null","June 17, 2016","The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01804634"
414,"NCT00060541","Evaluation and Treatment of Neurosurgical Disorders",,"Recruiting","No Results Available","Neurologic Disorders","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","4 Years and older   (Child, Adult, Older Adult)","","2500","NIH","Observational","","030164|03-N-0164","May 6, 2003","null","null","May 7, 2003","null","June 27, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00060541"
415,"NCT02986178","PVSRIPO With/Without Lomustine",,"Recruiting","No Results Available","Malignant Glioma","Biological: PVSRIPO|Drug: Lomustine","24-month overall survival|Percentage of participants with grade 3, 4, or 5 treatment-related adverse events","Istari Oncology, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","62","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00077024","June 1, 2017","May 2021","May 2023","December 8, 2016","null","December 18, 2017","Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02986178"
416,"NCT01272622","Prospective Study of Children and Adolescents With Craniopharyngioma",,"Recruiting","No Results Available","Craniopharyngioma|Obesity","Radiation: Radiation|Other: wait and watch","Quality of life|Rate of Progression or relapse","Klinikum Oldenburg gGmbH|Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|Arbeitsgemeinschaft Pädiatrische Endokrinologie (APE)|Deutsche Gesellschaft für Endokrinologie (DGE)|Arbeitsgemeinschaft Pädiatrische Radioonkologie (APRO)|Deutsche Gesellschafr für Radioonkologie (DEGRO)|Deutsche Kinderkrebsstiftung|International Society of Paediatric Oncology (SIOP)","All","up to 18 Years   (Child, Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DKSR 463","October 2007","December 2016","September 2017","January 10, 2011","null","September 16, 2016","Klinikum Oldenburg, Oldenburg, Niedersachsen, Germany","","https://ClinicalTrials.gov/show/NCT01272622"
417,"NCT03579602","Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery",,"Not yet recruiting","No Results Available","Pediatric Central Nervous System Tumor","Drug: tozuleristide|Device: Canvas System","Sensitivity and specificity of tozuleristide fluorescence to detect tumor in equivocal (ambiguous) tissue during surgery when imaged with the Canvas system|Safety - number of patients with adverse events|Extent of resection|Concentration of tozuleristide in the blood (pharmacokinetics)|Performance of the Canvas system","Blaze Bioscience Inc.|Pacific Pediatric Neuro-Oncology Consortium","All","1 Month to 30 Years   (Child, Adult)","Phase 2|Phase 3","114","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","BB-006|PNOC012","August 2018","August 2019","November 2019","July 6, 2018","null","July 6, 2018","","","https://ClinicalTrials.gov/show/NCT03579602"
418,"NCT02201381","Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer","METRICS","Recruiting","No Results Available","Cancer|Overall Survival","Drug: Metabolic treatment","Overall survival|Tumour size cancer types and by cancer type.|Tumour Spread|Tumour number|Blood cancer markers","Health Clinics Limited","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","207","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Metabolic Cancer 001","May 22, 2017","May 22, 2022","October 22, 2023","July 28, 2014","null","June 14, 2017","Care Oncology Clinic, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02201381"
419,"NCT02766699","A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)","CerebralEDV","Recruiting","No Results Available","Glioblastoma|Astrocytoma, Grade IV","Drug: EGFR(V)-EDV-Dox","Safety outcome measures: Adverse Events (AE's) graded according to CTCAE V.4.3, physical/neurologic examination, Karnofsky Performance Status (KPS), vital signs, echocardiogram, ECG, hematology, serum chemistry & urinalysis.|Efficacy outcome measure: Disease response will be measured by Magnetic Resonance Imaging (MRI) using Response Assessment in Neuro-Oncology (RANO).|Identification of a recommended Phase 2 dose (RP2D) of EGFR(V)-EDV-Dox in subjects with recurrent GBM : Dose limiting toxicity (DLT) evaluable subjects.|Overall survival outcome measure.","Engeneic Pty Limited|Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENG7","October 25, 2016","February 2019","December 2019","May 10, 2016","null","July 25, 2017","John Hopkins Hospital, Baltimore, Maryland, United States|Lenox Hill Hospital, Northwell Health, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02766699"
420,"NCT01621906","18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain",,"Recruiting","No Results Available","Metastatic Breast Cancer to the Brain","Device: 18F-FLT-PET Imaging","radiographic response|Analysis of surgical specimen","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-039","June 2012","June 2018","June 2018","June 18, 2012","null","January 4, 2018","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States","","https://ClinicalTrials.gov/show/NCT01621906"
421,"NCT02132598","Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases",,"Recruiting","No Results Available","Non Small Cell Lung Cancer (NSCLC)|Metastases to the Brain","Drug: cabozantinib","To assess the Overall Response Rate (ORR)|To assess the Disease Control Rate (DCR)|To assess the Progression-free Survival (PFS)|To assess the Overall Survival (OS)|Number of Participants with Serious and Non-Serious Adverse Events|Time to Progression (TTP) of intra-cranial disease","Liza Villaruz, MD|Exelixis|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-182","December 2015","June 2018","June 2028","May 7, 2014","null","September 8, 2017","University of Pittsburgh Cancer Institute- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02132598"
422,"NCT03179176","Evaluation of the Interest of Ultra-high Frequency Doppler Ultrasound (UFDU) in the Surgical Management of Patients Operated in an Awake Condition for a Cerebral Tumor","EUHF_PRC","Recruiting","No Results Available","Cerebral Tumor","Other: High Frequence Ultrasound Doppler (HFUD) utilisation","Diameter of the sulcus blood vessels","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17-PP-01","April 26, 2017","April 2018","July 2018","June 7, 2017","null","June 7, 2017","CHU de Nice, Nice, France","","https://ClinicalTrials.gov/show/NCT03179176"
423,"NCT01843413","Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases",,"Recruiting","No Results Available","Tumors Metastatic to Brain|Unspecified Adult Solid Tumor","Radiation: stereotactic radiosurgery|Procedure: quality-of-life assessment|Procedure: cognitive assessment","Maximum-tolerated dose based on the incidence of dose-limiting toxicity (DLT) defined as any grade III or IV toxicity as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Response associated with increased dose of SRS as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II)|Incidence of adverse events as assessed by CTCAE version 4.0 (Phase II)|Quality of life (QOL) as assessed by the Functional Assessment of Cancer Therapy-Brain (FACT-BR) and the European Organization for Research and Treatment (EORTC)- Quality of Life Questionnaire Core 30 (QLQ30)","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE8312|NCI-2013-00845","July 2, 2013","March 2019","March 2019","April 30, 2013","null","February 27, 2018","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01843413"
424,"NCT01992432","Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)","Brain fMRI-BC","Recruiting","No Results Available","Breast Cancer","","Intensity of brain activation during functional brain MRI.|NIH Tool box cognitive assessment.|Structural MRI brain parameters.|Chemotherapy toxicity.","City of Hope Medical Center|National Institute on Aging (NIA)","Female","65 Years and older   (Older Adult)","","25","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","13278|1R03AG045090","September 30, 2013","June 2018","June 2018","November 25, 2013","null","July 7, 2017","City of Hope Medical Center, Duarte, California, United States|South Pasadena Cancer Center, South Pasadena, California, United States","","https://ClinicalTrials.gov/show/NCT01992432"
425,"NCT03325166","Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases",,"Recruiting","No Results Available","Lung Carcinoma Metastatic in the Brain|PD-L1 Positive|Stage IV Non-Small Cell Lung Cancer AJCC v7","Drug: Ferumoxytol|Other: Laboratory Biomarker Analysis|Procedure: Magnetic Resonance Imaging|Biological: Pembrolizumab","Sensitivity and specificity of relative cerebral blood volume|Safety and tolerability of pembrolizumab when given with stereotactic radiosurgery (SRS) in subjects with brain metastasis|Progression free survival|Overall survival|Best response in brain disease|Best response in systematic disease|Duration of best response of brain and systemic disease","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00016709|NCI-2017-01730|P30CA069533","November 15, 2017","September 15, 2019","September 15, 2022","October 30, 2017","null","June 14, 2018","OHSU Knight Cancer Institute, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03325166"
426,"NCT03483012","Atezolizumab + Stereotactic Radiosurgery in Triple-negative Breast Cancer and Brain Metastasis",,"Recruiting","No Results Available","Breast Cancer","Drug: Atezolizumab|Procedure: Stereotactic radiosurgery (SRS)","Progression Free Survival|Extracranial Objective Response Rate|Progression free survival|Clinical Benefit Rate|Overall Survival|Patient-Reported Outcome|Development of radiation necrosis|Investigator-Assessed Neurological Evaluation|Dose Limiting Toxicity|Abscopal response rate","Dana-Farber Cancer Institute|Genentech, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-519","May 1, 2018","September 30, 2021","September 30, 2025","March 29, 2018","null","May 2, 2018","Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03483012"
427,"NCT02915744","A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine","ATTAIN","Recruiting","No Results Available","Metastasis|Breast Cancer","Drug: NKTR-102|Drug: Eribulin|Drug: Ixabepilone|Drug: Vinorelbine|Drug: Gemcitabine|Drug: Paclitaxel|Drug: Docetaxel|Drug: Nab-paclitaxel","Overall Survival (OS) of Patients|Progression-Free Survival (Outside the Central Nervous System)|Progression-Free Survival in Brain Metastasis (PFS-BM)|Progression-Free Survival (Overall)|Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC)|Clinical Benefit Rate (CBR)|Duration of Response (DoR)|WBRT|Compare Health-Related Quality of Life (HRQoL) using the European Organisation for Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30) module with the brain neoplasms 20-question (BN-20) subscale.|Compare Health-Related Quality of Life (HRQoL) using the the EuroQoL 5D (EQ-5D-5L™)|Compare Health-Related Quality of Life (HRQoL) using the Brief Fatigue Inventory (BFI)|Magnitude of Clinical Benefit|Maximum observed serum concentration (Cmax) of NKTR-102|Time of maximum observed serum concentration (Tmax) of NKTR-102|Area Under the serum Concentration time curve in the dosing interval (AUCtau) of NKTR-102|Half-life of (t1/2) of NKTR-102|Number of participants with adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.3","Nektar Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-102-14","November 2016","August 2019","February 2020","September 27, 2016","null","January 9, 2018","Investigator Site - Tucson, Tucson, Arizona, United States|Investigator Site - Orange, Orange, California, United States|Investigator Site - San Francisco, San Francisco, California, United States|Investigator Site - Miami, Miami, Florida, United States|Investigator Site - Plantation, Plantation, Florida, United States|Investigator Site - West Palm Beach, West Palm Beach, Florida, United States|Investigator Site - Athens, Athens, Georgia, United States|Investigator Site - Baltimore, Baltimore, Maryland, United States|Investigator Site - Boston, Boston, Massachusetts, United States|Investigator Site - Minneapolis, Minneapolis, Minnesota, United States|Investigator Site - Saint Louis, Saint Louis, Missouri, United States|Investigator Site - New York, New York, New York, United States|Investigator Site - Chapel Hill, Chapel Hill, North Carolina, United States|Investigator Site - Columbus, Columbus, Ohio, United States|Investigator Site - Germantown, Germantown, Tennessee, United States|Investigator Site - Nashville, Nashville, Tennessee, United States|Investigator Site - Fort Worth, Fort Worth, Texas, United States|Investigator Site - Houston, Houston, Texas, United States|Investigator Site - Salt Lake City, Salt Lake City, Utah, United States|Investigator Site - Seattle, Seattle, Washington, United States|Investigatory Site - Albury, Albury, New South Wales, Australia|Investigator Site - Darlinghurst, Darlinghurst, New South Wales, Australia|Investigator Site - Wollongong, Wollongong, New South Wales, Australia|Investigator Site - Brisbane, Brisbane, Queensland, Australia|Investigator Site - Subiaco, Subiaco, Western Australia, Australia|Investigator Site - Nedlands, Nedlands, Australia|Investigator Site - Brussels, Brussels, Belgium|Investigator Site - Brussels, Brussels, Belgium|Investigator Site - Brussels, Brussels, Belgium|Investigator Site - Charleroi, Charleroi, Belgium|Investigator Site - Edegem, Edegem, Belgium|Investigator Site - Liege, Liège, Belgium|Investigator Site - Namur, Namur, Belgium|Investigator Site - Sint-Niklaas, Sint-Niklaas, Belgium|Investigator Site - Montreal, Montréal, Quebec, Canada|Investigator Site - Praha, Praha, Czechia|Investigator Site - Grenoble, Grenoble, France|Investigator Site - Le Mans, Le Mans, France|Investigator Site - Nimes, Nîmes, France|Investigator Site - Paris, Paris, France|Investigator Site - Rennes, Rennes, France|Investigator Site - Rouen, Rouen, France|Investigator Site - Saint-Cloud, Saint-Cloud, France|Investigator Site - Strasbourg, Strasbourg, France|Investigator Site - Toulouse, Toulouse, France|Investigator Site - Be'er Ya'aqov, Be'er Ya'aqov, Israel|Investigator Site - Beersheba, Beersheba, Israel|Investigator Site - Haifa, Haifa, Israel|Investigator Site - Jerusalem, Jerusalem, Israel|Investigator Site - Tel Aviv, Tel Aviv, Israel|Investigator Site - Milan, Milan, Italy|Investigator Site - Napoli, Napoli, Italy|Investigator Site - Christchurch, Christchurch, New Zealand|Investigator Site - Lisbon, Lisbon, Portugal|Investigator Site - Porto, Porto, Portugal|Investigator Site - San Sebastián, San Sebastián, Gipuzkoa, Spain|Investigator Site - Barcelona, Barcelona, Spain|Investigator Site - Barcelona, Barcelona, Spain|Investigator Site - Granollers, Granollers, Spain|Investigator Site - Jaen, Jaén, Spain|Investigator Site - Madrid, Madrid, Spain|Investigator Site - Madrid, Madrid, Spain|Investigator Site - Santa Cruz de Tenerife, Santa Cruz de Tenerife, Spain|Investigator Site - Sevilla, Sevilla, Spain|Investigator Site - Sevilla, Sevilla, Spain|Investigator Site - Bradford, Bradford, United Kingdom|Investigator Site - Manchester, Manchester, United Kingdom|Investigator Site - Nottingham, Nottingham, United Kingdom","","https://ClinicalTrials.gov/show/NCT02915744"
428,"NCT03206021","Treatment of Children With Recurrent Refractory Brain/Solid Tumors and Recurrent Ependymoma",,"Recruiting","No Results Available","Recurrent Childhood CNS Tumor|Ependymoma, Recurrent Childhood|Childhood Solid Tumor","Drug: 5 Azacytidine","Establish maximum tolerated dose of carboplatin in combination with 5'azacytidine|Characterization of the pharmacodynamics of 5'-azacitidine in combination with carboplatin|Assessment of intratumoral DNA demethylation as a preliminary indication of biological efficacy of this combination.|Assessment of disease response as a preliminary indication of efficacy of this combination against recurrent, refractory pediatric brain and solid tumors","The Hospital for Sick Children","All","1 Year to 18 Years   (Child, Adult)","Phase 1","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OZM-077","August 1, 2017","July 1, 2020","July 1, 2022","July 2, 2017","null","January 11, 2018","Alberta Children's Hospital, Calgary, Alberta, Canada|BC Children's Hospital, Vancouver, British Columbia, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Centre hospitalier universitaire Sainte-Justine, Montréal, PQ, Canada|Montreal Children's Hospital, Montréal, PQ, Canada","","https://ClinicalTrials.gov/show/NCT03206021"
429,"NCT02514915","Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases",,"Recruiting","No Results Available","Malignant Neoplasm Brain","Radiation: Stereotactic Radiosurgery","Local control rate in subjects with solitary brain metastases treated with pre-operative SRS followed by surgical resection|Evaluate the overall survival with scans|Evaluate distant intracranial failure scans|Evaluate the subjects quality of life by Health Related Quality of Life (HRQL) Questionniare","University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-150","February 2016","December 2018","July 2021","August 4, 2015","null","April 27, 2018","UPMC Shadyside Radiation Oncology Department, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02514915"
430,"NCT02589522","VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors",,"Recruiting","No Results Available","Lung Carcinoma Metastatic in the Brain|Lung Neuroendocrine Neoplasm|Stage IV Non-Small Cell Lung Cancer AJCC v7|Stage IV Small Cell Lung Carcinoma AJCC v7","Drug: ATR Kinase Inhibitor M6620|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Quality-of-Life Assessment|Procedure: Therapeutic Conventional Surgery|Radiation: Whole-Brain Radiotherapy","Dose-limiting toxicity, defined as any grade 3 or more non-hematological toxicity requiring more than 5 day interruption in therapy or any grade 4 or higher hematological toxicity that is attributable to the VX-970 and/or whole brain radiotherapy|Incidence of delayed neurological toxicity using Hopkins Verbal Learning Test-Revised|Changes in quality of life as measured by the Functional Assessment of Cancer Therapy-Brain|Radiological response rate measured by morphological criteria|Intracranial progression-free survival (icPFS)|Overall survival (OS)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","46","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2015-01779|HP-00068292|9952|UM1CA186644|UM1CA186686|UM1CA186690","July 21, 2016","September 30, 2018","null","October 28, 2015","null","June 27, 2018","City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Case Western Reserve University, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02589522"
431,"NCT02162537","Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases","METAL2","Recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic|Non-small Cell Lung Cancer|Adenocarcinoma of Lung Metastatic to Brain|Cerebral Metastases","Drug: Cisplatin|Drug: Pemetrexed|Drug: Bevacizumab|Radiation: Cerebral Radiotherapy","To compare the progression-free survival rate in both arms|Overall survival|Disease control rate (response + stability)|Toxicity|Quality of life assessment|Neurological assessment","Centre Hospitalier Intercommunal Creteil|Groupe Francais De Pneumo-Cancerologie","All","18 Years and older   (Adult, Older Adult)","Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","METAL 2","December 2013","May 2018","January 2019","June 12, 2014","null","August 1, 2017","Centre Hospitalier du Pays d'Aix, Aix En Provence, France|Centre Hospitalier Victor Dupouy, Argenteuil, France|Centre d'Oncologie et de Radiothérapie du Pays Basque, Bayonne, France|Centre Hospitalier, Beauvais, France|Hôpital Avicenne, Bobigny, France|HIA de Clermont-Tonnerre, Brest, France|CHU, Brest, France|Centre François Baclesse, Caen, France|Centre Hospitalier, Charleville Meziere, France|Centre Hospitalier Laennec, Creil, France|Centre Hospitalier Intercommunal, Creteil, France|Centre Hospitalier, Draguignan, France|Centre Hospitalier, GAP, France|Centre Hospitalier Robert Boulin, Libourne, France|Hôpital Le Cluzeau, Limoges, France|Centre Hospitalier Régional, Longjumeau, France|Centre Hospitalier de Bretagne Sud, Lorient, France|Centre Léon Bérard, Lyon, France|Centre Hospitalier Les Chanaux, Macon, France|Centre Hospitalier F. QUESNAY, Mantes La Jolie, France|Institut Paoli Calmette, Marseille, France|Hôpital Nord APHM, Marseille, France|Centre Hospitalier, Meaux, France|Centre Hospitalier Intercommunal, Meulan, France|Clinique du Pont de Chaume, Montauban, France|Centre Hospitalier, Perigueux, France|Centre Catalan d'Oncologie, Perpignan, France|Centre Hospitalier René Dubos, Pontoise, France|Centre Hospitalier de la Région d'Annecy (CHRA), Pringy, France|Centre Hospitalier Intercommunal de Cornouaille, Quimper, France|Hôpital Pontchailloux, Rennes, France|Hôpital Charles Nicolle, Rouen, France|Clinique Mutualiste de l'Estuaire, Saint Nazaire, France|Institut de Cancérologie de la Loire (I.C.L), Saint Priest En Jarez, France|Centre Hospitalier de Salon de Provence, Salon de Provence, France|Centre Hospitalier, Sens, France|Centre Paul Strauss, Strasbourg, France|Hopital d'Instruction des Armées Sainte Anne, Toulon, France|Hôpital Larrey, Toulouse, France|Clinique Pasteur, Toulouse, France|Centre Hospitalier, Villefranche Sur Saone, France","","https://ClinicalTrials.gov/show/NCT02162537"
432,"NCT02896504","Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients",,"Recruiting","No Results Available","Breast Cancer","Drug: Exposure: Adjuvant chemotherapy treatment|Drug: Exposure: Adjuvant hormonal therapy treatment","Change in Structural Integrity of the Corpus Collusum as measure by MRI-DTI|Change in Structural Integrity of the cortico-spinal tract as measure by MRI-DTI|Change in out-of-phase bimanual finger tapping task performance|Change in interhemispheric EEG coherence between the left and right motor brain areas|Change in corticomuscular conduction time using Transcranial Magnetic Stimulation|Change in response time to a simple reaction time","Kessler Foundation","Female","20 Years to 70 Years   (Adult, Older Adult)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","R-739-12","September 2013","September 2018","September 2018","September 12, 2016","null","January 23, 2018","Kessler Foundation, West Orange, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT02896504"
433,"NCT03412955","A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes",,"Recruiting","No Results Available","Breast Cancer","Drug: Eribulin Mesylate","Objective Tumor Response Rate in Brain as measured using RANO-BM criteria|Extracranial objective tumor response rate as measured using RECIST 1.1 criteria|Duration of Response in Brain|Assessment of toxicities such as neuropathy, hematological and hepatological toxicities","Tan Tock Seng Hospital","Female","21 Years to 99 Years   (Adult, Older Adult)","Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JS16104","March 8, 2017","April 30, 2020","April 30, 2020","January 29, 2018","null","February 27, 2018","Tan Tock Seng Hospital, Singapore, Singapore|Chang-Gung Memorial Hospital, Taoyuan city, Taiwan","","https://ClinicalTrials.gov/show/NCT03412955"
434,"NCT02898727","A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer","Local HER-O","Recruiting","No Results Available","Breast Neoplasms","Other: Local Therapy","to assess the percentage of patients treated with whole brain radiotherapy within 12 months after completion of local therapy|To describe distant brain failure incidence (overall and by number of treated metastases)|To describe local brain failure incidence, at any site of SRS or surgery|To describe extra-cranial failure incidence|To describe the pattern of first failure|To describe overall survival and cause of death (neurologic vs. non-neurologic)|To describe adverse events and need for corticosteroids|To describe neurocognitive function using the mini-mental state examination (MMSE)","Trans-Tasman Radiation Oncology Group (TROG)","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TROG 16.02","November 20, 2017","May 2020","May 2020","September 13, 2016","null","February 28, 2018","Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT02898727"
435,"NCT03328884","Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients","Phenomenal","Recruiting","No Results Available","Breast Cancer Metastatic","Drug: Irinotecan Hydrochloride","CNS Overall Response Rate (ORR)|CNS disease stabilization on week 12|ORR, according to a volumetric parameter, and to the RECIST v.1.1 criteria|CBR|Safety profile of nal-IRI in this population by Common Terminology Criteria for Adverse Events version 4 (CTCAE v.4) criteria|Progression-Free Survival (PFS)|Overall Survival (OS)","MedSIR","All","18 Years and older   (Adult, Older Adult)","Phase 2","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MedOPP107","May 2, 2017","December 15, 2019","April 20, 2020","November 1, 2017","null","November 1, 2017","MedSIR Site, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT03328884"
436,"NCT02448576","PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy",,"Not yet recruiting","No Results Available","Breast Cancer|Brain Metastasis","Radiation: prophylactic cranial irradiation","brain metastasis-free survival|cumulative risk of brain metastases within 1 year|progression-free survival|overall survival|life quality score|central nervous function score","wang shusen|Sun Yat-sen University","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","326","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SYSU-5010-TNBC-PCI","August 2017","August 2025","August 2025","May 19, 2015","null","June 1, 2017","State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02448576"
437,"NCT02714010","EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC",,"Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: EGFR-TKI|Radiation: whole brain radiotherapy","intracranial PFS (iPFS)|overall survival (OS)|objective response rate (ORR)","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","601","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GASTO1014","August 2015","December 2021","December 2022","March 21, 2016","null","October 27, 2017","Sun Yat-sen University of cancer center, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02714010"
438,"NCT01891318","Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study",,"Recruiting","No Results Available","Tumors Metastatic to Brain","Radiation: radiosurgery|Procedure: therapeutic conventional surgery|Procedure: quality-of-life assessment","Maximum tolerated dose of radiosurgery determined by dose-limiting toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 (Phase I)|Local control of brain metastases (Phase II)|Rate of distant brain failure|Rate of radiation necrosis/steroid dependency|Rate of salvage treatment|Changes in neurocognitive function as measured by the Hopkins Verbal Learning Test (HVLT), Controlled Oral Word Association (COWA) & Trailmaking Test B, and Trailmaking Test A|Quality of life as assessed using Functional Assessment of Cancer Therapy-Brain (FACT-BR) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ)30","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE7312|NCI-2013-00644","July 3, 2013","September 2018","September 2018","July 3, 2013","null","February 27, 2018","University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01891318"
439,"NCT02571530","Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer",,"Recruiting","No Results Available","Neoplasm Metastasis","Drug: Intra-arterial Cerebral Infusion of Trastuzumab","Maximum tolerated dose (MTD)|Adverse events and dose-limiting toxicities|Response Evaluation Criteria in Solid Tumors (RECIST)|Overall Survival (OS)|Intracranial Time to Progression","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-312","September 2015","September 2020","null","October 8, 2015","null","December 2, 2017","Lenox Hill Brain Tumor Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02571530"
440,"NCT03143894","Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation",,"Recruiting","No Results Available","Breast Cancer|Cognitive Dysfunction|Fatigue","Device: TDCS","Change on Paced Auditory Serial Attention Test|Change on Functional Assessment of Cancer Therapy Cognitive Scale|Change in Multidimensional Fatigue Symptom Inventory- SF","Johns Hopkins University|Under Armour","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00110211|J16135","April 21, 2017","June 2018","June 2018","May 8, 2017","null","May 8, 2017","Sibley Memorial Hospital, Washington, D.C., District of Columbia, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Johns Hopkins Greenspring Station, Lutherville, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03143894"
441,"NCT02312622","Phase II Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer",,"Recruiting","No Results Available","Extensive Stage Small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer|Tumors Metastatic to Brain|Metastatic Breast Cancer","Drug: pegylated irinotecan NKTR 102|Other: laboratory biomarker analysis","CNS disease control rate (number of patients with stable disease + partial response + complete response divided by the total number of evaluable patients) (Cohort A and C)|Overall disease control rate (Cohort A and C)|Overall response rate (Cohort A and C)|Systemic (non-CNS) disease control rate (Cohort A and C)|Systemic (non-CNS) response rate (Cohort A and C)|Progression-free survival (PFS) (Cohort A and C)|Overall survival (Cohort A and C)|CNS and/or systemic disease control (Cohort B)|Incidence of toxicity, graded according to National Cancer Institute Common Terminology for Adverse Events version 4.0 (Cohorts A, B, and C)","Joel Neal|National Cancer Institute (NCI)|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LUN0067|NCI-2014-02101|P30CA124435|IRB - 30982","January 2015","July 2018","July 2019","December 9, 2014","null","February 27, 2018","Stanford University, School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT02312622"
442,"NCT02336451","A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges","Ascend-7","Recruiting","No Results Available","ALK-positive Non-small Cell Lung Cancer","Drug: LDK378","Overall response rate (ORR)|Disease Control Rate (DCR)|Overall Intracranial Response Rate (OIRR) per modified RECIST 1.1|Intracranial Disease Control Rate (IDCR) per modified RECIST 1.1|Time to intracranial tumor response (TTIR) per modified RECIST 1.1|Duration of intracranial response (DOIR) per modified RECIST 1.1|Overall Extracranial Response Rate (OERR) per RECIST 1.1|Extracranial Disease Control Rate (EDCR) per RECIST 1.1|Time to extracranial tumor response (TTER) per RECIST 1.1|Duration of extracranial response (DOER) per RECIST 1.1|Overall response rate (ORR) (whole body) per RECIST 1.1|Disease control rate (DCR) (whole body) per RECIST 1.1|Time to tumor response (TTR) (whole body) per RECIST 1.1|Duration of response (DOR) (whole body) per RECIST 1.1|Progression free survival (PFS) (whole body) per RECIST 1.1|Overal survival|Overall Safety|Pharmacokinetics of ceritinib in study population","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLDK378A2205","April 1, 2015","November 2, 2018","November 2, 2018","January 13, 2015","null","October 27, 2017","USC/Kenneth Norris Comprehensive Cancer Center SC-3, Los Angeles, California, United States|University of California San Francisco SC, San Francisco, California, United States|Stanford University Medical Center SC-5, Stanford, California, United States|Lynn Cancer Institute SC, Boca Raton, Florida, United States|Indiana University Health Goshen Center for Cancer SC, Goshen, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Dana Farber Cancer Institute SC-12, Boston, Massachusetts, United States|Karmanos Cancer Institute SC-3, Detroit, Michigan, United States|Cleveland Clinic Foundation Burkhardt Brain Tumor, Cleveland, Ohio, United States|Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State University, Columbus, Ohio, United States|Southwestern Regional Medical Center, Tulsa, Oklahoma, United States|Seattle Cancer Care Alliance SC-2, Seattle, Washington, United States|Novartis Investigative Site, Auckland, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Salvador, Bahia, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Itajai, SC, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, Brazil|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Bron, France|Novartis Investigative Site, Limoges Cedex, France|Novartis Investigative Site, Marseille cedex 20, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bad Berka, Germany|Novartis Investigative Site, Gauting, Germany|Novartis Investigative Site, Pokfulam, Hong Kong|Novartis Investigative Site, Livorno, LI, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Verona, VR, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|NKI-AVL, Department of Thoracic-Oncology, Amsterdam, Netherlands|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom","","https://ClinicalTrials.gov/show/NCT02336451"
443,"NCT03257124","Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS",,"Recruiting","No Results Available","Non-Small Cell Lung Cancer With EGFR T790M Mutation|With Brain and/or Leptomeningeal Metastasis|Failed Tyrosine Kinase Inhibitors","Drug: AZD9291","Overall response rate (ORR) in CNS -brain metastasis cohort|Overall survival - Leptomeningeal with or without brain metastasis cohort|Whole body disease control rate (DCR)|Time to brain progression|Progression free survival (PFS) in BM cohort|Overall survival (OS)|Adverse events (AEs)|Exploratory analysis of EGFR mutation/T790M","Samsung Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-09-058","May 8, 2017","December 31, 2018","December 31, 2019","August 22, 2017","null","September 7, 2017","Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03257124"
444,"NCT03497767","A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases","OUTRUN","Not yet recruiting","No Results Available","Metastatic Non Small Cell Lung Cancer","Drug: Osimertinib|Radiation: Stereotactic Radiosurgery (SRS)","Intracranial progression free survival at 12 months|Use of salvage whole-brain radiotherapy (WBRT)|Local brain failure|Distant brain failure|Extra-cranial progression|Overall Survival","Trans-Tasman Radiation Oncology Group (TROG)","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TROG 17.02","August 2018","September 2021","March 2022","April 13, 2018","null","April 13, 2018","","","https://ClinicalTrials.gov/show/NCT03497767"
445,"NCT02774681","Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis",,"Recruiting","No Results Available","Breast Carcinoma Metastatic in the Brain|Estrogen Receptor Negative|HER2/Neu Negative|HER2/Neu Positive|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer","Procedure: Cognitive Assessment|Drug: Palbociclib|Procedure: Quality-of-Life Assessment|Biological: Trastuzumab","Radiographic response rate in the CNS in patients with HER2- positive breast cancer who have brain metastasis treated with palbociclib|Incidence of Adverse Events|Overall Survival (OS)|Progression Free Survival (PFS)|Overall Response Rate (ORR)|Time to CNS progression","Northwestern University|Pfizer|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","33","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 15B08|STU00202582|P30CA060553|NCI-2016-00626","May 2016","November 2019","February 2020","May 17, 2016","null","June 21, 2018","Northwestern University, Chicago, Illinois, United States|Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States|Houston Methodist Hospital/Houston Methodist Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02774681"
446,"NCT01891708","VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer",,"Recruiting","No Results Available","Non Small Cell Lung Cancer|Brain Metastasis","Other: bevacizumab, standard chemotherapy and radiation","PFS|OS","Li Liu|Huazhong University of Science and Technology","All","18 Years to 75 Years   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","XHZL02","June 2013","December 2014","December 2018","July 3, 2013","null","July 3, 2013","Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT01891708"
447,"NCT02595905","Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases",,"Recruiting","No Results Available","Breast Carcinoma Metastatic in the Brain|Deleterious BRCA1 Gene Mutation|Deleterious BRCA2 Gene Mutation|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7|Triple-Negative Breast Carcinoma","Drug: Cisplatin|Other: Laboratory Biomarker Analysis|Other: Placebo|Drug: Veliparib","Progression-free survival (PFS)|Overall survival (OS)|Response rate (measurable disease only)|Clinical benefit rate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","333","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2015-01912|S1416|U10CA180888","July 7, 2016","October 31, 2021","null","November 4, 2015","null","July 3, 2018","Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|University of Arizona Cancer Center at Saint Joseph's, Phoenix, Arizona, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Sutter Davis Hospital, Davis, California, United States|Epic Care-Dublin, Dublin, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Palo Alto Medical Foundation-Fremont, Fremont, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Mercy UC Davis Cancer Center, Merced, California, United States|Memorial Medical Center, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Kaiser Permanente-Ontario, Ontario, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Eisenhower Medical Center, Rancho Mirage, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program NCORP, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Comprehensive Cancer Care and Research Institute of Colorado LLC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Grand Valley Oncology, Grand Junction, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Danbury Hospital, Danbury, Connecticut, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Middlesex Hospital, Middletown, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Halifax Health Medical Center-Centers for Oncology, Daytona Beach, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Cleveland Clinic-Weston, Weston, Florida, United States|Augusta University Medical Center, Augusta, Georgia, United States|Dekalb Medical Center, Decatur, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|South Georgia Medical Center/Pearlman Cancer Center, Valdosta, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Mount Sinai Hospital Medical Center, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Weiss Memorial Hospital, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|AMITA Health Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|AMITA Health Cancer Institute and Outpatient Center, Hinsdale, Illinois, United States|Presence Saint Mary's Hospital, Kankakee, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|West Suburban Medical Center, River Forest, Illinois, United States|SwedishAmerican Regional Cancer Center/ACT, Rockford, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Memorial and Saint Elizabeth's Health Care Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Springmill Medical Center, Indianapolis, Indiana, United States|Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States|Woodland Cancer Care Center, Michigan City, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Chancellor Center for Oncology, Newburgh, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Genesis Medical Center - East Campus, Davenport, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Covenant Medical Center, Waterloo, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Baptist Health Corbin, Corbin, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|Hardin Memorial Hospital, Elizabethtown, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Baptist Health Louisville, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Baptist Health Madisonville/Merle Mahr Cancer Center, Madisonville, Kentucky, United States|Baptist Health Paducah, Paducah, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Christus Saint Frances Cabrini Hospital, Alexandria, Louisiana, United States|Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States|Medical Center of Baton Rouge, Baton Rouge, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|University Health-Conway, Monroe, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States|CHRISTUS Highland Medical Center, Shreveport, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Penobscot Bay Medical Center, Rockport, Maine, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Winchester Hospital, Winchester, Massachusetts, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|Henry Ford Cancer Institute¿Downriver, Brownstown, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Beaumont Hospital - Farmington Hills, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Lymphoma Clinic of Michigan, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|William Beaumont Hospital-Grosse Point, Grosse Pointe, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Monroe Cancer Center, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Assarian Cancer Center, Novi, Michigan, United States|Henry Ford Medical Center-Columbus, Novi, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Michigan Cancer Specialists, Roseville, Michigan, United States|Oakland Colon and Rectal Association, Royal Oak, Michigan, United States|Cancer Care Associates PC, Royal Oak, Michigan, United States|Comprehensive Medical Center PLLC, Royal Oak, Michigan, United States|Hematology Oncology Consultants PC, Royal Oak, Michigan, United States|Oakland Medical Group, Royal Oak, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Providence Hospital-Southfield Cancer Center, Southfield, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Premier Hematology Oncology Care, Sterling Heights, Michigan, United States|Mitchell Folbe MD PC, Sterling Heights, Michigan, United States|Saint Joseph Health System-Tawas City, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Michigan Institute of Urology-Town Center, Troy, Michigan, United States|Claudia BR Herke MD PC, Troy, Michigan, United States|Hematology Oncology Consultants PC-Troy, Troy, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Bhadresh Nayak MD PC-Warren, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi, United States|Hattiesburg Clinic - Hematology/Oncology Clinic, Hattiesburg, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Nebraska Medicine-Bellevue, Bellevue, Nebraska, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Manchester, Manchester, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|AtlantiCare Health Park-Cape May Court House, Cape May Court House, New Jersey, United States|AtlantiCare Surgery Center, Egg Harbor Township, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Holy Name Hospital, Teaneck, New Jersey, United States|MD Anderson Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, United States|Lovelace Medical Center-Downtown, Albuquerque, New Mexico, United States|Lovelace Medical Center-Saint Joseph Square, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, United States|Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States|Christus Saint Vincent Regional Cancer Center, Santa Fe, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Winthrop Hospital, Mineola, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Dickstein Cancer Treatment Center, White Plains, New York, United States|Asheville Hematology-Oncology Associates, Asheville, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Haywood Infusion Center, Clyde, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Hendersonville Hematology and Oncology at Pardee, Hendersonville, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Park Ridge Health, Hendersonville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Vidant Oncology-Kinston, Kinston, North Carolina, United States|FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst, North Carolina, United States|Southeastern Medical Oncology Center-Wilson, Wilson, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Mercy Medical Center, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc - Anderson, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physicians LLC-Samaritan North, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Cleveland Clinic Cancer Center Independence, Independence, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Saint Rita's Medical Center, Lima, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|Dayton Physicians LLC-Signal Point, Middletown, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Dayton Physicians LLC-Wilson, Sidney, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Trinity's Tony Teramana Cancer Center, Steubenville, Ohio, United States|Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|South Pointe Hospital, Warrensville Heights, Ohio, United States|University Pointe, West Chester, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Integris Southwest Medical Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Integris Cancer Institute of Oklahoma, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|SWOG, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|UPMC-Heritage Valley Health System Beaver, Beaver, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Crozer-Keystone Regional Cancer Center at Broomall, Broomall, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|The Regional Cancer Center, Erie, Pennsylvania, United States|Crozer Regional Cancer Center at Brinton Lake, Glen Mills, Pennsylvania, United States|UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|UPMC-Johnstown/John P. Murtha Regional Cancer Center, Johnstown, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania, United States|Riddle Memorial Hospital, Media, Pennsylvania, United States|UPMC-Coraopolis/Heritage Valley Radiation Oncology, Moon, Pennsylvania, United States|Consultants in Medical Oncology and Hematology?Newtown Square, Newtown Square, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Margaret, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States|UPMC Jefferson Regional Radiation Oncology, Pittsburgh, Pennsylvania, United States|UPMC-Passavant Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|UPMC Uniontown Hospital Radiation Oncology, Uniontown, Pennsylvania, United States|UPMC Washington Hospital Radiation Oncology, Washington, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|UPMC Susquehanna, Williamsport, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Health System Cancer Institute-Laurens, Clinton, South Carolina, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|McLeod Regional Medical Center, Florence, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Boston Baskin Cancer Center-Bartlett, Bartlett, Tennessee, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States|Baptist Memorial Hospital for Women, Memphis, Tennessee, United States|Family Cancer Center-Memphis, Memphis, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|The Don and Sybil Harrington Cancer Center, Amarillo, Texas, United States|Dell Seton Medical Center at The University of Texas, Austin, Texas, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|UTMB Cancer Center at Victory Lakes, League City, Texas, United States|Farmington Health Center, Farmington, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|South Jordan Health Center, South Jordan, Utah, United States|Norris Cotton Cancer Center-North, Saint Johnsbury, Vermont, United States|Danville Hematology Oncology, Danville, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Seattle Cancer Care Alliance at EvergreenHealth, Kirkland, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, Washington, United States|Skagit Valley Hospital, Mount Vernon, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Rockwood North Cancer Treatment Center, Spokane, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|West Virginia University Charleston Division, Charleston, West Virginia, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center - Eau Claire, Eau Claire, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Marinette, Marinette, Wisconsin, United States|Vince Lombardi Cancer Clinic-Marinette, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Clinic-Rice Lake Center, Rice Lake, Wisconsin, United States|HSHS Saint Nicholas Hospital, Sheboygan, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Big Horn Basin Cancer Center, Cody, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Advance Oncology Center, Aguadilla, Puerto Rico|Doctor's Cancer Center-Arecibo, Arecibo, Puerto Rico|Cancer Center-Metro Medical Center Bayamon, Bayamon, Puerto Rico|Hematologia Oncologia San Pablo, Bayamon, Puerto Rico|HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico|Doctors Cancer Center, Manati, Puerto Rico|Instituto Oncologia Moderna Ponce, Ponce, Puerto Rico|San Juan Community Oncology Group, San Juan, Puerto Rico|Primary Care Physician Group, San Juan, Puerto Rico|San Juan City Hospital, San Juan, Puerto Rico|Centro de Hematologia y Oncologia del Sur, Santa Isabel, Puerto Rico","","https://ClinicalTrials.gov/show/NCT02595905"
448,"NCT02953717","Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B)",,"Recruiting","No Results Available","Neoplasm Metastasis","Radiation: Gamma Knife radiosurgery|Radiation: Whole Brain Radiation Therapy","Cognitive decline at 3 months|Verbal memory|Cognitive flexibility|Word Fluency|Working memory|Processing speed|Motor dexterity|Health Related Quality Of Life (HRQOL)|Fatigue|Depression and anxiety|Median Overall Survival|Local tumor control|Distant tumor control","Elisabeth-TweeSteden Ziekenhuis|University of Tilburg|ZonMw: The Netherlands Organisation for Health Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","842003006|NTR5463","February 2016","March 2019","March 2019","November 3, 2016","null","March 2, 2018","Gamma Knife Center Tilburg, Elisabeth-TweeSteden Hospital, Tilburg, Noord-Brabant, Netherlands","","https://ClinicalTrials.gov/show/NCT02953717"
449,"NCT02736513","Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases",,"Recruiting","No Results Available","Lung Cancer","Drug: AZD9291","Intracranial overall response rate as defined by modified RECIST|Intracranial disease control rate (IDCR) as defined by mRECIST|median time to intracranial response (mTTIR) as defined by mRECIST|median intracranial progression free survival (mIPFS) as defined by mRECIST","Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0785-15-RMC","May 2016","May 2020","May 2020","April 13, 2016","null","June 21, 2016","Rabin Medical Center, Petach Tikva, Israel","","https://ClinicalTrials.gov/show/NCT02736513"
450,"NCT03526900","Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis","ATEZO-BRAIN","Not yet recruiting","No Results Available","Non-small Cell Lung Cancer Stage IV","Drug: Atezolizumab","Efficacy of atezolizumab + CBDCA + pemetrexed by evaluating PFS|Efficacy of atezolizumab + CBDCA + pemetrexed by measuring objective response.","Spanish Lung Cancer Group","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GECP 17/05_ATEZO-BRAIN","June 15, 2018","June 15, 2021","December 15, 2022","May 16, 2018","null","June 6, 2018","Hospital General Universitario de Elche, Elche, Alicante, Spain|ICO-Badalona, Badalona, Barcelona, Spain|ICO-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Complejo Hospitalario de la Coruña, La Coruña, Coruña, Spain|Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas, Spain|Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain|Hospital General de Alicante, Alicante, Spain|H.U.Vall D´Hebrón, Barcelona, Spain|Hospital de Santa Creu i Sant Pau, Barcelona, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Fundación Jiménez Díaz, Madrid, Spain|H. La Paz, Madrid, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain","","https://ClinicalTrials.gov/show/NCT03526900"
451,"NCT02220127","RCT of the 4mm vs. the 8mm Collimator for GKR of Brain Micrometastases",,"Recruiting","No Results Available","Brain Micrometastases","Radiation: GKR with a single shot of the 8 mm collimator|Radiation: GKR with a single shot of the 4 mm collimator","Local control rate (LCR)|Adverse radiation effects (ARE)","University College, London|University College London Hospitals","All","18 Years and older   (Adult, Older Adult)","Not Applicable","298","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","14/0050|14/LO/0791|145268","September 2014","April 2020","April 2021","August 19, 2014","null","March 20, 2015","Gamma Knife Centre at BUPA Cromwell Hospital, London, United Kingdom|The Gamma Knife Centre at Queen Square, London, United Kingdom|BMI Thornbury Hospital, Sheffield, United Kingdom","","https://ClinicalTrials.gov/show/NCT02220127"
452,"NCT03458676","Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies",,"Recruiting","No Results Available","Brain Lesion","Procedure: Advanced Magnetic Resonance Imaging Scan|Procedure: Standard of Care Brain Biopsy and Tumor Removal","Comparison of the Accuracy of the Pathological Grades of Tumor Observed at the Biopsy Locations Identified Using Conventional Versus Advanced Imaging|Target Sample Grading","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2011-0370","September 6, 2012","September 2020","September 2021","March 8, 2018","null","March 8, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03458676"
453,"NCT00887146","Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma",,"Recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: concomitant temozolomide (TMZ)|Radiation: radiotherapy|Drug: procarbazine|Drug: adjuvant temozolomide (TMZ)|Drug: CCNU|Drug: vincristine","Progression-free survival|Time to progression|Time to neurocognitive progression, assessed using the Hopkins Verbal Learning Test-Revised for Free Recall, Delayed Recall, and Delayed Recognition; the Controlled Oral Word Association test; and the Trail Making Test Part A or B|Overall survival|Objective tumor response defined as a complete response or partial response|Treatment-related adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|European Organisation for Research and Treatment Center (EORTC)|NCIC Clinical Trials Group","All","18 Years and older   (Adult, Older Adult)","Phase 3","360","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","N0577|NCI-2011-01915|EORTC-26081-22086|EudraCT-2008-007295-14|CDR0000640442","September 2009","December 2018","null","April 23, 2009","null","June 12, 2018","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Providence Hospital, Mobile, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Arizona Oncology-Deer Valley Center, Phoenix, Arizona, United States|Arizona Oncology Services Foundation, Scottsdale, Arizona, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|University Oncology Associates, Fresno, California, United States|California Cancer Center - North Fresno, Fresno, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|The Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Yale University, New Haven, Connecticut, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Florida Hospital Orlando, Orlando, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|AMITA Health Adventist Medical Center, La Grange, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa-Wide Oncology Research Coalition NCORP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Norton Hospital Pavilion and Medical Campus, Louisville, Kentucky, United States|Maine Medical Center-Bramhall Campus, Portland, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Cancer Trials Support Unit, Rockville, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Hematology and Oncology, Lincoln, Nebraska, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Nebraska Cancer Specialists - Omaha, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Regional West Medical Center Cancer Center, Scottsbluff, Nebraska, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Highland Hospital, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|UTMB Cancer Center at Victory Lakes, League City, Texas, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Tri-Cities Cancer Center, Kennewick, Washington, United States|Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, Washington, United States|Skagit Valley Hospital, Mount Vernon, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Medical University Vienna, Vienna, Austria|Alegemeen Ziekenhuis Middelheim, Antwerpen, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario, Canada|Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Centre Leon Berard, Lyon, France|Centre Antoine Lacassagne, Nice, France|Gustave Roussy, Villejuif, France|Academ Zienkenhuis Bij De University, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Maastro Clinic-Maastricht Radiation Oncology, Maastricht, Netherlands|Erasmus University Medical Center, Rotterdam, Netherlands|University Hospital Zurich, Zürich, Switzerland","","https://ClinicalTrials.gov/show/NCT00887146"
454,"NCT02353000","Whole Brain Radiotherapy (WBRT) Versus Stereotactic Radiosurgery (SRS) for 4 Upto 10 Brain Metastases","WBRTvsSRS","Recruiting","No Results Available","Neoplasm Metastasis","Radiation: Stereotactic Radiosurgery|Radiation: Whole Brain Radiotherapy","Quality of life in patients with 4 - 10 brain metastases comparing WBRT and SRS|Overall survival steroid use (mg), toxicity including hair loss and fatigue.|Time that patient is functioning independently (Karnofsky ≥ 70)|Steroid use|Toxicity measured by hair loss and fatigue|Degree of independence","Maastricht Radiation Oncology","All","18 Years and older   (Adult, Older Adult)","Not Applicable","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01-2015","July 2016","December 2018","December 2019","February 2, 2015","null","April 5, 2018","VUmc, Amsterdam, Netherlands|AMC, Amsterdam, Netherlands|Haaglanden MC, Den Haag, Netherlands|Maastricht Radiation Oncology (MAASTRO clinic), Maastricht, Netherlands|Erasmus MC, Rotterdam, Netherlands|Instituut Verbeeten, Tilburg, Netherlands|ZRTI, Vlissingen, Netherlands","","https://ClinicalTrials.gov/show/NCT02353000"
455,"NCT02753790","Whole Brain Radiation Using IMRT for Patients With Brain Metastases",,"Recruiting","No Results Available","Neoplasm Metastasis|Central Nervous System Metastases","Radiation: Intensity Modulated Radiotherapy","Overall response rate (ORR)|Change in memory|Rate of permanent alopecia","New Mexico Cancer Care Alliance","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INST 1409","February 2016","December 2020","September 2022","April 28, 2016","null","September 19, 2017","Universtiy of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States","","https://ClinicalTrials.gov/show/NCT02753790"
